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Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, has a fatality rate 
as high as 10%, even with appropriate treatment. In the UK, penicillin is administered to 
patients in primary care whilst cefotaxime and ceftriaxone are administered in secondary 
care. The first-choice antibiotic for chemoprophylaxis of close contacts is ciprofloxacin, 
followed by rifampicin. IMD caused by non-groupable (NG) meningococci affects mainly 
immunocompromised individuals, who are recommended antibiotic chemoprophylaxis 
due to a greater risk of IMD development.   
 
Resistance to antibiotics among meningococci is relatively rare, however reduced 
susceptibility and resistance to penicillin is increasing globally. Limited data exist regarding 
the prevalence of antibiotic resistance among meningococci in the UK.  
 
The Public Health England Meningococcal Reference Unit receives all isolates from IMD 
cases in England, Wales and Northern Ireland. The aims of this project were to i) investigate 
the distribution of antibiotic resistance to penicillin, rifampicin, ciprofloxacin and 
cefotaxime among IMD isolates from 2010/11-2018/19 (n=4,122), ii) investigate a recent 
outbreak of IMD in England caused by a ciprofloxacin-resistant NG meningococcal strain 
and iii) investigate increasing levels of penicillin resistance among serogroup W ST-11 clonal 
complex isolates in England.  
 
Out of the 4,122 IMD isolates, 113 were penicillin-resistant, two were rifampicin-resistant, 
five were ciprofloxacin-resistant and one was cefotaxime-resistant. Penicillin resistance 
was mainly due to altered penA alleles. Rifampicin and ciprofloxacin resistance were due 
to altered rpoB and gyrA alleles, respectively. Cefotaxime resistance was observed in an 
isolate with an altered penA allele containing additional mutations to those harboured by 
penicillin-resistant isolates. 
 
A ciprofloxacin-resistant strain of the ST-175 CC with an apparent propensity for reduced 
susceptibility to penicillin was identified and found to be of concern among 
immunocompromised individuals. An increase in penicillin-resistant English serogroup W 
xv 
 
ST-11 CC isolates was due to several strains; in particular, a strain first identified in Australia 
in 2016. This research highlights the need for continued surveillance of antibiotic resistance 
among meningococci and the need for vigilance among immunocompromised patients to 






1.1 Neisseria meningitidis  
 
The bacterium Neisseria (N). meningitidis, (the meningococcus), is an exclusively human 
commensal/pathogen colonising the nasopharynx of approximately 10% of people 
(Caugant and Maiden, 2009). Rarely the bacteria cross the endothelium causing invasive 
disease. The genus Neisseria also includes N. gonorrhoeae, causing the sexually transmitted 
disease gonorrhoea, along with several other non-pathogenic commensals (Liu et al., 
2015).  
 
1.1.1 Meningococcal carriage 
 
Carriage is the main source of meningococcal transmission, occurring  through respiratory 
secretions via person-to-person contact (Yazdankhah and Caugant, 2004). Carriage rates 
vary among different age groups, with relatively low rates among infants, which increase 
gradually, peaking at around 25% in adolescents and young adults (Christensen et al., 
2010). Carriage risk factors include social behaviours and confinement to closed/semi-
closed populations, e.g. pilgrims, university students and military personnel, where close 
contact and therefore transmission increases (Peterson et al., 2018). Carriage is a 
prerequisite for invasive meningococcal disease (IMD).   
 
1.1.2 Invasive meningococcal disease 
 
IMD was first reported in the early 19th century following an outbreak in Geneva, 
Switzerland (Vieusseux, 1805).  It occurs when colonised meningococci cross the epithelial 
barrier of the nasopharynx into the bloodstream, and from here, may cause sepsis. If 
meningococci cross the blood brain barrier, gaining entry to the cerebral spinal fluid (CSF), 
they may cause meningitis (Coureuil et al., 2012).  Other sites that can be affected alone or 
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in combination include joints, the pericardium and inner eye (Morgan et al., 2002; Joyce et 
al., 2003; Orden et al., 2003).  
IMD, manifesting in meningitis and/or sepsis, is a life-threatening illness. Even with early 
diagnosis and treatment, IMD is associated with a mortality rate of around 5-10%; 
considerably lower than if left untreated (Brouwer et al., 2010; Castillo et al., 2011). 
Survivors may face long-term sequelae, such as limb amputations and sensorineural 
hearing loss (Pace and Pollard, 2012).   
 
1.1.2.1 Clinical manifestations 
 
IMD may present in various manifestations ranging in severity, including transient 
meningococcaemia, septic shock, multiple organ failure and death (Brandtzaeg et al., 
1989). Meningitis is the most common presentation of IMD, occurring in around 40% of 
IMD cases (European Centre for Diseases Prevention and Control, 2013). Symptoms include 
fever, headache, neck stiffness, nausea and vomiting. Children <2 years may lack typical 
symptoms, presenting mainly with irritability, lethargy and occasionally, raised fontanelles 
(Riordan et al., 1995; Hart and Thomson, 2006).  
Sepsis, which may lead to septic shock, circulatory and organ failure, presents as the main 
manifestation of IMD in around 30% of cases (Cai et al., 2010). It may also present in 
conjunction with meningitis (European Centre for Diseases Prevention and Control, 2013).  
Symptoms during the early stages of septicaemia include leg pain, cold peripheries and a 
non-blanching rash, which if left untreated causes skin discolouration and necrosis  
(Thompson et al., 2006; Pace and Pollard, 2012). Subsequent skin grafts, and in severe cases 
limb amputations, are just some of the complications that 10-20% of IMD survivors may 
face (Olbrich et al., 2018). Other sequelae include hearing loss and neurological 
impairment.  
Uncommon manifestations of IMD, occurring in less than 10% of cases,  include 




1.1.2.2 Laboratory diagnosis and treatment 
 
Hospital admission is a priority when IMD is suspected (Public Health England, 2012). In the 
UK, patients in primary care with suspected meningococcal disease are administered a 
single dose of benzylpenicillin (National Institute for Health and Care Excellence, 2015). 
Third generation cephalosporins (3GCs), ceftriaxone and cefotaxime, are administered 
following hospital admission and confirmation of IMD.  
Confirmation of IMD is achieved by obtaining a culture of the organism or by detection of 
meningococcal DNA in a usually sterile site. 
 
1.1.2.2.1 Meningococcal Reference Unit 
 
In England, Wales and Scotland, identification of meningococci requires notification to 
Public Health England (PHE). Voluntary notification to the Public Health Agency is applied 
in Northern Ireland. The PHE Meningococcal Reference Unit (MRU) offers a free national 
reference service for confirmation and characterisation of meningococcal isolates in 
England, Wales and Northern Ireland (E, W and NI). 
Culture remains the gold standard for IMD diagnosis, however early administration of 
antibiotics often prevents culture obtainment. The meningococcal PCR screening assay for 
clinical specimens targets the meningococcal capsular gene, ctrA, and has led to improved 
IMD confirmation since its implementation into the MRU service in 1996 (Hackett et al., 
2002; Gray et al., 2006). Around 50% of IMD cases in E, W and NI are confirmed solely by 
PCR (Heinsbroek et al., 2013). 
The screening PCR and associated PCR assays also serve to characterise the meningococcal 
capsular group (section 1.3.1.1). All cultured isolates undergo capsular serogrouping and 
serotyping and serosubtyping for the outer membrane proteins Porin B (PorB) and Porin A 
(PorA), respectively. They also undergo antibiotic susceptibility testing (AST) (section 





1.1.3 Cell surface features  
 
1.1.3.1 Capsule 
The capsule is the main virulence factor of meningococci with its anti-phagocytic properties 
essential for survival and growth in the bloodstream of healthy individuals. An increased 
resistance to cationic antimicrobial peptides, which are essential components of the host 
innate defence system, is the likely protective mechanism of the meningococcal capsule 
(Spinosa et al., 2007).   Almost all meningococcal isolates recovered from non-
immunocompromised individuals are encapsulated, with unencapsulated meningococci 
very rarely the cause of IMD (McNamara et al., 2016; Santos-Neto et al., 2019). The 
polysaccharide capsule composition of meningococci forms the basis for the species’ main 
classification system: grouping (section 1.3.1.1). 
 
1.1.3.2 Outer membrane proteins 
 
The outer membrane of meningococci contains various outer membrane proteins (OMPs), 
including porins (porin A and porin B), opacity associated proteins and surface adhesins 
(type IV pili).  Many contribute to the organisms’ pathogenicity by aiding in adhesion and 
invasion of epithelial cells as well as in the evasion of complement mediated killing (Table 
1-1).  
 





Porin A (PorA)/ 
Porin B (PorB) 
- Enables diffusion of hydrophilic 
molecules in and out of cell 
-  Provides characterisation due to 
variation between strains 
- Forms basis of typing/subtyping 
(section 1.3.1.2) 
- Vaccine antigen (porA) 
(Jeanteur et al., 1991) 
(Jolley et al., 2007) 
(Jodar et al., 2002; 





- Mediates interaction between host 
- Facilitates adhesion and 
colonisation in the nasopharynx 
(Virji et al., 1993) 
(De Jonge et al., 2002) 
Type IV pili - Facilitates initial contact of 
encapsulated meningococci 
- Aids in attachment to epithelial 
cells in nasopharynx 
-Has a role in DNA uptake for 
transformation 
- Has a role in motility 
(Nassif et al., 1997) 
(Cehovin et al., 2013) 
(Eriksson et al., 2015) 
Factor H binding 
protein (fHbp) 
- Binds factor H promoting evasion 
of complement mediated killing 
- Vaccine antigen (section 1.2.2) 
(Madico et al., 2006) 
 Neisserial adhesin A 
(NadA) 
- Aids in adhesion to epithelial cells 
and subsequent invasion 
- Vaccine antigen (section 1.2.2) 




- Binds heparin promoting evasion of 
complement mediated killing 
- Vaccine antigen (section 1.2.2) 
(Vacca et al., 2016) 
 
1.1.4  The meningococcal genome 
 
The meningococcal genome consists of a single circular chromosome of ~2.2 million base 
pairs (bp) (Parkhill et al., 2000; Tettelin et al., 2000). It contains a high proportion of 
repeated DNA sequences, including the 10-12 bp DNA uptake sequence (DUS) (Goodman 
and Scocca, 1988; Ambur et al., 2007). DUS is essential for uptake of exogenous DNA via 
horizontal gene transfer (HGT) by transformation, and integration into the chromosome by 
homologous recombination (Bäckman et al., 2000). Transformation allows for exchange of 
antibiotic resistance-associated genes between both the same and different species (Spratt 
et al., 1992; Alfsnes et al., 2018). The large number of DUSs and the natural competence of 
N. meningitidis make it readily available for DNA uptake, and co-colonisation with 
commensal Neisseria species in the nasopharynx  makes transformation and 
recombination the main source of new genetic information and the main mechanism for 
the spread of antibiotic resistant-associated genes (Caugant and Brynildsrud, 
2020).   Plasmids exchanged through conjugation may also confer antibiotic resistance 








Transfer of maternal antibodies offers protection against IMD during the first six months of 
life, after which IMD incidence increases (Goldschneider et al., 1969a). Naturally acquired 
immunity, a result of carriage acquisition, leads to a decrease in IMD incidence from  
around two years of age (Goldschneider et al., 1969b). Circulating serum bactericidal 
antibodies against meningococci act as opsonins, targeting cells for phagocytosis and 
activating the complement system (Kvalsvig and Unsworth, 2003).  
The complement system, inducing phagocytosis and cell lysis, is vital for IMD prevention. 
The complement system is activated by three pathways: the classical, alternative and lectin 
pathways. Both alternative and lectin pathways form part of the innate immune response, 
directly activated by components on the pathogens surface. The classical pathway is 
antibody mediated, an effector of the adaptive immune response. All three pathways lead 
to cleavage of the complement protein, C3 (Lewis and Ram, 2014). C3b is produced, acting 
as an opsonin to promote phagocytosis of invading meningococcal cells (Ehlenberger and 
Nussenzweig, 1977).  It is also used in the formation of C5 convertase, which cleaves C5 
initiating the terminal complement pathway and formation of the Membrane Attack 
Complex (MAC). A multiprotein structure consisting of C5b-9, the MAC imbeds into the 




First licenced in the 1970s, meningococcal capsular polysaccharide (CPS) vaccines proved 
successful in controlling epidemics worldwide (Gold and Artenstein, 1971; Wahdan et al., 
1973; Peltola et al., 1977). Plain meningococcal polysaccharides are limited by their low 
and short-lived immunity in young children (Gold et al., 1975, 1979). Thus, these were 
superseded by CPS-conjugate vaccines eliciting stronger, longer-lived immune responses, 
including in infants, the initiation of immune memory and the reduction of carriage 
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acquisition (Baraldo et al., 2005; Khatami et al., 2011; Terranella et al., 2011; Baxter et al., 
2016). Implementation of these into the UK routine immunisation schedule (Table 1-2) 
have been crucial in controlling IMD, particularly IMD caused by meningococcal serogroups 
C (MenC) and W (MenW). 
 
Table 1-2: Vaccines in the UK routine immunisation schedule for meningococcal 
serogroups A, C, W and Y. 
 





- In response to UK increase in MenC disease 
during the 1990s (Wise, 1999). 
- Overall reduction of 86.7% in targeted age group 
(<20 years) (Balmer et al., 2002). 
- Removed from UK immunisation schedule in 
2006 due to low MenC disease and protection 





- Combined Hib (Haemophilus influenzae type 





- In response to UK increase in MenW disease 
from 2009 (Campbell et al., 2017).   
-Replaced MenC vaccine in 13-14-year olds and 
offered to new university students ≤25 years. 
- 69% reduction in MenW cases compared with 
predicted cases (Campbell et al., 2017). 
 
CPS vaccines have proved unsuccessful against serogroup B meningococcal (MenB) disease 
due to a lack of immunogenicity of the MenB capsule (Finne et al., 1983). Vaccine 
approaches against serogroup B strains have therefore focused on the use of outer 
membrane vesicles (OMVs) and sub-capsular proteins of meningococci. OMV vaccines have 
been successful during outbreaks of MenB resulting from a single strain with a particular 
porA (Bjune et al., 1991; Arnold et al., 2011), however their use can be limited due to poor 
cross reactivity against diverse strains.  Two MenB vaccines (Table 1-3) are currently 
licenced in the UK and elsewhere (Rivero-Calle et al., 2019); 4CMenB (Bexsero), which 
contains sub-capsular proteins combined with OMVs derived from the meningococcal 
outbreak strain of New Zealand (NZ98/254 strain) (Martin et al., 1998; Serruto et al., 2012) 
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and MenB-fHbp (Trumenba) (Perez et al., 2018). The UK was the first country to implement 
4CMenB into the UK routine immunisation schedule in 2015. Over the first three years, 
vaccine effectiveness in England was 59% in infants receiving two doses and a booster, 
rising to 71.2% when considering only vaccine-preventable MenB isolates  (Ladhani et al., 
2020).  
Peptides, and their antigenic cross reactivity, can vary. Owing to the diversity of peptide 
antigens among meningococci and differences in surface expression levels, MenB vaccines 
do not offer protection against all MenB strains. This has led to the development of several 
phenotypic predictors of coverage, including ELISA-based meningococcal antigens typing 
system (MATS; Bexsero) and flow cytometry-based meningococcal antigen surface 
expression (MEASURE; Trumenba) assay. There are also genotypic methods including 
MATS-based genotypic (g)MATS for Bexsero and the meningococcal deduced vaccine 
antigen reactivity (MenDeVAR) based on MATS (Bexsero) and MEASURE/hSBA (Trumenba). 
Sub-capsular antigens may cause immune responses against meningococci irrespective of 
serogroups and therefore potentially against unencapsulated meningococci (Mulhall et al., 
2018).  
 
Table 1-3: Components of meningococcal serogroup B vaccines licensed for use 
in the UK. 
 
Vaccine Antigens Cross reacts with 
4CMenB (Bexsero®) NadA peptide 8 (variant 
NadA2/3) 
 
NadA-1 and NadA-2/3 
peptides (Serruto et al., 
2012). 
fHbp peptide 1 (nonlipidated 
variant 1) 
 
fHbp variant 1 peptides 
(Serruto et al., 2012). 
NHBA peptide 2 Cross-reactive variant 
groups not defined.  
Outer membrane vesicles 
containing PorA subtype 
P1.4 (from the NZ98/254 





MenB-fHbp (Trumenba) fHbp peptide 55 (lipidated 
variant 1) 
fHbp Variant 1 peptides 
(Jiang et al., 2010). 
fHbp peptide 45 (lipidated 
variant 3) 
fHbp variant 2 and 3 





To eliminate carriage and onward transmission/secondary cases, antibiotic 
chemoprophylaxis is offered to IMD cases where intravenous 3GCs were not used in 
treatment and offered to close contacts of cases. In the UK, ciprofloxacin is the antibiotic 
of choice, followed by rifampicin (Public Health England, 2012). Ongoing chemoprophylaxis 
is recommended for individuals with deficiencies of the terminal complement pathway, 
where IMD development risk is 1,000-10,000-fold higher than in those with functioning 
complement systems (Hellenbrand et al., 2015), and recurrent infection is prevalent 
(Figueroa et al., 1993). 
 
1.3 Surveillance and epidemiology of invasive meningococcal disease 
 
National surveillance of IMD is essential for identifying emerging hyper-virulent strains and 
during cluster/outbreak periods. It’s essential for monitoring epidemiology to guide public 
health management, vaccination strategies and surveillance of ABR (Brehony et al., 2007). 
 
1.3.1 Classification/characterisation of meningococcal strains 
 
Historically, meningococcal strains have been characterised by phenotypic methods to 
determine the capsular group, PorB serotype and PorA serosubtype. Developments of 
genotypic methods have enabled characterisation at higher resolution, revolutionising 




1.3.1.1 Grouping of meningococcal strains  
 
Meningococci can be classified into twelve serogroups, six of which (A,B C, W, X and Y)  are 
responsible for most IMD (Halperin et al., 2012). The serogroup can be determined for 
culture isolates using the phenotypic methods co-agglutination and dot-blot ELISA, which 
utilise polyclonal and monoclonal antibodies (Mabs), respectively (Gray et al., 2006). 
Genotypic methods  can be used to determine the genogroup, and are essential for IMD 
confirmation and group determination in the absence of an isolate (Hackett et al., 2002).  
PCR assays for genogroup determination target the siaD gene for serogroups B, C, W and Y 
and the mynA gene for serogroup A (Hackett et al., 2002). In the MRU, the screening PCR 
includes detection of the serogroup B determinant gene siaDb. If this is negative, then 
further PCR assays are used to detect the other common disease-causing serogroups (C 
[siaDc], W [siaDw], Y [siaDy] and A [mynA]).  
 
1.3.1.2 Typing and subtyping of meningococcal strains 
 
The type and subtype of meningococci is derived from variable regions (VRs) in eight 
surface exposed loops of major OMPs PorB (Class 2 and 3) and PorA (Class 1; P1) 
respectively (Jolley et al., 2007). Loops I, V, VI and VII give variation in PorB and loops I, IV 










Figure 1-1: Variable regions of  PorA 
Eight (I-VIII) surface exposed loops of PorA and PorB. VR = variable region. PorA variable 
regions are highlighted.  
 
Traditionally determined using dot-blot ELISA, limited availability of Mabs for recognition 
of surface exposed epitopes often results in unrecognition of certain variants, deeming 
isolates non typeable/subtypable (NT) (Wedege and Rosenqvist, 1990). Genotypic methods 
provide a more sensitive and specific method for typing/subtyping (Sacchi et al., 1998a; 
Sacchi et al., 1998b).  
 
1.3.1.3 Multi-locus sequence typing 
 
First employed in the 1990s (Maiden et al., 1998), Multilocus sequence typing (MLST) has 
been a successful method for long-term global surveillance of meningococci. 
Owing to high rates of recombination among meningococci, MLST is based on the 
sequences of seven widely distributed ‘housekeeping’ genes, which are slow-evolving due 
to their central role in metabolic function (Urwin and Maiden, 2003). An allelic profile is 
established and designated a sequence type (ST).  STs sharing ≥ four alleles with a predicted 
founder ST are grouped into clonal complexes (CCs).  
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The development of an online database (Neisseria PubMLST database; 
http://pubmlst.org/neisseria) has enabled the collection and exchange of MLST data 
worldwide (Jolley et al., 2004). 
Whilst MLST is successful in defining population structure, its application in epidemiology 
is limited, providing no further discrimination between strains of the same ST.  
 
1.3.1.4 Whole genome sequencing 
 
WGS enables discrimination of strains with high genetic similarity. WGS on clinical 
specimens is not currently routinely performed and sequencing is limited to MLST genes, 
and more routinely porA and fHbp. (Diggle and Clarke, 2003; Birtles et al., 2005; Clark et al., 
2014).  
The first whole genome sequences of N. meningitidis strains  determined by Sanger 
sequencing in 2000 were serogroup A and serogroup B (Parkhill et al., 2000; Tettelin et al., 
2000). Improvements in sequencing techniques led to the introduction of high-throughput 
‘next generation’ parallel sequencing technology (Harrison et al., 2017). WGS is now 
routinely used by many public health laboratories across the globe (Köser et al., 2012).   
In line with advancements made in sequencing techniques, the storage, accessibility and 
analytical tools for genomic data have also evolved. The PubMLST database expanded in 
2010 with the development of the Bacterial Isolate Genome Sequence Database (BIGSdb) 
platform, to include WGS data of Neisseria isolates (Jolley and Maiden, 2010). As WGS data 
is deposited into the database, allele numbers are assigned to recognised gene sequences 
at each defined locus. 
This expanding database allows for gene-by-gene pairwise comparisons of isolates using 
the BIGSdb Genome Comparator Tool (Maiden et al., 2013). Comparisons of 1605 
meningococcal ‘core genes’, defined in pubMLST (cgMLST), which are present among all 
meningococcal isolates, enable accurate analysis at high resolution (Maiden et al., 2013; 
Bratcher et al., 2014). Distance matrices based on the number of mismatching genes are 
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used for phylogenetic analysis, enabling visualisation of genetic relationships between 
isolates. 
WGS is an invaluable method for determining the origins and evolution of virulent strains 
(Lucidarme et al., 2015) and aids in predicting vaccine strain coverage (Brehony et al., 2015) 
and establishing the emergence of ABR strains (Mowlaboccus et al., 2017).  
 
1.3.1.5 Antibiotic susceptibility testing 
 
Antibiotic susceptibly testing determines the susceptibility of an organism to antibiotics. It 
is essential for therapeutic decision making and long-term surveillance of antibiotic 
susceptibility among meningococci. Several AST methods exist for determination of an 
isolate’s minimum inhibitory concentration (MIC) value; defined as the lowest 
concentration of an antibiotic required to inhibit the visible growth of an organism under 
defined test conditions (Andrews, 2001). These include agar dilution, broth dilution and 
gradient diffusion (Etest) methods. Methods and guidelines vary across 
laboratories/countries, providing challenges upon interpretation of MIC results (Vázquez 
et al., 2003; World Health Organization, 2011). MIC results determine the susceptibility 
category of an organism, which are defined by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) as per Table 1-4. 
 
Table 1-4: Categories of isolates following antibiotic susceptibility testing . 
Susceptibility Testing Category Definition 
‘Susceptible, standard dosing’ (S) 
Therapeutic success is highly likely where the 
standard dosing regimen of the antibiotic is 
used. 
‘Susceptible, increased exposure’ (I) 
Therapeutic success is highly likely where 
antibiotic exposure is enhanced by altering the 
concentration or dosing regimen. 
‘Resistant’ (R) Therapeutic failure is highly likely even with 
increased exposure. 
As defined by EUCAST (European Committee on Antimicrobial Susceptibility Testing, 2019). 
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The Clinical and Laboratory Standards Institute (CLSI), USA, recommends agar and broth 
dilution methods and interpretation using CLSI clinical breakpoints (Clinical and Laboratory 
Standards Institute, 2015). Most European reference laboratories use the gradient 
diffusion (Etest) method followed by interpretation of EUCAST breakpoints, which is 
recommended by the European Monitoring Group on Meningococci (Vázquez, 2007). The 
agar and gradient diffusion (Etest) methods have been shown to be highly comparable, 
with 100% agreement observed for penicillin (Vázquez et al., 2003). MIC breakpoints of 
both CLSI (Clinical and Laboratory Standards Institute, 2019) and EUCAST are listed in Table 
1-5.  
 
Table 1-5: Breakpoint comparisons: CLSI and EUCAST. 
Antibiotic Organisation 
MIC Breakpoint (mg/L) 
S* I* R* 
Penicillin 
CLSI ≤ 0.06 
0.12–0.25 
≥ 0.5 
EUCAST ≤ 0.06 > 0.25 
Cefotaxime 
CLSI ≤ 0.12 - - 
EUCAST ≤ 0.125 - > 0.125 
Ciprofloxacin 
CLSI ≤ 0.03 0.06 ≥ 0.12 
EUCAST ≤ 0.03 - > 0.03 
Rifampicin 
CLSI ≤ 0.5 1 ≥ 2 
EUCAST ≤ 0.25 - > 0.25 
Clinical breakpoint tables of EUCAST and CLSI for interpretation of MICs. * S= Susceptible, 
standard dosing regimen, I= Susceptible, increased exposure, R= Resistant. CLSI = Clinical 
Laboratory Standards Institute. EUCAST = European Committee on Antimicrobial 
Susceptibility Testing.  
 
1.3.2 Epidemiology of invasive meningococcal disease 
 
IMD is endemic worldwide, with incidence rates varying with geographical area. In Europe, 
incidence rates range from 0.45 cases/100,000 in Northern and Southern Europe, to 1.33 
cases/100,000 in the UK and Ireland (Parikh et al., 2020). Historically, the ‘meningitis belt’ 
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of Sub-Saharan Africa has had the highest incidence of meningococcal disease, with 
incidence rates as high as 10-1000 cases/100,000 during epidemics, which have occurred 
frequently in the past. However, following the introduction of a highly effective serogroup 
A meningococcal vaccine (MenAfriVac) in 2010, meningococcal serogroup A (MenA) 
disease, previously responsible for most outbreaks in the area, has decreased dramatically 
(Djingarey et al., 2015; Pelton, 2016; Mustapha and Harrison, 2018; Fernandez et al., 2019).  
IMD has a case-fatality rate of around 5-10% in developed countries (Hahné et al., 2005; 
Heckenberg et al., 2008; European Centre for Disease Prevention and Control, 2017), 
however, this is higher in less developed countries or during outbreaks (Smith et al., 2006; 
Zunt et al., 2018). IMD affects all age groups with most cases observed among young 
children, with a second peak in cases in many western countries among adolescents and 
young adults (Hart and Thomson, 2006).  
 
1.3.2.1 Serogroup distribution  
 
Serogroup distribution of meningococci varies geographically (Figure 1-2), with IMD caused 
by MenB, MenC and more recently MenW, most prevalent across Europe (Pelton, 2016; 
European Centre for Disease Prevention and Control, 2017). Following the introduction of 
the MenA conjugate vaccine in 2010, MenC and MenW outbreaks are primarily reported in 










Figure 1-2: Global distribution of disease-causing meningococcal serogroups 
(Adapted from Millar et al., 2016). 
 
1.3.2.2 Serogroup W disease 
 
Up until the 21st century, the incidence of MenW disease worldwide was low and 
associated with sporadic cases (Hansman, 1983; Spanjaard et al., 1987; Jackson and 
Wenger, 1993; Gray et al., 2006). Following the first recorded outbreak of MenW disease 
in 2000 following the annual pilgrimage to Hajj, Kingdom of Saudi Arabia (KSA), the 
incidence of MenW disease increased globally (Aguilera et al., 2002) 
The Hajj, and other religious mass gatherings, see millions of pilgrims from numerous 
countries descend on KSA. Crowded conditions facilitate transmission of meningococci and 
the return of pilgrims to respective countries permits global spread (Yezli et al., 2016).  
The 2000 Hajj outbreak resulted in localised outbreaks across Europe, Africa,  Asia, USA and 
the Middle East (Fine et al., 2000; Aguilera et al., 2002; Lingappa et al., 2003; Wilder‐Smith 
et al., 2003a; Ceyhan et al., 2012). A similar Hajj-related MenW outbreak  in 2001 (World 
Health Organization, 2001) resulted in mandatory vaccination of subsequent travellers to 
KSA with the MenACWY plain polysaccharide vaccine, preventing any further major 
pilgrimage-associated outbreaks (Yezli, Bin Saeed, et al., 2016). 
Brazil
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The Hajj outbreak strain was characterised as belonging to the ST-11 CC, and is the 
predominant MenW lineage in several countries of the Middle East and caused a large 
outbreak in South Africa between 2003 and 2008 (Abad et al., 2014; Lucidarme et al., 2016; 
Knol et al., 2017). It has also caused large epidemics in sub-Saharan Africa (Koumaré et al., 
2007; Mustapha et al., 2016). 
South America observed an increase in IMD caused by a distinct serogroup W ST-11 CC 
strain from 2003, starting in Brazil (Weidlich et al., 2008), spreading to Argentina and Chile 
(Sorhouet-Pereira et al., 2013; Araya et al., 2015). The causative strain was genetically 
distinct from the ‘Hajj Outbreak strain’, and was termed the ‘South American strain’ 
(Lucidarme et al., 2015). The UK observed a rise in MenW disease caused by ST-11 CC 
isolates from 2009, caused by a descendant of the ‘South American strain’, and was termed 
the ‘Original UK strain’ (Knol et al., 2017). Genomic analysis revealed an additional variant 
outbreak strain, descended from the ‘Original UK strain’, emerging in the UK in 2013, 
termed the ‘UK 2013 strain’ (Figure 1-3) (Lucidarme et al., 2016). Collectively, the Hajj 
outbreak strain and related strains belong to the ‘Hajj strain sublineage’ and the South 
American strain and related strains belong to the ‘South American strain sublineage’.  
The ‘Original UK strain’ and ‘2013 strain’ have spread to Europe, Canada and Australia 
(Bond et al., 2016; Lucidarme et al., 2016; Martin et al., 2016; Knol et al., 2017; Tsang et al., 
2018). Australia identified the emergence of a penicillin-resistant clade of the ‘Original UK 
strain’ in 2016, which encompassed isolates from Australia, France, Sweden, the 









Figure 1-3: The population structure of the South American strain sublineage, 
including the ‘South American strain’, ‘Original UK strain’ and ‘UK 2013 strain’ 
(Lucidarme et al., 2016).  
 
 
CC = clonal complex. The scale bar indicates the number of variable loci between genomes 
of isolates compared. 
 
1.3.2.3 Non-groupable meningococcal disease and the immunocompromised 
 
IMD caused by unencapsulated meningococci (non-groupable; MenNG) is rare, as capsule 
absence hinders evasion of the complement system and killing by phagocytosis (Rouphael 
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and Stephens, 2012). MenNG disease is mainly observed in patients with hereditary or 
acquired deficiencies of the terminal complement pathway, however, it has also been 
reported in seemingly immunocompetent individuals (Hoang et al., 2005; Xu et al., 2015).  
Acquired complement deficiencies often result from medical conditions and their 
associated treatments, particularly the use of Eculizumab (Soliris®, Alexion®) to treat 
atypical haemolytic-uremic syndrome and paroxysmal nocturnal haemoglobinuria (Hillmen 
et al., 2006; Legendre et al., 2013). A terminal complement pathway inhibitor, Eculizumab 
prevents the generation of the MAC, also defective in those with inherent deficiencies of 
the terminal complement pathway. Preventative vaccination is recommended, however 
cases of IMD have still been reported, including fatal cases (McNamara et al., 2017) (Nolfi-
Donegan et al., 2018). 
In addition, antibiotic prophylaxis regimes e.g. with penicillin, amoxicillin or ciprofloxacin 
(Nester et al., 2011; Noone et al., 2012; Struijk et al., 2013) are recommended for 
immunocompromised patients in certain countries such as the UK and France (Nolfi-
Donegan et al., 2018). Penicillin-resistant strains of meningococci have been known to 
subvert antibiotic prophylaxis regimes in complement deficient individuals (McNamara et 
al., 2017; Parikh et al., 2017). Antibiotics for rescue therapies may therefore be prescribed 
(Hawkins et al., 2017; Arnold et al., 2020). 
 
1.4 Antibiotics for meningococcal disease 
 
Antibiotics currently used in the UK for the treatment of meningococcal disease include 
penicillin, cefotaxime and ceftriaxone. Those used for chemoprophylaxis include 
ciprofloxacin and rifampicin. The MRU performs AST on isolates for penicillin, rifampicin, 
ciprofloxacin and cefotaxime. 
 
1.4.1 Beta-lactam antibiotics  
 
Beta-lactam antibiotics, so-called because they contain a beta-lactam ring in their 
molecular structure (Kong et al., 2010) prevent the synthesis of the peptidoglycan layer of 
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the bacterial cell wall by binding to one or more penicillin binding proteins (PBPs) of 
bacteria (Williamson et al., 1986). Beta-lactam antibiotics used in the treatment of IMD 
include penicillin and the 3GCs cefotaxime and ceftriaxone. Unlike penicillin, 3GCs are less 




 Fluoroquinolones, which contain a fluorine atom in their chemical structure, inhibit DNA 
replication by targeting two bacterial enzymes essential for the process: DNA gyrase and 
topoisomerase IV (Hooper, 2001).  Each is encoded by two genes; gyrA and gyrB and parC 
and parE, respectively (Drlica and Zhao, 1997). Ciprofloxacin is the fluoroquinolone that is 




Ansamycins are macrocytic antibiotics which have a cyclic structure containing an aliphatic 
chain connecting two ends of a naphthoquinone  core (Maslow and Portal-Celhay, 2015). 
They inhibit RNA synthesis by binding to the beta subunit of RNA polymerase, encoded by 
the rpoB gene (Wehrli, 1983). Rifampicin is the ansamycin used for chemoprophylaxis of 
IMD. 
 
1.5 Antibiotic resistance  
 
 ABR amongst pathogenic bacteria is deemed one of the most serious public health threats 
of the 21st century (World Health Organization, 2014). Approximately 700,00 deaths per 
year are currently attributed to antimicrobial resistance, which without preventative 
action, is predicted to rise to 10 million deaths per year by 2050 (O’Neill, 2016).  Infectious 
diseases are becoming more difficult to treat due to increasing numbers of resistant 
bacteria and, with the lack of new antibiotic development, ABR is a worldwide health 





Modern medicine was revolutionised in 1928 following the discovery of the first natural 
antibiotic, penicillin, by Alexander Fleming (Fleming, 1929) . However, in 1940, resistance 
to penicillin was first reported, before its widespread use as a therapeutic agent (Abraham, 
E.P and Chain, 1940; Davies, J & Davies, 2010).  The widespread and improper use of 
antibiotics has accelerated the rate at which resistance has developed and spread. 
Exposure of bacteria to an array of antibiotics at varying concentrations over decades has 




Random mutations in bacterial DNA underpins evolution and development of ABR 
populations by natural selection (Woodford and Ellington, 2007). Acquisition of ABR genes 
from the environment in previously susceptible bacteria occurs via three main mechanisms 
of HGT (Table 1-6). Acquired resistance presents the greatest threat, due to increased 
dissemination of resistance-associated genes between bacteria, occurring at a faster rate 
than the emergence of resistance through random mutation and natural selection 
(Peterson and Kaur, 2018).  
 
Table 1-6: Mechanisms of horizontal gene transfer . 
HGT Mechanism Definition 
Transformation Direct uptake and incorporation of exogenous DNA 
Transduction phage transfer of DNA 
Conjugation plasmid-mediated transfer of DNA via cell-to-cell contact 
 
Pathogenic bacteria have developed resistance mechanisms against all classes of 
antibiotics produced so far (Peterson and Kaur, 2018). Mechanisms include the inactivation 
or modification of antibiotics, alteration of antibiotic’s target sites, limitation of antibiotic 
uptake and the active efflux of antibiotics from the bacterial cell. 
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1.5.3 Antibiotic resistance in Neisseria meningitidis  
 
Apart from the sulphonamides, which target the bacterial enzyme dihydropteroate 
synthase preventing folate biosynthesis, meningococci have remained largely susceptible 
to antibiotics used in IMD treatment. Over the last few decades, concerns over the 
susceptibility of meningococci to penicillin have been growing and resistance has been 
observed against other antibiotics used in treatment and prophylaxis. High levels of ABR in 
the closely related species N. gonorrhoeae, adds to concerns that N. meningitidis may also 
develop such levels of resistance, especially given the high capacity for genetic exchange 




Meningococci have acquired two resistant mechanisms to penicillin; i) modification of the 
chromosomally encoded penicillin binding protein 2 (PBP2) which results in a reduced 
affinity for the antibiotic and ii) antibiotic inactivation by the production of the enzyme, 
beta-lactamase.   
Beta-lactamase production among meningococci is rare. During the 1980s and 1990s, six 
cases were reported in South Africa, Canada and Spain (MICs of 2 to >256 mg/L (Dillon et 
al., 1983; Botha, 1988; Fontanals et al., 1989).  Plasmids sequenced were almost identical 
to those from N. gonorrhoeae, known to confer penicillin resistance in this species 
(Bäckman et al, 2000). Plasmid transfer between the two species has been demonstrated 
in-vitro; concerning given their occasional co-existence in the genitourinary tract (Ikeda et 
al., 1986).   
More recently, plasmid-negative beta-lactamase producing penicillin-resistant 
meningococcal isolates have been identified containing a chromosomally-encoded ROB-1-
type beta-lactamase gene (blaROB-1) (Deghmane et al., 2018; Tsang et al., 2019). A recent 
study in America, identified 33 meningococcal isolates from IMD cases from 2011-2020 
containing a blaROB-1 beta-lactamase gene which all belonged to ST-23 CC (McNamara et al., 
2020). BlaROB-1 is almost identical to a DNA fragment found in a plasmid (pB1000) of 
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Haemophilus influenzae (Tsang et al., 2019) known to cause resistance to beta-lactams in 
this and other species (San Millan et al., 2007, 2010).  
Non-beta-lactamase producing IMD isolates with reduced susceptibility to penicillin were 
first reported in 1985 (Van Esso et al., 1987).  Resulting from alterations in the structure of 
PBP2 (PubMLST locus NEIS1753), levels of resistance are lower than that of beta-lactamase 
producing meningococci and is now the most frequently observed mechanism associated 
with reduced susceptibility and resistance to penicillin among meningococci (Sáez-Nieto et 
al., 1992; Tzanakaki et al., 1992; Lopardo et al., 1993; Woods et al., 1994; du Plessis et al., 
2008; Hedberg et al., 2009; Gorla et al., 2018a; Vacca et al., 2018). 
Alterations in PBP2 conferring reduced susceptibility or resistance to penicillin are located 
in C-terminal half of the protein; a 402 bp fragment of NEIS1753, encoded by a gene 
fragment designated penA (Thulin et al., 2006). PenA alleles of penicillin-susceptible 
meningococcal isolates are uniform in DNA sequence compared to those of resistant 
isolates, which have a mosaic structure made up of sections that are the same as those 
found in susceptible isolates and sections that are highly variable (Spratt et al., 1992). HGT 
between meningococci and commensal Neisseria species e.g. Neisseria flavescens, which 
are intrinsically more resistant to penicillin (Zapun et al., 2016), has enabled susceptible 
meningococci to replace parts of their penA genes,  producing altered forms of PBP2 and 
reducing affinity to penicillin. 
Five amino acid substitutions (AASs) are usually always present in the penA gene of isolates 
with reduced susceptibility or resistance to penicillin; F504L, A510V, I515V, H541N, and 
I566V (Taha et al., 2007). Reduced penicillin susceptibility has also been observed among 
meningococcal isolates harbouring a penA gene with only four of these substitutions; 
penA327 (Zapun et al., 2016), with additional AASs I312M, V316T, N512Y and G545S. 
PenA327 has also been associated with reduced susceptibility to the 3GC, cefotaxime 





1.5.3.2 Cefotaxime and ceftriaxone  
 
Only one study has reported meningococcal resistance to 3GCs, with six MenA isolates from 
IMD cases in India displaying resistance to ceftriaxone (MICs = 0.25-8 mg/L) and cefotaxime 
(MICs = 0.5->32 mg/L) (Manchanda and Bhalla, 2006). No further characterisation of these 
isolates was performed despite requests from researchers who challenged the methods 
used for species confirmation (gram staining and latex agglutination only) (Nicolas, 2007).  
Recently, reduced susceptibility to cefotaxime has been reported among IMD isolates in 
France (n=25; MICs = 0.047-0.125 mg/L), which also displayed reduced susceptibility or 
resistance to penicillin (0.125-0.38 mg/L) (Deghmane et al., 2017). All isolates harboured 
penA327, proven to be responsible for reduced susceptibility to 3CGs in meningococci 
when transformed into a 3GC susceptible isolate.  
PenA327 has previously been identified among meningococcal isolates in men who have 
sex with men, and in patients with meningococcal urethritis (Taha et al., 2016; Deghmane 
et al., 2017). The allele is identical in sequence to an allele found among N. gonorrhoeae 
with increased resistance to 3GCs (PBP2 XXXIV) (Ohnishi et al., 2011), and suggestions have 
been made regarding meningococcal acquisition of the allele during co-colonisation in the 
genitourinary tract (Deghmane et al., 2017). An additional AAS in PBP2 XXXIV, A501P, 
which has been shown to further enhance levels of 3GC resistance among gonococci, has 
raised concerns regarding the selection of the same mutation among meningococci (Zapun 




Ciprofloxacin resistance is caused by mutations in the gyrA gene, altering the antibiotic 
target site to prevent binding.  
Since ciprofloxacin resistance was first observed among meningococci in 1992 (Tzanakaki 
et al., 1992), it has been infrequently reported, mainly associated with sporadic cases 
among diverse isolates (Shultz et al., 2000; Alcalá et al., 2004; Skoczyńska et al., 2008; 
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Lapadula et al., 2009; Zhu et al., 2014; Gorla et al., 2018b; Vacca et al., 2018). Ciprofloxacin 
resistance remains rare worldwide, except for China, where its prevalence has resulted in 
withdrawal of its use as a first line prophylactic agent (Zhu et al., 2014; Chen et al., 2015). 
A high proportion of ciprofloxacin-resistant meningococci in China belong to the ST-4821 
CC, a hyperinvasive strain in this country (Zhu et al., 2014, 2015). Other countries have also 
reported ciprofloxacin-resistant isolates belonging to this CC (Tsang et al., 2017; Kawasaki 
et al., 2018). In India, ciprofloxacin-resistant MenA strains emerged from an outbreak of 
IMD in 2005  (Singhal et al., 2007), and in the US, a cluster of three  MenB ciprofloxacin  
resistant  isolates belonging to ST-162 CC was reported in 2007-2008 (Wu et al., 2009). 
More recently, eleven ciprofloxacin-resistant isolates belonging to ST-23 CC were identified 
in the US, which were also penicillin-resistant due to the production of beta-lactamase 
owing to the BlaROB-1 gene (McNamara et al., 2020). In 2019, three cases of meningococcal 
disease caused by a ciprofloxacin-resistant NG ST-175 CC strain were identified in England, 
linked to travel to Mecca, KSA (Public Health England, 2019; Willerton et al., 2020).  
Ciprofloxacin resistance among meningococci is mainly attributed to point mutations in the 
quinolone-resistance-determining region of the gyrA gene. The most common among 
meningococci is a single AAS; T91I or D95N (Hong et al., 2013).  Other AASs in the gyrA gene 
of ciprofloxacin-resistant meningococci have been less frequently reported (A103A, I111V 
and V120I) (Tsang et al., 2017; Villalba et al., 2008).  
Mutations in the parC gene have been observed among ciprofloxacin-resistant 
meningococci, however always accompanied by gyrA AAS T91I  (Kawasaki et al., 2018; Chen 
et al., 2020). Chen and colleagues demonstrated that while mutations in ParC are not 
sufficient alone to confer ciprofloxacin resistance among meningococci, they result in 
enhanced levels of resistance when present in conjunction with altered gyrA genes (MICs 
0.5-1.0 mg/L) (Chen et al., 2020). 
It has been suggested that ciprofloxacin resistance-associated gyrA alleles originate from 
commensal Neisseria species, including Neisseria lactamica and Neisseria cinerea, 
highlighting the significance of HGT amongst Neisseria and its role in ABR among 





Meningococcal resistance to rifampicin results from single point mutations in the central 
region of the rpoB gene (Carter et al., 1994)  preventing binding of rifampicin to RNA 
polymerase (Hartmann et al., 1967).  
Resistance among meningococci is associated with AASs at amino acid (AA) position 552, 
with AASs at other positions also reported (542, 548 and 557) (Taha et al., 2010). 
Significantly different levels of rifampicin resistance (MICs 8-256 mg/L) have been observed 
among strains with the same rpoB mutations, suggesting that other factors may contribute 
to rifampicin resistance (Carter et al., 1994; Stefanelli et al., 2001; Taha et al., 2010). 
Mutations in the mtrR gene and its promoter region, which encode a transcription 
repressor of the mtrCDE efflux pump (Skoczynska et al., 2009) have been associated with 
high levels of rifampicin resistance among N. gonorrhoeae (Hagman et al., 1995). Whilst N. 
meningitidis isolates generally possess a functional mtrCDE efflux pump, its regulation and 
expression appears to differ from that of N. gonorrhoeae (Rouquette-Loughlin et al., 2004), 
with no evidence suggesting that such mutations confer resistance among N. meningitidis 
(Abadi et al., 1996; Skoczynska et al., 2009). 
Rifampicin resistance is rare among invasive meningococci, more frequently reported in 
isolates from secondary cases following the use of rifampicin for chemoprophylaxis (Berkey 
et al., 1988; Almog et al., 1994; Dawson et al., 1999; Rainbow et al., 2005; M. Taha et al., 
2006b). Reports of rifampicin resistance among IMD strains of index cases have however 
been reported (Stefanelli et al., 2001; Rainbow et al., 2005). Rifampicin resistance has been 
reported across diverse meningococcal isolates and lack of clonal expansion of resistant 
strains suggests mutations in rpoB may have major biological costs for meningococci (Taha 







1.6 Aims and objectives 
 
The PHE MRU has MIC and WGS data from all invasive IMD case isolates in E, W and NI 
from July 2010, however, this has yet to be reviewed collectively and systematically 
analysed.  The primary aims of this project were to:  
1) Provide a timely review of ABR among IMD isolates received at the MRU from 
epidemiological years 2010/11-2018/19. 
2) Investigate ciprofloxacin resistance amongst isolates of the ST-175 CC following an 
outbreak of meningococcal disease caused by ciprofloxacin-resistant ST-175 CC 
isolates in England, 2019.  
3) Investigate the observed increase of penicillin resistance among English serogroup 





















2 Materials and Methods 
Each of the methods described here have been performed personally for the generation of 
data included in this study. MIC and WGS data were obtained continuously by colleagues 
of the MRU, including myself, as isolates were received. All MIC and WGS data obtained 
prior to January 2018 were generated by other MRU colleagues. All PCR and sequencing 
data, the obtainment of genomic data, and phylogenetic analyses conducted in this study 
were performed solely by me.  
 
2.1 Isolate/genome panels  
 
2.1.1 Panel 1 
 
Panel 1 (n=4,122; Appendix 1) was used to investigate ABR among all IMD isolates received 
at the MRU and whose genomes were available on the MGL database (accessed 
29/06/2020), from E, W and NI from epidemiological years (July-June) 2010/2011 (n=500), 
2011/2012 (n=400), 2012/2013 (n=450), 2013/2014 (n=403), 2014/2015 (n=505), 
2015/2016 (n=521), 2016/2017 (n=501), 2017/2018 (n=488) and 2018/2019 (n=354) 
(section 3.1). These comprised blood culture (n=3,730), CSF (n=279), joint (n=101), brain 
(n=3), pericardium (n=3), bone marrow (n=2), pus/hip (n=2), spleen (n=1) and chest drain 
(n=1) isolates. 
 
2.1.2 Panel 2 
 
Panel 2 (n=79; Appendix 2) was used to investigate a recent cluster of IMD/conjunctivitis 
cases involving ciprofloxacin-resistant ST-175 CC isolates in England (section 3.2).  It 
comprised English invasive (n=2; 2015 & 2019) and conjunctivitis (n=2; 2019) ST-175 CC 
isolates/genomes received at the MRU, carriage genomes from two UK carriage studies 
(n=6; 2015-2018) (Carr et al., 2018; Bratcher et al., 2019), and ST-175 CC genomes of IMD 
isolates from South Africa (n=16; 2003-2017), Germany (n=4;2016-2019), Italy (n=3; 2014-
2018), Burkina Faso (n=2; 2012), Spain (n=2; 2002 & 2005), France (n=1; 2012), Sweden 
(n=1; 2016) and Togo (n=1; 2007). The panel also included genomes of carrier isolates or 
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isolates with unknown disease status from Ethiopia (n=10; 2014), Niger (n=3; 2003-2006), 
Norway (n=3; 2018-2019), Benin (n=2; 2006-2007), Burkina Faso (n=2; 2008-2010), Italy 
(n=2; 2016), Brazil (n=1; 2014), France (n=1; 2016), South Africa (n=1; 2003), Spain (n=1; 
2018), Togo (n=1; 2007) and USA (n=1; 2000). Other closely related genomes included in 
this panel with at least four ST-175 MLST alleles were unassigned to a clonal complex (n=9) 
or had incomplete MLST profiles (n=2).  
 
2.1.3 Panel 3 
 
Panel 3 (n=897; Appendix 1, n=879 and Appendix 3, n=18) was used to investigate penicillin 
resistance amongst English invasive serogroup W ST-11 CC isolates (section 3.3). It 
comprised English invasive serogroup W ST-11 CC isolates (n=867) and closely related 
isolates/genomes with at least four ST-11 MLST alleles (n=30) received at the MRU between 
July 2010 and August 2019. To investigate penicillin resistance among serogroup W ST-11 
CC isolates in a wider context, also included were invasive/carrier serogroup W ST-11 CC 
genomes from PubMLST closely related to English invasive PenR serogroup W ST-11 CC 
isolates/genomes including genomes from New Zealand (n=35; 2017-2018), Canada (n=22; 
2014-2019), Ireland (n=12; 2013-2019), Scotland (n=10; 2015-2020), Spain (n=10; 2017-
2020), Sweden (n=8; 2016-2019), The Netherlands (n=7; 2016-2019), Germany (n=6; 2018-
2019), France (n=4; 2016-2018), Wales (n=4; 2015-2019), Chile (n=2, unknown), Finland 
(n=2; 2015), Italy (n=2; unknown & 2014), Greece (n=1; 2017), Japan (n=1; 2017), Northern 
Ireland (n=1; 2016), Portugal (n=1; 2019), UK (n=1; unknown) and USA (n=1; 2009). 
 
2.2 Storage/culture of isolates 
 
All meningococcal cultures received at PHE’s MRU since July 2010 underwent routine 
receipt, culture, species confirmation, characterisation (including AST and WGS) and 
archiving.  
All manipulations of live cultures and suspensions were performed in a Class 1 safety 
cabinet within a category 2+ laboratory.  Fresh cultures of meningococcal isolates were 
prepared from cultures, submitted by diagnostic laboratories or archived cultures, on 
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Columbia blood agar (CBA) (Oxoid, UK). Archived cultures were stored on Microbank® 
beads (Prolab Diagnostics, Canada) or Microorganism Preservation System - Protect beads 
(Technical Service Consultants Ltd, Lancashire, UK) at -80°C.  Fresh cultures were incubated 
overnight (16-24 hours) at 37°C under 5% CO2. The following day, plates were checked for 
purity and subcultured to CBA where necessary.  
 
2.2.1 Streak plate for isolated colonies 
 
Using a 10 µL sterile loop (Sarstedt, Germany), the desired inoculum (diagnostic laboratory 
submitted, subculture or archived culture) was initially spread in a tight streak across the 
first quadrant of the agar plate. Using the same loop, streaks were then drawn from the 
preceding area into the next quadrant until the fourth quadrant was reached. A final streak 
was made downwards towards the centre of the plate in a zigzag motion. 
 
2.2.2 Lawns for antibiotic susceptibility testing 
 
Following overnight incubation of a streak plate (section 2.2.1), approximately five isolated 
colonies were selected using a sterile swab and inoculated in five millilitres of sterile water 
contained in a glass bijou (Oxoid, UK) to achieve a suspension turbidity of McFarland 
standard 0.5 (visually determined using McFarland standard set; 0.5-4.0). The swab was 
gently pressed against the inside wall of the bijou and then used to spread the inoculum 
over the entire surface of a Mueller Hinton agar plate supplemented with 5% horse blood 
and 20 mg/L β-nicotinamide adenine dinucleotide (Oxoid, UK; Isolates received after 9th 
May 2019) or Iso-sensitest blood agar supplemented with 5% (v/v) defibrinated horse 
blood and 20 mg/L NAD (Oxoid, UK; Isolates received prior to 9th May 2019). Spreading was 
repeated three to four times with the plate rotated 90° each time to ensure even 
distribution and full coverage. The plate was left to dry for five to ten minutes at room 




2.3 Antibiotic susceptibility testing 
 
Antibiotic susceptibility testing was performed using gradient diffusion methodology using 
Etest (bioMerieux UK Limited, UK) or MIC Evaluator (Oxoid, UK) strips coated with 
predefined gradients of antibiotics. For each isolate, MICs for both therapeutic (penicillin 
and cefotaxime) and prophylactic (rifampicin and ciprofloxacin) antibiotics were 
determined. 
A lawn was prepared (section 2.2.2) and the appropriate gradient diffusion strip was placed 
in the centre of the plate using sterile forceps in accordance with the manufacturer’s 
instructions.  The plate was incubated overnight (16-24 hours) at 37°C under 5% CO2.  
MIC values were recorded at half-dilutions for epidemiological purposes as opposed to 
doubling dilutions for clinical interpretation. MIC values were interpreted according to 
EUCAST guidelines (Table 1-4; EUCAST; v10.0; 2020-01-01) (European Committee on 
Antimicrobial Susceptibility Testing, 2019). 
 
2.3.1 Beta-lactamase testing 
 
Using sterile forceps, an Interlactam strip (MAST, UK) was placed in the centre of an empty 
petri dish. A drop of sterile water was added to each area of the strip using a sterile 
disposable pastette. Following overnight incubation of a steak plate (section 2.2.1), a loop 
full of the test culture was added to the appropriate test area on the Interlactam strip using 
a 10 µL sterile loop. Following the overnight incubation of streak plates of both negative 
(beta-lactamase negative N. meningitidis) and positive (beta-lactamase positive 
Haemophilus influenzae) control organisms, a loop full of each were added to the 
appropriate control areas of the Interlactam strip using a fresh 10 µL sterile loop. The strip 






2.4 DNA extraction 
 
For PCR and DNA sequencing, heated DNA extracts were prepared (section 2.4.1). DNA 
extraction from meningococcal isolates for WGS was performed using either the Wizard 
Genomic DNA Purification Kit (Promega, WI, USA) for up to 24 samples (section 2.4.2) or 
the MagMax DNA multi sample ultra-kit (Thermo Fisher Scientific, MA, USA) with the 
Kingfisher flex Purification System (Molecular Devices, CA, USA) for >24 samples (section 
2.4.3).  
 
2.4.1 Heated DNA extracts 
 
Following overnight incubation of a streak plate (section 2.2.1), 10-15 colonies were 
collected using a sterile swab and emulsified in two millilitres sterile saline contained in a 
glass bijou (Oxoid, UK). Two hundred and fifty microliters of the suspension were then 
transferred to a 1.5 mL microtube and heated at 100°C for 10-11 minutes. The microtube 
was then snap chilled at -20°C for five to six minutes and centrifuged at 12,000 g for five 
minutes. The supernatant was then collected using a sterile fine-tipped pastette, retained 
and stored at 4°C.  
 
2.4.2 Lawns for DNA extraction 
 
Lawns were prepared from archived cultures using a 10 µL sterile loop to obtain a single 
bead or loop full of frozen inoculum and spread in a ~5mm thick line across the centre of a 
CBA plate. The plate was rotated 90° and the inoculum was spread from top to bottom 






2.4.3 DNA extraction – Promega Wizard 
 
Using a sterile swab, eight full length sweeps of overnight growth (section 2.2.2) were 
suspended in 250 µL of saline (Oxoid, UK) to a turbidity ≥ McFarland 4 (visually determined 
using McFarland standard set; 0.5-4.0). Fifty microlitres of suspension was transferred to a 
1.5 mL microtube containing 550 µL nuclei lysis solution using a pipette and mixed 
thoroughly. The microtube was transferred to an 80°C heating block for five minutes and 
then cooled to RT for 10-11 minutes. Following a pulse spin (button released at 5000 rpm), 
three microlitres of RNase solution was added to the tube which was then inverted several 
times to mix. Following a pulse spin (button released at 5000 rpm) the microtube was 
incubated at 3°C for 15 minutes. Once cooled to RT, the tube was centrifuged using a pulse 
spin (button released at 5000 rpm) before 200 µL protein precipitation solution was added.  
The microtube was then vortexed for 20 seconds to mix. Following incubation in a cool box 
(-20°C cooling cartridge with 4°C aluminium block) for five minutes, the tube was vortexed 
for two seconds and centrifuged at 16,000 g for three minutes. The supernatant was 
discarded and 600 µL of 70% v/v ethanol added. The tube was inverted several times to 
mix and centrifuged at 16,000 g for two minutes. The supernatant was carefully removed 
leaving a DNA pellet for which, size/external sequence provider dependant, the 
appropriate volume of DNA rehydration solution was added to achieve a DNA 
concentration suitable for WGS (Figure 2-1).  
 
Figure 2-1: A guide of DNA rehydration solution volume versus DNA pellet size 
to achieve a DNA concntration suitable for genome sequence analysis . 
DNA pellet = green oval. White tube = 1.5 mL microtube. OGC = Oxford Genomics Centre. 








90 µL 150 µL 200 µL
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2.4.4 DNA extraction - Kingfisher flex purification system 
 
Using a sterile swab, eight full length sweeps of overnight growth (section 2.2.2) were 
suspended in 200 µL of saline (Oxoid, UK) to a turbidity ≥ McFarland 4 (visually determined 
using McFarland standard set; 0.5-4.0). 
Twenty-five microlitres of suspension were transferred to a microtube containing 200 µL 
proteinase K mix (8 µL of proteinase K and 192 µL of PK buffer) using a pipette and mixed 
thoroughly. The microtube was transferred to a 60°C water bath for 60-70 minutes before 
cooling at RT for 10-11 minutes. Following a pulse-spin (button released at 5000 rpm), 24 
µL of RNase solution (1.2% v/v RNase in molecular grade water) was added to the tube and 
vortexed at ~1800 rpm for approximately 10 seconds, inverting the tube twice throughout. 
Following a pulse spin (button released at 5000 rpm), 456 µL of lysis solution (200 µL multi-
sample lysis buffer, 16 µL DNA binding beads and 240 µL isopropanol [Sigma-Aldrich, UK]) 
was added and mixed gently but thoroughly until homogenous using the pipette. The lysate 
was then transferred to a well of a 96 deep well plate (Thermo Fisher Scientific, MA, USA) 
for loading onto the KingFisher Flex Purification System.  
Other plates used in the extraction (all 96 deep well plates) included an elution plate 
prepared by adding 150 µL AE elution buffer (Qiagen, Germany) or 75 µL of elution buffer 
1 and elution buffer 2 per well, wash plate 1 prepared by adding 150 µL of wash solution 1 
per well and wash plates 2 and 3, prepared by adding 150 µL of wash solution 2 per well.  
DNA extracts were transferred to a microamp optical 96 well reaction plate (Thermo Fisher 
Scientific, MA, USA) on a dynamag side skirted magnet (Thermo Fisher Scientific, MA, USA) 
for 15-20 minutes to remove residual beads. The extracts were then transferred using a 
multichannel pipette to a fresh microplate and sealed with microamp strip caps (Thermo 
Fisher Scientific, MA, USA).  
 
2.5 DNA Quantification 
 
DNA quantification was performed using the SptectraMax Quant AccuBlue HiRange dsDNA 
assay kit (Molecular Devices, CA, USA) with the SpectraMax M5e plate reader (Molecular 
35 
 
Devices, CA, USA) or using the Qubit dsDNA BR assay kit (Thermo Fisher Scientific, MA, USA) 




Standards and samples were pre-mixed as appropriate (vortex or gentle pipetting) and 
centrifuged using a pulse spin (~5000 rpm). Working solution 1 was prepared by diluting 
Accublue Hirange dye 1:100 in Accublue Hirange buffer. Working solution 2 was prepared 
by diluting Accublue Hirange enhancer 1:100 in working solution 1. Ten microlitres of each 
kit standard (0, 2, 6.25, 12.5, 25, 20, 100, 150, 200 ng/µL) was added to the wells of a 
Greiner black polystyrene flat-bottom 96 well microplate (Sigma-Aldrich, UK) in duplicate. 
Ten microlitres of each sample was transferred to the remaining wells. Two hundred 
microlitres of working solution 2 was added to active wells and gently mixed. The plate was 
sealed with microplate sealing tape (Thermo Fisher Scientific, MA, USA), wrapped in 
aluminium foil and incubated at RT for 5-10 minutes. The foil and seal were removed, and 
the plate was placed in the plate reader and fluorescence measured with excitation at 350 




Qubit solution was prepared by diluting dsDNA BR reagent 1:200 in Qubit dsDNA BR buffer 
in a suitable container (microtube or universal tube) as per number of samples. One 
hundred and ninety-five microlitre of Qubit solution was transferred into appropriately 
labelled 0.5 mL PCR tubes (Thermo Fisher Scientific, MA, USA) for the samples and 190 µL 
was transferred to labelled microtubes for the two standards (0, 100ng/µL). Five microlitres 
of each sample and 10 µL of each standard were added to the corresponding tubes and 
vortexed (~750 rpm for three seconds). The tubes containing the standards were inserted 
into the Qubit reader and concentrations recorded to generate a standard line. Each 
sample was then inserted, and the concentration of each sample recorded on completion 
of measurement.  
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2.6 Whole genome sequencing 
 
Extracts were sent to external sequence providers (The Sanger Institute, PHE Genomic 
Services or the Oxford Genomics Centre) for WGS on the Illumina HiSeq platform after 
adjusting to the required DNA concentration for the sequence provider (20 ng/µL, 6-100 
ng/µL, 30-50 ng/µL, respectively). Sequence data were then transferred to the Maiden 
laboratory at the University of Oxford for assembly and inclusion on the PubMLST Neisseria 
database and the Meningitis Research Foundation (MRF) Meningococcus Genome Library 
(MGL;  https://pubmlst.org/bigsdb?db=pubmlst_neisseria_mrfgenomes), a distinct project 
within the PubMLST Neisseria database.  
 
2.7 Obtaining genomic data 
 
2.7.1 Genomic data from MGL/PubMLST 
 
Genomic data for IMD isolates received at the MRU were accessed from the MGL. Genomic 
data for non-invasive meningococcal isolates received at the MRU and genomic data for 
meningococcal isolates from other countries were accessed from the PubMLST Neisseria 
database. Associated metadata (e.g. country, year, number of contigs per genome, total 
genome length and MICs where available) and genotypic data (e.g. allele IDs for PorA, 
NadA, nhba, fHbp variant, fHbp peptide and MLST data) were exported from the MGL 
database or PubMLST Neisseria database using the ‘export dataset’ function.  
 
2.7.2 BLAST searches  
 
BLAST searches were performed using the BLAST function on the PubMLST Neisseria 
database. The isolate ID and query sequence were pasted into the search box and the 
required number of hits and length of flanking sequence were selected. Sequences were 




2.7.3 Identifying genes broken between contigs 
 
Where genes were broken between different contigs, corresponding hits were exported in 
FASTA format for alignment with a reference sequence (section 2.7.4). Provided there was 
complete homology in the overlapping region, which was at least 10 bp in length, the 
sequences were trimmed, ligated and used in a sequence query (section 2.7.5). If there was 
a discrepancy in the overlapping region, or if it was less than 10 bp in length, PCR and 
Sanger sequencing were performed (section 2.8).  
 
2.7.4 Sequence alignments  
 
Multiple sequence alignments were performed using  BioEdit (Version 2.7.5.0, Hall, 1999) 
either manually by eye or using the ClustalW tool with default settings followed by manual 
adjustment. Alternatively, multiple sequence alignments or alignment of contiguous 
sequences were performed using the ‘align automatically’ feature of Sequencher (version 
4.7; Gene Codes Corporation, MI, USA). 
 
2.7.5 Sequence query  
 
To identify an allele ID, the query sequence was pasted into the query sequence tool on 
the PubMLST Neisseria database. If the search returned no exact match, the sequence was 
submitted to the database as a new allele (section 2.7.6). 
 
2.7.6 Sequence submission 
 
Sequences of new alleles were submitted to the PubMLST Neisseria database for 
verification and allele assignment by a database curator. The ‘submit alleles’ function and 
appropriate loci were selected and the FASTA sequence entered into the sequence box. 
New sequences arising from Sanger sequencing (section 2.8) were submitted along with 
generated raw AB1 files (section 2.8.2.4).  
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2.8 PCR and sequencing of penA 
 
Where isolates were missing allele IDs for penA genes and where BLAST searching failed to 




2.8.1.1 Primer Preparation 
 
Primers were received lyophilised (Eurofins Genomics, Germany) and reconstituted in 
molecular grade water to a master stock concentration of 100 µM as per the 
manufacturer’s datasheet. Working stocks (5 µM) were prepared by diluting master stocks 
1/20 in molecular grade water.  
 
2.8.1.2 PCR master mix preparation 
 
PCR master mix was prepared within a PCR cabinet in a clean room using the HotStar Taq 
DNA polymerase kit and dNTP mix (Qiagen, Germany). The reagents were added to a sterile 
universal tube (Table 2-1) and mixed thoroughly using a sterile pipette. Twenty-three 
microlitres of master mix was transferred to the wells of a MicroAmp optical 96-well 
reaction plate (Thermo Fisher Scientific, MA, USA). 
 
Table 2-1: PCR master mix reagents. 
Primer details 
PenA Forward primer  
(PenA1F)* 
5’-gttttcccagtcacgacgttgtaATCGAACAGGCGACGATGTC-3’ 
PenA Reverse primer 
(PenA1R)* 
5’-ttgtgagcggataacaatttcGATTAAGACGGTGTTTTGACGG-3’ 
Reagent volumes (µL per 1X reaction) 
10x PCR buffer 2.5 
Primer PenA1F (5 µM) 2.5 
Primer PenA1R (5 µM) 2.5 
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dNTPs (10 mM) 0.5 
Taq polymerase (5 units/µL) 0.125 
Molecular water 14.125 
MgCl₂ (25 mM) 0.8 
Total 23.05 
Volumes of mastermix reagents used in the penA PCR assay. *Universal forward/reverse 
sequences (lowercase) added as adapters and used as sequencing primers as previously 
described by Taha et al. (Taha et al., 2007). 
 
2.8.1.3 Addition of DNA extracts and reaction 
 
DNA extracts (section 2.4.1) were spun using a pulse spin (button released at 5000 rpm). 
One microlitre of each extract was added to the corresponding wells of the PCR reaction 
plate containing the master mix using a sterile pipette.  Microamp cap strips were used to 
seal the plate which was then transferred to a thermal cycler and run under the conditions 
listed in Table 2-2.   
 
Table 2-2: PCR thermal cycler conditions. 
Stage Temperature (°C) Time  
Taq activation 95 15 minutes 
Denaturation  
x35 cycles 
95 30 seconds 
Annealing  59 30 seconds 
Extension  72 130 seconds 
Final extension 72 7 minutes 
Holding 4 ∞ 






2.8.1.4 Visualisation of PCR products 
 
Gel electrophoresis was performed to establish the presence of amplified products. A 2% 
agarose gel was prepared by adding three grams of agarose (Sigma-Aldrich, UK) to 150 mL 
1x Tris-Borate EDTA buffer (Sigma-Aldrich, UK) and heating in a microwave until fully 
dissolved. Fifteen microlitres of SYBR Safe DNA stain (Thermo Fisher Scientific, MA, USA) 
was then added and mixed. The dissolved agar was poured into a casting tray with gel 
combs and left to set at RT. The gel was transferred to a gel tank and covered with 1x TBE 
buffer.   
Five microlitres of gel loading buffer (30% v/v glycerol solution with a small amount of 
Bromophenol blue [Sigma-Aldrich, UK]) was mixed with five microlitres of each PCR product 
and loaded into the wells of the agarose gel using a sterile pipette. Ten microlitres of 
ExACTGene low range plus DNA ladder (Thermo Fisher Scientific, MA, USA) was loaded per 
row. The gel was run at 130 volts for 15-20 minutes. The gel was visualised using the G:BOX 
transilluminator (Syngene, MD, USA).  
 
2.8.1.5 Clean-up of PCR products 
 
Two microlitres of Exo-SAP-IT (Thermo Fisher Scientific, MA, USA) were added to the wells 
of a MicroAmp fast optical 96-well reaction plate (Thermo Fisher Scientific, MA, USA). Five 
microlitres of each PCR product was transferred to the wells using a sterile pipette, mixed 
thoroughly and sealed using MicroAmp cap strips. The plate was transferred to an ABI 9800 
Fast thermal cycler (Applied Biosystems, MA, USA) and heated at 37°C for 15 minutes then 
at 80°C for 15 minutes. The plate was removed and 21 µL of molecular grade water was 






2.8.2 Sanger Sequencing  
 
2.8.2.1 Sequencing primer preparation 
 
Sequencing primers were prepared as detailed in section 2.8.1.1. 
 
2.8.2.2 Sequencing master mix preparation  
 
Sequencing master mix was prepared per primer using the BigDye terminator v3.1 cycle 
sequencing kit (Thermo Fisher Scientific, MA, USA). The reagents were added to sterile 
1.5 mL microtubes (Table 2-3).  
 
Table 2-3:  Sequencing master mix reagents. 
Reagent Volume (µL per 1x reaction per primer) 
Molecular water 6.09 
Sequencing primer 5 µm (UniF/UniR)* 0.66 
ABI 5x sequencing buffer 1.75 
ABI bigdye v3.1 0.5 
Total 9 
Volumes of sequencing reagents used in the penA PCR and sequencing assay. * As 
described by Taha et al. (Taha et al., 2007) 
 
Nine microlitres of master mix was added to a Microamp 96 well plate. One microlitre of 
each cleaned up PCR product was added to the master mix and transferred to a thermal 
cycler and run under appropriate conditions (Table 2-4). 
 
Table 2-4: Sequencing reaction thermal cycler conditions . 
Stage Temperature (°C) Time  





95 10 seconds 
Annealing  55 5 seconds 
Extension  60 4 minutes 
Holding 4 ∞ 
Sequencing reaction thermal cycler conditions of the penA sequencing assy.  
 
2.8.2.3 Clean-up of sequencing products 
 
A solution of 4% sodium acetate (v/v) buffer in ethanol was prepared by adding 1.6 µL of 
sodium acetate buffer (Sigma-Aldrich, UK) to 38.4 µL of molecular grade absolute ethanol 
(Sigma-Aldrich, UK) per active well of the sequencing plate. The plate was sealed with a foil 
lid (Beckman Coulter, IN, USA), gently vortexed and centrifuged at 2000 g for 20 minutes. 
The seal was removed, and the plate was inverted onto tissue. The plate was then 
centrifuged (plate wells facing upwards) at 150 g for one minute to remove excess 
moisture. Two hundred microlitres of 70% v/v ethanol was added to each well and both 
centrifugation cycles were repeated.  Fifteen microlitres of Hidi formamide (Thermo Fisher 
Scientific, MA, USA) was added to each well.   
 
2.8.2.4 Sequencing and analysis 
 
Plates of cleaned up sequencing products/HiDi formamide were loaded onto an ABI 3130xl 
genetic analyser and underwent capillary electrophoresis with POP-7 polymer separation 
matrix (Thermo Fisher Scientific, MA, USA).  Electropherogram traces for each primer were 
saved as AB1 files and imported into Sequencher. For each sample, traces for each primer 
were assembled into a contig using the ‘assemble automatically’ option. The start and stop 
codon of the gene were located and all upstream/downstream sequence was deleted from 
the contig. Electropherograms were visually inspected for any erroneous base calls/gaps. 
The final consensus sequence was exported and queried on the PubMLST Neisseria 




2.9 Phylogenetic analyses 
 
2.9.1 Core genome comparisons 
 
Genomes were compared in terms of 1605 core genes (N. meningitidis cgMLST c1.0) using 
the PubMLST genome comparator tool (Bratcher et al., 2014).  
 
2.9.1.1 Refining genome comparator tool variable loci output 
 
Where two allele IDs were present for a single locus, the DNA sequences of both alleles 
were aligned in BioEdit (section 2.7.4) and compared to determine if genuine differences 
between the sequences existed. Where they did not, e.g. where the two alleles comprised 
a single allele and a fragment thereof, the comparison was repeated excluding the affected 
locus. Where genuine differences did exist, a BLAST search of the sequences was performed 
against a complete circular genome e.g. MC58 (section 2.7.2) to identify potential 
paralogues/pseudogenes that may give erroneous results in the comparator. Comparisons 
were then rerun excluding the affected loci.  
 
2.9.2 Neighbor-Net phylogenetic networks  
 
Following core genome comparisons (section 2.9.1), the resulting distance matrices were 
exported in Nexus format and imported into SplitsTree4 (version 4.13.1)  for visualisation 
as Neighbor-Net networks (Huson, 1998). 
 
2.9.3 Neighbor joining trees  
 
Multiple nucleotide/amino acid alignments (section 2.7.4) were imported into MEGA4 
(Tamura et al., 2007) and a phylogenetic tree was generated by using the neighbor-joining 
method and the ‘number of differences’ model. The tree was annotated by adding labels 
to the alleles of interest. In order to annotate clades by species, the distribution of the 
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respective alleles was determined by using the ‘search’ and ‘allele designations/scheme 


























3.1 Antibiotic resistance among N. meningitidis isolates in England, Wales and 
Northern Ireland (2010/11-2018/19) 
 
Objective: To review ABR among IMD isolates received at the MRU from epidemiological 
years 2010/11-2018/19.  
 
3.1.1 Serogroup and clonal complex distribution 
 
From July 2010 – June 2019, 4,122 IMD isolates received at the MRU from culture-
confirmed cases whose genomes were available and downloaded from MGL (accessed 
29/06/2020; Appendix 1). Out of the 4,122 isolates, 53% (n=2,178) were serogroup B, 24% 
(n=1,004) were serogroup W, 16% were serogroup Y (n=651) and 6% were serogroup C 
(n=237). The remaining isolates (1%) were NG (n=34), serogroup W/Y (n=11), serogroup E 
(n=4), serogroup X (n=2) and serogroup A (n=1).  
The majority of IMD isolates received at the MRU from 2010/11-2018/19 (n=3,449; 84%) 
belonged to eight main clonal complexes (ST-11 CC, n=1,101; ST-41/44 CC, n=719; ST-23 
CC, n=549; ST-269 CC, n=507; ST-213 CC, n=238; ST-32 CC, n=184; ST-461 CC, n=76 and ST-
22 CC, n=75). The remaining isolates belonged to less prevalent CCs (n=290), were 
unassigned to a CC (n=233) or had incomplete MLST profiles (n=150).  
 
3.1.2 Penicillin susceptibility 
 
3.1.2.1 MIC distribution 
 
Of the 4,122 IMD isolates, 63% (n=2,591) were penicillin-susceptible, standard exposure 
(PenS; MICs 0.004-0.064 mg/L), 34% (n=1,418) were penicillin-susceptible, increased 
exposure (PenI; MICs 0.094-0.25 mg/L) and 3% (n=113) were penicillin-resistant (PenR; 
MICs 0.38-0.75 mg/L). The lowest proportion of PenS isolates were received in 
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epidemiological years 2015/16 and 2018/19 (52%) and the highest proportion of PenR 
isolates were received in 2018/19 (7%) (Table 3-1). 
 
Table 3-1: Distribution of penicillin susceptibility among IMD isolates in 
England, Wales and Northern Ireland from 2010/11-2018/19. 
 


















































































































































































PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines. The annual 
percentage of PenS, I and R isolates is also displayed.  
 
Penicillin MIC values of all IMD isolates ranged from 0.004 - 0.75 mg/L (Figure 3-1). Isolates 
with MICs of 0.047 mg/L were most common (n= 1,093; 27%). The MIC50 and the MIC90, 
defined as the lowest concentration of the antibiotic required to inhibit the growth of 50% 
and 90% of organisms, respectively, were 0.064 mg/L and 0.19 mg/L, respectively. In 







Figure 3-1: Penicillin MICs among invasive meningococcal disease isolates in 
England, Wales and Northern Ireland from 2010/11-2018/19. 
 
The green bars represent PenS isolates, blue bars represent PenI isolates and red bars 
represent PenR isolates. PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-
susceptible, increased exposure; PenR = Penicillin-resistant according to EUCAST 












Figure 3-2: Annual proportion of penicillin MICs among IMD isolates in England, 
Wales and Northern Ireland from 2010/11-2018/19. 
 
Percentage of IMD isolates with each MIC value per epidemiological year (2010/11; n=500, 
2011/12; n=400, 2012/13; n=450, 2013/14; n=403, 2014/15; n=505, 2015/16; n=521,  
2016/17; n=501, 2017/18; n=488, 2019/19; n=354). 
 
3.1.2.2 PenA allele distribution 
 
The 402 bp penA fragment of the NEIS1753 PBP2 gene, corresponding to AA residues 441-
575, was obtained for the 4,122 IMD isolates received at the MRU from 2010/11-2018/19. 
One hundred and thirty-three penA alleles were identified, with frequencies of isolates 
harbouring these alleles varying from 1 to 1,549. The most prevalent penA alleles (penA1, 
penA2, penA3, penA5, penA7, penA9, penA14, penA22, penA27, penA34 and penA52) found 
among 89% of isolates, are displayed in Figure 3-3 with the corresponding distribution of 
penicillin susceptibility. PenA1 was the most prevalent (n=1,549; 38%) followed by penA22 
(n=571; 14%). Isolates harbouring penA1 and penA22 were PenS (86% and 83%, 
respectively) and PenI (14% and 17%, respectively). Among the most prevalent alleles, the 
highest proportion of PenR isolates were those with PenA9, where 30% of isolates with 
penA9 were PenR.  PenA alleles 7, 14 and 52 were also found among PenR isolates. The 
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highest proportion of PenI isolates were those with PenA7 and penA52 (95%) followed by 
those with penA14 (93%). 
Isolates harbouring penA1 increased in number from 2011/12 to 2016/17, decreasing in 
subsequent years (Figure 3-4). A decrease in the number of isolates harbouring penA3 and 
penA27, mainly associated with PenS isolates, was observed over time. The number of 
isolates harbouring penA7, penA14 and penA52 (associated with mainly PenI isolates), 
remained stable annually. 
 
Figure 3-3: Penicillin susceptibility among IMD isolates with the most prevalent 
penA alleles in England, Wales and Northern Ireland from 2010/11-2018/19. 
 
PenA alleles observed among n=4,122 IMD isolates. PenS = Penicillin-susceptible, standard 
exposure; PenI = Penicillin-susceptible, increased exposure; PenR = Penicillin-resistant 






Figure 3-4: PenA alleles among IMD isolates in England, Wales and Northern 
Ireland and the distribution of penicillin susceptibility  from 2010/11-2018/19. 
 
PenA alleles among n=4,122 IMD isolates.  PenS = Penicillin-susceptible, standard exposure; 





































































































































































Thirty-one penA alleles were identified among the 133 PenR IMD isolates. These are listed 
in Table 3-2, along with other penA alleles (n=19) identified among PenI isolates 
represented by four or more isolates. The geometric mean MIC, MIC50 and MIC90 of 
penicillin were determined for the isolates with each of these alleles. Twenty-eight out of 
the 31 penA alleles among the PenR IMD isolates harboured all five of the AASs associated 
with conferring reduced susceptibility or resistance to penicillin (F504L, A510V, I515V, 
H541N, and I566V; Appendix 4). Three penA alleles (penA171, penA209, and penA327) did 
not have all five of these AASs. PenA327 contained four (F504L, A510V, I515V, H541N), 
penA209 contained three (F504L, A510V, I515V) whilst penA171 contained none. Further 























Table 3-2: PenA alleles among PenR and PenI IMD isolates in England, Wales 
and Northern Ireland from 2010/11-2018/19. 
 
Alleles among n=3,981 IMD isolates. Alleles among PenI IMD isolates represented by 4+ 
isolates only. PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, 
increased exposure; PenR = Penicillin-resistant according to EUCAST guidelines. MIC50 and 



















associated amino acid 
alterations
1 1549 1327 222 0 0.004-0.25 0.047 0.094 0
2 84 61 23 0 0.016-0.25 0.064 0.125 0
3 364 259 105 0 0.047-0.25 0.064 0.094 0
4 13 11 2 0 0.016-0.094 0.047 0.094 0
5 73 66 7 0 0.012-0.19 0.047 0.064 0
7 257 7 243 7 0.064-0.38 0.190 0.250 5
9 86 1 59 26 0.047-0.75 0.250 0.380 5
10 5 0 2 3 0.25-0.38 5
11 1 0 0 1 0.5 5
12 16 0 14 2 0.125-0.5 0.190 0.380 5
13 7 0 5 2 0.125-0.38 5
14 308 11 285 12 0.047-0.5 0.190 0.250 5
16 9 8 1 0 0.023-0.094 0
19 22 1 18 3 0.047-0.38 0.190 0.380 5
20 6 0 5 1 0.125-0.5 5
21 3 0 1 2 0.19-0.38 5
22 571 473 98 0 0.012-0.19 0.064 0.094 0
25 3 0 2 1 0.125-0.38 5
27 196 188 8 0 0.008-0.125 0.047 0.064 0
33 43 0 27 16 0.094-0.75 0.250 0.500 5
34 122 105 17 0 0.012-0.19 0.047 0.094 0
42 11 0 10 1 0.125-0.38 0.190 0.250 5
52 60 1 57 2 0.064-0.38 0.190 0.250 5
54 1 0 0 1 0.38 5
62 5 3 2 0 0.032-0.094 0
66 5 0 5 0 0.094-0.25 5
83 4 2 2 0 0.047-0.125 0
90 5 0 5 0 0.125-0.19 5
91 4 0 4 0 0.125-0.19 5
110 2 0 1 1 0.125-0.38 5
119 4 1 3 0 0.032-0.125 0
157 15 14 1 0 0.032-0.094 0.047 0.064 0
171 1 0 0 1 0.38 0
179 1 0 0 1 0.38 5
209 1 0 0 1 0.5 3
238 5 0 5 0 0.094-0.19 5
248 46 1 35 10 0.047-0.38 0.250 0.380 5
295 6 0 3 3 0.25-0.5 5
327 5 1 3 1 0.047-0.38 4
331 1 0 0 1 0.5 5
342 4 2 2 0 0.047-0.094 0
348 16 2 11 3 0.047-0.38 0.125 0.380 5
371 5 0 4 1 0.125-0.38 5
386 10 1 9 0 0.047-0.125 0.125 0.125 5
414 8 0 7 1 0.125-0.38 5
419 1 0 0 1 0.5 5
420 8 0 8 0 0.125-0.25 5
435 1 0 0 1 0.38 5
540 6 0 1 5 0.25-0.38 5
593 1 0 0 1 0.38 5
921 1 0 0 1 0.38 5
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3.1.2.3 Serogroup distribution 
 
3.1.2.3.1 Serogroup B 
 
Serogroup B IMD isolates (n=2,178) were PenS (n=1203; 55%), PenI (n=911; 42%) and PenR 
(n=64; 3%). The number of serogroup B isolates decreased over the time period, from the 
highest in 2010/11 (n=382) to the lowest in 2018/19 (n=157) (Figure 3-5). As the number 
of serogroup B isolates decreased, so did the proportion of serogroup B PenS isolates, from 
67% in 2010/11 to 38% in 2018/19. The number and proportion of PenI isolates has 
increased gradually over time from 32% in 2010/11 to 54-55% in 2017/18 - 2018/19. The 
highest annual proportions of serogroup B PenR isolates were in 2015/16 (8%) and 2018/19 
(8%).  
 
Figure 3-5: Annual distribution of penicillin susceptiblity among serogroup B 
IMD isolates in England, Wales and Northern Ireland from 2010/11-2018/19. 
 
n=2,178 serogroup B isolates. PenS = Penicillin-susceptible, standard exposure; PenI = 
Penicillin-susceptible, increased exposure; PenR = Penicillin-resistant according to EUCAST 
guidelines.   
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3.1.2.3.2 Serogroup C  
 
Serogroup C IMD isolates (n=237) were PenS (n=125; 53%), PenI (n=99; 42%) and PenR 
(n=13; 5%). Overall, an increase was observed in the number of serogroup C isolates over 
the time period, from 13 in 2010/11 to 35 in 2018/19 (Figure 3-6). The highest proportion 
of serogroup C PenS isolates was observed in 2010/11 (92%) and the lowest was observed 
in 2015/16 (28%). The highest annual proportion of PenI (50%) and PenR isolates (22 %) 
was observed in 2015/16. The distribution of PenS, PenI and PenR serogroup C isolates 
varied year by year.  
 
Figure 3-6: Annual distribution of penicillin susceptibility among serogroup C 
IMD isolates in England, Wales and Northern Ireland from 2010/11-2018/19. 
 
n=237 serogroup C isolates. PenS = Penicillin-susceptible, standard exposure; PenI = 






3.1.2.3.3 Serogroup W 
 
Serogroup W IMD isolates (n=1,004) were PenS (n=765; 76%), PenI (n=214; 21%) and PenR 
(n=25; 3%). The number of serogroup W isolates increased annually from 2010/11 (n=24), 
peaked in 2016/17 (n=199) and fell annually to 2018/19 (n=103) (Figure 3-7). Overall, as 
the number of serogroup W isolates increased over time, so did the number and proportion 
of serogroup W PenS isolates. An annual increase in the proportion of PenR serogroup W 
isolates from 2015/16 (1%) to 2018/19 (8%) was observed.  
 
Figure 3-7: Annual distribution of penicillin susceptibility among serogroup W 
IMD isolates in England, Wales and Northern Ireland from 2010/11-2018/19. 
 
n=1,004 serogroup W IMD isolates. PenS = Penicillin-susceptible, standard exposure; PenI 






3.1.2.3.4 Serogroup Y 
 
Six hundred and fifty-one serogroup Y isolates were received from 2010/11-2018/9 (16%). 
Seventy-three percent (n=474) were PenS, 26% were PenI (n=168) and 1% were PenR (n=9). 
The annual number of serogroup Y isolates remained relatively stable over the time period, 
as did the number and proportion of PenS isolates (Figure 3-8). The highest proportion of 
PenI serogroup Y isolates (41%) was in 2015/16. In 2018/19, the highest proportion of 
serogroup Y PenR isolates was observed (4%).  
 
Figure 3-8: Annual distribution of penicillin susceptibly among serogroup Y IMD 
isolates in England, Wales and Northern Ireland from 2010/11-2018/19. 
 
n=651 serogroup Y IMD isolates. PenS = Penicillin-susceptible, standard exposure; PenI = 







3.1.2.3.5 Serogroup distribution among the penicillin-resistant IMD isolates 
 
Out of the 113 PenR isolates received at the MRU from 2010/11-2018/19, 64 were 
serogroup B, 25 were serogroup W, 13 were serogroup C, nine were serogroup Y, one was 
serogroup W/Y and one was NG.  
 




The most prevalent CC was the ST-11 CC (n=1,101, 27%) followed by the ST-41/44 CC 
(n=720, 17%) (Figure 3-9). The proportion of PenS isolates among these two CCs were 76% 
and 54%, respectively. The ST-461 CC had the highest proportion of PenR isolates (21%) 
and had the lowest proportion of PenS isolates (12%). All PenR ST-461 CC isolates 
harboured penA33 as did 47% of PenI ST-461 CC isolates. The CC with the second highest 













Figure 3-9: Distribution of penicillin  susceptibility among IMD isolates in the 
most prevalent clonal complexes in England, Wales and Northern Ireland from 
2010/11-2018/19. 
 
Clonal complexes of n=4,122 IMD isolates and distribution of PenS, I and R isolates. PenS = 
Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased exposure; 
PenR = Penicillin-resistant according to EUCAST guidelines.  
 
3.1.2.4.2 Among the penicillin-resistant IMD isolates 
 
Out of the 113 PenR isolates received at the MRU from 2010/11–2018/19, 36 belonged to 
ST-11 CC, 16 belonged to ST-461 CC, 11 belonged to ST-32 CC, nine belonged to ST-41/44 
CC, seven belonged to ST-269 CC, six belonged to ST-23 CC, five belonged to ST-213 CC, four 
belonged to ST-162 CC, three belonged to ST-22 CC, two belonged to ST-53 CC and one 
belonged to ST-4821 CC, ST-174 CC and ST-167 CC. Eight PenR isolates were unassigned to 





3.1.2.4.3 The ST-11 clonal complex 
 
Ninety-seven percent of ST-11 CC isolates were serogroup W or serogroup C (81% and 16%, 
respectively).  Overall, serogroup C ST-11 CC isolates had greater proportions of PenI and 
PenR isolates compared with serogroup W ST-11 CC isolates (Figure 3-10). Since 2015/16, 
the annual proportion of PenR serogroup W ST-11 isolates increased from 1% in 2015/16 
to 8% in 2018/19. An investigation into this increase is detailed in section 3.3.  
 
Figure 3-10: Distribution of penicillin susceptibility among Serogroup C and W 
ST-11 clonal complex IMD isolates in England, Wales and Northern Ireland from 
2010/11-2018/19. 
PenS = Penicillin -susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines. 
Serogroup C ST-11 clonal complex (n=181)
Serogroup W ST-11 clonal complex (n=897)
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The most prevalent allele among serogroup C and W ST-11 CC isolates was penA1 (Figure 
3-11), found among 57% of serogroup C ST-11 CC isolates and 94 % of serogroup W ST-11 
CC isolates. The number of serogroup C ST-11 CC isolates harbouring penA1 increased 
annually from 2010/11, except for in 2018/19. PenA248 was harboured by 28% of 
serogroup C ST-11 CC isolates. The annual number of serogroup C ST-11 CC isolates with 
penA248 remained relatively stable and was associated mainly with PenI and PenR isolates. 
The number of serogroup W ST-11 CC isolates harbouring penA1 increased from 2010/11 
before decreasing in 2017/18. PenA9 was harboured by 3% of serogroup W ST-11 CC 
isolates. The number of PenR isolates harbouring penA9 increased over time, from one 
























Figure 3-11: Distribution of penicillin susceptibility among serogroup C and W 
ST-11 clonal compelx IMD isolates with the corresponding most prevalent penA 
alleles in England, Wales and Northern Ireland from 2010/11-2018/19. 
 
 
PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines.  
 
Serogroup C ST-11 clonal complex (n=181)
Serogroup W ST-11 clonal complex (n=897)
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3.1.2.4.4 ST-41/44 clonal complex 
 
The number of ST-41/44 CC isolates received at the MRU decreased over the time period, 
from 138 in 2010/11 to 59 in 2018/19 (Figure 3-12). As the number of isolates decreased, 
so did the number and proportion of PenS ST-41/41 CC isolates. The highest proportion of 
PenS ST-41/44 CC isolates was in 2010/11 (n=89; 64.5%), the lowest in 2018/19 (n=16, 
27%). Most ST-41/44 CC isolates were serogroup B (n=707, 98%). The most prevalent penA 
alleles found among serogroup B ST-41/44 isolates were penA1 (48%), penA7 (30%) and 
penA14 (7%). Overall, the annual number of serogroup B ST-44/44 CC isolates with penA1 
(mainly PenS) decreased over time whilst isolates with penA7 and penA14 (mainly PenI) 
remained stable (Figure 3-13). The decrease in the number of serogroup B ST-41/44 C 
isolates with penA1 over time did not appear to be associated with a particular lineage of 
this clonal complex (Figure 3-14).  
 
Figure 3-12: Annual distribution of penicil lin susceptibility among serogroup B 
ST-41/44 clonal complex IMD isolates in England, Wales and Northern Ireland 
from 2010/11-2018/19. 
n=719 ST-41/44 CC IMD isolates. PenS = Penicillin-susceptible, standard exposure; PenI = 




Figure 3-13: Distribution of penicillin susceptbility among serogroup B ST-
41/44 clonal complex isolates with the corresponding most prevalent penA  
alleles in England, Wales and Northern Ireland from 2010/11-2018/19. 
 
 
n=707 serogroup B ST-41/44 CC IMD isolates. PenS = Penicillin-susceptible, standard 
exposure; PenI = Penicillin-susceptible, increased exposure; PenR = Penicillin-resistant 
















Figure 3-14: Annual distribution of serogroup B ST-41/44 CC IMD isolates from 
E,W and NI harbouring penA1 among all ST-41/44 CC IMD isolates from E,W and 
NI 2011/11-2018/19. 
Core genome comparison of 1605 core genome loci among ST 41-44 clonal complex IMD 
isolates from E, W and NI. Genomes split into two groups: a) = ST-41/44 clonal complex 
genomes from 2010/11-2013/14 (n=394), b) = ST-41/44 clonal complex genomes from 
2014/15-2018/19 (n=325). MenB = meningococcal serogroup B. The number of variable 














3.1.2.4.5 The ST-269 clonal complex 
 
Twelve percent of all IMD isolates received from 2010/11-2018/19 belonged to ST-269 CC 
(n=507). The number of ST-269 CC isolates decreased over time, along with the number 
and proportion of PenS ST-269 CC isolates (Figure 3-15). The annual number of PenI ST-269 
CC isolates remained relatively stable.  
 
Figure 3-15: Annual distribution of penicillin susceptibility among ST-269 clonal 
complex IMD isolates in England, Wales and Northern Ireland from 2010/11-
2018/19. 
 
n=507 ST-269 clonal complex IMD isolates. PenI = Penicillin-susceptible, increased 






ST-269 CC comprised isolates of two main clusters: ST-269 and ST-275 clusters (Appendix 
5). Fifty-five percent of ST-269 CC isolates belonged to the ST-275 cluster (n=279) and 44% 
belonged to the ST-269 cluster (n=223). One percent of ST-269 CC isolates did not fall into 
either cluster. PenS isolates in both clusters decreased annually (Figure 3-16). The ST-269 
cluster comprised mainly PenS isolates, whilst PenI isolates were more prevalent among 
the ST-275 cluster. Most ST-269 CC isolates were serogroup B, comprising 96% and 99% of 
ST-269 and ST-275 cluster isolates, respectively. PenA27 was the most prevalent among 
serogroup B ST-269 cluster isolates, harboured by 85% of isolates. An overall decrease of 
serogroup B ST-269 cluster isolates with penA27 was observed over time (Figure 3-17). 
PenA3 and penA14 were the most prevalent alleles among serogroup B ST-275 cluster 
isolates, harboured by 57% and 30% of isolates, respectively. A decrease was observed in 
PenS ST-275 cluster isolates with penA3 over the time. Overall, the annual number of PenI 
ST-275 cluster isolates with penA14 remained relatively stable.  
The decrease over time in the number of serogroup B ST-269 cluster isolates with penA27 
and the number of serogroup B ST-275 cluster isolates with penA3 did not appear to be 

















Figure 3-16: Annual distribution of penicillin susceptibility among ST-269 and 
ST-275 cluster isolates of ST-269 clonal complex in England, Wales and 
Northern Ireland from 2010/11-2018/19. 
 
PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines.  
ST-269 cluster isolates (n=223)
ST-275 cluster isolates (n=279)
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Figure 3-17: Distribution of penicillin susceptibility among serogroup B ST-269 
and ST-275 cluster isolates of ST-269 clonal complex with the corresponding 




PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines.  
Serogroup B ST-269 cluster isolates (n=214)
Serogroup B ST-275 cluster isolates (n=278)
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Figure 3-18: Annual distribution of serogroup B ST-269 and ST-275 cluster IMD 
isolates from E,W and NI 2011/11-2018/19 harbouring penA27 and penA3, 
respectively.  
 
Core genome comparisons of 1605 core genome loci among ST 269 cluster (a) and ST-275 
cluster (b) IMD isolates from E, W and NI. MenB = meningococcal serogroup B. The number 
of variable loci among the 1605 that were compared is represented by the scale bars.  
a) ST-269 cluster (n=223)





















3.1.2.4.6 The ST-32 clonal complex 
 
Over the last four years (2015/16-2018/19), an increase was observed in the annual 
proportion of PenR isolates among ST-32 CC (Figure 3-19), with the highest proportion of 
PenR isolates in 2018/19 (16%). The annual proportion of PenI isolates has remained 
relatively stable. The number and proportion of PenS isolates decreased over time. Most 
ST-32 CC isolates were serogroup B (n=180; 98%). The most prevalent penA alleles among 
serogroup B ST-32 CC isolates were alleles 3, 9 and 52 (Figure 3-20). The number of PenS 
isolates with penA3 decreased over the time. An increase in PenR isolates with penA9 over 
the last four years was observed. 
 
Figure 3-19: Annual distribution of penicillin susceptibility among ST-32 clonal 
complex IMD isolates in England, Wales and Northern Ireland from 2010/11-
2018/19. 
 
n=184 ST-32 CC IMD isolates. PenS = Penicillin-susceptible, standard exposure; PenI = 




Figure 3-20: Annual distribution of penicillin susceptibility among serogroup B 
ST-32 clonal complex IMD isolates with the corresponding most prevalent penA 




n=180 serogroup B ST-32 clonal complex IMD isolates. PenS = Penicillin-susceptible, 
standard exposure; PenI = Penicillin-susceptible, increased exposure; PenR = Penicillin-
resistant according to EUCAST guidelines.   
 
 
3.1.2.4.7 Other main clonal complexes 
 
Two percent of IMD isolates received from 2010/11-2018/19 belonged to ST-461 CC and 
2% belonged to ST-22 CC. Overall there was a decrease in the number of isolates belonging 
to these CCs over time (Figure 3-21). PenI isolates represented the greatest proportion of 
these isolates annually. Thirteen percent of IMD isolates belonged to ST-23 CC and 6% 




Figure 3-21: Annual distribution of penicillin susceptibility among ST-461, ST-
22, ST-23 and ST-213 clonal complex IMD isolates in England, Wales and 
Northern Ireland from 2010/11-2018/19. 
 
PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines.  
 
ST-22 clonal complex isolates (n=75)







































































Figure 3-21: (continued).  
 
PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines.  
 
ST-23 clonal complex isolates (n=549)







One PenR isolate (PubMLST ID 28138; MIC = 0.38 mg/L, beta-lactamase negative) 
harboured penA171. This allele did not contain any of the five AASs associated with 
conferring reduced susceptibility or resistance to penicillin (F504L, A510V, I515V, H541N, 
I566V; Appendix 4). It had one AAS when aligned to wild type (WT) allele penA1; P551S. 
Three other penA alleles (penA111, penA312 penA324) with P551S, which also did not 
contain any of the five AASs associated with conferring reduced susceptibility or resistance 
to penicillin, were identified on PubMLST (accessed 05/10/2020; Appendix 6). 
Meningococcal isolates identified on PubMLST with alleles containing P551S alone were 
not penicillin-resistant (MICs = 0.016–0.094 mg/L) (accessed 05/10/2020; Appendix 7).  
The PenR isolate (28138) was serogroup W belonging to ST-11 CC. A genome comparison 
of this and two closely related PenS isolates (28132 and 28135; Appendix 8) identified a 
different mtrR gene (NEIS1635). The mtrR allele harboured by the PenR isolate, mtrR217, 
was not found among any other isolate on PubMLST (accessed 27/10/2020). When aligned 
to WT mtrR allele 1 (Appendix 9), there was one AAS; S32W. Other mtrR alleles with this 
AAS (alleles 190 and 426) and isolates containing these alleles on PubMLST were identified 
(Table 3-3; accessed 27/10/2020). No other meningococcal isolates with either of these 
alleles were identified. Gonococcal isolates with mtrR alleles 190 (n=16) and 426 (n=3) were 
identified and, where known, had penicillin MICs of 0.25-4 mg/L. All the gonococcal isolates 
had penA85, which only had three out of the five AASs associated with conferring reduced 










Table 3-3: PubMLST isolates harbouring mtrR alleles with the amino acid 
substitution S32W. 
 















ID Country Year Species Penicillin MIC (mg/L)
mtrR  allele 
(NEIS1635) penA  allele
28138 UK [England] 2013 Neisseria meningitidis 0.38 217 171
27271 USA 2009 Neisseria gonorrhoeae 4 190 85
37101 USA 2012 Neisseria gonorrhoeae 1 190 85
37125 USA 2007 Neisseria gonorrhoeae 1 190 85
37199 USA 2012 Neisseria gonorrhoeae 1 190 85
37318 USA 2005 Neisseria gonorrhoeae 1 190 85
37341 USA 2006 Neisseria gonorrhoeae 1 190 85
37100 USA 2012 Neisseria gonorrhoeae 0.5 190 85
37104 USA 2012 Neisseria gonorrhoeae 0.5 190 85
37121 USA 2006 Neisseria gonorrhoeae 0.5 190 85
37368 USA 2007 Neisseria gonorrhoeae 0.5 190 85
37103 USA 2012 Neisseria gonorrhoeae 0.25 190 85
36269 Kenya 2012 Neisseria gonorrhoeae NK 426 664
36273 Kenya 2012 Neisseria gonorrhoeae NK 426 664
39135 Kenya 2012 Neisseria gonorrhoeae NK 426 664
48193 UK [England] 2014 Neisseria gonorrhoeae NK 190 664
48269 UK [England] 2014 Neisseria gonorrhoeae NK 190 664
48283 UK [England] 2014 Neisseria gonorrhoeae NK 190 664
74477 Spain NK Neisseria gonorrhoeae NK 190 85





One PenR isolate (39380; MIC = 0.5 mg/L) harboured penA209. This allele had only three 
out of the five AASs associated with conferring reduced susceptibility or resistance to 
penicillin (F504L, A510V and I515V; Appendix 4). When aligned to the WT allele penA1, the 
allele had additional AASs at position 447 (V447L) and position 516 (A516G). Other penA 
alleles on PubMLST with the same three out of five AASs (F504L, A510V and I515V) were 
identified (n=8; Figure 3-22; accessed 30/09/2020; alleles 85, 359, 410, 416, 477, 516, 646 
and 721).  PenA alleles 85, 410, 477 and 516 also harboured A447L and A516G whilst alleles 
359, 416, 646 and 721 did not. 
Meningococcal isolates harbouring these penA alleles were identified on the PubMLST 
database (n=28; accessed 30/09/2020) (Table 3-4). Penicillin MIC values among these 
isolates (where available) ranged from 0.047-0.5 mg/L. The MICs of isolates harbouring 
penA alleles with V447L and A516G (n=24) ranged from 0.12–0.5 mg/L whilst those without 
(n=4) ranged from 0.047-0.094 mg/L. PenA alleles containing A447L and A516G were found 
among gonococcal isolates on PubMLST (penA85; n=503, penA209; n=878, penA410; 










Figure 3-22: Allignment of penA alleles harbouring three out of the five amino 
acid substitutiosns (F504L, A510V, I515V) assocated with conferring reduced 
susceptilbity or resistance to penicillin.  
   































Table 3-4: PubMLST meningococcal isolates harbouring penA alleles with only 
three out of the five amino acid substitutions (F504L, A510V and I515V) 
associated with conferring reduced susceptibility or resistance to penicillin.  
CSF = cerebral spinal fluid. NK = not known. 
 
 













39380 UK [England] 2015 Invasive (unspecified/other) Blood 0.5 209 Yes
72293 UK [England] 2019 Carrier Rectal 0.38 209 Yes
72294 UK [England] 2019 Carrier Rectal 0.38 410 Yes
16983 France 2006 Invasive (unspecified/other) CSF 0.25 85 Yes
39371 UK [England] 2015 Invasive (unspecified/other) Blood 0.25 410 Yes
72314 UK [England] 2019 Carrier Rectal 0.25 209 Yes
20445 UK [England] 2011 Invasive (unspecified/other) CSF 0.19 410 Yes
35358 UK [Scotland] 2012 Invasive (unspecified/other) Blood 0.12 209 Yes
31181 UK [England] 2011 Carrier Rectal NK 209 Yes
31185 UK [England] 2011 Carrier Rectal NK 410 Yes
38957 Italy 2013 Carrier Throat NK 209 Yes
59108 USA 2006 Carrier Throat NK 209 Yes
59163 USA 2006 Carrier Throat NK 209 Yes
59193 USA 2006 Carrier Throat NK 209 Yes
59199 USA 2006 Carrier Throat NK 209 Yes
59254 USA 2007 Carrier Throat NK 209 Yes
59265 USA 2007 Carrier Throat NK 209 Yes
61162 Italy 2016 NK NK NK 209 Yes
61176 Italy 2016 NK NK NK 209 Yes
83723 Sweden NK NK NK NK 209 Yes
85839 USA 2006 Carrier Throat NK 209 Yes
92821 Portugal 2018 Carrier Throat NK 209 Yes
94512 Sweden NK NK NK NK 209 Yes
95841 Sweden NK Invasive (unspecified/other) NK NK 410 Yes
21104 UK [Wales] 2011 Invasive (unspecified/other) Blood 0.094 416 No
35474 UK [England] 2013 Invasive (unspecified/other) Blood 0.094 646 No
44735 UK [England] 2016 Invasive (unspecified/other) Blood 0.094 721 No
38077 UK [England] 2015 Carrier Throat 0.064 646 No





PenA allele 327 was found among one PenR isolate (MIC = 0.38 mg/L), three PenI isolates 
(MICs = 0.125-0.25 mg/L) and one PenS isolate (MIC = 0.47 mg/L). When aligned to WT 
allele penA1, penA327 harboured four out of the five AASs associated with conferring 
reduced susceptibility or resistance to penicillin (F504L, A510V, I515V, H541N). Other penA 
alleles with the same four out of five AASs (n=16) were identified on PubMLST (accessed 
24/09/2020, Appendix 10). Meningococcal isolates harbouring any of these penA alleles 
were identified on PubMLST (n=34; Appendix 11). MIC values were known for 12 isolates 
which were PenS (n=2; alleles 65 and 292; accessed 24/09/2020), PenI (n=8; alleles 178, 
330, 372, 387 and 565) and PenR (n=2; alleles 65 and 361). PenA327 did not share any 
unique AASs with penA alleles among PenR isolates. 
PenA327 had an AAS (G545S) that was not present among any other penA alleles that had 
only four out of the five AASs associated with conferring reduced susceptibility or 
resistance to penicillin. Other penA alleles with G545S were identified on PubMLST (n=41; 
Appendix 12) and all contained all five AASs associated with conferring reduced 
susceptibility or resistance to penicillin (n=38) or none (n=3). No MIC data were available 
for isolates on PubMLST harbouring alleles with G545S only. 
All five IMD isolates with penA327 also displayed reduced susceptibility to cefotaxime 











3.1.3 Cefotaxime susceptibility 
 
3.1.3.1 MIC distribution 
 
Of the 4,122 IMD isolates received at the MRU from culture-confirmed cases from July 
2010-June 2019, 4,121 were cefotaxime-susceptible (MICs = <0.002–0.125 mg/L and one 
was cefotaxime-resistant (MIC = 0.25 mg/L; Table 3-5). 
Cefotaxime MIC values of all isolates ranged from <0.002–0.25 mg/L (Figure 3-23). Isolates 
with MICs of 0.004 mg/L were most common (31%). The MIC50 was 0.004 mg/L and the 
MIC90 was 0.008 mg/L.  
 
Table 3-5: Distribution of cefotaxime susceptibility among IMD isolates in 
England, Wales and Northern Ireland from 2010/11-2018/19. 
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Figure 3-23: Cefotaxime MICs among IMD isolates in England, Wales and 





Out of the 4,122 IMD isolates, only seven had cefotaxime MICs ≥ 0.047 mg/L (0.2%). These 
isolates harboured penA327 (n=5), penA11 (n=1) and penA419 (n=1). Bar one, isolates were 
also PenR (0.38-0.5 mg/L) or PenI (0.125-0.25 mg/L).  The characteristics of these isolates 







Table 3-6: IMD isolates with cefotaxime MICs ≥ 0.047 mg/L in England, Wales 
and Northern Ireland from 2010/11-2018/19. 
PubMLST 
ID 






35758 B ST-41/44 0.047 0.047 327 
44811 B INCOMPLETE MLSTa 0.047 0.5 11 
39403 C ST-11 0.064 0.125 327 
41472 C ST-11 0.094 0.38 327 
42499 C ST-11 0.094 0.19 327 
60650 C ST-11 0.125 0.25 327 
20267 B ST-162 0.25 0.5 419 
a Exact match for ST-1867 for five loci.  
 
3.1.3.2 Cefotaxime-resistant isolate 
 
One IMD isolate was cefotaxime-resistant (20267; MIC = 0.25 mg/L). It was also penicillin-
resistant (MIC = 0.5 mg/L).   The isolate belonged to ST-162 CC. A core genome comparison 
of all ST-162 CC isolates on PubMLST (n=72; 07/10/2020) identified the closest related 
cefotaxime-susceptible isolates (n=19; Appendix 13). Variable loci between these 20 ST-
162 CC isolates and probable recombination sites were determined (Appendix 14). A 
probable recombination region of 12 loci, corresponding to the cell wall-associated genes, 
which included the penA gene (NEIS1753), was identified. The corresponding alleles were 
also found among non-pathogenic Neisseria isolates on PubMLST (N. bergeri and N. 
polysaccharea).  
 
3.1.3.2.1 penA allele in cefotaxime isolate 20267 
 
The penA gene harboured by the cefotaxime-resistant isolate (NEIS1753 allele 379; 
penA419) was not found in any other isolate on PubMLST. Five equidistant fragments (120 
bp each) from across the length of NEIS1753 allele 379 shared 100% identity with those of 




Figure 3-24: Five fragments of NEIS1753 allele 379 and species with sequences 
with 100% identity to that of the fragments.  
 
Isolates identified on PubMLST. 1 = bp 1-120 of NEIS1753 allele 379, 2 = bp 361-480, 3 = bp 
721-840, 4 = bp 1201-1320 5 = bp 1441-1560 of NEIS1753_379. NB = N. bergeri, NC = N. 
cinerea, NG = N. gonorrhoea, NM = N. meningitidis, NL= N. lactamica, NP = N. 
polysaccharea. The scale bar indicates the bp position. 
 
 
When aligned to WT NEIS1753 allele 1, NEIS1753 allele 379 had two unique AAS that were 
not found among those alleles harboured by cefotaxime-susceptible PenR isolates (and 
therefore containing the five AASs associated with conferring reduced susceptibility or 
resistance to penicillin) (Appendix 15). The two unique AASs were A501T and D511A. Both 
AASs fell within the 402 bp fragment of NEIS1753_379; penA419. Other penA alleles 























alleles on PubMLST were identified (n=69; Table 3-7). Among these were N. meningitidis 
(n=50), N. lactamica (n=5) and N. polysaccharea (n=1) isolates. All penA alleles harboured 
by these isolates had the AAS at position 501; A501T (n=17) or A501V (n=39). Six isolates 
harbouring a penA allele with A501T had an additional AAS at position 511; D511A 
(penA419; n=1), D511G (penA910; n=2, penA836; n=1) or D511V (penA670; n=1, penA805; 
n=1). Where known, cefotaxime MICs of isolates with A501V mutation were 0.003-0.012 
mg/L. Isolates with the A501T mutation had MICs of 0.016-0.125 mg/L. Isolates with both 















 Figure 3-25: Alignment of penA419  with a wild type penA allele and penA 
alleles harbouring amino acid substitutions at position A501 and/or D511.  
 
   
PenA alleles identified on PubMLST. Amino acid positions 501 and 511 are highlighted. 
The scale bar indicates the amino acid position. 
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Table 3-7: PubMLST isolates harbouring penA alleles with amino acid 
substitutions at amino acid position 501 and/or 511. 
 
NK = not known. AASs = amino acid substitutions.        













Other 5 AASs 
associated with PenR 
and PenI isolates
2011 Invasive (unspecified/other) Blood Neisseria menigitidis 0.5 0.25 419 A501T D511A Yes
2020 Meningitis and septicaemia NK Neisseria menigitidis 0.5 0.125 910 A501T D511G Yes
2020 Meningitis and septicaemia NK Neisseria menigitidis 0.5 0.19 910 A501T D511G Yes
2015 Carrier Throat swab Neisseria lactamica NK NK 836 A501T D511G Yes
2013 Carrier Throat swab Neisseria menigitidis NK NK 670 A501T D511V Yes
2015 NK NK Neisseria polysaccharea NK NK 805 A501T D511V Yes
2016 Meningitis Blood Neisseria menigitidis 0.25 0.047 909 A501T None Yes
2016 Meningitis Blood Neisseria menigitidis 0.5 0.047 909 A501T None Yes
1961 Invasive (unspecified/other) CSF Neisseria menigitidis 0.016 NK 84 A501T None No
2010 Invasive (unspecified/other) CSF Neisseria menigitidis 0.125 0.047 341 A501T None Yes
2005 Invasive (unspecified/other) CSF Neisseria menigitidis 0.38 0.125 61 A501T None Yes
2016 Invasive (unspecified/other) NK Neisseria menigitidis 0.38 0.016 734 A501T None Yes
2013 Invasive (unspecified/other) Blood Neisseria menigitidis 0.012 0.004 24 A501V None No
2011 Invasive (unspecified/other) CSF Neisseria menigitidis 0.015 0.004 24 A501V None No
2010 Invasive (unspecified/other) Blood Neisseria menigitidis 0.023 0.004 411 A501V None No
2013 Invasive (unspecified/other) Blood Neisseria menigitidis 0.023 0.008 311 A501V None No
2011 Septicaemia Blood Neisseria menigitidis 0.023 0.06 311 A501V None No
2011 Invasive (unspecified/other) Blood Neisseria menigitidis 0.032 0.003 311 A501V None No
2017 Invasive (unspecified/other) Blood Neisseria menigitidis 0.032 0.006 161 A501V None No
2011 Septicaemia Blood Neisseria menigitidis 0.032 0.008 311 A501V None No
2015 Invasive (unspecified/other) Blood Neisseria menigitidis 0.032 0.008 311 A501V None No
2017 Invasive (unspecified/other) Blood Neisseria menigitidis 0.032 0.008 161 A501V None No
NK Invasive (unspecified/other) Blood Neisseria menigitidis 0.047 0.006 24 A501V None No
2016 Invasive (unspecified/other) Blood Neisseria menigitidis 0.047 0.006 671 A501V None No
2014 Invasive (unspecified/other) Blood Neisseria menigitidis 0.047 0.012 24 A501V None No
2011 Invasive (unspecified/other) Blood Neisseria menigitidis 0.064 0.008 24 A501V None No
2004 Invasive (unspecified/other) CSF Neisseria menigitidis 0.094 NK 24 A501V None No
2016 Meningitis CSF Neisseria menigitidis NK NK 61 A501T None Yes
2014 Carrier Throat swab Neisseria lactamica NK NK 605 A501T None Yes
2015 Carrier Throat swab Neisseria lactamica NK NK 611 A501T None Yes
2015 Carrier Throat swab Neisseria lactamica NK NK 611 A501T None Yes
2015 Carrier Throat swab Neisseria lactamica NK NK 611 A501T None Yes
1999 Carrier Throat swab Neisseria menigitidis NK NK 311 A501V None No
2001 Invasive (unspecified/other) CSF Neisseria menigitidis NK NK 161 A501V None No
2010 Invasive (unspecified/other) Blood Neisseria menigitidis NK NK 311 A501V None No
NK NK Throat swab Neisseria menigitidis NK NK 503 A501V None No
1998 NK NK Neisseria menigitidis NK NK 24 A501V None No
2013 Invasive (unspecified/other) Blood Neisseria menigitidis NK NK 411 A501V None No
2006 Invasive (unspecified/other) NK Neisseria menigitidis NK NK 519 A501V None No
2005 Invasive (unspecified/other) NK Neisseria menigitidis NK NK 311 A501V None No
2014 Invasive (unspecified/other) Blood Neisseria menigitidis NK NK 311 A501V None No
2013 Invasive (unspecified/other) Blood Neisseria menigitidis NK NK 161 A501V None No
2015 NK NK Neisseria menigitidis NK NK 660 A501V None No
2013 NK NK Neisseria menigitidis NK NK 311 A501V None No
2013 NK NK Neisseria menigitidis NK NK 311 A501V None No
2016 Invasive (unspecified/other) Blood Neisseria menigitidis NK NK 24 A501V None No
2015 Carrier Throat swab Neisseria menigitidis NK NK 740 A501V None Yes
NK NK NK Neisseria menigitidis NK NK 311 A501V None No
2015 Carrier Throat swab Neisseria menigitidis NK NK 740 A501V None No
2015 Carrier Throat swab Neisseria menigitidis NK NK 740 A501V None No
2017 NK NK Neisseria menigitidis NK NK 311 A501V None No
2012 Meningitis Blood Neisseria menigitidis NK NK 311 A501V None No
2004 NK NK Neisseria menigitidis NK NK 24 A501V None No
1999 Carrier throat swab Neisseria menigitidis NK NK 671 A501V None No
NK NK NK Neisseria menigitidis NK NK 311 A501V None No
2007 Invasive (unspecified/other) Sputum Neisseria menigitidis NK NK 311 A501V None No
1960 NK NK Neisseria animalis NK NK 502 None A511S No
NK NK NK Neisseria wadsworthii NK NK 504 None A511N No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
2014 NK NK Neisseria musculi NK NK 524 None A511S No
1999 NK NK Neisseria canis NK NK 521 None A511N No
1962 NK NK Neisseria canis NK NK 521 None A511N No
1974 NK NK Neisseria weaveri NK NK 501 None A511S No
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3.1.3.2.2 MtrR allele in cefotaxime-resistant isolates 20267 
 
The mtrR gene (NIES1635) was one of the variable loci identified between the cefotaxime-
resistant isolate and the closely related cefotaxime-susceptible isolates. The cefotaxime-
resistant isolate harboured mtrR249 whilst all susceptible isolates harboured mtrR4. No 
other isolate on PubMLST had mtrR249. When aligned to a WT mtrR allele, mtrR4 had the 
same AA sequence, whereas mtrR249 had a frameshift at AA position five (Figure 3-26).  
Other mtrR alleles with a frameshift at the beginning of the gene (first 60 AAs) were 
identified (n=13; Appendix 16). Frameshifts among these alleles were at AA positions later 
than position five. Isolates harbouring these mtrR alleles on PubMLST (n=17; alleles 244, 
246, 248, 252, 259 or 266) were cefotaxime-susceptible (MICs = <0.002-0.008 mg/L; 
Appendix 17).  
 
Figure 3-26: MtrR249  alignment with a wild type mtrR allele and  mtrR4. 
NEIS1635 1 = wild type mtrR allele. The scale bar indicates the amino acid position. 
*=frameshift.   
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3.1.3.3 Elevated cefotaxime MICs  
 
In addition to the isolates previously identified (section 3.1.3) with elevated cefotaxime 
MICs, 14 non-IMD (non-MGL) isolates with elevated cefotaxime MICs (≥ 0.047 mg/L) were 
identified at the MRU (Table 3-8) and underwent PCR analysis for penA allele 
determination. All penA alleles found among these isolates, along with those alleles 
previously identified among isolates with known elevated cefotaxime MICs were aligned 
with a WT penA allele (Figure 3-27). PenA alleles harboured by cefotaxime-susceptible PenR 
isolates were also included in the alignment (and therefore contained the five AASs 
associated with conferring reduced susceptibility or resistance to penicillin). PenA AASs 
unique to those harboured by isolates with cefotaxime MIC values ≥0.047 mg/L compared 
to those with cefotaxime MICs <0.047 mg/L were identified (Table 3-9; V417L, N472D, 
A501T, D511A/G, A516G, E537D, G545S, P571S). MICs of isolates harbouring alleles with 
A501T were 0.047-0.25 mg/L. MICs of isolates harbouring alleles with AASs at D511 in 
addition to A501T were 0.125-0.25 mg/L. MICs of isolates harbouring alleles with N572D 
were 0.047-0.125 mg/L.  
 
Table 3-8: Non-IMD (non-MGL) MRU isolates with cefotaxime MICs  ≥0.047 
mg/L. 
 
Five penA sequences not yet assigned a PubMLST penA allele ID are termed NEW1-5. NK= 
not known. NT = non-typable. NG= non-groupable.  





















M17 240186 Neisseria spp Eye swab 1.5 1.0 0.25 0.25 NEW1
M14 240600 Neisseria meningitidis Urethral swab W 2A NT P1.2 NT 0.38 0.012 0.006 0.19 9
M15 240173 Neisseria meningitidis Throat swab NG NT NT NT P1.6 0.19 0.023 0.004 0.125 209
M13 240711 Neisseria spp Eye swab NG NT NT NT NT 1.0 0.5 0.023 0.125 796
M11 240095 Neisseria cinerea Blood 1.5 0.5 0.008 0.094 NEW2
M13 240159 Neisseria spp Blood 1.5 0.38 0.008 0.094 NEW3
M17 240460 Neisseria meningitidis Blood C 2A P1.5 NT NT 0.25 0.016 0.008 0.094 327
M13 240621 Neisseria meningitidis Sputum Y NT P1.5 NT NT 0.38 0.003 0.006 0.064 2
M16 240658 Neisseria polysaccharae Blood 1.0 0.38 0.003 0.064 NEW4
M20 240247 Neisseria meningitidis Blood C 2A NT NT NT 0.38 0.047 0.002 0.064 327
M14 240642 Neisseria spp Blood 0.75 1.0 0.023 0.047 490
M15 240571 Neisseria spp Bronchoaveolar Lavage 1.0 1.0 0.012 0.047 NEW5
M15 240293 Neisseria meningitidis Throat swab NG NT P1.12 NT NT 0.5 0.094 0.008 0.047 179
M19 240153 Neisseria meningitidis Sputum NG NT P1.7 NT NT 2.0 0.064 0.006 0.047 11
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Figure 3-27: PenA alleles harbored by isolates with cefotaxime MICs ≥0.047 
mg/L and alleles harboured by cefotaxime-susceptible penicillin-resistant 
isolates. 
         
PenA alleles identified in this study. PenA NEW1-5 alleles identified by PCR and sanger 
sequencing among non-IMD isolates yet to be assigned a PubMLST penA allele ID (Table 3-
8). Amino acid substitutions unique to alleles with isolates displaying elevated cefotaxime 
resistance are highlighted (boxed). 
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Table 3-9: PenA alleles identified among Neisseria isolates with cefotaxime 
MICs ≥0.047 mg/L.  
 
PenA NEW1-5 alleles identified by PCR and sanger sequencing among non-IMD isolates yet 
to be assigned a PubMLST penA allele ID (Table 3-8). NB = N. bergeri, NC = N. cinerea, NG = 
N. gonorrhoea, NM = N. meningitidis, Nmu = N. mucosa NL= N. lactamica, NP = N. 
polysaccharea, NS = N. species. * = unique mutations of penA alleles found among isolates 
with cefotaxime MICs ≥0.047 mg/L compared to those found among PenR isolates with 
cefotaxime MICs <0.047 mg/L. ^ New1-5 penA alleles among species identified at the MRU.  
 
 
3.1.4 Rifampicin susceptibility  
 
3.1.4.1 MIC distribution 
 
Of the 4,122 IMD isolates received at the MRU from culture-confirmed cases from July 2010 
- June 2019, 4,120 (99.95%) were rifampicin-susceptible (MICs = <0.002-0.25 mg/L) and two 
(0.05%) were rifampicin-resistant (MICs = 0.5 and >32 mg/L). Rifampicin-resistant isolates 








mutations* Species distribution on PubMLST^
419 0.25 A501T, D511A 1 x NM
NEW1 0.25 A501T 1 x NS
910 0.125-0.19 A501T, D511G, G541D 2 x NM
61 0.125 A501T, E537D 2 x NM
9 <0.002-0.19 None  779 x NM,  40 x NG, 35 x NL, 4 x NC, 4 x NP, 1 x NB
209 0.023-0.125 V447L, A516G 838 x NG, 18 x NM
796 0.125 N572D 2 x NMu
NEW2 0.094 N572D 1 x NC
NEW3 0.094 N572D  1 x NS
327 0.047-0.125 G545S 958 x NG, 50 x NM
2 <0.002-0.064 None 901 x NM, 1 x NG
NEW4 0.064 N572D 1 x NP
490 0.047 N572D, P571S 2 x NMu
NEW5 0.047 None 1 x NS
179 0.023-0.047 None 16 x NM, 6 x NG
11 0.047 None 39 x NM
909 0.047 A501T 2 x NM
341 0.047 A501T 1 x NM
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Rifampicin MIC values of all IMD isolates ranged from <0.002 - >32 mg/L (Figure 3-28). 
Isolates with MICs of 0.006 mg/L were most common, representing 18% of all isolates. The 
MIC50 was 0.008 mg/L and the MIC90 was 0.023 mg/L.  
 
Table 3-10: Distribution of rifampicin susceptibility among IMD isolates in 
England, Wales and Northern Ireland from 2010/11-2018/19. 
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Figure 3-28: Rifampicin MICs among IMD isolates in England, Wales and 





3.1.4.2 RpoB allele distribution 
 
The 659 bp rpoB fragment of the NEIS0123 gene, corresponding to AA residues 455-674, 
was obtained for the 4,122 IMD isolates received at the MRU from 2010/11-2018/19. Fifty-
nine rpoB alleles were identified among the 4,122 IMD isolates, with frequencies of isolates 
varying from one to 1,035 (Appendix 18).  The most prevalent allele was rpoB9 (n=1,035; 
25%) followed by rpoB34 (n=834, 20%). Two different rpoB alleles were identified among 
the two rifampicin-resistant isolates: rpoB84 (MIC = >32 mg/L) and rpoB238 (MIC = 0.5 





3.1.4.3 Rifampicin-resistant isolates 
 
The characteristics of the rifampicin-resistant isolates are listed in Table 3-11. When aligned 
to a WT rpoB allele (Appendix 19), the resistance-associated alleles (rpoB84 and rpoB238) 
harboured rifampicin resistance-associated mutations D545E or H555N; referred to as AA 
positions 542 and 552 in the literature (Stefanelli et al., 2001; Taha et al., 2010).   
There was no evidence that suggested either of the two isolates were from close contacts 
of index cases.  
 
Table 3-11: Characteristics of rifampicin-resistant isolates in England, Wales 
and Northern Ireland from 2010/11-2018/19. 
 















42499 2015/16 C ST-11 0.5 238 D545E 21 
Epi = Epidemiological. CC = Clonal complex 
 
3.1.5 Ciprofloxacin susceptibility 
 
3.1.5.1 MIC distribution 
 
Of the 4,122 IMD isolates received at the MRU from culture-confirmed cases from July 2010 
- June 2019, 4,117 (99.9%) were ciprofloxacin-susceptible (MICs = <0.002-0.03 mg/L) and 
five (0.1%) were ciprofloxacin-resistant (MICs = 0.06-0.5 mg/L). Ciprofloxacin-resistant 
isolates were received in epidemiological years 2010/11 (n=1), 2014/15 (n=2), and 2018/19 
(n=2) (Table 3-12). 
94 
 
Ciprofloxacin MIC values of all IMD isolates ranged from <0.002 - 0.5 mg/L (Figure 3-29). 
Isolates with MICs of 0.004 mg/L were most common, representing 45% of all isolates. The 
MIC50 was 0.004 mg/L and the MIC90 was 0.008 mg/L.  
 
Table 3-12: Distribution of ciprofloxacin susceptibility among IMD isolates in 
England, Wales and Northern Ireland from 2010/11-2018/19. 




















































































































1 0 0 0 2 0 0 0 2 5 
Ciprofloxacin susceptibility categorisation according to EUCAST guidelines. 
 
Figure 3-29: Ciprofloxacin MICs among IMD isolates in England, Wales and 




3.1.5.2 GyrA allele distribution 
 
The 524 bp gyrA fragment of the NEIS1320 gene, corresponding to AA residues 39-213, was 
obtained for the 4,122 IMD isolates received at the MRU from 2010/11-2018/19. Thirty-six 
gyrA alleles were identified among the 4,122 IMD isolates, with frequencies of isolates 
varying from 1 to 2,072 (Appendix 20). The gyrA alleles of two isolates were not known.  
The most prevalent allele was gyrA4 (n=2,072; 50%) followed by gyrA12 (n=626, 15%). Five 
different gyrA alleles were identified among the five ciprofloxacin resistance isolates; gyrA6 
(MIC = 0.5 mg/L), gyrA8 (MIC = 0.18 mg/L), gyrA10 (MIC = 0.094 mg/L), gyrA146 (MIC = 0.19 
mg/L) and gyrA296 (MIC = 0.06 mg/L). These alleles were not harboured by any other IMD 
isolate from E, W and NI (2010/11 – 2018/9).  
 
3.1.5.3 Ciprofloxacin-resistant isolates  
 
The ciprofloxacin-resistant isolates all belonged to different clonal complexes (Table 3-13). 
When aligned to a WT gyrA allele (Appendix 21), the resistance-associated alleles (6, 8, 10, 
146, 266) harboured one of the ciprofloxacin resistance-associated mutations; either D95N 
(n=2; MICs = 0.06–0.094 mg/L) or T91I (n=3; MICs = 0.18-0.5 mg/L). The ciprofloxacin-
resistant isolate with the highest ciprofloxacin MIC value (0.5 mg/L) also harboured a 
mutation in parC (D86N). 
 
In July 2019 (outside the time period of this survey), additional ciprofloxacin-resistant 









Table 3-13: Characteristics of ciprofloxacin-resistant IMD isolates in England, 















































































































A 4789 5 0.5 6 T91I 191 D86N 
a ciprofloxacin resistance-associated mutation; b associated with enhanced ciprofloxacin 














3.2 An outbreak of meningococcal disease owing to ciprofloxacin-resistant non-
groupable ST-175 CC isolates in England, 2019. 
 
Declaration: Much of the work described in this section (3.2) was published in Willerton 
et al., 2020. Excepting minor corrections from co-authors, the article was written solely 
by me.  
Objective: Investigate ciprofloxacin resistance amongst isolates of the ST-175 CC, following 
an outbreak of meningococcal disease owing to ciprofloxacin-resistant NG ST-175 CC 
isolates in England, and to characterise the strain responsible in terms of population 
structure. 
 
3.2.1 Outbreak details  
 
In 2019, the MRU received isolates from invasive (n=1; 89713) and conjunctivitis (n=2; 
89565, 89712) cases of meningococcal disease in England. The two conjunctivitis case 
isolates were from patients presenting with meningococcal disease upon return from travel 
to Mecca, KSA. The invasive isolate was from a complement deficient patient that attended 
the same mosque as one of the conjunctivitis cases. Following characterisation, all three 
isolates were NG belonging to ST-175 CC, ciprofloxacin-resistant (MICs = 0.125 mg/L) with 
reduced susceptibility to penicillin (MICs = 0.25 mg/L) (Denoted by * in Table 3-14, section 
3.2.2.1).  
The outbreak led to the issue of a public health announcement (Public Health England, 
2019) and subsequently the National Reference Centre for Meningococci and Haemophilus 
influenzae in Germany (Institute for Hygiene and Microbiology, University of Würzburg) 
highlighted four similar invasive cases caused by ST-175 CC isolates, two of which were also 
in complement deficient patients and one in a cancer patient. Three of the isolates were 
resistant to ciprofloxacin (MICs = 0.064-0.094 mg/L) and all four displayed reduced 
susceptibly or resistance to penicillin (MICs = 0.19-0.5 mg/L) (Denoted by # in Table 3-14, 
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section 3.2.2.1). Three of German IMD cases occurred in asylum seekers from Afghanistan 
(n=2) and Nigeria (n=1).  
 
3.2.2 Phylogenetic analysis of the ST-175 clonal complex 
 
To identify related isolates, all PubMLST isolates with genomes >2mb were identified 
(n=19,802; accessed 22/10/2019). ST-175 CC isolates (n=62), closely related isolates (non-
ST-175 CC) sharing ≥ three ST-175 alleles and ST-175 CC isolates from published (n=5; 
(Bratcher et al., 2019)) and unpublished (n=1) UK carriage studies were identified 
(Appendix 2). All isolates underwent phylogenetic analysis (n=79; Figure 3-30).  Most 
genomes fell into six sublineages (n=70, sublineages 1-6) which included ST-175 CC isolates 
(n=68) and 2 ST-6525 isolates unassigned to a CC. The remaining non-ST-175 CC isolates 
were not included in the rest of the analyses (n=9). Isolates in sublineages 1 to 6 were from 
15 countries from 2000-2019, were of multiple serogroups and were invasive (n=32), 
carrier (n=20) and conjunctivitis (n=2). The remaining (n=16) had unknown disease status. 













Figure 3-30: ST-175 clonal complex and closely related genomes (Willerton et 
al., 2020). 
A core genome comparison of 1605 loci among ST-175 clonal complex (n=68) isolates, ST-
6525 (Unassigned clonal complex; n=2) isolates and closely related non-ST-175 clonal 
complex isolates (n=9). Sublineages 1-6 are indicated. The scale bar indicates variable loci 
among the 1605 that underwent the comparison. CC = clonal complex. 
Non-ST-175CC genomes










3.2.2.1 Sublineage 1: The non-groupable ST-175 clonal complex sublineage 
 
Sublineage 1 (the NG ST-175 CC sublineage), comprised NG isolates (n=31; Table 3-14), 
including the known English invasive/conjunctivitis and German invasive case isolates. Four 
other IMD isolates from England (n=1; 2015), Italy (n=2; 2017-2018) and Sweden (n=1; 
2016) were identified. Sublineage 1 included numerous clusters (clusters A-E) and a 
singleton (Figure 3-31).  
The known English cases were in Cluster A, along with two of the known invasive German 
cases (one cancer patient, one immune status unknown patient) and two newly identified 
invasive isolates from Italy (immune status of patients unknown). Ciprofloxacin-resistant 
isolates in cluster A (three English isolates and one German isolate from a cancer patient) 
harboured gyrA313 (MICs = 0.064-0.12 mg/L). GyrA313 had six AASs when aligned to a WT 
gyrA allele (A69S, T91I, N103D, I111V, V120I, D210E; Appendix 22).  The remaining Cluster 
A isolates were ciprofloxacin-susceptible (GyrA12; MICs = 0.003-0.006 mg/L). GyrA12 had 
no AASs when aligned to a WT gyrA allele (Appendix 22). 
Cluster B comprised the other known German case isolates (n=2; immunocompromised 
patients) and a newly identified Swedish invasive isolate (from a pregnant case). Isolates 
were ciprofloxacin-resistant (MICs = 0.094 mg/L; gyrA187). GyrA187 had six AASs when 
aligned to a WT gyrA allele (T91I, N103D, I111V, V120I, V199I, D210E; Appendix 22).  
Clusters C and D comprised carrier isolates with gyrA12 and, where known, MICs were 
0.002-0.004 mg/L. Cluster E isolates comprised carrier isolates with unknown ciprofloxacin 
MICs with gyrA alleles 152 (n=4) and 12 (n=1). GyrA152 had one AAS when aligned to a WT 
gyrA allele (D95N; Appendix 22).  
The singleton from England harboured gyrA12 and was ciprofloxacin-susceptible (MIC = 
0.004 mg/L).  
All isolates in sublineage 1 had penA alleles 662 (n=29) or 909 (n=2) and where MICs were 
known were PenR (n=1; 0.5 mg/L) and PenI (n=17; 0.094-0.25 mg/L). All isolates in 




Table 3-14: Sublineage 1 isolates: the non-groupable ST-175 clonal complex 
sublineage isolates (Willerton et al., 2020). 
All isolates had allele 583 for parC and allele 311 for nadA. aSingleton. bnhba allele had 1 bp 
different from allele 7.c/d Isolates both from same person 8 weeks difference. e complement 
deficiencies due to vasculitis and Eculizumab therapy, splenic dysfunction, HIV, 
glomerulonephritis, asplenia plus inherited deficiencies were ruled out. NK = not known. 








93631 2017 Germany Invasive NK 12 0.003 662 0.25 15-25 1 321 9
84075 2017 Italy Invasive NK 12 0.004 662 0.125 15-25 1 321 9
91539 2018 Italy Invasive NK 12 0.006 662 0.25 15-25 1 321 9
89565 2019 UK Conjunctivitis n/a 313 0.12 662 0.25 15-25 3 111 9
89712 2019 UK Conjunctivitis n/a 313 0.12 662 0.25 15-25 3 111 9
89713 2019 UK Invasive Complement deficiency 313 0.12 662 0.25 15-25 3 111 9
93679 2019 Germany Invasive Plasmacytoma 313 0.064 662 0.19 15-25 3 111 9
93629 2016 Germany Invasive Terminal complement deficiency 187 0.094 909 0.25 15-25 2 151 9
93630 2016 Germany Invasive Terminal complement deficiency 187 0.064 909 0.5 15-25 2 151 9
42784 2016 Sweden Invasive Pregnant 187 0.094 662 0.094 15-25 2 151 9
41896c 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15-56 2 151 1578b
41897c 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15-56 2 151 1578b
42666d 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15-56 2 151 9
42668d 2014 Ethiopia Carrier n/a 12 0.002 662 0.25 15-56 2 151 9
60134 2014 Ethiopia Carrier n/a 12 0.002 662 0.25 15-25 2 151 9
60143 2014 Ethiopia Carrier n/a 12 0.004 662 0.25 15-56 2 151 9
60308 2014 Ethiopia Carrier n/a 12 0.002 662 0.125 15-56 2 151 9
61207 2014 Ethiopia Carrier n/a 12 NK 662 NK 15-56 2 151 9
49960 2015 UK Carrier n/a 12 NK 662 NK 15-25 2 151 9
50082 2015 UK Carrier n/a 12 NK 662 NK 15-25 2 151 9
52614 2015 UK Carrier n/a 12 NK 662 NK 15-25 2 151 9
52715 2015 UK Carrier n/a 12 NK 662 NK 15-25 2 151 9
88632 2018 UK Carrier n/a 12 NK 662 NK 15-25 2 151 9
52572 2015 UK Carrier n/a 152 NK 662 NK 15-25 1 321 9
41727 2016 France Carrier n/a 152 0.125 662 NK 15-25 1 321 9
47101 2016 Italy Carrier n/a 152 NK 662 NK 15-25 1 321 9
47115 2016 Italy Carrier n/a 152 NK 662 NK 15-25 1 321 9
84968 2018 Norway Carrier n/a 12 NK 662 NK 15-25 1 321 9
85033 2018 Norway Carrier n/a 12 NK 662 NK 15-25 1 321 9
92641 2019 Norway Carrier n/a 12 NK 662 NK 15-75 1 321 9







































Figure 3-31:  Isolates belonging to Sublineage 1 - the non-groupable ST-175 
clonal compelx sublineage (Willerton et al., 2020). 
Core genome comparison based on 1605 loci among Sublineage 1 isolates of ST-175 clonal 
complex (n=31). The sublineage comprised clusters A-E (indicated) and a singleton. The 
scale bar indicates variable loci among the 1605 that underwent the comparison. Isolate 
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Remainder of ST-175 CC
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3.2.2.2 Sublineages 2-6 
 
Isolates in sublineages 2 to 6 (n=39) comprised invasive isolates (n=23) and those with 
unknown disease state (n=16) from 2000-2018 (Figure 3-32). They were from 10 different 
countries and were serogroup W (n=15), Y (n=12), C (n=7), NG (n=2), W/Y (n=1) and X (n=1). 





















Figure 3-32:  ST-175 clonal complex and ST-6525 isolates from 2000-2019 
(Willerton et al., 2020).  
 
Core genome comparison based on 1605 loci among ST-175 clonal complex (n=68), ST-6525 
(n=2) and non-ST-175 clonal complex isolates (n=9, not shown). The scale bar indicates 














































3.2.3 Origins of ciprofloxacin-resistant determinants  
 
On an alignment with all known gyrA alleles, the gyrA alleles identified in Sublineage 1 – 
the non-groupable ST-175 CC sublineage that had AASs when aligned to a WT gyrA allele 
(gyrA313, gyrA187 and gyrA152) belonged to two clades associated with N. meningitidis 
and N. cinerea (Figure 3-33). The N. cinerea cluster contained gyrA313 and gyrA187 (found 
in invasive and conjunctivitis case isolates) while the N. meningitidis clade contained 
gyrA152 (found only among carrier isolates).  
 
3.2.4 Potential vaccine coverage of the non-groupable ST-175 clonal complex sublineage 
isolates  
 
All isolates in Sublineage 1 had NadA311 which contained an insertion sequence (IS1301) 
rendering it non-expressible. PorA P1.4 was not expressed by any of the isolates. All the 
isolates possessed peptides 9 (n=29) or 1578 (n=2) NHBA alleles. FHbp variant 1 allele 
(peptide 321) was harboured by 10 isolates which included three invasive isolates. FHbp 
variant 2 and 3 alleles were harboured by the remaining isolates: peptide 151 (n=17) and 













Figure 3-33:  Phylogenetic analysis of all gyrA alleles and species distribution 
on PubMLST (Willerton et al., 2020).  
Neighbor-Joining tree of nucleotide sequences of available PubMLST gyrA alleles (n=379; 
accessed 13/05/2020). Altered gyrA alleles among sublineage 1 isolates (alleles 152, 187 
and 313) are highlighted. MEGA4 was used to construct the tree. The number of nucleotide 




N. subflava: n= 1
gyrA152
N. cinerea cluster
N. meningitidis: n= 26 (10 alleles)





3.3 Penicillin resistance among English invasive meningococcal serogroup W ST-11 
clonal complex isolates, July 2010-August 2019. 
 
Declaration: Much of the work described in this section (3.3) was published in Willerton 
et al., 2021. Excepting minor corrections from co-authors, the article was written solely 
by me.  
Objective: Investigate the observed increase in penicillin resistance among English 
serogroup W ST-11 CC IMD isolates received at the MRU in 2018 and identify closely related 
isolates on the PubMLST database. 
 
3.3.1 English invasive (MGL) serogroup W ST-11 clonal complex isolates 
 
In order to identify all English invasive serogroup W ST-11 CC and closely related MenW 
IMD isolates from July 2010, MLST data for all genomes available on the MGL database 
were exported (n=4,781, accessed 01/05/2020). Non-English genomes (n=826), followed 
by non-serogroup/genogroup W genomes (n=2,976), non-ST-11 CC genomes (n=69) and 
genomes with < four ST-11 MLST alleles (n=13) were removed from the dataset. The 
remaining genomes (n=897; Appendix 1 and 3), included English invasive serogroup W ST-
11 CC genomes (n=867) and closely related English invasive serogroup W ST-11 CC genomes 
with incomplete MLST profiles with four or more ST-11 MLST alleles (n=30). 
 
3.3.1.1 Distribution of penicillin resistance among English invasive serogroup W ST-11 clonal 
complex isolates 
 
Between July 2010 and August 2019, 897 English invasive ST-11 CC isolates were identified 
(section 3.3.1). Seven hundred and sixteen were PenS (80%; MICs = 0.004-0.064 mg/L), 156 
were PenI (17%; MICs = 0.094-0.25 mg/L) and 25 were PenR (3%, MICs = 0.038-0.75 mg/L). 




Table 3-15: Distribution of penicillin  susceptibility among English invasive 
serogroup W ST-11 clonal complex isolates from July 2010-August 2019. 
 










July – December 
2010 
2 (50) 1(25) 1(25) 4 
2011 11 (84.6) 2 (15.4) 0 13 
2012 21(91.30) 1 (4.35) 1 (4.35) 23 
2013 46 (79.3) 11 (19.0) 1 (1.7) 58 
2014 83 (88.3) 11(11.7) 0 94 
2015 123 (76.4) 37 (23.0) 1 (0.6) 161 
2016 134 (76.6) 39 (22.3) 2 (1.1) 175 
2017 145 (86.8) 20 (12.0) 2 (1.2) 167 
2018 107 (81.1) 13 (9.8) 12 (9.1) 132 
January – August 
2019 
44 (62.9) 21 (30.0) 5 (7.1) 70 
PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines. CC = clonal complex. 
 
Five penA alleles (alleles 9, 14, 171, 435 and 540) were identified among the 25 English 
invasive PenR serogroup W ST-11 CC isolates, and all but one allele (penA171) contained 
the five AASs conferring reduced susceptibility or resistance to penicillin (Table 3-16). An 
investigation into penA171 and the respective isolate was performed (section 3.1.2.5). 





Table 3-16: PenA  alleles among English invasive PenR and PenI serogroup W ST-
11 clonal complex isolates. 
 








Number of AASs 
associated with conferring 
reduced susceptibility or 
resistance to penicillin 


















































PenS = Penicillin-susceptible, standard exposure; PenI = Penicillin-susceptible, increased 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines. AASs = amino acid 
substitutions.  
 
The genomes of all English invasive serogroup W ST-11 CC isolates (n=897) were split into 
three manageable groups (a-c; Figure 3-34), each containing the genomes of the 25 PenR 
isolates, which underwent phylogenetic analysis with Argentinian South American 
reference genomes (n=5; 31148, 31149, 31150, 31151, 31152).  
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Genomes of English invasive PenS and PenI serogroup W ST-11 CC isolates were widely 
distributed throughout the population. The English invasive PenR serogroup W ST-11 CC 
isolates belonged to six distinct lineages (penicillin resistance-associated lineages 1-6) and 
one was a singleton (Appendix 23) (Willerton et al., 2021).   
Penicillin resistance-associated lineages 1, 4, 5 and the singleton belonged to the original 
UK strain.  Penicillin resistance-associated lineages 2 and 3 were of the UK 2013 strain 

























Figure 3-34: Penicillin susceptiblity of English invasive serogroup W ST-11 
clonal complex isolates, July 2010-August 2019 (Willerton et al., 2021).  
Core genome comparison of 1605 core genome loci among English invasive serogroup W 
ST-11 complex isolates (n=897). Genomes divided into three groups: a) July 2010-
September 2015, b) September 2015-April 2017 and c) April 2017-August 2019. Each 
network contains PenR English invasive serogroup W ST-11 clonal complex isolates (n=25) 
and South American reference genomes (Arg n=5); PubMLST IDs 31148, 31149, 31150, 
31151, 31152). The number of variable loci among the 1605 that were compared is 
represented by the scale bar. PenR = penicillin-resistant, PenI = penicillin-susceptible, 
increased exposure, PenS = penicillin-susceptible, standard exposure. Penicillin resistance-
































3.3.2 Non-invasive English and rest of the world (non-MGL) serogroup W ST-11 clonal 
complex isolates 
 
In order to identify all other (non-invasive English and rest of the world) serogroup W ST-
11 CC and closely related MenW isolates, MLST data for all available genomes on the 
PubMLST database (>1 Mb of sequence data) were exported (n=22,918; accessed 
01/05/2020). Non-meningococcal genomes (n=5,162), followed by non-ST-11 CC genomes 
(n=11,440), non-MenW genomes (n=1,798; genogroup annotation given priority over 
serogroup), poor quality genomes (n=20; <2Mb and/or >1000 contigs) and genomes with 
< four ST-11 MLST alleles (n=1,387) were removed from the dataset. The English invasive 
serogroup W ST-11 CC isolates (n=897; section 3.3.2) were also removed. The remaining 
genomes (n=2,214) were serogroup W ST-11 CC isolates (n=2,197) and closely related 
serogroup W ST-11 CC genomes with incomplete MLST profiles with four or more ST-11 
MLST alleles (n=17). 
 
3.3.2.1 Non-MGL isolates closely related to English invasive penicillin-resistant serogroup W 
ST-11 clonal complex isolates 
 
To firstly identify genomes of non-MGL serogroup W ST-11 CC isolates of the original UK 
and UK 2013 strains, genomes (n=2,214; section 3.3.3), were split into eight manageable 
groups and underwent phylogenetic analysis with the Argentinian South American strain 
reference genomes (n=5) and an Original UK strain reference genome (30154) (Appendix 
24).  
To identify those belonging to any of the penicillin-resistant associated lineages previously 
identified (1-6; section 3.3.2), non-MGL genomes of the Original UK and Original 2013 
(n=1,152) were split into four manageable groups (a-d; Figure 3-35) and each underwent 
phylogenetic analysis with the English invasive PenR serogroup W ST-11 CC genomes (n=25) 
and South American strain reference genomes (n=5). One hundred and thirty-one non-MGL 
serogroup W ST-11 CC genomes belonged to penicillin resistance-associated lineages 1 to 




Figure 3-35: Non-MGL serogroup W isolates of ST-11 clonal complex of South 
American sublineage belonging to the English penicillin resistance-associated 
























Figure 3-35 (continued). 
 
Core genome comparison of 1605 core genome loci of English penicillin-resistant invasive 
serogroup W ST-11 clonal complex isolates (n=25) and non-MGL serogroup W ST-11 
complex isolates (n=2,214; English invasive isolates removed). The non-MGL genomes split 
into groups labelled a-d. Each network contains English penicillin-resistant invasive 
serogroup W ST-11 complex isolates (PenR; n=25) and South American reference isolates 
































3.3.3 The penicillin resistance-associated lineages 
 
3.3.3.1 Penicillin resistance-associated lineage 1 – The Australian penicillin resistance-
associated lineage 
 
Penicillin resistance associated lineage 1, termed the Australian penicillin resistance-
associated lineage, included n=122 isolates, counting those PenR serogroup W ST-11 CC 
isolates previously reported  by Mowlaboccus and colleagues in 2016 (n=5) (Mowlaboccus 
et al., 2017).  
Genomes of isolates in the Australian penicillin resistance-associated lineage underwent 
phylogenetic analysis which revealed two separate clusters (A and B; Figure 3-36). Cluster 
A comprised n=18 genomes of isolates from England (n=12; 2014-2018), Ireland (n=4; 2013-
2015), Scotland (n=1; 2017) and Sweden (n=1; 2018). All genomes in cluster A harboured 
penA1 and where MIC data were available were PenS (n=10; MICs = 0.032-0.64 mg/L) or 
PenI (n=2; MICs = 0.094-0.125 mg/L).  
Cluster B comprised n=104 genomes of isolates from New Zealand (n=35; 2016-2018), 
Canada (n=21; 2015-2019), England (n=21; 2016-2019), Spain (n=8; 2017-2020), Ireland 
(n=5; 2017-2019), Sweden (n=5; 2016-2019), the Netherlands (n=4; 2016-2019), France 
(n=2; 2016), Greece (n=1; 2017), Italy (n=1; unknown) and Japan (n=1; 2017). Ninety-eight 
percent of cluster B genomes (n=102) harboured penA9 and for those with known MICs 
were PenR (n=35; MICs = 0.38-1.0 mg/L), PenI (n=19; 0.19-0.25 mg/L) or PenS (n=1; MIC = 
0.03 mg/L). Sixty-eight percent of Cluster B isolates (n=71) were identified in 2017 and 2018 









Figure 3-36: Serogroup W ST-11 clonal complex isolates of penicillin resistance-
associated lineage 1 (Willerton et al., 2021). 
 
Core genome comparison based on 1605 core genome loci of serogroup W ST-11 complex 
isolates belonging to penicillin resistance-associated Lineage 1 (n=122). The number of 
variable loci among the 1605 compared is represented by the scale bar. 
Non-Australian penicillin resistance-























3.3.3.2 Penicillin resistance-associated lineage 2 – The UK 2013 penicillin resistance-
associated lineage  
 
Penicillin resistance-associated lineage 2, termed the UK 2013 penicillin resistance-
associated lineage, contained n=62 genomes which underwent phylogenetic analysis to 
reveal two separate clusters (clusters A and B; Figure 3-37).  
Cluster A contained n=49 genomes from England (n=25; 2016-2019), Germany (n=6; 2018-
2019), Scotland (n=4; 2017-2020), Ireland (n=3; 2017-2018), the Netherlands (n=3; 2016-
2018), Wales (n=3; 2016-2019), France (n=1; 2018), Northern Ireland (n=1; 2016), Portugal 
(n=1; 2019), Spain (n=1; 2019) and Sweden (n=1; 2018). All genomes in Cluster A possessed 
penA1 and where MICs were known, isolates were PenS (n=23; MICs = 0.047-0/064mg/L) 
or PenI (n=6; MICs = 0.094 mg/L).  
Cluster B comprised n=13 genomes from England (n=11; 2017-2019), Scotland (n=1; 2019) 
and Sweden (n=1; 2018). All genomes harboured penA14 and where MICs were known 
were PenR (n=3; MICs = 0.38-0.5 mg/L) or PenI (n=8; MICs = 0.25 mg/L).  Sixty-nine percent 
of cluster B isolates (n=9) were identified in 2019 alone (Appendix 26).  
 
3.3.3.3 Penicillin resistance-associated lineage 3  
 
Penicillin resistance-associated lineage 3, belonging to the UK 2013 strain, comprised n=4 
genomes from England (n=2; 2018-2019), Spain (n=1; 2017) and Scotland (n=1; 2020). The 
English genomes harboured penA540 and were PenR (MICs = 0.38 mg/L). The remaining 
genomes harboured penA1 (MICs unknown).  
 
3.3.3.4 Penicillin resistance-associated lineage 4, 5, 6 and the singleton 
 
Penicillin resistance-associated lineages 4, 5 and 6 (comprised n=12, n=2 and n=10 isolates 
respectively) contained one PenR isolate each from England (penA9, penA435 and penA9, 
respectively; MIC = 0.38 mg/L) together with isolates harbouring penA1 (MICs = 0.006 – 
0.125 mg/L). The English singleton was PenR (MIC = 0.38 mg/L) harbouring penA171.  
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Figure 3-37: Serogroup W ST-11 clonal complex isolates of penicillin resistance-
associated lineage 2 (Willerton et al., 2021). 
 
Core genome comparison of 1605 core genome loci of serogroup W ST-11 clonal complex 
isolates of penicillin resistance-associated lineage 2 (n=62). The number of variable loci 
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3.3.3.5 Species distribution of penA alleles identified among English penicillin-resistant 
serogroup W ST-11 clonal complex isolates 
 
PubMLST genomes that had any of the penA alleles harboured by the English PenR 
serogroup W ST-11 CC isolates were identified (Table 3-17; penA14, n=1,099; penA9, 
n=763; penA540, n=18; penA171, n=8; penA435, n=1; accessed 12/06/2020). PenA540 and 
penA435 were found among meningococcal isolates only (n=18 and n=1 respectively). 
PenA9 was found among N. meningitidis (n=705), N. gonorrhoeae (n=37), N. lactamica 
(n=13), N. polysaccharea (n=4), N. cinerea (n=3) and N. bergeri (n=1).  PenA14 was found 
among N. meningitidis and N. gonorrhoeae isolates (n=1,085 and n=14, respectively) as was 
penA171 (n=6 and n=2, respectively) (Willerton et al., 2021).  
 
Table 3-17: PubMLST Neisseria isolates possessing penA alleles identified 
among English penicillin-resistant invasive serogroup W ST-11 clonal complex 



























































































9 763 1 3 37 13 4 705 
ST-11 (n=158), ST-32 (n=108), ST-198 
(n=85), UA (n=55), NK (n=50), ST-865 
(n=45), ST-41/44 (n=36), ST-23 (n=32), 
ST-213 (n=24), Incomplete MLST (n=10), 
Other (n=102) 
14 1099   14   
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5 
ST-22 (n=372), ST-269 (n=182), ST-41/44 
(n=88), UA (n=98), NK (n=81), ST-213 
(n=43), ST-162 (n=41), ST-11 (n=34), ST-
1157 (n=25), Incomplete MLST (n=24), 
ST-60 (n=23), Other (n=74) 
171 8   2   6 
ST-865 (n=2), ST-103 (n=1), ST-11 (n=1), 
ST 41/44 (n=1), UA (n=1) 
435 1      1 ST-11 (n=1) 
540 18      18 
UA (n=14), ST-11 (n=2), ST-269 (n=1), 
Incomplete MLST (n=1) 





Except for sulphonamides, N. meningitidis has remained largely susceptible to the 
antibiotics used for treatment and prophylaxis of IMD. Resistance to 3GCs, ceftriaxone and 
cefotaxime, among meningococci are seldom reported, with only one study having 
reported this thus far (Manchanda and Bhalla, 2006).  However, a lack of adequate strain 
characterisation has cast doubt among concerned researchers (Nicolas, 2007), whose calls 
for further testing of the isolates are yet to be answered. Ciprofloxacin resistance among 
meningococci had been sporadically reported across the globe, apart from in China, where 
it is highly prevalent (Zhu et al., 2014). Rifampicin resistance is uncommon in meningococci 
isolated from index cases and is more frequently reported amongst those from close 
contacts, where rifampicin has previously been used for chemoprophylaxis. Reduced 
susceptibility and resistance to penicillin among meningococci is becoming increasingly 
reported across the globe, due to alterations within the penA gene (Bowler et al., 1994).  
In the UK, the MRU has been performing AST on all IMD isolates alongside WGS of isolates 
since July 2010. Analysis of the data had not been undertaken prior to this project, and 
therefore the distribution of ABR among IMD isolates in the UK is currently unknown.  
The aim of this project was to analyse MIC values (penicillin, rifampicin, ciprofloxacin and 
cefotaxime) and WGS data for all isolates from culture-confirmed cases of IMD in England, 
Wales and Northern Ireland from July 2010 to June 2019. Further aims were to investigate 
an observed increase in IMD caused by penicillin-resistant serogroup W ST-11 CC isolates 
and to investigate a recent outbreak of meningococcal disease caused by ciprofloxacin-
resistant NG isolates.  






4.1 Penicillin susceptibility among IMD isolates in England, Wales and Northern 
Ireland 
 
Out of the 4,122 IMD isolates received at the MRU from July 2010 to June 2019, 113 were 
PenR (MICs = 0.38-0.75 mg/L). Sixty-four were serogroup B, 25 were serogroup W, 13 were 
serogroup C, nine were serogroup Y, one was serogroup W/Y and one was NG. Prior to 
2015/16, the annual proportion of PenR isolates was always less than or equal to 2%, 
however has been greater than 3% in each subsequent year, with the highest proportion 
of PenR isolates observed in 2018/19 (7%).  This was largely due to an increase in the 
number of PenR isolates received and suggests that, as has been reported in other 
countries, penicillin resistance among meningococci is increasing gradually with time 
(Bertrand et al., 2012; Mowlaboccus et al., 2017; Vacca et al., 2018). 
Amongst the PenR isolates, an increase in the number of Serogroup W ST-11 CC isolates 
was observed over recent years, particularly since 2018. From July 2010 to August 2019, 25 
English MenW ST-11 CC PenR isolates were received at the MRU; 17 of these were received 
from January 2018 – August 2019 alone. After an outbreak of MenW disease following a 
Hajj pilgrim in 2000, MenW disease has increased globally (Abad et al., 2014; Mustapha et 
al., 2016; Knol et al., 2017). In 2009, MenW disease in England began to increase, mainly 
due to the expansion of two strains, the Original UK and UK 2013 strains, that descended 
from a South American strain (Lucidarme et al., 2016). In 2016, Australia identified a 
penicillin-resistant clade of MenW ST-11 CC isolates belonging to the Original UK strain 
(Mowlaboccus et al., 2017).  
Among the serogroup W ST-11 CC English isolates, six distinct penicillin resistance-
associated sublineages (1-6) were identified. Penicillin resistance-associated lineage 1, 
which contained 16 English PenR isolates, was an expansion of the strain identified in 
Australia in 2016. Further analysis to include PubMLST isolates identified other serogroup 
W ST-11 CC isolates from nine countries across Europe and isolates from Canada, Japan and 
New Zealand, resulting in a total of 122 isolates within penicillin resistance-associated 
sublineage one. This signifies that this lineage is highly successful in causing IMD due to 
being widespread and suggests that it is likely to continue causing IMD.  
122 
 
Penicillin resistance-associated lineage 2 included three English PenR isolates from 2017-
2019 which harboured penA14 (five AASs associated with conferring reduced susceptibility 
and resistance to penicillin). An isolate from Scotland (2019) and an isolate from Sweden 
(2018) also belonged to penicillin resistance-associated lineage 2 and harbouring penA14. 
PenA14 has been previously reported among several meningococci with reduced 
susceptibility to penicillin  (Taha et al., 2007). Penicillin resistance-associated lineage 3 
included two PenR English isolates from 2018 and 2019 which harboured penA540 (five 
AASs associated with penicillin resistance). Given that the strain identified in Australia has 
spread over the last few years, penicillin resistance-associated lineages 2 and 3 require 
continued surveillance to monitor the potential spread. Penicillin resistance-associated 
lineages 4-6, contained just one PenR isolate (penA allele 9 or 435; five AASs associated 
with penicillin resistance), which suggests a transient recombinant that may not be 
encountered again.  Most isolates in these sublineages were identified after 2016 and 
appear more predominant with time, suggesting that PenR MenW ST-11 CC isolates may 
continue to rise.  
Historically, penicillin has been the antibiotic of choice in the treatment of IMD 
(Oppenheim, 1997; Sáez-Llorens and McCracken, 1999; van de Beek et al., 2002). Following 
initial observations of meningococci with reduced susceptibility to penicillin, usual doses of 
the antibiotic were thought to be effective against such strains (Uriz et al., 1991). However, 
reports of treatment failure in cases of IMD caused by strains with reduced susceptibility 
and resistance to penicillin were also reported (Turner et al., 1990; Bardi et al., 1994), which 
led to the recommendation of higher doses of penicillin (Jones and Sutcliffe, 1990). 
However, due to the ease of use of 3GCs, combined with inconsistent antibiotic 
susceptibility testing and increasing penicillin resistance among meningococci, 3GCs have 
been the preferred first line treatment of IMD over more recent years (Public Health 
England, 2012; Blain et al., 2016).  
In the UK, penicillin is only administered to patients in primary care with suspected IMD 
prior to the administration of 3GCs in secondary care (National Institute for Health and Care 
Excellence, 2015). In the USA, whilst either 3GCs or penicillin are recommended for 
treatment, recent studies suggest that penicillin is rarely used to treat IMD exclusively 
(Blain et al., 2016). Additionally, following a recent increase in penicillin resistant serogroup 
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Y meningococci in the USA, is it recommended that penicillin susceptibility of isolates is 
determined prior to use of the antibiotic in the treatment of IMD (Centers for Diseases 
Control and Prevention, 2019).  
Whilst the relatively limited use of penicillin suggests that the increase in penicillin 
resistance among meningococci observed in this study may not be as clinically significant 
as if penicillin was exclusively used in IMD treatment, surveillance and awareness of such 
resistance remains of importance, particularly for clinicians managing patients at high risk 
for IMD development, for which penicillin prophylaxis is recommended for IMD prevention. 
Individuals with terminal complement deficiencies and those undergoing Eculizumab 
treatment are at risk for IMD development due to their inability to mediate meningococcal 
cell lysis by the formation of the MAC (Ladhani et al., 2019). This remains the case even 
after receipt of preventative meningococcal vaccinations, where effectiveness is unclear in 
such individuals, with cases of vaccine failures reported (McNamara et al., 2017; Ladhani 
et al., 2019). Penicillin prophylaxis to further reduce the risk of IMD development is 
therefore also recommended, however cases of IMD among immunocompromised 
individuals due to meningococcal strains resistant to or displaying reduced susceptibility to 
penicillin have been reported (McNamara et al., 2017; Parikh et al., 2017). Awareness and 
vigilance of strains associated with penicillin resistance, such as the expanding serogroup 
W ST-11 CC strain identified in this study, is therefore essential for maintaining effective 
prophylactic regimes and in preventing IMD among high-risk patients. 
Even in immunocompetent individuals, not all meningococcal strains are covered by the 
preventative vaccines. Whilst IMD following vaccination with the ACWY vaccine is rare, the 
MenB Bexsero vaccine is estimated to cover only 73-88% of meningococcal group B strains 
(Parikh et al., 2016). Whilst global vaccination is key in the prevention of IMD, antibiotic 
treatment of the disease and therefore surveillance of antibiotic resistance amongst this 
species remains paramount.  
Most of the PenR isolates identified in this study harboured penA alleles that contained the 
five AASs (F504L, A510V, I515V, H541N, and I566V) associated with penicillin resistance 
which have been observed among isolates worldwide (Antignac et al., 2003; Vázquez et al., 
2003; Taha et al., 2006a; Vacca et al., 2018).  
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Three PenR isolates possessed penA alleles with only a partial set of the AASs associated 
with conferring reduced susceptibility and resistance to penicillin. One of these harboured 
penA327, which contains four out of the five AASs Penicillin-resistant meningococcal 
isolates possessing penA327 has been reported previously (Deghmane et al., 2017). 
PenA327 contains an additional AAS; G545S. Forty-one penA alleles were identified on 
PubMLST that contained G545S, three of which did not have any of the five AASs associated 
with penicillin resistance. MIC data were unavailable for the isolates containing G545S 
independently of the five AASs. Further work is therefore required to determine the 
possible role of residue G545, and the absence of I566V, in relation to penicillin resistance. 
PenA327 has also been associated with reduced susceptibility to 3GCs (Deghmane et al., 
2017).  All IMD isolates with penA327 that were received at the MRU, also displayed 
reduced susceptibility to cefotaxime (section 4.3).  
One PenR isolate received at the MRU harboured penA209, an allele that had only three of 
the AASs associated with conferring reduced susceptibility and resistance to penicillin 
(F504L, A510V and I515V). The allele also had AASs V447L and A516G. Other penA alleles 
on PubMLST that contained the same three AASs without V447L and A516 had lower 
penicillin MICs (0.047-0.094 mg/L) compared to those that did have V447L and A516 (0.12-
0.5 mg/L). This suggests that penA alleles harbouring only these three AASs associated with 
conferring reduced susceptibility and resistance to penicillin may not be adequate to confer 
penicillin resistance alone, however, it may be the case that they can cause reduced 
susceptibly and resistance to penicillin when in combination with V447 and A516. Future 
work is therefore needed to confirm the role that these AASs have in conferring resistance 
to penicillin. PenA alleles containing V447 and A516 were found among a much larger 
proportion of gonococcal isolates on PubMLST compared to meningococcal isolates, which 
suggest that these AASs may have originated in this species and were introduced into 
meningococci during a HGT event.  
One PenR isolate (MIC = 0.38 mg/L, serogroup W ST-11 CC) harboured penA171, an allele 
which contained none of the AASs associated with conferring reduced susceptibility and 
resistance to penicillin. PenA171 contained AAS P551S, which has been observed among 
gonococcal isolates resistant to penicillin (Whiley et al., 2010). However, this study did not 
confirm whether the penA alleles harboured by these gonococcal isolates also contained 
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the five AASs associated with penicillin resistance among meningococcal isolates.  Other 
meningococcal isolates that possessed penA171 were identified on the PubMLST database 
and were penicillin-susceptible, signifying that penA171, and the P551S AAS alone, are not 
responsible for causing penicillin resistance among meningococci. This suggests that 
another mechanism may be responsible for causing penicillin resistance in this PenR isolate 
and further work is therefore required to determine the cause. Penicillin resistance among 
meningococci caused by the production of beta-lactamase is rare and is associated with 
isolates displaying higher levels of penicillin resistance (MICs >2 mg/L) (Dillon et al., 1983; 
Botha, 1988; Fontanals et al., 1989). This isolate was beta-lactamase negative, which 
reflects the relatively low level of penicillin resistance displayed (MIC = 0.38 mg/L). 
Alternative mechanisms of penicillin resistance have been determined among N. 
gonorrhoeae, which include mutations in the transcriptional repressor of the efflux pump 
(mtrCDE) operon, which is encoded by the mtrR gene (Maness and Sparling, 1973). The 
operation of the mtrCDE efflux pump in meningococci appears to differ than in that of N. 
gonorrhoeae (Rouquette-Loughlin et al., 2004), where the mtrCDE operon is not subject to 
the mtrR regulatory scheme, and there is no evidence to suggest that mutations in the mtrR 
gene of meningococci can cause penicillin resistance as in gonococci.  
 
4.2 Ciprofloxacin susceptibility among IMD isolates in England, Wales and 
Northern Ireland 
 
Out of the 4,122 IMD isolates received at the MRU from July 2010 to June 2019, five were 
ciprofloxacin-resistant).  
Each of the ciprofloxacin-resistant isolates harboured AASs in the gyrA gene (D95N or T91I) 
which have previously been associated with conferring ciprofloxacin resistance among 
meningococcal isolates worldwide (Skoczyńska et al., 2008; Hong et al., 2013; Tsang et al., 
2017). The ciprofloxacin-resistant isolate with the highest MIC (MIC = 0.5 mg/L) also 
harboured an AAS in its parC allele (D86N). Mutations in parC among meningococcal 
isolates which also harbour mutations in gyrA have been shown to cause enhanced levels 
of resistance to ciprofloxacin (MICs of 0.5–1 mg/L). This is therefore likely to have caused 
the high level of ciprofloxacin resistance observed in this isolate. 
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The five ciprofloxacin-resistant isolates received at the MRU belonged to five different 
clonal complexes. In China, where ciprofloxacin resistance is prevalent, resistance is 
commonly seen among isolates belonging to ST-4821 CC, which has also been observed 
among ciprofloxacin-resistant isolates in other countries (Zhu et al., 2014; Tsang et al., 
2017; Kawasaki et al., 2018). In the USA, a recent study identified ciprofloxacin resistance 
among several meningococcal isolates belonging to ST-23 CC (McNamara et al., 2020). 
These also produced beta-lactamase rendering them resistant to penicillin. Since the 
ciprofloxacin-resistant isolates in the present study do not seem to be prevalent among a 
certain clonal complex, it may suggest that these particular meningococcal strains have not 
successfully expanded with the altered gyrA alleles and suggests that levels of ciprofloxacin 
resistance may continue to remain low within the population. Further work may be 
performed to determine whether the mutations responsible for ciprofloxacin in these 
isolates were due to single nucleotide polymorphisms or arose through recombination. This 
may be achieved by performing phylogenetic analyses with available CC-matched genomes 
to find closest relatives followed by pairwise alignments of gyrA with these.   
 
In July 2019, after the study period for ABR among IMD isolates in E, W and NI 2010/11-
2018/19, three NG ciprofloxacin-resistant (meningococcal isolates were received at the 
MRU. The isolates were invasive (n=1) and conjunctivitis (n=2) case isolates from England, 
and were characterised as belonging to ST-175 CC.  
A phylogenetic analysis of all available ST-175 CC genomes within the PubMLST database 
identified a sublineage of NG ST-175 CC isolates, which included the genomes of the three 
English isolates and genomes of eight other isolates responsible for causing IMD across 
Europe since 2015. Seven out of these 11 isolates were ciprofloxacin-resistant and 
harboured altered gyrA alleles (gyrA187 and gyrA313) with AAS T91I. The gyrA alleles were 
found to be of Neisseria cinerea origin, highlighting the important role of HGT in the spread 
of ABR genes among the Neisseria species (Chen et al., 2020). Given that bacteria that are 
closely related have a higher propensity for HGT (Didelot and Maiden, 2010), the fact that 
these gyrA alleles of N. cinerea origin have been able to establish a steady existence in the 
ST-175 CC is concerning, as they may go on to establish a presence within more virulent 
encapsulated strains of meningococci.   
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Another sublineage of the ST-175 CC contained carriage isolates (n=4) that all harboured a 
different altered gyrA allele (gyrA152) with AAS D95N, whilst the isolates comprising the 
other ST-175 CC sublineages did not harbour altered gyrA alleles.  
The three English NG cases were linked to recent travel to Mecca, KSA (Public Health 
England, 2019). Three other NG ST-175 CC IMD isolates, isolated in Germany, were from 
asylum seekers originally from Afghanistan and Nigeria. Asylum seekers may experience 
crowded conditions which has been associated with the spread of meningococcal carriage  
(Brundage et al., 2002; Tully et al., 2006; Yezli, 2018). This suggests that the NG ST-175 CC 
strain could be more widely distributed, and that further unreported cases may have 
occurred. This highlights the necessity of worldwide genomic surveillance of IMD and ABR, 
and the Global Meningitis Genome Partnership (Rodgers et al., 2020) has been created to 
enable all nations to do so as part of the ‘Global Roadmap to Defeat Meningitis by 2030’ 
(World Health Organization, 2020). 
Outbreaks of meningococcal disease have previously been associated with pilgrimages to 
Mecca, KSA (Moore et al., 1989; Al-Gahtani et al., 1995; Aguilera et al., 2002). 
Consequently, since 2002, all pilgrims have been required to be vaccinated with the 
MenACWY polysaccharide vaccine prior to travelling, which has since prevented any 
further outbreaks (Yezli, Bin Saeed, et al., 2016). This vaccine, however, does not prevent 
IMD caused by NG meningococci and, thus, this NG ST-175 CC strain. It would also not 
prevent carriage acquisition (Wilder-Smith et al., 2003b; Nicolas et al., 2005; Ceyhan et al., 
2013). In addition, prophylaxis with ciprofloxacin is compulsory for travellers to KSA from 
countries of the African meningitis belt. This would not be effective against ciprofloxacin-
resistant strains including this NG ST-175 CC strain. Millions of doses of ciprofloxacin are 
thought to have been distributed to pilgrims over the last ten years (Zumla and Memish, 
2019), and, with the emergence of meningococcal ciprofloxacin resistance, the benefits of 
ciprofloxacin prophylaxis among travellers to KSA have been challenged (Memish et al., 
2017). 
NG meningococci are seldom responsible for IMD among healthy individuals, with NG 
disease mainly reported among immunocompromised individuals with terminal 
complement deficiencies (Ladhani et al., 2019). Among the nine NG ST-175 CC IMD isolates, 
five were isolated from individuals with immune deficiencies. Immunocompromised 
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individuals are usually recommended to have preventative meningococcal vaccinations; 
MenACWY conjugate and MenB subcapsular vaccines. MenB vaccines can offer protection 
from other strains irrespective of serogroup, including NG strains, but is dependent upon 
sufficient expression and cross reactivity of one of the sub-capsular vaccine antigens (Jiang 
et al., 2010; Serruto et al., 2012).  Vaccine effectiveness among individuals with 
complement system deficiencies is uncertain, however, with cases of IMD still reported 
despite receipt of preventative meningococcal vaccinations (McNamara et al., 2017). 
Some countries, such as the UK and France, also recommend chemoprophylaxis with 
antibiotics for immunocompromised individuals, in addition to the recommended 
preventative vaccinations (Nolfi-Donegan et al., 2018). Penicillin is usually the 
chemoprophylactic agent of choice, however penicillin-resistant IMD strains have been 
known to subvert such regimes (McNamara et al., 2017; Parikh et al., 2017). All nine NG ST-
175 CC IMD isolates displayed reduced susceptibility or resistance to penicillin (MICs = 
0.094–0.5 mg/L). Although the penicillin MICs were mostly relatively low, one isolate did 
have an MIC of 0.5 mg/L. This level of penicillin resistance was observed in an isolate 
causing IMD in an immunocompromised patient receiving penicillin prophylaxis (Parikh et 
al., 2017). This NG ST-175 CC strain is therefore particularly concerning for 
immunocompromised individuals, and low-level penicillin prophylaxis doses may be 
ineffective.  
Occasionally, ciprofloxacin may be recommended to immunocompromised individuals or 
prescribed as a rescue therapy for when symptoms of IMD occur despite other prophylactic 
regimes (Nester et al., 2011; Noone et al., 2012; Struijk et al., 2013; Hawkins et al., 2017). 
In the UK, ciprofloxacin is also the first-choice antibiotic for chemoprophylaxis of close 
contacts of patients with IMD. Ciprofloxacin will be ineffective against this NG ST-175 CC 
ciprofloxacin-resistant strain, thus highlighting the continued need for surveillance of ABR 
amongst IMD isolates. It also highlights the need for vigilance in the use of ciprofloxacin for 





4.3 Cefotaxime susceptibility among IMD isolates (2010/11-2018/19) 
 
Out of the 4,122 IMD isolates received at the MRU from July 2010 to June 2019, only seven 
had cefotaxime MICs ≥ 0.047 mg/L, and therefore isolates with these elevated cefotaxime 
MICs were rare. One of the isolates was cefotaxime-resistant (MIC = 0.25 mg/L).  
One of the isolates (MIC = 0.047 mg/L, penA11) was serogroup B and had an incomplete 
MLST profile with an exact match for ST-1867 for five loci. The isolate did not possess fHbp 
or NadA; important antigens for the MenB vaccines. Several meningococcal isolates 
belonging to ST-1867 CC have previously been identified which lack fHbp (Lucidarme et al., 
2011). Whilst such strains are rare, given a possible association of sub-capsular vaccine 
subversion with decreasing antibiotic susceptibility, surveillance of these and their 
associated ABR is essential to monitor their potential expansion.    
Five of the seven isolates harboured penA327 (MICs = 0.047–0.125 mg/L), four of which 
were serogroup C belonging to ST-11 CC and one which was serogroup B belonging to ST-
41/44 CC. PenA327 has already been identified among meningococcal isolates associated 
with reduced susceptibility to both cefotaxime and penicillin. A study by Deghmane and 
colleagues identified 25 meningococcal isolates harbouring penA327 which all belonged to 
ST-11 CC of serogroups B and C, suggesting successful clonal expansion of this particular 
strain potentially involving capsular switching (Deghmane et al., 2017). As further work, the 
distribution of this allele on a cgMLST phylogeny of ST-11 CC may be performed to see how 
widespread the gene is and whether it affects one or more sublineages. 
PenA327 is identical to that of an allele (penAXXXIV) identified among gonococcal isolates 
displaying resistance to ceftriaxone in this species (Ohnishi et al., 2011).  PenA327 has 
previously been identified among several isolates causing IMD in men who have sex with 
men and has also been identified in isolates from meningococcal urethritis cases (Taha et 
al., 2016; Deghmane et al., 2017). As gonococci infect the urogenital tract, the identification 
of penA327 among isolates from meningococci urethritis cases, suggests acquisition of the 
allele during a HGT event during mixed gonococcal urethritis infection. Increasing numbers 
of urogenital and rectal meningococcal infections have been reported over recent years, 
including those identifying the co-colonisation of hyperinvasive penicillin-resistant 
meningococcal strains and multi-drug resistant gonococci (Odile B Harrison et al., 2017).  
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Over the past few years, the emergence of a NG meningococcal strain associated with 
meningococcal urethritis has been identified across the USA (Bazan et al., 2017; Retchless 
et al., 2018). This strain appears to have acquired genes from N. gonorrhoeae that allow 
capability of nitrate dependant anaerobic growth (Tzeng et al., 2017). NG (unencapsulated) 
meningococci rarely cause invasive disease due to lack of capsule protection from 
complement mediated killing, however invasive cases caused by this NG clade have been 
reported, although it was not known whether cases were among immunocompetent 
individuals (Retchless et al., 2018). Although acquisition of ABR genes amongst this NG 
clade has not been reported, the acquisition of other gonococcal genes among 
meningococci, including penA327, in combination with the increasing identification of co-
colonisation of both species, is a cause for concern. It suggests that meningococci may 
continue to acquire gonococcal genes in the future, which could result in increasing 
numbers of antibiotic resistant meningococci with a potential to threaten the future 
treatment and prevention of IMD. 
Apart from penA327, no other penA allele has yet been associated with reduced 
susceptibility or resistance to 3GCs among meningococci. PenA327 is  similar to a 
gonococcal penA allele (penA-C1) which has the AAS A501P and has been associated with 
high levels of 3GC resistance among gonococcal isolates (Unemo et al., 2012). Other AASs 
at this position, A501T and A501V have also been described among gonococcal isolates 
displaying reduced susceptibility to cefotaxime (Whiley et al., 2007; Tomberg et al., 2017).  
Amino acid 501 is positioned close to the core of the active site motif of PBP2 (Tomberg et 
al., 2010). It is thought that the substitution of methyl side chain alanine (A501) with larger 
side chains threonine (A501T) and valine (A501V) prevents effective binding of 3GCs, and 
proline substitutions (A501P) result in further structural modifications causing higher levels 
of 3GC resistance (Unemo et al., 2012). 
The cefotaxime-resistant meningococcal isolate identified in this study harboured 
penA419. There were two AASs in the penA allele harboured by the cefotaxime-resistant 
isolate that were unique when compared to cefotaxime-susceptible penicillin-resistant 
isolates; A501T, previously seen among gonococci with reduced susceptibility to 
cefotaxime and D511V. Other isolates with penA alleles with AASs at positions 501 and 511 
were identified on PubMLST and further isolates stored at the MRU (non-MGL) with 
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elevated cefotaxime MICs were also identified. Another unique AAS was identified among 
the non-MGL isolates that was harboured by isolates with reduced susceptibility to 
cefotaxime; N572D.   
MICs of isolates harbouring penA alleles with A501V were 0.003–0.012 mg/L while those 
with A501T were 0.047-0.125 mg/L. PenA alleles with AASs at D511 (D511V or D511G) in 
addition to A501T were 0.125-0.25 mg/L. MICs of isolates harbouring alleles with N572D 
were 0.047-0.125 mg/L. This suggests that AAS A501V does not confer reduced 
susceptibility to cefotaxime in meningococci, unlike in gonococci (Tomberg et al., 2017), 
whilst A501T may. When A501T was present in combination with an AAS at 511 (D511V or 
D511G), cefotaxime MICs among the meningococcal isolates were enhanced.   
PenA alleles with AASs at D511 are extremely rare, with only five penA alleles identified on 
PubMLST and six corresponding isolates. Further work is therefore required to determine 
the role that these AASs play in susceptibility to cefotaxime among meningococci. A501P, 
an AAS present in penA alleles among gonococcal isolates with reduced susceptibility to 
3GC, was not identified among any meningococcal penA alleles in this study.  However, it 
has been suggested that this mutation may eventually be selected in meningococci (Zapun 
et al., 2016), especially given that penA327 was likely acquired by gonococci through HGT 
during co-colonisation.  Whilst resistance to 3GC remains extremely rare among 
meningococci continued surveillance of resistance and reduced susceptibility to 3GCs is 
vital to ensure continued effective use in the treatment of IMD.   
Ceftriaxone is currently the final remaining treatment option for N. gonorrhoeae in many 
countries, for which treatment failures are still identified (Unemo, 2015). Failure to develop 
new effective antibiotics for the ever-increasing numbers of gonococcal infections could 
eventually contribute to increasing ABR among meningococci in the future, given the use 
of similar antibiotics and increasing reports of co-colonisation and opportunities for HGT 
between the two species. Major efforts in vaccine development for N. gonorrhoeae in 
recent years have, however, identified new targets in the hope to combat ABR gonococci 




In gonococci, mutations in the mtrR gene have previously been associated with reduced 
susceptibility to 3GCs (Lindberg et al., 2007; Zhao et al., 2009). The mtrR allele possessed 
by the cefotaxime-resistant IMD isolate in the present study was mtrR249. There was a 
frameshift at the beginning of the gene (AA position 5), however there were no other 
isolates on PubMLST harbouring this or other mtrR genes with a frameshift at a similarly 
early position. Those with frameshifts later in the gene were cefotaxime-susceptible. It 
might be speculated that the corresponding, relatively less-truncated, products are still 
able to function, however, it has been suggested that mtrCDE efflux pump is independent 
of the mtrR gene among meningococci (Rouquette-Loughlin et al., 2004), and with no 
studies suggesting mutations in the mtrR gene causes ABR among this species,  it is unlikely 
that the mtrR gene is responsible for the cefotaxime resistance displayed by this isolate. 
Further research is required to determine the role that the mtrR gene may play in ABR 
among meningococci. 
 
4.4 Rifampicin susceptibility among IMD isolates (2010/11-2018/19) 
 
Out of the 4,122 IMD isolates received at the MRU from 2010/11-2018/19, only two were 
resistant to rifampicin.  
Whilst resistance to rifampicin has been reported among meningococci, it is rare given its 
widespread use as a prophylactic agent. The majority of meningococcal rifampicin 
resistance is found among isolates from cases of close contacts following rifampicin 
prophylaxis (Rainbow et al., 2005; M. Taha et al., 2006b). However, rifampicin resistance 
has also been observed among index cases (Stefanelli et al., 2001; Skoczynska et al., 2009). 
There was no evidence to suggest that the two rifampicin-resistant isolates received at the 
MRU were from close contact cases.  
One rifampicin-resistant isolate (MIC = 0.5 mg/L) was serogroup C belonging to ST-11 CC 
harbouring rpoB238, whilst the other rifampicin-resistant isolate (MIC = >32 mg/L) was 
serogroup B belonging to ST-41/44 CC harbouring rpoB84.  When aligned to a WT rpoB 
allele (allele 1), rpoB238 harboured one AAS (D545E) whilst rpoB84 harboured four (H555N, 
I624V, D625N, S654K). Amino acid substitutions at AA positions 545 and 555 have been 
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reported among rifampicin-resistant meningococcal isolates, with mutations at AA position 
555 associated with higher levels of resistance than those with mutations at AA position 
545 (Taha et al., 2010).  Previous studies have also identified the same AASs among multiple 
isolates with varying levels of rifampicin resistance (Carter et al., 1994; Stefanelli et al., 
2001).   This, along with the observed difference in rifampicin MIC values displayed by the 
two resistant isolates in this study, may indicate that additional unknown mechanisms can 
cause increased levels of resistance among meningococci, and further work is needed to 
identify such factors. 
Mutations in the mtrR gene have been associated with increased levels of rifampicin 
resistance among gonococcal isolates (Hagman et al., 1995; Rouquette-Loughlin et al., 
2004).  However, the mtrR alleles possessed by the two rifampicin-resistant isolates in this 
study were also observed among rifampicin-susceptible isolates in this study, suggesting 
that this gene did not contribute to the observed rifampicin resistance.   
Rifampicin resistance has been observed among meningococcal isolates from a range of 
CCs (Stefanelli et al., 2001; M. Taha et al., 2006b). Resistance to rifampicin was rare among 
meningococcal isolates in this study and observed among different clonal complexes, 
suggesting a lack of clonal expansion. It has been suggested that mutations in the rpoB gene 
causes a biological fitness cost to meningococci, and a lack of survival in the bloodstream 
has been demonstrated in mice models (Colicchio et al., 2015).  
Despite the low levels of rifampicin resistance observed among IMD isolates in this study, 
continued monitoring of ABR among meningococci is essential to ensure that the low levels 
of rifampicin resistance remain. This will ensure the continued effective use of rifampicin 
as a chemoprophylactic agent, which may be administered as a suitable alternative to 
ciprofloxacin, for example against ciprofloxacin-resistant strains.  
 
4.5 Conclusion and further work 
 
From 2010/11-2018/19, ABR was rare among IMD isolates from E, W and NI. However, 
resistance to all four antibiotics (penicillin, rifampicin, cefotaxime and ciprofloxacin) was 
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observed among the IMD isolates. Only one isolate was resistant to more than one 
antibiotic (penicillin and cefotaxime). 
Out of the four antibiotics, meningococcal resistance to penicillin was the most common 
and appeared to become more prevalent over the last four years (2015/16 – 2018/19), with 
the highest annual proportion of penicillin-resistant isolates (MICs > 0.38 mg/L) observed 
in the final year of the study period (2018/19), where 7% of IMD isolates were penicillin-
resistant. The proportion of IMD isolates displaying reduced susceptibility to penicillin 
(MICs = 0.094-0.25 mg/L) remained fairly consistent each year, representing 34% of IMD 
isolates over the whole study period, however was highest in the final year of the study 
period, where 41% of IMD isolates displayed reduced susceptibility to penicillin.  
Penicillin resistance among the IMD isolates was mainly due to altered penA genes 
containing all five of the AASs previously associated with conferring penicillin resistance 
among meningococci. Penicillin resistance was also observed among IMD isolates 
possessing penA genes with only four of these AASs; penA allele 327, which has also been 
shown to be responsible for conferring penicillin resistance among meningococci. One 
penicillin-resistant IMD isolate harboured a penA gene with only three of these AASs 
(penA209), an allele which possessed additional AASs (V447L and A516G) and which were 
associated with meningococcal isolates displaying higher penicillin MIC values compared 
to penA alleles with only the three AASs without the additional AASs. One penicillin-
resistant IMD isolate harboured a penA gene with none of the five AASs. The isolate 
harboured an mtrR allele (mtrR217) which was unique to this isolate on PubMLST. 
However, the mtrR allele possessed an AAS (S32W) found among other mtrR alleles among 
gonococcal isolates on PubMLST that were penicillin-resistant and whose penA alleles did 
not contain all five of the AASs previously associated with conferring resistance to penicillin. 
Further work is needed to determine whether this mtrR gene, or any of the other unique 
genes identified in this isolate, can cause penicillin resistance among meningococci.  
Over the last four years (2015/16-2018/19) an annual increase in the proportion of 
penicillin-resistant serogroup W IMD isolates belonging to CC11 was observed. This 
coincides with the time in which Australia reported the emergence of a penicillin-resistant 
clade of serogroup W ST-11 CC isolates.  Phylogenetic analysis of serogroup W ST-11 CC 
isolates from England and the rest of the world identified an expansion of the penicillin-
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resistant Australian clade to include several penicillin-resistant serogroup W ST-11 CC 
isolates harbouring penA9 from England and several other countries from across the globe. 
A second expanding penicillin resistant-associated lineage of serogroup W ST-11 CC isolates 
harbouring penA14 from England and European countries was also identified.  
Isolates in these lineages were more frequently identified after 2016, becoming more 
prevalent with time, indicating successful clonal expansion and suggesting that the number 
of penicillin-resistant serogroup W ST-11 CC isolates may continue to increase over the 
coming years. Surveillance of penicillin resistance among IMD isolates with close 
monitoring of serogroup W ST-11 CC isolates is therefore paramount to ensure successful 
use of the antibiotic in treatment and as a chemoprophylactic agent.  
Five ciprofloxacin-resistant IMD isolates identified from 2010/11-2018/19 all belonged to 
different clonal complexes and all harboured different gyrA alleles, each with AASs 
associated with conferring ciprofloxacin resistance among meningococci. However, 
following an outbreak of meningococcal disease in England in July 2019, one strain of 
meningococci that was responsible for causing several cases of meningococcal disease 
throughout Europe, belonging to ST-175 CC, was identified.  
The strain comprised NG isolates and is therefore especially virulent among individuals with 
complement deficiencies who are at higher risk of IMD development and where vaccine 
effectiveness is unknown.  As well as immunocompromised individuals, the ciprofloxacin-
resistant NG ST-175 CC isolates were also found among pilgrims and asylum seekers, 
suggesting that strain may be circulating worldwide and with potentially more cases that 
may have gone unreported. Clinicians should continue to be vigilant when such individuals 
present with meningococcal disease to ensure effective treatment and prophylaxis regimes 
are maintained.  
Several IMD isolates from 2010/11-2018/19 that were penicillin-resistant also displayed 
reduced susceptibility to cefotaxime (cefotaxime MICs ≥ 0.047 mg/L). Most of these 
isolates harboured penA327, an allele already proven to cause reduced susceptibility to 
3GCs among meningococci. One isolate that displayed both penicillin and cefotaxime 
resistance harboured penA419, which, in addition to the five AASs associated with 
conferring penicillin resistance among meningococci, had other unique AASs: A501T and 
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D511A.  A wider search on PubMLST identified further isolates with penA alleles with AASs 
at these AA positions. Isolates with AASs at D511 were rare, with only five additional 
isolates identified. Where MIC values were available, the isolates displayed reduced 
susceptibility to cefotaxime (0.125 mg/L). Isolates with penA alleles with the AAS A501T 
alone also displayed reduced susceptibility to cefotaxime but MIC values were much lower 
than in isolates that harboured penA alleles with AASs at both AA positions.  
Further work is needed to confirm the role that these AASs have in conferring reduced 
susceptibility and resistance to cefotaxime.  
This study identified several IMD isolates with resistance to antibiotics used for current 
treatment and prophylaxis of IMD. It also identified emerging threats and the progression 
of antibiotic resistance among strains over time.  Sustained surveillance of ABR among the 
meningococcal population is therefore vital to maintain successful treatment regimens for 
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18968 England 2010/11 B B 269 ST-269 complex CSF 0.047 0.008 0.004 0.002
18969 England 2010/11 B B 1194 ST-41/44 complex Blood 0.064 0.008 0.004 0.003
19023 England 2010/11 B B 1161 ST-269 complex Blood 0.064 0.008 0.004 0.004
19024 England 2010/11 B B 1194 ST-41/44 complex Blood 0.19 0.006 0.003 0.003
19025 England 2010/11 B B 1831 UA Blood 0.064 0.004 0.004 0.004
19026 England 2010/11 B B 3754 ST-41/44 complex Blood 0.047 0.008 0.004 0.002
19027 England 2010/11 B B 1097 ST-41/44 complex Blood 0.047 0.008 0.004 0.004
19028 England 2010/11 B B 275 ST-269 complex Blood 0.047 0.023 0.004 0.003
19029 England 2010/11 B B 1049 ST-269 complex Blood 0.064 0.002 0.006 0.004
19030 England 2010/11 B B 461 ST-461 complex Blood 0.19 0.016 0.004 0.003
19031 England 2010/11 B B 1161 ST-269 complex Blood 0.094 0.016 0.006 0.006
19032 Wales 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.004 0.004 0.002
19958 England 2010/11 B B 9812 ST-213 complex Blood 0.047 0.006 0.003 0.003
19959 England 2010/11 B B 275 ST-269 complex Blood 0.047 0.006 0.004 0.003
19960 England 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.032 0.006 0.003
19961 England 2010/11 B B 340 ST-41/44 complex Blood 0.047 0.008 0.004 0.003
19962 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.008 0.003 0.004
19963 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
19964 England 2010/11 Y Y 183 ST-23 complex Blood 0.38 0.006 0.004 0.006
19965 England 2010/11 B B 1575 UA Blood 0.023 0.006 0.004 0.002
19966 England 2010/11 B B 4713 UA Blood 0.064 0.006 0.004 0.006
19967 England 2010/11 B B 41 ST-41/44 complex Blood 0.125 0.004 0.004 0.003
19969 England 2010/11 B B 269 ST-269 complex Blood 0.032 0.006 0.004 0.002
19970 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.006
19971 England 2010/11 B B 3802 ST-41/44 complex Blood 0.094 0.016 0.004 0.003
19972 England 2010/11 B B 41 ST-41/44 complex Blood 0.064 0.004 0.003 0.003
19973 England 2010/11 B B 2931 ST-32 complex Blood 0.125 0.023 0.004 0.008
19974 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.008 0.006 <0.002
19975 England 2010/11 B B 7833 ST-269 complex Blood 0.064 0.004 0.006 0.004
19976 England 2010/11 Y Y 9813 ST-23 complex Blood 0.064 0.006 0.004 0.004
19977 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.006
19978 England 2010/11 B B 41 ST-41/44 complex CSF 0.047 0.016 0.004 0.003
19979 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.006
19980 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
19981 England 2010/11 Y Y 9814 ST-23 complex Blood 0.047 0.004 0.004 0.003
19983 England 2010/11 B B 749 ST-32 complex Blood 0.19 0.008 0.003 0.004
19984 England 2010/11 B B 340 ST-41/44 complex Blood 0.047 0.006 0.006 0.003
19985 Wales 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.008 0.004 0.003
19986 England 2010/11 B B 1163 ST-269 complex Blood 0.25 0.006 0.006 0.004
19987 Wales 2010/11 B B 1161 ST-269 complex Blood 0.125 0.008 0.004 0.008
19988 England 2010/11 B B 9815 ST-41/44 complex CSF 0.047 0.016 0.004 0.004
19989 Wales 2010/11 B B 1992 ST-41/44 complex CSF 0.19 0.008 0.004 0.003
19990 Wales 2010/11 B B 162 ST-162 complex Blood 0.25 0.064 0.004 0.006
19991 England 2010/11 B B 213 ST-213 complex Blood 0.047 0.032 0.003 0.003
19992 England 2010/11 B B 213 ST-213 complex Blood 0.064 0.008 0.004 0.004
19993 England 2010/11 B B 18 ST-18 complex Blood 0.047 0.016 0.003 0.004
19994 England 2010/11 B B 5357 ST-41/44 complex Blood 0.047 0.004 0.004 0.002
19996 England 2010/11 B B 34 ST-32 complex Blood 0.064 0.094 0.004 0.006
19997 England 2010/11 B B 3687 UA Blood 0.047 0.023 0.004 0.003
19998 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.003
19999 Northern Ireland 2010/11 NG CNL 1136 ST-1136 complex Blood 0.19 0.032 0.006 0.006
20000 England 2010/11 B B 34 ST-32 complex Blood 0.064 0.016 0.004 0.004
20001 England 2010/11 B B 9816 UA CSF 0.047 0.023 0.004 0.004
20002 England 2010/11 B B 46 ST-41/44 complex Blood 0.047 0.012 0.004 0.003
20003 England 2010/11 B B 485 ST-41/44 complex Blood 0.19 0.006 0.004 0.004
20004 England 2010/11 B B 9879 ST-41/44 complex CSF 0.047 0.012 0.004 0.004
20005 England 2010/11 B B 40 ST-41/44 complex Blood 0.125 0.047 0.003 0.004
20006 England 2010/11 Y Y 23 ST-23 complex Blood 0.047 0.006 0.003 0.003
20007 England 2010/11 B B 461 ST-461 complex Blood 0.064 0.032 0.003 0.004
20008 England 2010/11 B B 6782 ST-41/44 complex Blood 0.032 0.023 0.003 0.004
20009 England 2010/11 B B 213 ST-213 complex CSF 0.047 0.016 0.004 0.004
20010 England 2010/11 B B 41 ST-41/44 complex Blood 0.032 0.016 0.003 0.002
20011 England 2010/11 B B 41 ST-41/44 complex Blood 0.064 0.012 0.006 0.003
20012 England 2010/11 B B 1161 ST-269 complex Blood 0.064 0.016 0.004 0.004
20013 Northern Ireland 2010/11 B B 8384 ST-41/44 complex Blood 0.032 0.012 0.004 0.003
20014 England 2010/11 B B 41 ST-41/44 complex Blood 0.032 0.012 0.003 0.003
20015 England 2010/11 B B 213 ST-213 complex Blood 0.016 0.047 0.003 0.003
20016 England 2010/11 C C 5133 ST-103 complex Blood 0.008 0.064 0.003 <0.002
20017 England 2010/11 B B 749 ST-32 complex Blood 0.125 0.012 0.004 0.008
20018 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.006 0.006 0.003
20019 England 2010/11 B B 1161 ST-269 complex CSF 0.064 0.012 0.006 0.004
20020 England 2010/11 B B 9817 UA Blood 0.064 0.094 0.003 0.006
20021 England 2010/11 W W 1224 ST-22 complex Blood 0.094 0.016 0.004 0.003
20022 England 2010/11 B B 213 ST-213 complex Blood 0.19 0.032 0.003 0.004
20023 England 2010/11 E E 2435 ST-60 complex Blood 0.25 0.032 0.003 0.006
20024 England 2010/11 B B 213 ST-213 complex Blood 0.032 0.016 0.004 0.003
20025 Wales 2010/11 B B 213 ST-213 complex CSF 0.064 0.047 0.003 0.003
20026 England 2010/11 B B 9880 UA Blood 0.023 0.012 0.004 0.004
20027 England 2010/11 B B 1161 ST-269 complex Blood 0.064 0.012 0.004 0.003
20028 England 2010/11 B B 275 ST-269 complex Blood 0.047 0.006 0.003 0.003
20029 England 2010/11 B B 4401 ST-269 complex Blood 0.19 0.004 0.004 0.004
20030 England 2010/11 B B 6083 ST-32 complex Blood 0.047 0.047 0.004 0.003





20032 England 2010/11 Y Y 1655 ST-23 complex Blood 0.032 0.006 0.003 0.003
20034 Northern Ireland 2010/11 B B 42 ST-41/44 complex Blood 0.047 0.012 0.006 0.002
20035 England 2010/11 B B 1157 ST-1157 complex CSF 0.094 0.064 0.004 0.006
20036 England 2010/11 B B 275 ST-269 complex Blood 0.047 0.016 0.004 0.003
20037 England 2010/11 B B 284 UA Blood 0.032 0.012 0.004 <0.002
20038 England 2010/11 B B 1831 UA Blood 0.064 0.012 0.004 0.004
20039 England 2010/11 W W 184 ST-22 complex Blood 0.125 0.016 0.006 0.003
20040 England 2010/11 B B 5335 UA Blood 0.023 0.006 0.004 <0.002
20041 England 2010/11 Y Y 23 ST-23 complex Blood 0.047 0.004 0.004 0.004
20042 England 2010/11 Y Y 3651 ST-22 complex Blood 0.094 0.023 0.008 0.008
20043 England 2010/11 B B 283 ST-269 complex Blood 0.047 0.006 0.004 0.003
20044 England 2010/11 B B 275 ST-269 complex Blood 0.064 0.008 0.004 0.003
20045 England 2010/11 B B 2123 UA Blood 0.023 0.023 0.004 0.002
20046 England 2010/11 B B 9881 ST-213 complex Blood 0.047 0.016 0.004 0.004
20047 England 2010/11 B B 275 ST-269 complex Blood 0.19 0.008 0.006 0.008
20048 England 2010/11 B B 35 ST-35 complex Blood 0.047 0.125 0.004 0.003
20049 England 2010/11 B B 41 ST-41/44 complex Blood 0.064 0.032 0.006 0.003
20050 England 2010/11 B B 1161 ST-269 complex Blood 0.125 0.006 0.004 0.004
20051 England 2010/11 B B 9882 ST-41/44 complex Blood 0.125 0.006 0.006 0.004
20052 England 2010/11 B B 213 ST-213 complex Blood 0.047 0.016 0.004 0.003
20053 England 2010/11 W/Y W/Y 1466 ST-174 complex Blood 0.125 0.032 0.003 0.006
20054 England 2010/11 X X 9839 UA Blood 0.19 0.012 0.006 0.004
20055 England 2010/11 B B 1992 ST-41/44 complex CSF 0.047 0.004 0.006 0.003
20056 England 2010/11 B B 269 ST-269 complex Blood 0.032 0.006 0.006 0.002
20058 England 2010/11 B B 41 ST-41/44 complex Blood 0.125 0.006 0.004 0.004
20059 England 2010/11 Y Y 168 ST-167 complex Blood 0.047 0.006 0.006 0.004
20060 England 2010/11 B B 9828 UA CSF 0.047 0.032 0.006 0.002
20061 England 2010/11 B B 1575 UA Blood 0.094 0.032 0.004 0.003
20062 England 2010/11 B B 340 ST-41/44 complex Blood 0.125 0.008 0.004 0.003
20063 England 2010/11 B B 9883 ST-41/44 complex Blood 0.047 0.004 0.003 0.003
20064 Northern Ireland 2010/11 B B 269 ST-269 complex Blood 0.032 0.032 0.006 0.003
20065 Wales 2010/11 B B 18 ST-18 complex Blood 0.032 0.016 0.004 <0.002
20066 England 2010/11 B B 11 ST-11 complex Blood 0.047 0.064 0.004 0.003
20067 England 2010/11 Y Y 1655 ST-23 complex Blood 0.032 0.006 0.003 0.003
20068 England 2010/11 B B 60 ST-60 complex Blood 0.064 0.125 0.006 0.004
20069 England 2010/11 B B 154 ST-41/44 complex Blood 0.023 0.003 0.003 <0.002
20070 Wales 2010/11 B B 1090 ST-41/44 complex Blood 0.125 0.004 0.003 0.002
20071 England 2010/11 B B 1430 ST-60 complex Blood 0.064 0.016 0.004 0.004
20072 England 2010/11 Y Y 1466 ST-174 complex Blood 0.094 0.008 0.003 0.003
20073 England 2010/11 B B 282 ST-282 complex Blood 0.032 0.008 0.006 0.002
20074 England 2010/11 Y Y 6463 ST-23 complex Blood 0.047 0.006 0.004 0.003
20075 England 2010/11 B B 213 ST-213 complex Blood 0.047 0.006 0.003 0.003
20076 England 2010/11 B B 154 ST-41/44 complex Blood 0.047 0.016 0.004 0.003
20077 England 2010/11 B B 9884 ST-213 complex Blood 0.064 0.012 0.006 0.004
20078 England 2010/11 B B 269 ST-269 complex Blood 0.032 0.006 0.006 0.002
20079 England 2010/11 C C 5133 ST-103 complex CSF 0.016 0.002 0.004 <0.002
20080 England 2010/11 B B 1194 ST-41/44 complex Blood 0.19 0.008 0.004 0.004
20081 England 2010/11 B B 1195 ST-269 complex Blood 0.047 0.006 0.006 0.003
20082 England 2010/11 B B 479 ST-269 complex Blood 0.047 0.006 0.006 0.002
20083 England 2010/11 B B 275 ST-269 complex Blood 0.094 0.004 0.006 0.004
20084 England 2010/11 B B 213 ST-213 complex Blood 0.023 0.004 0.004 0.003
20085 England 2010/11 B B 9829 ST-269 complex Blood 0.032 0.006 0.004 <0.002
20086 England 2010/11 B B 461 ST-461 complex CSF 0.094 0.047 0.003 0.004
20087 England 2010/11 B B 9830 ST-213 complex Blood 0.047 0.016 0.006 0.003
20088 England 2010/11 B B 9885 ST-60 complex Blood 0.19 0.012 0.004 0.004
20089 England 2010/11 B B 34 ST-32 complex Blood 0.125 0.008 0.004 0.008
20090 England 2010/11 B B 479 ST-269 complex Blood 0.032 0.012 0.004 0.002
20091 England 2010/11 B B 318 ST-41/44 complex Blood 0.064 0.008 0.006 0.004
20092 England 2010/11 B B 41 ST-41/44 complex Blood 0.25 0.008 0.006 0.004
20093 Wales 2010/11 B B 41 ST-41/44 complex Blood 0.032 0.006 0.006 0.003
20094 England 2010/11 B B 1194 ST-41/44 complex Blood 0.047 0.006 0.006 0.002
20095 England 2010/11 B B 9840 ST-269 complex Blood 0.064 0.004 0.006 0.004
20096 England 2010/11 B B 1049 ST-269 complex Blood 0.047 0.016 0.008 0.003
20097 England 2010/11 B B 9886 ST-41/44 complex CSF 0.047 0.008 0.006 0.003
20098 England 2010/11 B B 9887 UA Blood 0.047 0.012 0.004 0.004
20099 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.004 0.008 0.008
20100 England 2010/11 B B 3934 UA Blood 0.064 0.004 0.004 0.004
20101 England 2010/11 W W 1281 ST-22 complex Blood 0.125 0.006 0.006 0.003
20102 England 2010/11 B B 8955 ST-213 complex Blood 0.064 0.012 0.004 0.004
20103 England 2010/11 B B 269 ST-269 complex Blood 0.125 0.016 0.006 0.006
20105 England 2010/11 B B 9841 ST-41/44 complex Blood 0.19 0.008 0.006 0.004
20106 England 2010/11 B B 1097 ST-41/44 complex Blood 0.064 0.004 0.004 0.003
20107 England 2010/11 B B 485 ST-41/44 complex Blood 0.25 0.006 0.006 0.004
20108 England 2010/11 B B 485 ST-41/44 complex Blood 0.19 0.006 0.008 0.004
20109 England 2010/11 B B 8203 ST-41/44 complex Blood 0.047 0.008 0.006 0.003
20110 England 2010/11 B B 213 ST-213 complex CSF 0.125 0.004 0.004 0.003
20111 England 2010/11 B B 1161 ST-269 complex Blood 0.064 0.008 0.006 0.006
20112 England 2010/11 B B 34 ST-32 complex Blood 0.047 0.032 0.006 0.004
20113 England 2010/11 B B 46 ST-41/44 complex Blood 0.047 0.006 0.008 0.002
20114 England 2010/11 W W 2114 ST-22 complex Blood 0.064 0.006 0.006 0.004
20115 England 2010/11 Y Y 1466 ST-174 complex Blood 0.094 0.032 0.003 0.004
20116 England 2010/11 B B 1938 ST-41/44 complex Blood 0.032 0.003 0.002 0.002
20117 England 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
20118 England 2010/11 B B 4051 UA Blood 0.032 0.016 0.003 0.003






20120 Wales 2010/11 B B 34 ST-32 complex Blood 0.047 0.012 0.006 0.003
20121 England 2010/11 B B 2873 ST-269 complex Blood 0.064 0.008 0.006 0.003
20122 England 2010/11 B B 1195 ST-269 complex CSF 0.047 0.008 0.006 0.002
20123 England 2010/11 B B 8068 ST-282 complex CSF 0.064 0.023 0.006 0.004
20124 England 2010/11 B B 1161 ST-269 complex Blood 0.094 0.008 0.004 0.004
20125 England 2010/11 B B 9841 ST-41/44 complex Joint 0.19 0.008 0.004 0.006
20126 Wales 2010/11 B B 1161 ST-269 complex Blood 0.094 0.008 0.006 0.004
20127 England 2010/11 B B 41 ST-41/44 complex Blood 0.25 0.008 0.006 0.006
20128 England 2010/11 Y Y 1655 ST-23 complex CSF 0.047 0.004 0.004 0.004
20129 England 2010/11 Y Y 23 ST-23 complex Blood 0.047 0.004 0.003 0.002
20130 Wales 2010/11 B B 9187 ST-213 complex Blood 0.094 0.016 0.004 0.004
20131 England 2010/11 B B 269 ST-269 complex Blood 0.032 0.006 0.006 0.003
20132 England 2010/11 Y Y 3651 ST-22 complex Blood 0.064 0.016 0.006 0.004
20133 England 2010/11 B B 1161 ST-269 complex Blood 0.094 0.032 0.004 0.004
20134 England 2010/11 B B 3447 ST-41/44 complex Blood 0.047 0.008 0.006 0.003
20135 England 2010/11 Y Y 9831 ST-23 complex Blood 0.064 0.004 0.006 0.004
20136 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
20137 Wales 2010/11 B B 5981 ST-41/44 complex Blood 0.047 0.006 0.006 0.003
20138 Wales 2010/11 B B 283 ST-269 complex Blood 0.064 0.016 0.006 0.003
20139 England 2010/11 B B 259 ST-32 complex Blood 0.064 0.008 0.006 0.006
20140 England 2010/11 B B 6782 ST-41/44 complex Blood 0.125 0.023 0.004 0.004
20141 England 2010/11 B B 32 ST-32 complex Blood 0.19 0.008 0.004 0.004
20142 England 2010/11 B B 136 ST-41/44 complex Blood 0.032 0.064 0.004 0.003
20143 England 2010/11 Y Y 1655 ST-23 complex Joint 0.047 0.004 0.004 0.003
20144 England 2010/11 B B 213 ST-213 complex Blood 0.064 0.016 0.004 0.004
20145 England 2010/11 B B 1194 ST-41/44 complex Blood 0.38 0.006 0.006 0.004
20146 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.004
20147 England 2010/11 B B 4713 UA Blood 0.064 0.008 0.004 0.004
20148 England 2010/11 B B 41 ST-41/44 complex Blood 0.19 0.006 0.004 0.004
20149 England 2010/11 B B 1092 ST-269 complex Blood 0.19 0.006 0.003 0.008
20150 England 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.012 0.004 0.003
20151 England 2010/11 B B 162 ST-162 complex Blood 0.064 0.047 0.003 0.003
20152 England 2010/11 B B 9888 ST-1157 complex Blood 0.032 0.004 0.003 0.002
20153 Wales 2010/11 B B 1161 ST-269 complex Blood 0.064 0.008 0.003 0.004
20155 England 2010/11 C C 11 ST-11 complex Blood 0.064 0.047 0.004 0.004
20156 England 2010/11 B B 1163 ST-269 complex Blood 0.064 0.006 0.004 0.003
20157 England 2010/11 B B 41 ST-41/44 complex Blood 0.032 0.004 0.003 0.003
20159 England 2010/11 W W 1224 ST-22 complex Blood 0.19 0.008 0.004 0.004
20160 England 2010/11 B B 1097 ST-41/44 complex Blood 0.064 0.003 0.004 0.003
20161 England 2010/11 B B 32 ST-32 complex Blood 0.047 0.004 0.004 0.004
20162 England 2010/11 B B 9818 ST-60 complex CSF 0.047 0.004 0.004 0.003
20163 England 2010/11 B B 7789 ST-269 complex CSF 0.064 0.006 0.004 0.004
20164 England 2010/11 Y Y 23 ST-23 complex Joint 0.25 0.004 0.004 0.008
20165 England 2010/11 B B 1946 ST-461 complex Blood 0.38 0.006 0.004 0.006
20166 England 2010/11 B B 4954 UA Blood 0.25 0.008 0.004 0.008
20167 England 2010/11 B B 9889 ST-41/44 complex Blood 0.19 0.008 0.003 0.006
20168 Wales 2010/11 B B 1161 ST-269 complex Blood 0.094 0.006 0.004 0.004
20169 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 <0.002 0.003 0.003
20170 Wales 2010/11 B B 8049 ST-32 complex Blood 0.19 0.003 0.003 0.003
20171 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.004
20172 England 2010/11 B B 2783 ST-41/44 complex Blood 0.032 0.008 0.003 0.002
20173 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.004 0.004 0.003
20174 England 2010/11 B B 42 ST-41/44 complex Blood 0.012 <0.002 0.003 <0.002
20175 England 2010/11 B B 154 ST-41/44 complex Blood 0.047 0.003 0.003 0.003
20176 England 2010/11 B B 9890 ST-32 complex CSF 0.047 0.032 0.004 0.004
20177 England 2010/11 B B 9891 ST-461 complex Blood 0.023 0.012 0.003 <0.002
20178 England 2010/11 B B 1159 UA Blood 0.047 0.004 0.003 0.003
20179 Wales 2010/11 B B 1096 ST-32 complex CSF 0.047 0.006 0.003 0.003
20180 Northern Ireland 2010/11 B B 9819 ST-41/44 complex Blood 0.032 0.006 0.004 0.004
20181 England 2010/11 B B 9820 ST-41/44 complex Blood 0.064 0.008 0.003 0.006
20182 England 2010/11 B B 8063 ST-35 complex Blood 0.125 0.012 0.003 0.004
20183 England 2010/11 B B 259 ST-32 complex Blood 0.094 0.012 0.003 0.006
20184 Wales 2010/11 B B 1161 ST-269 complex Blood 0.064 0.016 0.004 0.004
20185 Wales 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.004 0.002 0.003
20186 Wales 2010/11 B B 1097 ST-41/44 complex Blood 0.047 0.008 0.004 0.003
20187 England 2010/11 B B 1049 ST-269 complex Blood 0.047 0.003 0.003 0.003
20188 England 2010/11 B B 1049 ST-269 complex Blood 0.064 0.008 0.004 0.003
20189 England 2010/11 B B 60 ST-60 complex Blood 0.047 0.004 0.003 0.002
20190 England 2010/11 B B 60 ST-60 complex Blood 0.032 0.004 0.002 0.003
20191 England 2010/11 W W 1286 ST-22 complex Blood 0.094 0.004 0.003 0.002
20192 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.004 0.004 0.003
20193 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.004
20194 England 2010/11 B B 5849 UA Blood 0.094 0.016 0.002 0.004
20195 England 2010/11 B B 5861 ST-41/44 complex CSF 0.094 0.006 0.002 0.003
20196 Wales 2010/11 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.004
20197 Wales 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.003 0.004
20198 England 2010/11 B B 34 ST-32 complex Blood 0.19 0.004 0.004 0.008
20199 England 2010/11 Y Y 168 ST-167 complex Blood 0.047 0.008 0.003 0.002
20200 Wales 2010/11 B B 1802 ST-282 complex Blood 0.047 0.004 0.004 0.003
20201 England 2010/11 B B 1196 ST-41/44 complex Blood 0.047 0.004 0.003 0.003
20202 England 2010/11 B B 477 ST-41/44 complex Blood 0.064 0.094 0.004 0.008
20203 England 2010/11 B B 1946 ST-461 complex Blood 0.19 0.006 0.003 0.004
20204 England 2010/11 Y Y 9842 ST-23 complex Blood 0.094 0.008 0.004 0.008
20205 Wales 2010/11 B B 9843 ST-269 complex Blood 0.032 0.006 0.002 0.003




20207 England 2010/11 B B 213 ST-213 complex Blood 0.047 0.012 0.003 0.004
20208 England 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.006 0.003 0.003
20209 England 2010/11 B B 60 ST-60 complex Blood 0.064 0.004 0.003 0.004
20210 England 2010/11 B B 213 ST-213 complex CSF 0.064 0.008 0.003 0.004
20211 Wales 2010/11 B B 461 ST-461 complex Blood 0.19 0.006 0.003 0.006
20212 England 2010/11 B B 41 ST-41/44 complex Blood 0.064 0.006 0.004 0.003
20213 Wales 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.002
20214 Wales 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.004 0.003 0.003
20215 England 2010/11 B B 11 ST-11 complex Blood 0.064 0.016 0.003 0.004
20217 England 2010/11 B B 275 ST-269 complex Blood 0.19 0.008 0.004 0.006
20218 England 2010/11 B B 9832 ST-41/44 complex Blood 0.047 0.006 0.003 0.003
20219 England 2010/11 B B 2380 ST-35 complex Blood 0.064 0.004 0.003 0.003
20220 England 2010/11 B B 9833 ST-213 complex Blood 0.047 0.016 0.002 0.003
20222 England 2010/11 B B 41 ST-41/44 complex CSF 0.19 0.008 0.004 0.006
20223 England 2010/11 Y Y 7786 UA Blood 0.064 0.012 0.003 0.006
20224 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
20225 England 2010/11 B B 275 ST-269 complex Blood 0.047 0.002 0.004 0.004
20227 England 2010/11 NG Y 9844 UA Blood 0.094 0.023 0.004 0.006
20228 England 2010/11 B B 35 ST-35 complex Blood 0.047 0.006 0.004 0.003
20229 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.016 0.003 0.003
20230 England 2010/11 Y Y 767 ST-167 complex Blood 0.064 0.002 0.004 0.004
20231 England 2010/11 B B 275 ST-269 complex Blood 0.064 0.004 0.003 0.003
20232 England 2010/11 Y Y 1466 ST-174 complex Blood 0.125 0.016 0.002 0.006
20233 Wales 2010/11 B B 213 ST-213 complex CSF 0.125 0.023 0.004 0.008
20234 England 2010/11 C C 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
20235 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.004 0.003 0.002
20236 England 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.006 0.003 0.003
20237 England 2010/11 B B 1194 ST-41/44 complex Blood 0.047 0.004 0.004 0.003
20238 England 2010/11 B B 290 ST-32 complex Blood 0.064 0.006 0.003 0.002
20239 England 2010/11 B B 461 ST-461 complex Blood 0.125 0.006 0.003 0.004
20240 Wales 2010/11 B B 4997 ST-18 complex Blood 0.25 0.016 0.004 0.008
20241 England 2010/11 B B 340 ST-41/44 complex Blood 0.064 0.008 0.004 0.003
20242 England 2010/11 B B 1774 ST-269 complex Blood 0.064 0.006 0.004 0.002
20243 England 2010/11 B B 485 ST-41/44 complex Blood 0.19 0.064 0.004 0.003
20244 Wales 2010/11 C C 5133 ST-103 complex Blood 0.016 0.002 0.002 <0.002
20245 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.002
20246 England 2010/11 B B 2799 ST-41/44 complex Blood 0.047 0.003 0.003 0.002
20248 England 2010/11 B B 9239 ST-103 complex Blood 0.023 0.008 0.003 0.002
20249 England 2010/11 B B 2632 ST-41/44 complex CSF 0.047 0.012 0.003 0.002
20250 England 2010/11 B B 2931 ST-32 complex CSF 0.25 0.003 0.003 0.006
20251 England 2010/11 B B 1194 ST-41/44 complex Blood 0.19 0.006 0.003 0.004
20252 England 2010/11 B B 213 ST-213 complex Blood 0.064 0.012 0.003 0.003
20253 England 2010/11 B B 8052 ST-41/44 complex Blood 0.032 0.008 0.003 0.002
20255 Wales 2010/11 B B 5981 ST-41/44 complex Blood 0.125 0.032 0.003 0.006
20256 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.003
20257 England 2010/11 B B 9821 ST-60 complex Blood 0.094 0.008 0.003 0.002
20258 England 2010/11 B B 437 ST-41/44 complex Blood 0.064 0.004 0.003 0.003
20259 England 2010/11 B B 213 ST-213 complex Blood 0.064 0.012 0.003 0.003
20260 England 2010/11 B B 4713 UA Blood 0.064 0.003 0.003 0.003
20261 England 2010/11 B B 3537 ST-11 complex Blood 0.064 0.004 0.003 0.004
20263 England 2010/11 B B 3818 ST-41/44 complex Blood 0.047 0.006 0.003 <0.002
20264 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.003 0.003 0.003
20265 England 2010/11 B B 4713 UA Blood 0.094 0.008 0.003 0.003
20266 England 2010/11 B B 282 ST-282 complex Blood 0.047 0.012 0.003 0.003
20267 England 2010/11 B B 162 ST-162 complex Blood 0.5 0.032 0.004 0.25
20268 England 2010/11 B B 269 ST-269 complex Blood 0.064 0.008 0.004 0.004
20269 Wales 2010/11 B B 18 ST-18 complex Blood 0.047 0.008 0.003 0.004
20270 England 2010/11 B B 213 ST-213 complex CSF 0.19 0.006 0.003 0.004
20271 England 2010/11 B B 213 ST-213 complex Blood 0.064 0.012 0.003 0.003
20272 England 2010/11 B B 1161 ST-269 complex Blood 0.25 0.006 0.004 0.004
20273 England 2010/11 B B 2080 ST-41/44 complex Blood 0.023 0.003 0.002 0.002
20274 England 2010/11 B B 275 ST-269 complex CSF 0.064 0.008 0.003 0.003
20275 England 2010/11 B B 213 ST-213 complex Blood 0.094 0.008 0.003 0.004
20276 England 2010/11 B B 41 ST-41/44 complex Blood 0.047 0.004 0.003 0.002
20277 England 2010/11 B B 2314 ST-41/44 complex Blood 0.25 0.003 0.003 0.004
20278 Wales 2010/11 B B 7939 ST-269 complex Blood 0.19 0.003 0.004 0.002
20279 England 2010/11 B B 479 ST-269 complex Blood 0.047 0.032 0.004 0.002
20280 England 2010/11 B B 1475 ST-41/44 complex CSF 0.19 0.003 0.003 0.003
20281 England 2010/11 Y Y 10138 ST-23 complex Blood 0.125 0.006 0.003 0.006
20282 England 2010/11 Y Y 1466 ST-174 complex Blood 0.125 0.023 0.003 0.004
20283 England 2010/11 B B 327 ST-41/44 complex Blood 0.19 0.004 0.003 0.004
20284 England 2010/11 B B 5861 ST-41/44 complex Blood 0.25 0.008 0.004 0.003
20285 England 2010/11 Y Y 1466 ST-174 complex Blood 0.125 0.008 0.003 0.006
20286 England 2010/11 Y Y 23 ST-23 complex Blood 0.016 0.003 0.002 <0.002
20287 England 2010/11 B B 9327 ST-60 complex Blood 0.125 0.023 0.003 0.008
20289 England 2010/11 B B 10139 ST-41/44 complex Blood 0.032 0.047 0.003 0.002
20290 England 2010/11 B B 5981 ST-41/44 complex Blood 0.032 0.004 0.002 <0.002
20291 England 2010/11 B B 35 ST-35 complex Blood 0.064 0.004 0.003 0.003
20292 England 2010/11 B B 33 ST-32 complex Blood 0.064 0.008 0.003 0.003
20293 England 2010/11 B B 3138 UA Blood 0.19 0.008 0.002 0.004
20294 England 2010/11 B B 1049 ST-269 complex Blood 0.047 0.006 0.003 0.002
20295 England 2010/11 B B 213 ST-213 complex Blood 0.19 0.012 0.002 0.004
20296 Wales 2010/11 B B 9834 UA Blood 0.19 0.004 0.003 0.003
20297 England 2010/11 B B 32 ST-32 complex Blood 0.064 0.064 0.003 0.003




20300 England 2010/11 B B 8068 ST-282 complex Blood 0.094 0.008 0.003 0.004
20301 England 2010/11 B B 9892 ST-41/44 complex Blood 0.094 0.008 0.003 0.002
20302 Wales 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.002 0.004
20303 England 2010/11 B B 1097 ST-41/44 complex Blood 0.032 0.008 0.004 0.003
20304 England 2010/11 B B 1475 ST-41/44 complex Blood 0.023 0.006 0.003 <0.002
20305 Northern Ireland 2010/11 B B 340 ST-41/44 complex Blood 0.064 0.008 0.003 0.004
20306 England 2010/11 B B 461 ST-461 complex Blood 0.19 0.016 0.002 0.008
20307 England 2010/11 C C 839 ST-41/44 complex CSF 0.047 0.008 0.003 0.002
20308 England 2010/11 Y Y 1466 ST-174 complex Blood 0.125 0.008 0.002 0.003
20309 England 2010/11 Y Y 23 ST-23 complex Blood 0.125 0.002 0.002 0.004
20310 Northern Ireland 2010/11 Y Y 9893 ST-174 complex Blood 0.094 0.006 <0.002 0.004
20312 England 2010/11 B B 1194 ST-41/44 complex Blood 0.032 0.004 0.003 0.002
20313 England 2010/11 B B 1946 ST-461 complex Blood 0.125 0.016 0.002 0.003
20314 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.002 0.003 0.003
20315 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.003
20317 England 2010/11 Y Y 6463 ST-23 complex Blood 0.064 0.003 0.002 0.004
20318 England 2010/11 W W 184 ST-22 complex Blood 0.19 0.047 0.004 0.003
20319 England 2010/11 B B 35 ST-35 complex Blood 0.047 0.004 0.003 0.002
20320 England 2010/11 NG NG 9835 ST-226 complex Blood 0.047 0.19 0.004 0.002
20321 England 2010/11 C C 5238 UA Blood 0.094 0.023 0.004 0.003
20322 England 2010/11 B B 1161 ST-269 complex CSF 0.094 0.008 0.004 0.004
20323 England 2010/11 B B 3482 UA Blood 0.047 0.006 0.002 0.003
20324 England 2010/11 B B 1194 ST-41/44 complex Blood 0.094 0.008 0.004 0.003
20325 England 2010/11 B B 1194 ST-41/44 complex Blood 0.064 0.004 0.004 0.003
20326 England 2010/11 B B 9845 UA Blood 0.064 0.006 0.004 0.004
20327 England 2010/11 B B 1960 ST-41/44 complex Blood 0.094 0.006 0.004 0.004
20328 England 2010/11 NG E 60 ST-60 complex PUS, HIP 0.032 0.004 0.003 0.003
20329 England 2010/11 C C 11 ST-11 complex CSF 0.064 0.125 0.004 0.003
20330 England 2010/11 B B 1194 ST-41/44 complex Blood 0.064 0.006 0.004 0.002
20331 England 2010/11 B B 8944 UA Blood 0.094 0.016 0.003 0.004
20333 England 2010/11 B B 1090 ST-41/44 complex Blood 0.19 0.008 0.003 0.002
20334 England 2010/11 B B 9822 ST-41/44 complex Blood 0.064 0.032 0.004 0.003
20335 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.002 0.003 0.004
20336 England 2010/11 B B 41 ST-41/44 complex Blood 0.25 0.008 0.004 0.003
20337 England 2010/11 W W 184 ST-22 complex Blood 0.094 0.002 0.004 0.002
20338 England 2010/11 A A 4789 ST-5 complex Blood 0.047 0.125 0.5 0.003
20339 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.004
20340 England 2010/11 B B 9836 ST-269 complex Blood 0.047 0.008 0.004 0.002
20341 England 2010/11 B B 213 ST-213 complex Blood 0.064 0.016 0.004 0.003
20342 England 2010/11 B B 213 ST-213 complex Blood 0.19 0.008 0.003 0.004
20343 England 2010/11 B B 1090 ST-41/44 complex Blood 0.19 0.012 0.002 0.003
20344 England 2010/11 B B 269 ST-269 complex Blood 0.125 0.004 0.003 0.002
20345 England 2010/11 B B 41 ST-41/44 complex CSF 0.125 0.006 0.003 0.006
20346 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.003 0.004
20347 England 2010/11 Y Y 1655 ST-23 complex Blood 0.023 <0.002 0.002 0.003
20348 Northern Ireland 2010/11 B B 278 ST-35 complex Blood 0.25 0.008 0.002 0.006
20349 England 2010/11 B B 275 ST-269 complex CSF 0.064 0.003 0.002 0.003
20350 England 2010/11 B B 213 ST-213 complex Blood 0.19 0.016 0.003 0.006
20351 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.008 0.002 0.004
20352 England 2010/11 B B 1161 ST-269 complex CSF 0.19 0.006 0.003 0.006
20353 England 2010/11 B B 33 ST-32 complex Blood 0.032 0.003 0.003 0.004
20354 England 2010/11 B B 9894 UA Blood 0.064 0.016 0.002 0.006
20355 Northern Ireland 2010/11 B B 9846 ST-865 complex Blood 0.023 0.004 0.003 0.002
20356 Northern Ireland 2010/11 B B 340 ST-41/44 complex Blood 0.064 0.006 0.003 0.002
20357 England 2010/11 B B 9895 ST-213 complex Blood 0.064 0.004 0.002 0.003
20358 England 2010/11 B B 2363 ST-41/44 complex Blood 0.064 0.008 0.004 0.003
20359 England 2010/11 C C 11 ST-11 complex Joint 0.032 0.016 0.003 0.003
20360 England 2010/11 B B 303 ST-41/44 complex Blood 0.38 0.032 0.002 0.008
20361 England 2010/11 B B 34 ST-32 complex Blood 0.19 0.006 <0.002 0.008
20362 England 2010/11 B B 213 ST-213 complex Blood 0.047 0.006 0.002 0.003
20363 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.003
20364 England 2010/11 B B 2314 ST-41/44 complex Blood 0.125 0.002 0.002 0.003
20365 England 2010/11 W W 184 ST-22 complex Blood 0.19 0.003 0.004 0.004
20366 England 2010/11 B B 275 ST-269 complex Blood 0.25 0.004 0.003 0.006
20367 England 2010/11 B B 2888 UA Blood 0.064 0.008 0.004 0.003
20369 England 2010/11 B B 41 ST-41/44 complex Blood 0.25 0.008 0.003 0.006
20370 England 2010/11 B B 9837 UA Blood 0.19 0.003 0.003 0.006
20371 England 2010/11 B B 9896 ST-41/44 complex Blood 0.064 0.004 0.002 0.002
20372 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.004 0.003 0.004
20373 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.004
20374 England 2010/11 B B 1161 ST-269 complex Blood 0.19 0.006 0.002 0.004
20375 England 2010/11 B B 1161 ST-269 complex Blood 0.25 0.012 0.003 0.004
20376 England 2010/11 B B 479 ST-269 complex Blood 0.047 0.006 0.003 0.003
20377 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.004 0.003 0.002
20378 Northern Ireland 2010/11 B B 9004 ST-269 complex Blood 0.047 0.006 0.003 0.003
20379 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.004
20380 England 2010/11 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.008
20381 England 2010/11 B B 9847 UA Blood 0.064 0.008 0.004 0.006
20382 England 2010/11 C C 32 ST-32 complex Blood 0.064 0.006 0.003 0.003
20383 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.003 0.003
20384 England 2010/11 B B 1194 ST-41/44 complex Blood 0.19 0.016 0.003 0.004
20385 England 2010/11 B B 1161 ST-269 complex Blood 0.094 0.006 0.003 0.004
20386 England 2010/11 B B 833 ST-41/44 complex Blood 0.047 0.004 0.003 0.002
20387 England 2010/11 B B 6604 ST-269 complex Blood 0.25 0.004 0.003 0.008




20389 England 2010/11 B B 213 ST-213 complex Blood 0.047 0.004 0.002 0.003
20390 England 2010/11 B B 3737 ST-1157 complex Blood 0.125 0.004 0.002 0.006
20391 England 2010/11 B B 60 ST-60 complex Blood 0.19 0.004 0.002 0.004
20393 England 2010/11 B B 32 ST-32 complex Blood 0.064 0.006 0.003 0.003
20394 England 2010/11 B B 1200 ST-41/44 complex Blood 0.047 0.006 0.004 0.002
20395 England 2010/11 B B 213 ST-213 complex CSF 0.19 0.012 0.003 0.008
20396 England 2010/11 Y Y 168 ST-167 complex Blood 0.064 0.004 0.003 0.004
20397 England 2010/11 C C 5133 ST-103 complex Blood 0.016 0.006 0.002 <0.002
20400 England 2010/11 B B 9838 ST-41/44 complex CSF 0.19 0.006 0.004 0.006
20401 England 2010/11 B B 1161 ST-269 complex Blood 0.064 0.008 0.003 0.008
20402 England 2010/11 B B 275 ST-269 complex Blood 0.064 0.003 0.004 0.004
20403 England 2010/11 B B 32 ST-32 complex Blood 0.047 0.012 0.003 0.003
20404 England 2010/11 W/Y W/Y 23 ST-23 complex Blood 0.38 0.008 0.003 0.023
20405 England 2010/11 B B 180 ST-41/44 complex CSF 0.023 0.004 0.002 0.002
20406 England 2010/11 C C 5315 UA CSF 0.016 0.012 0.003 0.006
20407 England 2010/11 B B 154 ST-41/44 complex Blood 0.047 0.012 0.003 0.006
20408 England 2010/11 B B 41 ST-41/44 complex CSF 0.047 0.006 0.003 0.002
20409 Northern Ireland 2010/11 B B 33 ST-32 complex Blood 0.064 0.003 0.003 0.003
20410 England 2010/11 B B 46 ST-41/44 complex Blood 0.047 0.012 0.002 <0.002
20411 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.012 0.004 0.003
20412 England 2010/11 B B 41 ST-41/44 complex Blood 0.25 0.004 0.003 0.008
20413 England 2010/11 B B 162 ST-162 complex Blood 0.064 0.094 0.004 0.004
20414 England 2010/11 NG Y 1655 ST-23 complex Blood 0.032 0.003 0.003 0.002
20415 England 2010/11 B B 1194 ST-41/44 complex CSF 0.064 0.004 0.003 0.003
20416 England 2010/11 B B 269 ST-269 complex Blood 0.032 0.008 0.003 0.002
20417 England 2010/11 B B 269 ST-269 complex Blood 0.19 0.002 0.003 0.004
20418 England 2010/11 B B 162 ST-162 complex Blood 0.094 0.016 0.004 0.004
20419 England 2010/11 B B 485 ST-41/44 complex Joint 0.25 0.003 0.003 0.004
20420 England 2010/11 B B 3077 ST-35 complex Blood 0.047 0.023 0.003 0.002
20421 England 2010/11 B B 41 ST-41/44 complex Blood 0.19 0.006 0.003 0.004
20422 England 2010/11 W W 184 ST-22 complex Blood 0.125 0.004 0.003 0.003
20423 England 2010/11 B B 9823 ST-269 complex Blood 0.047 0.006 0.003 0.002
20425 England 2010/11 B B 1159 UA CSF 0.047 0.003 0.003 0.003
20426 England 2010/11 B B 9824 ST-41/44 complex Blood 0.047 0.004 0.003 0.002
20427 England 2010/11 B B 290 ST-32 complex Blood 0.064 0.006 0.003 0.004
20428 England 2010/11 B B 5103 ST-60 complex Blood 0.064 0.006 0.003 0.003
20429 England 2010/11 B B 1163 ST-269 complex Blood 0.064 0.006 0.002 0.004
20430 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.002 0.002 0.004
20431 England 2010/11 B B 1161 ST-269 complex Blood 0.047 0.006 0.003 0.003
20432 Wales 2010/11 B B 41 ST-41/44 complex Blood 0.064 0.032 0.003 0.003
20433 England 2010/11 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.003
20434 England 2010/11 B B 1161 ST-269 complex CSF 0.125 0.008 0.003 0.006
20435 England 2010/11 B B 9825 UA Blood 0.25 0.008 0.002 0.012
20437 England 2010/11 B B 1161 ST-269 complex Blood 0.094 0.012 0.003 0.004
20438 England 2010/11 B B 32 ST-32 complex Blood 0.047 0.004 0.003 0.003
20439 England 2010/11 B B 269 ST-269 complex Blood 0.047 0.016 0.004 0.002
20440 England 2010/11 Y Y 4183 ST-23 complex Blood 0.094 0.023 0.002 0.008
20441 England 2010/11 B B 1430 ST-60 complex Blood 0.032 0.004 0.002 0.002
20442 England 2010/11 B B 9826 ST-269 complex Blood 0.064 0.008 0.003 0.004
20443 England 2010/11 B B 5551 ST-41/44 complex Blood 0.016 0.016 <0.002 <0.002
20445 England 2010/11 B B 41 ST-41/44 complex CSF 0.19 0.004 0.003 0.008
20446 England 2010/11 B B 467 ST-269 complex Blood 0.047 0.004 0.003 0.002
20447 England 2010/11 B B 3101 ST-41/44 complex Blood 0.047 0.006 0.003 0.003
20448 England 2010/11 B B 41 ST-41/44 complex Blood 0.19 0.006 0.003 0.004
20450 England 2010/11 B B 275 ST-269 complex CSF 0.047 0.004 0.003 0.003
20451 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.006 0.002 0.003
20452 England 2010/11 B B 9827 UA Blood 0.047 0.004 0.003 0.003
20453 England 2010/11 B B 1194 ST-41/44 complex CSF 0.047 0.006 0.003 0.002
20454 England 2010/11 Y Y 1655 ST-23 complex Blood 0.125 0.004 0.003 0.008
20455 England 2010/11 B B 1161 ST-269 complex Blood 0.094 0.016 0.003 0.003
20456 Northern Ireland 2010/11 Y Y 784 ST-92 complex Blood 0.094 0.004 0.003 0.003
20457 England 2010/11 B B 60 ST-60 complex Blood 0.032 0.002 0.003 <0.002
20458 England 2010/11 W W 2977 ST-174 complex Blood 0.125 0.008 0.002 0.008
20459 England 2010/11 Y Y 23 ST-23 complex Blood 0.064 0.003 0.006 0.004
20470 England 2010/11 B B 41 ST-41/44 complex Blood 0.19 0.008 0.003 0.004
21092 England 2011/12 B B 461 ST-461 complex Blood 0.125 0.008 0.002 0.003
21093 England 2011/12 B B 1161 ST-269 complex Blood 0.064 0.047 0.004 0.003
21094 England 2011/12 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.004
21095 England 2011/12 B B 1960 ST-41/44 complex Blood 0.064 0.012 0.004 0.003
21096 Wales 2011/12 B B 8049 ST-32 complex Blood 0.25 0.004 0.003 0.003
21097 England 2011/12 B B 1161 ST-269 complex CSF 0.094 0.012 0.003 0.004
21098 England 2011/12 B B 1194 ST-41/44 complex Blood 0.047 0.006 0.002 0.003
21099 England 2011/12 B B 213 ST-213 complex Blood 0.125 0.016 0.003 0.004
21100 England 2011/12 B B 275 ST-269 complex CSF 0.25 0.023 0.003 0.006
21101 England 2011/12 B B 2391 ST-213 complex Blood 0.047 0.006 0.003 0.004
21102 England 2011/12 B B 9200 ST-41/44 complex Blood 0.047 0.006 0.003 0.006
21103 England 2011/12 B B 1163 ST-269 complex Blood 0.125 0.006 0.003 0.004
21104 Wales 2011/12 B B 6428 ST-269 complex Blood 0.094 0.012 0.004 0.006
21105 England 2011/12 Y Y 23 ST-23 complex Blood 0.094 0.004 0.003 0.008
21106 England 2011/12 B B 1161 ST-269 complex CSF 0.064 0.004 0.004 0.004
21107 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.004
21108 England 2011/12 Y Y 8096 ST-23 complex Blood 0.19 0.004 0.004 0.003
21109 England 2011/12 B B 162 ST-162 complex Blood 0.064 0.032 0.004 0.004
21110 England 2011/12 B B 10260 ST-11 complex Blood 0.19 0.012 0.004 0.008




21112 England 2011/12 B B 60 ST-60 complex Blood 0.047 0.032 0.004 0.004
21113 England 2011/12 B B 2009 ST-41/44 complex Blood 0.064 0.004 0.004 0.003
21114 England 2011/12 B B 485 ST-41/44 complex Blood 0.19 0.004 0.004 0.004
21115 Northern Ireland 2011/12 C C 10261 UA Blood 0.032 0.004 0.003 0.003
21116 England 2011/12 B B 4051 UA Blood 0.032 0.032 0.003 0.002
21117 England 2011/12 B B 1097 ST-41/44 complex Blood 0.047 0.004 0.006 0.003
21118 England 2011/12 B B 467 ST-269 complex Blood 0.064 0.006 0.003 0.004
21119 England 2011/12 B B 162 ST-162 complex Blood 0.023 0.016 0.004 0.004
21120 England 2011/12 B B 269 ST-269 complex Blood 0.032 0.008 0.004 0.004
21121 England 2011/12 B B 1163 ST-269 complex Blood 0.19 0.004 0.004 0.008
21122 England 2011/12 B B 2799 ST-41/44 complex CSF 0.125 0.008 0.004 0.008
21124 England 2011/12 B B 10262 UA CSF 0.25 0.006 0.003 0.016
21125 England 2011/12 B B 4237 ST-865 complex Blood 0.047 0.016 0.004 0.004
21126 England 2011/12 B B 213 ST-213 complex Blood 0.032 0.008 0.003 0.003
21127 England 2011/12 B B 3050 ST-41/44 complex BRAIN 0.094 0.003 0.002 0.003
21128 England 2011/12 B B 9822 ST-41/44 complex Blood 0.064 0.008 0.003 0.004
21129 England 2011/12 B B 154 ST-41/44 complex Blood 0.016 0.002 0.003 <0.002
21130 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.004
21131 England 2011/12 B B 259 ST-32 complex Blood 0.094 0.012 0.003 0.006
21132 England 2011/12 W W 1281 ST-22 complex Blood 0.25 0.016 0.006 0.008
21133 England 2011/12 B B 10263 UA Blood 0.125 0.016 0.006 0.012
21134 England 2011/12 C C 11 ST-11 complex Blood 0.047 0.032 0.004 0.004
21137 England 2011/12 B B 8988 UA Blood 0.19 0.012 0.004 0.006
21138 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.004
21139 England 2011/12 W W 184 ST-22 complex Joint 0.125 0.004 0.004 0.004
21140 England 2011/12 B B 1163 ST-269 complex Blood 0.032 0.008 0.003 0.003
21141 England 2011/12 B B 213 ST-213 complex CSF 0.19 0.125 0.002 0.008
21142 England 2011/12 B B 41 ST-41/44 complex Blood 0.125 0.008 0.003 0.004
21143 England 2011/12 B B 10264 ST-269 complex Blood 0.047 0.023 <0.002 0.003
21144 England 2011/12 B B 41 ST-41/44 complex Blood 0.25 0.023 0.004 0.006
21145 England 2011/12 B B 213 ST-213 complex Blood 0.064 0.023 0.003 0.004
21146 England 2011/12 B B 1161 ST-269 complex Blood 0.047 0.016 0.003 0.004
21147 England 2011/12 B B 213 ST-213 complex Joint 0.047 0.008 0.003 0.004
21148 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.003 0.004
21151 England 2011/12 Y Y 23 ST-23 complex Blood 0.016 0.002 0.003 0.003
21152 England 2011/12 B B 1097 ST-41/44 complex CSF 0.047 0.006 0.003 0.004
21153 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.004
21154 Wales 2011/12 B B 5906 ST-41/44 complex Blood 0.19 0.006 0.003 0.004
21155 England 2011/12 B B 6781 UA Blood 0.25 0.032 0.003 0.012
21156 England 2011/12 W W 3795 ST-22 complex Blood 0.125 0.004 0.004 0.004
21157 Northern Ireland 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.004
21158 England 2011/12 Y Y 3582 ST-23 complex Blood 0.094 0.004 0.003 0.008
21159 England 2011/12 B B 41 ST-41/44 complex Blood 0.19 0.008 0.003 0.004
21160 England 2011/12 B B 1345 UA Blood 0.064 0.016 0.003 0.004
21161 England 2011/12 B B 5357 ST-41/44 complex Blood 0.032 0.006 0.003 0.003
21162 England 2011/12 B B 275 ST-269 complex Blood 0.064 0.003 0.003 0.004
21164 England 2011/12 B B 213 ST-213 complex Blood 0.25 0.008 0.003 0.006
21165 England 2011/12 B B 9889 ST-41/44 complex Blood 0.125 0.008 0.003 0.006
21167 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 <0.002 0.006
21168 England 2011/12 B B 1161 ST-269 complex Blood 0.125 0.006 0.003 0.006
21169 England 2011/12 Y Y 23 ST-23 complex Blood 0.094 0.004 0.003 0.008
21170 England 2011/12 B B 6604 ST-269 complex Blood 0.064 0.006 0.004 0.004
21171 England 2011/12 B B 1097 ST-41/44 complex Blood 0.047 0.016 0.004 0.003
21172 Wales 2011/12 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.003 0.003
21173 England 2011/12 B B 213 ST-213 complex Blood 0.064 0.008 0.003 0.004
21174 England 2011/12 B B 10265 UA Blood 0.047 0.008 0.003 0.002
21175 England 2011/12 W W 1286 ST-22 complex Blood 0.19 0.016 0.003 0.006
21176 England 2011/12 B B 35 ST-35 complex Blood 0.047 0.064 0.002 0.003
21177 England 2011/12 B B 162 ST-162 complex Blood 0.25 0.008 0.003 0.006
21178 England 2011/12 Y Y 8411 ST-23 complex PUS, HIP 0.064 0.004 0.003 0.003
21179 England 2011/12 B B 749 ST-32 complex Blood 0.19 0.003 0.004 0.008
21180 England 2011/12 B B 1942 ST-269 complex Blood 0.047 0.016 0.004 0.003
21181 England 2011/12 B B 275 ST-269 complex Blood 0.19 0.006 0.003 0.004
21182 England 2011/12 B B 10266 UA Blood 0.125 0.006 0.003 0.008
21183 England 2011/12 Y Y 1655 ST-23 complex Joint 0.047 0.003 0.003 0.004
21184 England 2011/12 B B 8054 ST-41/44 complex Blood 0.064 0.008 0.004 0.003
21186 England 2011/12 B B 18 ST-18 complex Blood 0.032 0.047 0.003 0.003
21187 England 2011/12 Y Y 1655 ST-23 complex Blood 0.016 0.003 <0.002 <0.002
21188 England 2011/12 B B 41 ST-41/44 complex Blood 0.047 0.023 0.003 0.003
21189 England 2011/12 B B 269 ST-269 complex Blood 0.064 0.012 0.003 0.003
21190 England 2011/12 B B 283 ST-269 complex Blood 0.047 0.008 0.003 0.002
21191 England 2011/12 B B 1161 ST-269 complex CSF 0.064 0.008 0.003 0.004
21192 England 2011/12 Y Y 6463 ST-23 complex Blood 0.047 0.008 0.003 0.004
21193 England 2011/12 W/Y W/Y 3651 ST-22 complex Blood 0.047 0.012 0.004 0.003
21194 England 2011/12 B B 269 ST-269 complex Blood 0.064 0.012 0.003 0.003
21195 Northern Ireland 2011/12 B B 4496 ST-41/44 complex Blood 0.032 0.008 0.003 0.003
21196 England 2011/12 C C 11 ST-11 complex Blood 0.047 0.004 0.003 0.003
21198 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.003
21199 England 2011/12 B B 103 ST-103 complex CSF 0.094 0.008 0.003 0.003
21200 England 2011/12 B B 136 ST-41/44 complex CSF 0.094 0.004 0.002 0.004
21201 England 2011/12 Y Y 23 ST-23 complex Blood 0.032 0.006 0.003 0.002
21202 England 2011/12 B B 269 ST-269 complex Blood 0.032 0.012 0.003 0.003
21203 Wales 2011/12 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
21204 England 2011/12 B B 33 ST-32 complex Blood 0.047 0.008 0.004 0.004




21207 Northern Ireland 2011/12 B B 1163 ST-269 complex Blood 0.19 0.012 0.002 0.003
21208 England 2011/12 C C 11 ST-11 complex Blood 0.19 0.047 0.003 0.004
21209 England 2011/12 B B 275 ST-269 complex CSF 0.047 0.004 0.003 0.003
21210 England 2011/12 B B 340 ST-41/44 complex Blood 0.032 0.006 0.003 <0.002
21211 England 2011/12 B B 1161 ST-269 complex Blood 0.094 0.006 0.003 0.006
21212 England 2011/12 B B 213 ST-213 complex CSF 0.047 0.006 0.003 0.003
21213 England 2011/12 B B 41 ST-41/44 complex Blood 0.19 0.006 0.003 0.004
21214 Wales 2011/12 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.004
21215 England 2011/12 B B 1161 ST-269 complex Blood 0.064 0.008 0.003 0.003
21217 England 2011/12 B B 213 ST-213 complex Blood 0.047 0.012 0.003 0.003
21218 England 2011/12 B B 213 ST-213 complex Blood 0.032 0.004 0.003 0.003
21219 England 2011/12 B B 13 ST-269 complex Blood 0.047 0.008 0.004 0.003
21220 England 2011/12 B B 275 ST-269 complex Blood 0.064 0.008 0.003 0.003
21221 Wales 2011/12 B B 10267 ST-213 complex CSF 0.047 0.016 0.002 0.003
21222 England 2011/12 B B 41 ST-41/44 complex Blood 0.032 0.004 0.003 0.002
21223 Northern Ireland 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.002
21224 England 2011/12 B B 1159 UA Blood 0.032 0.012 0.003 0.003
21225 England 2011/12 B B 32 ST-32 complex Blood 0.047 0.016 0.003 0.003
21226 England 2011/12 B B 1161 ST-269 complex Blood 0.094 0.004 0.003 0.004
21227 England 2011/12 Y Y 23 ST-23 complex Blood 0.094 0.006 0.002 0.006
21228 England 2011/12 B B 461 ST-461 complex Blood 0.125 0.006 0.002 0.004
21229 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.002 0.004
21230 England 2011/12 B B 1194 ST-41/44 complex CSF 0.047 0.006 0.003 0.003
21231 England 2011/12 B B 7226 ST-269 complex Blood 0.032 0.004 0.002 0.003
21232 England 2011/12 C C 11 ST-11 complex Blood 0.032 0.016 0.003 0.003
21233 England 2011/12 B B 1161 ST-269 complex Blood 0.064 0.032 0.003 0.004
21234 England 2011/12 B B 41 ST-41/44 complex Blood 0.047 0.032 0.002 0.003
21235 England 2011/12 B B 41 ST-41/44 complex Blood 0.064 0.004 0.003 0.003
21236 England 2011/12 B B 41 ST-41/44 complex Blood 0.125 0.004 0.003 0.004
21237 England 2011/12 B B 11 ST-11 complex Blood 0.064 0.016 0.003 0.004
21238 Wales 2011/12 B B 1194 ST-41/44 complex Blood 0.047 0.004 0.003 0.003
21239 England 2011/12 B B 33 ST-32 complex Blood 0.125 0.003 0.002 0.004
21240 England 2011/12 B B 5529 ST-18 complex CSF 0.032 0.016 0.003 0.003
21241 England 2011/12 B B 269 ST-269 complex Joint 0.064 0.012 0.003 0.004
21242 England 2011/12 B B 6605 ST-35 complex Blood 0.016 <0.002 <0.002 <0.002
21243 England 2011/12 B B 10268 ST-1157 complex Blood 0.047 0.006 0.002 0.004
21244 England 2011/12 B B 1161 ST-269 complex Blood 0.047 0.006 0.003 0.003
21245 England 2011/12 B B 41 ST-41/44 complex Blood 0.125 0.003 0.003 0.004
21246 England 2011/12 B B 461 ST-461 complex Blood 0.19 0.006 0.002 0.006
21247 England 2011/12 B B 485 ST-41/44 complex Blood 0.19 0.006 0.003 0.004
21248 England 2011/12 B B 269 ST-269 complex Blood 0.047 0.006 0.003 0.003
21249 England 2011/12 B B 282 ST-282 complex Blood 0.047 0.012 0.002 0.003
21250 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.004
21252 England 2011/12 B B 1157 ST-1157 complex Blood 0.047 0.012 <0.002 0.004
21253 England 2011/12 C C 11 ST-11 complex Blood 0.25 0.012 0.003 0.008
21254 England 2011/12 B B 10269 ST-41/44 complex Blood 0.25 0.006 0.004 0.006
21255 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.004
21256 England 2011/12 C C 11 ST-11 complex Blood 0.25 0.023 0.003 0.008
21257 England 2011/12 B B 1194 ST-41/44 complex Blood 0.032 0.008 0.003 0.003
21258 Northern Ireland 2011/12 B B 10270 ST-41/44 complex CSF 0.047 0.008 0.003 0.003
21259 England 2011/12 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.003 0.003
21260 England 2011/12 B B 275 ST-269 complex Blood 0.064 0.008 0.003 0.004
21261 England 2011/12 B B 1194 ST-41/44 complex Blood 0.047 0.008 0.002 0.002
21262 England 2011/12 Y Y 23 ST-23 complex Blood 0.064 0.004 0.003 0.004
21263 England 2011/12 B B 1194 ST-41/44 complex Blood 0.047 0.006 0.003 0.002
21264 England 2011/12 B B 41 ST-41/44 complex Blood 0.047 0.023 0.003 0.003
21265 England 2011/12 B B 32 ST-32 complex Blood 0.19 0.094 0.003 0.004
21266 England 2011/12 B B 162 ST-162 complex Blood 0.064 0.012 0.004 0.004
21267 England 2011/12 B B 10271 ST-1157 complex Blood 0.016 0.016 0.002 0.002
21268 Northern Ireland 2011/12 B B 575 ST-213 complex CSF 0.19 0.006 0.003 0.004
21269 England 2011/12 B B 1049 ST-269 complex Blood 0.032 0.003 0.003 0.003
21270 England 2011/12 B B 41 ST-41/44 complex Blood 0.125 0.006 0.002 0.004
21271 England 2011/12 Y Y 3651 ST-22 complex Blood 0.047 0.004 0.004 0.004
21272 England 2011/12 Y Y 1655 ST-23 complex Blood 0.125 0.006 0.003 0.008
21273 England 2011/12 B B 41 ST-41/44 complex Blood 0.25 0.016 0.003 0.006
21274 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.004
21275 England 2011/12 B B 213 ST-213 complex Blood 0.047 0.012 0.002 0.003
21276 England 2011/12 Y Y 23 ST-23 complex Blood 0.012 0.003 <0.002 0.002
21277 England 2011/12 B B 8988 UA Blood 0.125 0.012 0.003 0.003
21278 England 2011/12 B B 41 ST-41/44 complex Blood 0.125 0.006 0.003 0.004
21279 England 2011/12 B B 1163 ST-269 complex Blood 0.125 0.012 <0.002 0.003
21280 Wales 2011/12 B B 60 ST-60 complex Blood 0.032 0.006 0.002 0.003
21281 England 2011/12 B B 10272 ST-213 complex Blood 0.047 0.016 0.003 0.002
21282 England 2011/12 B B 1161 ST-269 complex Blood 0.094 0.012 0.003 0.004
21283 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.004
21284 England 2011/12 B B 213 ST-213 complex CSF 0.064 0.016 0.003 0.004
21285 England 2011/12 B B 1161 ST-269 complex CSF 0.064 0.008 0.003 0.003
21286 England 2011/12 B B 7385 ST-41/44 complex Blood 0.19 0.004 0.004 0.004
21287 England 2011/12 B B 1161 ST-269 complex Blood 0.094 0.004 0.003 0.004
21288 Wales 2011/12 W W 11 ST-11 complex Blood 0.047 0.012 0.006 0.003
21289 England 2011/12 B B 1161 ST-269 complex Blood 0.064 0.008 0.004 0.004
21290 England 2011/12 W W 184 ST-22 complex Blood 0.19 0.016 0.006 0.004
21291 England 2011/12 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
21292 England 2011/12 B B 154 ST-41/44 complex Blood 0.032 0.003 0.003 0.002




21294 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.003
21295 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.003 0.003
21296 England 2011/12 C C 877 ST-41/44 complex Blood 0.125 0.004 0.004 0.004
21299 England 2011/12 B B 154 ST-41/44 complex Blood 0.094 0.012 0.003 0.004
21300 England 2011/12 B B 461 ST-461 complex CSF 0.023 0.023 0.003 <0.002
21301 Wales 2011/12 B B 3754 ST-41/44 complex Blood 0.047 0.003 0.004 0.003
21303 England 2011/12 B B 213 ST-213 complex CSF 0.047 0.012 0.004 0.003
21304 England 2011/12 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
21306 England 2011/12 B B 213 ST-213 complex Blood 0.064 0.008 0.004 0.004
21307 Wales 2011/12 B B 1161 ST-269 complex Blood 0.094 0.008 0.004 0.006
21308 England 2011/12 B B 275 ST-269 complex Blood 0.19 0.012 0.004 0.006
21309 England 2011/12 B B 162 ST-162 complex Blood 0.064 0.012 0.004 0.004
21311 Wales 2011/12 B B 11 ST-11 complex Blood 0.064 0.012 0.003 0.004
21312 England 2011/12 B B 1774 ST-269 complex Blood 0.047 0.006 0.003 0.004
21313 England 2011/12 B B 1194 ST-41/44 complex Blood 0.047 0.004 0.003 0.003
21314 England 2011/12 B B 41 ST-41/44 complex Blood 0.047 0.003 0.004 0.003
21315 England 2011/12 B B 162 ST-162 complex Blood 0.064 0.008 0.004 0.004
21316 England 2011/12 B B 154 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
21317 England 2011/12 B B 1049 ST-269 complex Blood 0.032 0.006 0.004 0.002
21318 Wales 2011/12 B B 3754 ST-41/44 complex Blood 0.047 0.003 0.002 0.003
21319 Wales 2011/12 B B 41 ST-41/44 complex Blood 0.064 0.19 0.004 0.003
21320 England 2011/12 B B 10273 UA CSF 0.064 0.008 0.004 0.004
21321 England 2011/12 B B 41 ST-41/44 complex Blood 0.064 0.004 0.004 0.004
21322 England 2011/12 B B 1161 ST-269 complex CSF 0.125 0.006 0.006 0.006
21323 England 2011/12 B B 10274 ST-213 complex Blood 0.19 0.032 0.003 0.004
21324 England 2011/12 B B 10275 UA Blood 0.047 0.125 0.003 0.004
21325 England 2011/12 B B 162 ST-162 complex Blood 0.047 0.016 0.004 0.003
21326 England 2011/12 B B 32 ST-32 complex Blood 0.047 0.012 0.004 0.003
21327 England 2011/12 B B 269 ST-269 complex Blood 0.064 0.012 0.004 0.002
21328 England 2011/12 B B 32 ST-32 complex Blood 0.047 0.004 0.004 0.003
21329 England 2011/12 B B 1161 ST-269 complex CSF 0.094 0.047 0.004 0.004
21330 Wales 2011/12 B B 11 ST-11 complex Blood 0.064 0.032 0.006 0.006
21331 England 2011/12 B B 10276 ST-18 complex Joint 0.032 0.032 0.004 0.003
21332 England 2011/12 B B 3635 ST-213 complex CSF 0.047 0.016 0.003 0.004
21333 England 2011/12 B B 269 ST-269 complex Blood 0.064 0.047 0.006 0.004
21335 England 2011/12 B B 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
21336 England 2011/12 B B 10277 UA Blood 0.064 0.023 0.006 0.004
21337 England 2011/12 B B 10278 ST-41/44 complex Joint 0.094 0.006 0.004 0.003
21338 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.003
21339 England 2011/12 Y Y 1466 ST-174 complex Blood 0.125 0.047 0.003 0.006
21341 England 2011/12 B B 1194 ST-41/44 complex Blood 0.19 0.004 0.003 0.003
21342 England 2011/12 B B 1161 ST-269 complex Blood 0.125 0.006 0.004 0.006
21343 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.003 0.003
21344 England 2011/12 B B 9352 ST-41/44 complex Tissue 0.19 0.004 0.004 0.003
21345 England 2011/12 B B 10279 ST-213 complex Blood 0.19 0.125 0.004 0.003
21346 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.002
21347 England 2011/12 B B 10280 ST-41/44 complex Blood 0.032 0.012 0.003 0.002
21348 England 2011/12 B B 1049 ST-269 complex Blood 0.047 0.006 0.004 0.003
21349 England 2011/12 W W 1224 ST-22 complex Blood 0.125 0.004 0.004 0.002
21350 England 2011/12 B B 1163 ST-269 complex Blood 0.19 0.004 0.004 0.004
21351 England 2011/12 B B 3496 ST-213 complex Blood 0.125 0.064 0.004 0.004
21352 England 2011/12 E E 4146 ST-60 complex Blood 0.032 0.008 0.004 0.002
21353 England 2011/12 B B 41 ST-41/44 complex Blood 0.125 0.006 0.003 0.004
21355 England 2011/12 B B 41 ST-41/44 complex Blood 0.023 0.008 0.004 0.004
21356 England 2011/12 Y Y 1655 ST-23 complex Blood 0.023 0.004 0.004 0.002
21357 England 2011/12 B B 1163 ST-269 complex Blood 0.047 0.003 0.004 0.004
21358 England 2011/12 B B 269 ST-269 complex Blood 0.032 0.004 0.004 0.003
21359 England 2011/12 C C 11 ST-11 complex Blood 0.016 0.047 0.006 0.002
21360 England 2011/12 B B 6058 ST-41/44 complex CSF 0.19 0.012 0.004 0.006
21362 England 2011/12 B B 1161 ST-269 complex Blood 0.25 0.016 0.004 0.008
21363 England 2011/12 B B 10281 ST-213 complex Blood 0.047 0.008 0.003 0.004
21364 England 2011/12 C C 11 ST-11 complex Blood 0.023 0.016 0.006 0.003
21365 England 2011/12 B B 7309 ST-213 complex Blood 0.064 0.008 0.004 0.004
21366 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.003 0.003
21367 England 2011/12 B B 1195 ST-269 complex Blood 0.023 0.008 0.004 0.003
21368 Wales 2011/12 B B 340 ST-41/44 complex Blood 0.19 0.008 0.006 0.012
21369 Wales 2011/12 B B 10282 ST-41/44 complex Blood 0.19 0.012 0.004 0.004
21370 Northern Ireland 2011/12 B B 10283 UA Blood 0.19 0.004 0.004 0.004
21371 England 2011/12 W W 184 ST-22 complex Blood 0.125 0.016 0.006 0.004
21372 England 2011/12 Y Y 1655 ST-23 complex CSF 0.016 0.003 0.003 0.003
21373 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.003 0.006
21374 Wales 2011/12 B B 41 ST-41/44 complex Blood 0.032 0.008 0.003 0.002
21376 England 2011/12 B B 1194 ST-41/44 complex Blood 0.032 0.003 0.004 0.003
21378 England 2011/12 B B 46 ST-41/44 complex Blood 0.032 0.006 0.006 0.003
21380 England 2011/12 W W 184 ST-22 complex Blood 0.19 0.008 0.006 0.006
21382 England 2011/12 B B 9171 ST-41/44 complex Blood 0.047 0.006 0.004 0.004
21383 Wales 2011/12 B B 1157 ST-1157 complex CSF 0.016 0.003 0.003 0.003
21384 England 2011/12 B B 1097 ST-41/44 complex Blood 0.032 0.003 0.004 0.004
21385 England 2011/12 B B 213 ST-213 complex Blood 0.032 0.006 0.004 0.003
21387 England 2011/12 B B 213 ST-213 complex Blood 0.047 0.023 0.004 0.008
21388 England 2011/12 B B 10285 ST-32 complex Blood 0.064 0.008 0.004 0.006
21390 England 2011/12 B B 10286 ST-32 complex Blood 0.25 0.008 0.004 0.006
21391 England 2011/12 B B 2307 UA Blood 0.19 0.004 0.003 0.004
21392 England 2011/12 B B 213 ST-213 complex Blood 0.023 0.012 0.003 <0.002




21394 England 2011/12 B B 41 ST-41/44 complex Blood 0.032 0.003 0.003 0.002
21396 England 2011/12 B B 10287 ST-60 complex Blood 0.064 0.004 0.004 0.004
21398 England 2011/12 B B 41 ST-41/44 complex Blood 0.064 0.003 0.003 0.002
21399 England 2011/12 Y Y 23 ST-23 complex Blood 0.032 <0.002 0.006 0.003
21400 England 2011/12 B B 1194 ST-41/44 complex Blood 0.125 0.003 0.003 0.003
21401 England 2011/12 B B 43 ST-41/44 complex CSF 0.047 0.003 0.004 0.003
21402 England 2011/12 NG B 414 ST-41/44 complex Blood 0.064 0.002 0.004 0.003
21403 England 2011/12 Y Y 1655 ST-23 complex Blood 0.023 <0.002 0.004 0.003
21404 England 2011/12 Y Y 23 ST-23 complex Blood 0.094 0.002 0.006 0.008
21405 England 2011/12 B B 1163 ST-269 complex CSF 0.125 0.004 0.006 0.006
21406 Wales 2011/12 B B 10288 ST-269 complex CSF 0.064 0.006 0.006 0.004
21407 England 2011/12 C C 11 ST-11 complex Blood 0.023 0.012 0.006 0.003
21408 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.004 0.003
21410 Wales 2011/12 Y Y 23 ST-23 complex Blood 0.047 0.004 0.006 0.002
21411 England 2011/12 B B 6782 ST-41/44 complex Blood 0.032 0.012 0.006 0.003
21412 England 2011/12 B B 2314 ST-41/44 complex Blood 0.094 0.002 0.006 0.003
21413 England 2011/12 B B 10289 ST-18 complex Blood 0.064 0.016 0.004 0.006
21414 England 2011/12 B B 6058 ST-41/44 complex CSF 0.19 0.008 0.006 0.006
21415 England 2011/12 B B 5151 UA Blood 0.125 0.004 0.006 0.004
21416 England 2011/12 B B 162 ST-162 complex CSF 0.032 0.094 0.006 0.002
21417 England 2011/12 C C 5133 ST-103 complex Blood 0.012 0.003 0.006 <0.002
21418 England 2011/12 B B 269 ST-269 complex Blood 0.023 0.003 0.006 <0.002
21419 England 2011/12 C C 11 ST-11 complex Blood 0.125 0.016 0.006 0.006
21420 England 2011/12 B B 162 ST-162 complex Blood 0.125 0.008 0.006 0.006
21421 England 2011/12 Y Y 1466 ST-174 complex Blood 0.064 0.016 0.004 0.006
21423 England 2011/12 B B 154 ST-41/44 complex Blood 0.032 0.006 0.006 <0.002
21424 England 2011/12 B B 9884 ST-213 complex Blood 0.064 0.016 0.006 0.004
21425 England 2011/12 B B 269 ST-269 complex Blood 0.023 0.006 0.006 0.002
21426 England 2011/12 B B 41 ST-41/44 complex CSF 0.19 0.006 0.006 0.004
21427 England 2011/12 B B 10290 UA Blood 0.25 0.004 0.004 0.008
21428 England 2011/12 B B 3496 ST-213 complex Blood 0.125 0.006 0.006 0.006
21429 England 2011/12 B B 4713 UA CSF 0.064 0.008 0.008 0.004
21430 Northern Ireland 2011/12 C C 10291 ST-269 complex Blood 0.032 0.012 0.004 0.004
21431 England 2011/12 B B 485 ST-41/44 complex Blood 0.125 0.004 0.006 0.004
21432 England 2011/12 B B 10292 ST-60 complex Blood 0.023 0.002 0.008 0.002
21433 England 2011/12 B B 1161 ST-269 complex Blood 0.064 0.004 0.006 0.004
21434 England 2011/12 B B 41 ST-41/44 complex Blood 0.023 0.016 0.006 0.003
21435 Wales 2011/12 B B 2660 ST-213 complex Blood 0.032 0.006 0.006 0.004
21436 England 2011/12 B B 213 ST-213 complex CSF 0.19 0.004 0.008 0.006
21437 England 2011/12 B B 485 ST-41/44 complex CSF 0.094 0.006 0.006 0.003
21438 England 2011/12 B B 213 ST-213 complex Blood 0.032 0.016 0.008 0.003
21439 Wales 2011/12 B B 275 ST-269 complex Blood 0.023 0.003 0.004 0.002
21440 England 2011/12 Y Y 23 ST-23 complex Blood 0.125 0.004 0.006 0.006
21441 England 2011/12 B B 749 ST-32 complex CSF 0.19 0.003 0.006 0.004
21442 England 2011/12 B B 9311 UA Blood 0.047 0.016 0.006 0.003
21443 England 2011/12 Y Y 1655 ST-23 complex Joint 0.047 0.004 0.004 0.004
21444 England 2011/12 B B 7143 UA CSF 0.016 0.003 0.006 0.002
21445 Northern Ireland 2011/12 B B 269 ST-269 complex Blood 0.023 0.004 0.006 0.002
21447 England 2011/12 Y Y 23 ST-23 complex Blood 0.016 0.004 0.006 <0.002
21448 England 2011/12 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.006 0.003
21449 England 2011/12 B B 269 ST-269 complex Blood 0.023 0.008 0.006 0.002
21450 England 2011/12 B B 340 ST-41/44 complex Blood 0.064 0.004 0.006 0.003
21451 England 2011/12 Y Y 6463 ST-23 complex Blood 0.032 0.003 0.006 0.003
21452 England 2011/12 B B 41 ST-41/44 complex Blood 0.023 0.004 0.004 0.002
21453 England 2011/12 B B 2766 UA Blood 0.032 0.006 0.004 0.004
21454 England 2011/12 W W 1281 ST-22 complex Blood 0.125 0.006 0.006 0.003
21455 England 2011/12 B B 2203 ST-41/44 complex Blood 0.032 0.008 0.006 0.002
21456 England 2011/12 B B 213 ST-213 complex Blood 0.064 0.047 0.004 0.003
21457 England 2011/12 B B 213 ST-213 complex CSF 0.047 0.047 0.006 0.003
21458 England 2011/12 C C 11 ST-11 complex Blood 0.047 0.008 0.008 0.004
21460 England 2011/12 B B 571 ST-41/44 complex CSF 0.047 0.094 0.006 0.002
21461 England 2011/12 B B 7395 UA Blood 0.19 0.006 0.004 0.004
21462 England 2011/12 B B 34 ST-32 complex Blood 0.094 0.006 0.004 0.004
21463 England 2011/12 B B 3619 ST-41/44 complex Blood 0.094 0.006 0.003 0.004
21464 England 2011/12 B B 41 ST-41/44 complex Blood 0.023 0.006 0.004 <0.002
21465 England 2011/12 B B 269 ST-269 complex Blood 0.016 0.006 0.004 <0.002
21466 England 2011/12 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.004 0.004
21467 England 2011/12 B B 213 ST-213 complex Blood 0.125 0.032 0.006 0.003
21468 England 2011/12 B B 41 ST-41/44 complex Blood 0.19 0.006 0.003 0.002
21469 Northern Ireland 2011/12 B B 639 ST-32 complex Blood 0.047 0.012 0.006 0.003
21470 England 2011/12 B B 10293 ST-41/44 complex Blood 0.064 0.002 0.004 <0.002
21471 Wales 2011/12 B B 1161 ST-269 complex Blood 0.064 0.008 0.006 0.003
21472 England 2011/12 Y Y 23 ST-23 complex Blood 0.047 0.003 0.004 0.002
21473 England 2011/12 Y Y 10294 ST-23 complex Blood 0.047 0.003 0.006 0.002
21474 England 2011/12 B B 340 ST-41/44 complex Blood 0.032 0.006 0.006 0.002
21475 England 2011/12 Y Y 23 ST-23 complex Blood 0.064 0.003 0.004 0.003
21476 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
21477 England 2011/12 B B 467 ST-269 complex Blood 0.032 0.003 0.006 <0.002
21478 England 2011/12 B B 571 ST-41/44 complex CSF 0.064 0.003 0.004 0.003
21479 England 2011/12 B B 3818 ST-41/44 complex Blood 0.047 0.008 0.004 <0.002
21480 England 2011/12 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.006 0.003
21481 England 2011/12 B B 10295 ST-41/44 complex Blood 0.047 0.012 0.006 0.002
21482 England 2011/12 B B 10296 UA CSF 0.032 0.006 0.004 <0.002
21483 England 2011/12 B B 5849 UA Blood 0.25 0.004 0.006 0.004




21485 Wales 2011/12 B B 10297 UA Blood 0.047 0.006 0.004 0.002
21486 England 2011/12 B B 1195 ST-269 complex Blood 0.032 0.008 0.004 <0.002
21487 England 2011/12 B B 41 ST-41/44 complex Blood 0.125 0.006 0.004 0.004
21488 England 2011/12 B B 2266 ST-41/44 complex Blood 0.032 0.002 0.004 <0.002
21489 England 2011/12 B B 269 ST-269 complex Blood 0.032 0.004 0.004 <0.002
21490 England 2011/12 B B 340 ST-41/44 complex Blood 0.032 0.004 0.004 0.002
21493 England 2011/12 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 <0.002
21494 England 2011/12 B B 41 ST-41/44 complex Blood 0.19 0.012 0.006 0.003
21495 England 2011/12 B B 7460 ST-32 complex Blood 0.19 0.006 0.004 0.003
21496 England 2011/12 B B 1403 ST-41/44 complex Blood 0.047 0.006 0.004 0.002
21497 England 2011/12 Y Y 23 ST-23 complex Blood 0.064 0.003 0.004 0.003
21498 England 2011/12 C C 467 ST-269 complex Blood 0.047 0.008 0.008 0.003
21499 Wales 2011/12 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.003
21500 England 2011/12 B B 41 ST-41/44 complex Blood 0.047 0.004 0.004 0.002
21501 England 2011/12 B B 213 ST-213 complex Blood 0.047 0.006 0.004 0.002
21502 England 2011/12 Y Y 23 ST-23 complex Blood 0.064 0.004 0.004 0.004
21503 England 2011/12 B B 575 ST-213 complex Blood 0.19 0.006 0.006 0.004
21504 England 2011/12 Y Y 884 ST-167 complex Blood 0.064 0.004 0.006 0.003
21505 England 2011/12 Y Y 5987 ST-103 complex Blood 0.125 0.016 0.006 0.003
21506 England 2011/12 B B 41 ST-41/44 complex Blood 0.25 0.023 0.008 0.006
21507 England 2011/12 B B 340 ST-41/44 complex Blood 0.047 0.003 0.008 0.002
21508 England 2011/12 B B 1163 ST-269 complex Blood 0.047 0.003 0.004 0.004
26732 England 2013/14 C C 11 ST-11 complex Blood 0.25 0.016 0.004 0.012
27778 England 2012/13 B B 1475 ST-41/44 complex CSF 0.064 0.006 0.004 0.003
27779 England 2012/13 B B 10692 ST-35 complex Blood 0.064 0.003 0.006 0.003
27780 England 2012/13 B B 213 ST-213 complex Blood 0.047 0.023 0.004 0.003
27781 England 2012/13 B B 9180 ST-269 complex Blood 0.19 0.006 0.006 0.003
27782 England 2012/13 B B 461 ST-461 complex Blood 0.064 0.094 0.004 0.002
27783 England 2012/13 B B 1097 ST-41/44 complex CSF 0.047 0.004 0.004 0.002
27784 England 2012/13 B B 4051 UA Blood 0.094 0.032 0.004 0.003
27785 Wales 2012/13 B B 1096 ST-32 complex Blood 0.047 0.016 0.004 0.002
27786 England 2012/13 B B 41 ST-41/44 complex Blood 0.19 0.008 0.006 0.003
27787 England 2012/13 B B 1194 ST-41/44 complex Blood 0.032 0.006 0.006 <0.002
27788 England 2012/13 B B 154 ST-41/44 complex Blood 0.19 0.002 0.004 0.003
27789 Wales 2012/13 B B 1161 ST-269 complex Blood 0.047 0.012 0.004 0.002
27790 England 2012/13 B B 10693 ST-41/44 complex Blood 0.047 0.002 0.004 <0.002
27791 England 2012/13 B B 3695 ST-41/44 complex Blood 0.094 0.008 0.006 0.002
27792 England 2012/13 B B 42 ST-41/44 complex Blood 0.094 0.004 0.008 0.004
27793 England 2012/13 B B 1617 ST-22 complex Blood 0.064 0.004 0.006 0.003
27794 England 2012/13 B B 41 ST-41/44 complex CSF 0.125 0.004 0.006 0.004
27795 England 2012/13 B B 1194 ST-41/44 complex Blood 0.047 0.003 0.006 0.002
27796 England 2012/13 B B 41 ST-41/44 complex Blood 0.064 0.006 0.006 <0.002
27797 England 2012/13 B B 10694 UA Blood 0.064 0.003 0.004 0.002
27798 England 2012/13 B B 1097 ST-41/44 complex Blood 0.064 0.016 0.004 0.002
27799 England 2012/13 B B 1161 ST-269 complex Blood 0.094 0.023 0.004 0.003
27800 England 2012/13 B B 10695 ST-269 complex CSF 0.064 0.004 0.006 0.002
27801 Northern Ireland 2012/13 B B 269 ST-269 complex Blood 0.047 0.004 0.006 0.002
27802 England 2012/13 B B 571 ST-41/44 complex Blood 0.047 0.004 0.006 0.002
27803 England 2012/13 B B 11 ST-11 complex Blood 0.047 0.012 0.006 0.003
27804 England 2012/13 B B 2157 ST-269 complex Blood 0.047 0.012 0.004 0.003
27805 England 2012/13 B B 9199 UA CSF 0.19 0.003 0.004 0.006
27806 England 2012/13 B B 3242 UA CSF 0.064 0.004 0.006 0.003
27807 England 2012/13 B B 1161 ST-269 complex Blood 0.094 0.023 0.006 0.003
27808 England 2012/13 B B 1161 ST-269 complex Blood 0.125 0.016 0.006 0.003
27809 England 2012/13 B B 290 ST-32 complex Blood 0.125 0.012 0.006 0.004
27810 England 2012/13 B B 1855 ST-269 complex Blood 0.032 0.002 0.003 <0.002
27811 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.008 0.006 0.002
27812 England 2012/13 B B 10696 ST-41/44 complex CSF 0.032 0.006 0.006 <0.002
27813 England 2012/13 B B 213 ST-213 complex Blood 0.19 0.032 0.006 0.006
27814 England 2012/13 B B 7261 ST-461 complex Blood 0.25 0.032 0.006 0.004
27815 Wales 2012/13 B B 10697 ST-213 complex CSF 0.012 0.008 0.003 <0.002
27816 England 2012/13 B B 10698 ST-41/44 complex Joint 0.19 0.016 0.003 0.003
27817 England 2012/13 B B 269 ST-269 complex Blood 0.064 0.003 0.006 0.002
27818 England 2012/13 B B 154 ST-41/44 complex Blood 0.047 0.003 0.006 0.002
27819 England 2012/13 B B 259 ST-32 complex Blood 0.094 0.008 0.004 0.006
27820 England 2012/13 B B 1163 ST-269 complex CSF 0.19 0.004 0.004 0.003
27821 England 2012/13 B B 1161 ST-269 complex Blood 0.25 0.004 0.008 0.006
27822 England 2012/13 B B 41 ST-41/44 complex Blood 0.064 0.003 0.006 0.003
27823 England 2012/13 B B 7676 ST-213 complex CSF 0.094 0.047 0.004 0.006
27824 England 2012/13 B B 35 ST-35 complex Blood 0.064 0.003 0.006 0.003
27825 England 2012/13 B B 275 ST-269 complex CSF 0.064 0.016 0.003 0.003
27826 England 2012/13 B B 34 ST-32 complex Blood 0.064 0.016 0.003 0.003
27827 Wales 2012/13 B B 8049 ST-32 complex Blood 0.25 0.004 0.004 0.004
27828 England 2012/13 B B 10699 ST-213 complex Blood 0.064 0.032 0.003 0.006
27829 England 2012/13 B B 749 ST-32 complex Blood 0.25 0.004 0.004 0.008
27830 England 2012/13 B B 162 ST-162 complex Blood 0.064 0.012 0.003 0.004
27831 England 2012/13 B B 479 ST-269 complex CSF 0.023 0.008 0.003 0.002
27832 England 2012/13 B B 162 ST-162 complex Blood 0.064 0.012 0.003 0.003
27833 England 2012/13 B B 8054 ST-41/44 complex CSF 0.047 0.004 0.002 0.003
27834 England 2012/13 B B 1774 ST-269 complex Blood 0.064 0.004 0.004 0.004
27835 England 2012/13 B B 4713 UA Blood 0.25 0.004 0.003 0.006
27836 England 2012/13 B B 41 ST-41/44 complex Blood 0.125 0.003 0.002 0.003
27837 Northern Ireland 2012/13 B B 154 ST-41/44 complex Blood 0.064 0.003 0.003 0.002
27838 England 2012/13 B B 10700 ST-32 complex Blood 0.032 0.002 0.002 0.002




27840 England 2012/13 B B 2738 ST-269 complex Blood 0.064 <0.002 0.002 0.006
27841 England 2012/13 B B 1572 ST-1572 complex Blood 0.25 0.008 0.002 0.008
27842 England 2012/13 B B 1049 ST-269 complex Blood 0.032 0.012 0.002 0.002
27843 England 2012/13 B B 1946 ST-461 complex Blood 0.25 0.002 0.002 0.004
27844 England 2012/13 B B 275 ST-269 complex Blood 0.047 0.002 0.002 0.002
27845 Wales 2012/13 B B 213 ST-213 complex Blood 0.032 0.008 0.003 0.002
27846 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.003 0.003 0.003
27847 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.003 0.003 0.003
27848 England 2012/13 B B 1359 UA Blood 0.023 0.012 0.002 0.002
27849 Wales 2012/13 B B 1946 ST-461 complex Blood 0.19 0.012 0.002 0.006
27850 England 2012/13 B B 33 ST-32 complex Blood 0.064 0.003 0.003 0.004
27851 England 2012/13 B B 7789 ST-269 complex Blood 0.064 0.004 0.002 0.003
27852 England 2012/13 B B 10701 ST-35 complex Blood 0.047 0.006 0.002 0.003
27853 England 2012/13 B B 34 ST-32 complex Blood 0.25 0.004 0.002 0.008
27854 England 2012/13 B B 4953 ST-1572 complex Blood 0.25 0.003 0.003 0.006
27855 Northern Ireland 2012/13 B B 9774 ST-18 complex Blood 0.047 0.008 0.003 0.004
27856 England 2012/13 B B 10702 UA Blood 0.125 0.002 0.004 0.006
27857 England 2012/13 B B 282 ST-282 complex CSF 0.047 0.008 0.003 0.003
27858 England 2012/13 B B 8944 UA Blood 0.047 0.004 0.003 0.006
27859 Northern Ireland 2012/13 B B 269 ST-269 complex Blood 0.047 0.006 0.003 0.002
27860 England 2012/13 B B 479 ST-269 complex Blood 0.064 0.003 0.003 0.003
27861 England 2012/13 B B 10703 ST-269 complex Blood 0.25 0.004 0.003 0.004
27862 England 2012/13 B B 32 ST-32 complex Blood 0.064 0.006 0.003 0.003
27863 England 2012/13 B B 259 ST-32 complex CSF 0.094 0.012 0.002 0.004
27864 England 2012/13 B B 461 ST-461 complex Blood 0.125 0.003 0.002 0.006
27865 England 2012/13 B B 485 ST-41/44 complex Blood 0.19 0.004 0.003 0.004
27866 England 2012/13 B B 1161 ST-269 complex Blood 0.125 0.008 0.003 0.003
27867 England 2012/13 B B 1049 ST-269 complex Blood 0.047 0.003 0.003 0.003
27868 England 2012/13 B B 479 ST-269 complex Blood 0.047 0.004 0.003 0.002
27869 England 2012/13 B B 1161 ST-269 complex CSF 0.094 0.002 0.003 0.004
27870 England 2012/13 B B 1976 UA Blood 0.032 0.004 0.003 0.002
27871 England 2012/13 B B 8223 ST-461 complex Blood 0.064 0.004 0.002 0.004
27872 England 2012/13 B B 41 ST-41/44 complex Blood 0.19 0.008 0.002 0.008
27873 England 2012/13 B B 3666 ST-41/44 complex CSF 0.125 0.003 0.003 0.003
27874 England 2012/13 B B 213 ST-213 complex Blood 0.064 0.008 0.003 0.004
27875 England 2012/13 B B 41 ST-41/44 complex Blood 0.032 0.006 0.003 0.002
27876 England 2012/13 B B 1194 ST-41/44 complex Blood 0.19 0.002 0.002 0.003
27877 England 2012/13 B B 275 ST-269 complex CSF 0.19 0.002 0.002 0.006
27878 England 2012/13 B B 269 ST-269 complex Blood 0.032 0.003 0.003 0.002
27879 England 2012/13 B B 269 ST-269 complex Blood 0.064 0.008 0.003 0.003
27880 England 2012/13 B B 269 ST-269 complex Blood 0.125 0.003 0.003 0.003
27881 England 2012/13 B B 2123 UA CSF 0.047 0.006 0.004 0.002
27882 England 2012/13 B B 10704 ST-18 complex CSF 0.094 0.006 0.002 0.008
27883 England 2012/13 B B 213 ST-213 complex Blood 0.047 0.094 0.002 0.003
27884 Wales 2012/13 B B 479 ST-269 complex Blood 0.032 0.003 0.003 0.002
27885 England 2012/13 B B 1090 ST-41/44 complex Blood 0.094 0.002 0.002 0.002
27886 England 2012/13 B B 11142 UA Blood 0.047 0.004 <0.002 0.003
27887 Wales 2012/13 B B 10705 ST-461 complex Blood 0.047 0.004 0.002 0.003
27888 England 2012/13 B B 74 ST-32 complex Blood 0.064 0.003 0.003 0.003
27889 England 2012/13 B B 2821 ST-41/44 complex Blood 0.047 0.006 0.002 0.003
27890 Wales 2012/13 B B 1161 ST-269 complex Blood 0.012 0.002 0.002 0.002
27891 England 2012/13 B B 162 ST-162 complex Blood 0.032 0.016 0.002 0.002
27892 England 2012/13 B B 1161 ST-269 complex Blood 0.25 0.004 0.002 0.004
27893 England 2012/13 B B 269 ST-269 complex Blood 0.023 0.003 0.002 0.002
27894 England 2012/13 B B 32 ST-32 complex Blood 0.047 0.032 0.003 0.003
27895 England 2012/13 B B 1153 ST-41/44 complex Blood 0.023 0.004 0.003 0.002
27896 England 2012/13 B B 8288 ST-269 complex Blood 0.016 0.004 0.003 0.002
27897 Wales 2012/13 B B 1096 ST-32 complex CSF 0.032 0.006 0.003 0.003
27898 England 2012/13 B B 213 ST-213 complex Blood 0.032 0.003 0.002 0.003
27899 Wales 2012/13 B B 2592 ST-269 complex Blood 0.016 0.002 0.003 0.002
27900 England 2012/13 B B 10706 ST-41/44 complex Blood 0.25 >32 0.003 0.012
27901 England 2012/13 B B 1233 ST-41/44 complex Blood 0.032 0.003 0.003 0.003
27903 England 2012/13 B B 41 ST-41/44 complex CSF 0.19 0.006 0.003 0.004
27904 England 2012/13 B B 269 ST-269 complex Blood 0.047 0.006 0.004 0.003
27905 England 2012/13 B B 479 ST-269 complex CSF 0.064 0.006 0.003 0.003
27906 England 2012/13 B B 2166 ST-269 complex Blood 0.047 0.004 0.003 0.002
27907 England 2012/13 B B 461 ST-461 complex Blood 0.19 0.006 0.003 0.006
27908 England 2012/13 B B 1194 ST-41/44 complex Blood 0.047 0.016 0.002 <0.002
27909 England 2012/13 B B 2799 ST-41/44 complex Blood 0.25 0.006 0.003 0.006
27910 England 2012/13 B B 41 ST-41/44 complex Blood 0.19 0.004 0.003 0.004
27911 England 2012/13 B B 1161 ST-269 complex CSF 0.25 0.006 0.003 0.004
27912 Wales 2012/13 B B 10707 ST-32 complex Blood 0.25 0.004 0.003 0.004
27914 England 2012/13 B B 461 ST-461 complex Blood 0.19 0.008 0.002 0.004
27915 England 2012/13 B B 35 ST-35 complex Blood 0.064 0.004 0.002 0.003
27916 England 2012/13 B B 213 ST-213 complex Blood 0.032 0.016 0.002 0.002
27917 England 2012/13 B B 10708 ST-269 complex Blood 0.094 0.008 0.003 0.004
27918 England 2012/13 B B 337 ST-41/44 complex Blood 0.064 0.012 0.006 0.003
27919 England 2012/13 B B 35 ST-35 complex Blood 0.064 0.004 0.003 0.002
27920 England 2012/13 B B 1161 ST-269 complex Blood 0.125 0.006 0.003 0.004
27921 England 2012/13 B B 10709 UA Blood 0.094 0.006 0.003 0.003
27922 England 2012/13 B B 479 ST-269 complex Blood 0.047 0.006 0.003 0.002
27923 England 2012/13 B B 479 ST-269 complex Blood 0.032 0.006 0.003 0.002
27924 England 2012/13 B B 10710 ST-41/44 complex Blood 0.064 0.012 0.003 0.003
27925 England 2012/13 B B 8006 UA Blood 0.032 0.032 0.003 0.002




27927 England 2012/13 B B 1946 ST-461 complex CSF 0.38 0.016 0.002 0.008
27928 England 2012/13 B B 275 ST-269 complex Blood 0.064 0.006 0.003 0.003
27929 England 2012/13 B B 8054 ST-41/44 complex Blood 0.064 0.006 0.003 0.003
27930 England 2012/13 B B 1161 ST-269 complex Blood 0.094 0.006 0.002 0.004
27931 England 2012/13 B B 479 ST-269 complex Blood 0.064 0.004 0.002 0.003
27932 England 2012/13 B B 1774 ST-269 complex Blood 0.064 0.008 0.003 0.002
27933 England 2012/13 B B 5983 ST-461 complex Blood 0.047 0.004 0.002 0.002
27934 England 2012/13 B B 461 ST-461 complex Blood 0.19 0.006 0.002 0.004
27935 England 2012/13 B B 275 ST-269 complex Blood 0.094 0.004 0.003 0.004
27936 England 2012/13 B B 1161 ST-269 complex Blood 0.064 0.125 0.004 0.002
27937 England 2012/13 B B 269 ST-269 complex CSF 0.032 0.003 0.003 <0.002
27938 England 2012/13 B B 461 ST-461 complex Blood 0.19 0.012 0.004 0.004
27939 England 2012/13 B B 7196 UA Blood 0.19 0.006 0.002 0.004
27940 England 2012/13 B B 10711 UA CSF 0.25 0.012 0.003 0.006
27941 England 2012/13 B B 1946 ST-461 complex Blood 0.19 0.003 0.002 0.002
27942 England 2012/13 B B 9194 ST-213 complex Blood 0.047 0.006 0.002 0.002
27943 England 2012/13 B B 1475 ST-41/44 complex Blood 0.064 0.064 0.003 0.002
27944 England 2012/13 B B 40 ST-41/44 complex Blood 0.047 0.003 0.003 0.002
27945 England 2012/13 B B 1434 UA Blood 0.38 0.012 0.003 0.016
27946 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.003 0.003 0.002
27947 England 2012/13 B B 6761 ST-41/44 complex Blood 0.064 0.003 0.004 0.003
27948 England 2012/13 B B 162 ST-162 complex Blood 0.047 0.004 0.003 0.002
27949 England 2012/13 B B 1049 ST-269 complex Blood 0.032 0.003 0.004 0.002
27950 Wales 2012/13 B B 3893 ST-41/44 complex CSF 0.125 0.008 0.004 0.003
27951 Wales 2012/13 B B 1097 ST-41/44 complex CSF 0.064 0.004 0.004 0.003
27952 England 2012/13 B B 1572 ST-1572 complex CSF 0.25 0.008 0.004 0.008
27953 England 2012/13 B B 32 ST-32 complex Blood 0.064 0.006 0.004 0.004
27954 England 2012/13 B B 1194 ST-41/44 complex Blood 0.064 0.002 0.004 0.002
27955 England 2012/13 B B 269 ST-269 complex Blood 0.047 0.003 0.004 0.002
27956 England 2012/13 B B 1194 ST-41/44 complex Blood 0.064 0.004 0.004 0.002
27957 England 2012/13 B B 34 ST-32 complex Blood 0.032 0.032 0.003 0.002
27958 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.004 0.004 0.003
27959 England 2012/13 B B 1161 ST-269 complex BONE MARROW 0.125 0.006 0.003 0.006
27960 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.004 0.004 0.003
27961 England 2012/13 B B 1161 ST-269 complex CSF 0.094 0.004 0.004 0.004
27962 England 2012/13 B B 1802 ST-282 complex Blood 0.047 0.003 0.004 0.002
27963 England 2012/13 B B 213 ST-213 complex Blood 0.19 0.006 0.004 0.004
27964 England 2012/13 B B 749 ST-32 complex Blood 0.38 0.012 0.004 0.008
27965 England 2012/13 B B 213 ST-213 complex Blood 0.064 0.004 0.004 0.002
27966 England 2012/13 B B 1194 ST-41/44 complex Blood 0.064 0.004 0.004 0.004
27967 England 2012/13 B B 1770 ST-41/44 complex CSF 0.094 0.006 0.004 0.004
27968 England 2012/13 B B 9293 ST-162 complex Blood 0.19 0.004 0.004 0.004
27969 England 2012/13 B B 282 ST-282 complex Blood 0.094 0.006 0.006 0.003
27970 England 2012/13 B B 10712 ST-269 complex Blood 0.19 0.004 0.004 0.002
27971 Northern Ireland 2012/13 B B 10713 UA Blood 0.064 0.008 0.004 0.004
27972 England 2012/13 B B 10714 UA CSF 0.064 0.004 0.004 0.003
27973 England 2012/13 B B 9327 ST-60 complex Blood 0.047 0.004 0.004 0.003
27974 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.004 0.004 0.002
27975 Wales 2012/13 B B 269 ST-269 complex Blood 0.047 0.004 0.006 0.003
27976 England 2012/13 B B 35 ST-35 complex Blood 0.047 0.012 0.004 0.002
27977 England 2012/13 B B 269 ST-269 complex Blood 0.016 0.006 0.003 0.002
27978 England 2012/13 B B 1194 ST-41/44 complex Blood 0.064 0.004 0.004 0.003
27979 England 2012/13 B B 269 ST-269 complex Blood 0.032 0.004 0.004 0.002
27980 England 2012/13 B B 575 ST-213 complex Blood 0.19 0.006 0.002 0.003
27981 England 2012/13 B B 5357 ST-41/44 complex Blood 0.064 0.003 0.004 0.003
27982 England 2012/13 B B 275 ST-269 complex Blood 0.094 0.003 0.004 0.002
27983 England 2012/13 B B 4256 ST-41/44 complex CSF 0.032 0.003 0.006 0.003
27984 England 2012/13 B B 2203 ST-41/44 complex Blood 0.064 0.003 0.003 0.004
27985 England 2012/13 B B 10535 ST-41/44 complex Joint 0.064 0.003 0.004 0.004
27986 England 2012/13 B B 41 ST-41/44 complex CSF 0.064 0.003 0.002 0.003
27987 England 2012/13 B B 5151 UA Blood 0.19 0.004 0.003 0.008
27988 England 2012/13 B B 213 ST-213 complex Blood 0.047 0.008 0.002 0.004
27989 England 2012/13 B B 1163 ST-269 complex Blood 0.19 0.003 0.002 0.008
27990 England 2012/13 B B 275 ST-269 complex Blood 0.19 0.008 0.003 0.008
27991 England 2012/13 B B 9829 ST-269 complex CSF 0.023 0.002 0.002 0.002
27992 Wales 2012/13 B B 11 ST-11 complex CSF 0.047 0.016 0.002 0.004
27993 England 2012/13 B B 7143 UA Blood 0.032 0.003 0.003 0.003
27994 England 2012/13 B B 1194 ST-41/44 complex Blood 0.047 0.003 0.003 0.003
27995 England 2012/13 B B 485 ST-41/44 complex Blood 0.25 0.012 0.003 0.004
27996 England 2012/13 B B 207 ST-41/44 complex Blood 0.032 0.004 0.002 0.002
27997 Wales 2012/13 B B 1161 ST-269 complex Blood 0.25 0.003 0.003 0.006
27998 England 2012/13 B B 41 ST-41/44 complex Blood 0.19 0.006 0.002 0.006
27999 England 2012/13 B B 5849 UA CSF 0.25 0.003 0.003 0.008
28000 England 2012/13 B B 3101 ST-41/44 complex Blood 0.064 0.003 0.003 0.004
28001 Northern Ireland 2012/13 B B 275 ST-269 complex Blood 0.023 0.004 0.003 0.002
28002 Wales 2012/13 B B 8049 ST-32 complex Blood 0.19 0.003 0.002 0.004
28003 England 2012/13 B B 1194 ST-41/44 complex Blood 0.125 0.004 0.002 0.004
28004 Wales 2012/13 B B 10715 UA Blood 0.064 0.032 0.003 0.004
28005 Wales 2012/13 B B 1161 ST-269 complex Blood 0.047 0.004 0.002 0.003
28006 England 2012/13 B B 41 ST-41/44 complex Blood 0.094 0.003 0.002 0.004
28007 Wales 2012/13 B B 1096 ST-32 complex Blood 0.047 0.006 0.003 0.004
28009 Wales 2012/13 B B 8539 ST-41/44 complex Blood 0.047 0.004 0.003 0.003
28010 England 2012/13 B B 213 ST-213 complex Blood 0.094 0.008 0.002 0.004
28011 England 2012/13 B B 275 ST-269 complex Blood 0.064 0.002 0.003 0.004




28013 Wales 2012/13 B B 41 ST-41/44 complex Blood 0.19 0.047 0.003 0.006
28014 England 2012/13 B B 41 ST-41/44 complex Blood 0.125 0.012 0.002 0.004
28015 Northern Ireland 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.016 0.003 0.002
28016 England 2012/13 B B 269 ST-269 complex Blood 0.032 0.003 0.002 0.002
28017 England 2012/13 B B 1946 ST-461 complex Blood 0.125 0.047 0.002 0.006
28019 England 2012/13 B B 840 ST-167 complex Blood 0.064 0.008 0.002 0.004
28020 England 2012/13 B B 1161 ST-269 complex Blood 0.094 0.008 0.003 0.008
28021 England 2012/13 B B 1163 ST-269 complex Blood 0.19 0.016 0.002 0.008
28022 England 2012/13 B B 1273 ST-269 complex Blood 0.047 0.002 0.002 0.004
28023 England 2012/13 B B 10338 ST-213 complex Blood 0.064 0.008 0.002 0.006
28024 England 2012/13 B B 41 ST-41/44 complex Blood 0.032 0.004 0.002 0.004
28025 England 2012/13 B B 10717 ST-32 complex Blood 0.047 0.004 0.002 0.006
28026 England 2012/13 B B 41 ST-41/44 complex Blood 0.19 0.006 0.002 0.008
28027 England 2012/13 B B 1157 ST-1157 complex CSF 0.047 0.006 0.002 0.006
28028 England 2012/13 B B 10718 ST-41/44 complex Blood 0.125 0.023 0.008 0.008
28029 England 2012/13 B B 162 ST-162 complex Blood 0.064 0.008 0.004 0.006
28030 England 2012/13 B B 1194 ST-41/44 complex Blood 0.064 0.004 0.004 0.004
28031 England 2012/13 B B 1049 ST-269 complex Blood 0.064 0.008 0.004 0.006
28032 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.004 0.004 0.004
28033 England 2012/13 B B 1823 ST-41/44 complex Blood 0.125 0.004 0.006 0.008
28034 England 2012/13 B B 10719 ST-213 complex Blood 0.064 0.012 0.006 0.004
28035 England 2012/13 B B 10720 ST-269 complex Blood 0.032 0.003 0.004 0.003
28036 England 2012/13 B B 5330 UA Joint 0.047 0.023 0.004 0.004
28037 England 2012/13 B B 6791 ST-269 complex Blood 0.047 0.004 0.006 0.004
28038 England 2012/13 B B 32 ST-32 complex CSF 0.094 0.016 0.006 0.004
28039 England 2012/13 B B 8176 ST-41/44 complex Blood 0.064 0.008 0.006 0.003
28040 England 2012/13 B B 1159 UA Blood 0.064 0.006 0.006 0.006
28041 England 2012/13 B B 1575 UA Blood 0.064 0.004 0.004 0.004
28042 England 2012/13 B B 269 ST-269 complex Blood 0.047 0.006 0.006 0.003
28043 England 2012/13 B B 1946 ST-461 complex Blood 0.38 0.006 0.004 0.008
28044 England 2012/13 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.006
28045 Wales 2012/13 B B 283 ST-269 complex Blood 0.047 0.004 0.004 0.003
28046 England 2012/13 B B 10721 ST-41/44 complex Blood 0.125 0.003 0.004 0.006
28047 England 2012/13 B B 162 ST-162 complex Blood 0.064 0.006 0.006 0.004
28048 England 2012/13 B B 1430 ST-60 complex Blood 0.047 0.006 0.004 0.004
28049 England 2012/13 B B 46 ST-41/44 complex Blood 0.064 0.006 0.006 0.004
28050 England 2012/13 B B 1049 ST-269 complex Blood 0.047 0.004 0.004 0.003
28051 England 2012/13 B B 1163 ST-269 complex Blood 0.19 0.003 0.004 0.008
28052 England 2012/13 B B 10722 UA Blood 0.047 0.004 0.004 0.004
28053 England 2012/13 B B 5849 UA Blood 0.064 0.004 0.004 0.004
28054 Wales 2012/13 B B 213 ST-213 complex Blood 0.064 0.004 0.006 0.006
28055 England 2012/13 B B 275 ST-269 complex Blood 0.064 0.008 0.008 0.004
28056 England 2012/13 B B 269 ST-269 complex Blood 0.047 0.004 0.006 0.003
28057 England 2012/13 B B 254 ST-254 complex Blood 0.064 0.006 0.004 0.006
28058 England 2012/13 B B 213 ST-213 complex Blood 0.094 0.016 0.004 0.006
28059 England 2012/13 B B 7955 ST-41/44 complex Blood 0.064 0.006 0.004 0.004
28060 England 2012/13 B B 103 ST-103 complex Blood 0.032 0.004 0.003 0.004
28061 England 2012/13 B B 154 ST-41/44 complex Blood 0.032 0.006 0.004 0.006
28063 England 2012/13 B B 3120 ST-213 complex Blood 0.19 0.023 0.008 0.004
28064 England 2012/13 B B 41 ST-41/44 complex Blood 0.19 0.004 0.008 0.004
28065 England 2012/13 B B 269 ST-269 complex Blood 0.047 0.004 0.003 0.008
28066 England 2012/13 B B 275 ST-269 complex Blood 0.064 0.008 0.008 0.004
28067 England 2012/13 B B 103 ST-103 complex Blood 0.032 0.006 0.006 0.002
28068 England 2012/13 B B 1159 UA Blood 0.125 0.047 0.008 0.012
28069 England 2012/13 B B 1161 ST-269 complex Blood 0.064 0.008 0.004 0.006
28070 England 2012/13 B B 275 ST-269 complex Blood 0.032 0.004 0.006 0.003
28071 England 2012/13 B B 162 ST-162 complex Blood 0.25 0.004 0.006 0.008
28072 England 2012/13 B B 41 ST-41/44 complex Blood 0.064 0.006 0.006 0.004
28073 England 2012/13 B B 2080 ST-41/44 complex Blood 0.094 0.006 0.008 0.008
28074 England 2012/13 B B 1161 ST-269 complex Blood 0.012 0.006 0.006 0.004
28075 England 2012/13 B B 1161 ST-269 complex Blood 0.094 0.032 0.006 0.004
28076 England 2012/13 B B 41 ST-41/44 complex Blood 0.094 0.008 0.004 0.006
28077 England 2012/13 B B 10723 ST-213 complex Blood 0.047 0.016 0.006 0.004
28078 England 2012/13 B B 10724 ST-269 complex Blood 0.19 0.008 0.006 0.004
28079 England 2012/13 C C 5133 ST-103 complex Blood 0.016 0.008 0.004 <0.002
28080 England 2012/13 C C 11 ST-11 complex CSF 0.047 0.004 0.008 <0.002
28081 England 2012/13 C C 467 ST-269 complex Blood 0.047 0.004 0.006 0.002
28082 England 2012/13 C C 11 ST-11 complex Blood 0.25 0.125 0.006 0.004
28083 England 2012/13 C C 11 ST-11 complex Blood 0.25 0.016 0.006 0.006
28084 England 2012/13 C C 11 ST-11 complex Blood 0.094 0.004 0.008 0.004
28085 England 2012/13 C C 11 ST-11 complex Blood 0.094 0.032 0.003 0.004
28086 England 2012/13 C C 1466 ST-174 complex Blood 0.094 0.012 <0.002 0.004
28087 England 2012/13 C C 1466 ST-174 complex Blood 0.125 0.012 <0.002 0.004
28088 England 2012/13 C C 9777 UA Blood 0.032 0.012 <0.002 0.002
28089 England 2012/13 C C 11 ST-11 complex Blood 0.094 0.012 0.003 0.004
28090 England 2012/13 C C 11 ST-11 complex Joint 0.047 0.016 0.003 0.004
28091 Northern Ireland 2012/13 C C 467 ST-269 complex Blood 0.064 0.006 0.003 0.004
28092 England 2012/13 C C 11 ST-11 complex Blood 0.125 0.008 0.004 0.006
28093 England 2012/13 C C 11 ST-11 complex Blood 0.25 0.012 0.004 0.008
28094 England 2012/13 C C 11 ST-11 complex Blood 0.25 0.012 0.006 0.006
28095 England 2012/13 C C 11 ST-11 complex Blood 0.19 0.023 0.003 0.008
28096 England 2012/13 C C 5315 UA Blood 0.004 0.016 <0.002 <0.002
28097 England 2012/13 C C 11 ST-11 complex Blood 0.19 0.003 0.003 0.004
28098 England 2012/13 C C 11 ST-11 complex Blood 0.19 0.023 0.004 0.008




28100 England 2012/13 C C 11 ST-11 complex Blood 0.19 0.008 0.004 0.012
28101 England 2012/13 C C 5133 ST-103 complex Blood 0.125 0.006 0.004 0.002
28102 England 2012/13 C C 11 ST-11 complex Blood 0.094 0.006 0.006 0.006
28103 England 2012/13 C C 11 ST-11 complex Blood 0.25 0.012 0.004 0.008
28104 England 2012/13 C C 11 ST-11 complex Blood 0.25 0.016 0.006 0.008
28105 England 2012/13 C C 11 ST-11 complex Blood 0.25 0.016 0.004 0.008
28106 England 2012/13 C C 11 ST-11 complex Blood 0.047 0.004 0.008 0.004
28107 England 2012/13 NG E 10301 ST-1157 complex Blood 0.047 0.006 0.008 0.002
28109 England 2012/13 NG CNL 823 ST-198 complex Blood 0.25 0.125 0.006 0.008
28111 England 2012/13 NG B 213 ST-213 complex Blood 0.125 0.003 0.003 0.004
28112 England 2012/13 NG B 41 ST-41/44 complex Blood 0.19 0.004 0.004 0.006
28113 England 2012/13 NG E 1157 ST-1157 complex Blood 0.032 0.016 0.003 0.003
28118 England 2012/13 W W 184 ST-22 complex Blood 0.094 0.006 0.008 0.003
28120 England 2012/13 W W 1286 ST-22 complex Blood 0.19 0.012 0.003 0.003
28121 Wales 2012/13 W W 10651 ST-11 complex Blood 0.047 0.004 0.003 0.003
28123 England 2012/13 W W 184 ST-22 complex Blood 0.125 0.006 0.004 0.004
28124 England 2012/13 W W 22 ST-22 complex Blood 0.125 0.002 0.003 0.004
28126 Wales 2012/13 W W 184 ST-22 complex CSF 0.125 0.016 0.003 0.003
28127 England 2012/13 W W 1286 ST-22 complex Blood 0.125 0.004 0.004 0.003
28129 England 2012/13 W W 1281 ST-22 complex Blood 0.125 0.006 0.002 0.002
28130 England 2012/13 W/Y W/Y 1655 ST-23 complex Blood 0.047 0.004 0.002 0.003
28133 England 2012/13 W W 1286 ST-22 complex CSF 0.19 0.008 0.003 0.003
28140 England 2012/13 W W 184 ST-22 complex Blood 0.19 0.008 0.006 0.003
28145 England 2012/13 W W 22 ST-22 complex Blood 0.25 0.008 0.008 0.004
28148 Wales 2012/13 W W 10651 ST-11 complex Blood 0.064 0.008 0.003 0.004
28155 England 2012/13 W W 10726 ST-22 complex Joint 0.19 0.094 0.004 0.004
28159 Northern Ireland 2012/13 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.004
28160 England 2012/13 W W 184 ST-22 complex Blood 0.094 0.012 0.008 0.003
28165 England 2012/13 Y Y 23 ST-23 complex Blood 0.064 0.004 0.006 0.003
28166 Northern Ireland 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.006 0.003
28167 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
28168 England 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.003
28170 England 2012/13 Y Y 23 ST-23 complex Blood 0.094 0.016 0.006 0.003
28171 Wales 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.006 0.002
28172 England 2012/13 Y Y 23 ST-23 complex Blood 0.047 <0.002 0.004 0.006
28173 England 2012/13 Y Y 1466 ST-174 complex Blood 0.094 0.006 0.003 0.006
28174 England 2012/13 Y Y 23 ST-23 complex Blood 0.19 0.003 0.003 0.004
28175 England 2012/13 Y Y 3030 ST-23 complex Blood 0.19 0.002 <0.002 0.003
28176 England 2012/13 Y Y 103 ST-103 complex Blood 0.023 0.003 0.004 0.002
28177 England 2012/13 Y Y 1655 ST-23 complex Blood 0.19 0.002 0.002 0.006
28178 England 2012/13 Y Y 1655 ST-23 complex Joint 0.094 0.004 0.002 0.008
28179 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.002 0.002 0.003
28180 England 2012/13 Y Y 1466 ST-174 complex Joint 0.5 0.008 0.002 0.016
28181 England 2012/13 Y Y 10294 ST-23 complex Joint 0.064 0.003 0.003 0.003
28182 England 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.002 0.003
28183 England 2012/13 Y Y 10727 ST-167 complex Blood 0.032 0.006 0.002 0.003
28184 England 2012/13 Y Y 10728 ST-167 complex Blood 0.19 0.003 0.002 0.012
28185 England 2012/13 Y Y 23 ST-23 complex Blood 0.125 0.002 0.002 0.003
28186 England 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.002 0.002 0.003
28187 England 2012/13 Y Y 114 ST-22 complex Blood 0.094 0.003 0.003 0.008
28188 England 2012/13 Y Y 23 ST-23 complex Blood 0.125 0.003 0.002 0.004
28189 England 2012/13 Y Y 10729 ST-167 complex Blood 0.032 0.002 0.002 0.003
28190 England 2012/13 Y Y 23 ST-23 complex Joint 0.047 0.003 0.002 0.003
28191 England 2012/13 Y Y 23 ST-23 complex Blood 0.064 0.003 0.002 0.003
28192 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.003
28193 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.004
28194 England 2012/13 Y Y 23 ST-23 complex Blood 0.125 0.002 0.002 0.004
28195 England 2012/13 Y Y 23 ST-23 complex Blood 0.064 0.006 0.002 0.004
28196 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.002 0.003
28197 England 2012/13 Y Y 23 ST-23 complex Blood 0.125 0.004 0.002 0.006
28198 England 2012/13 Y Y 1655 ST-23 complex Blood 0.094 0.003 0.003 0.004
28199 England 2012/13 Y Y 114 ST-22 complex Blood 0.064 0.003 0.004 0.003
28200 England 2012/13 Y Y 1655 ST-23 complex CSF 0.064 0.006 0.003 0.006
28201 Northern Ireland 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.002 0.004
28202 England 2012/13 Y Y 10730 ST-167 complex Blood 0.064 0.004 0.002 0.003
28203 England 2012/13 Y Y 114 ST-22 complex Blood 0.064 0.003 0.003 0.006
28204 England 2012/13 Y Y 10728 ST-167 complex Blood 0.19 0.002 0.002 0.016
28205 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.003 0.002
28206 England 2012/13 Y Y 23 ST-23 complex Blood 0.032 0.003 0.003 0.002
28207 England 2012/13 Y Y 1655 ST-23 complex BRAIN 0.012 0.003 0.002 0.002
28208 England 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.003
28209 England 2012/13 Y Y 1655 ST-23 complex CSF 0.064 0.004 0.003 0.003
28210 England 2012/13 Y Y 1655 ST-23 complex Blood 0.125 0.004 0.004 0.006
28211 Northern Ireland 2012/13 Y Y 3980 ST-167 complex Blood 0.5 0.006 0.004 0.016
28212 England 2012/13 Y Y 23 ST-23 complex Blood 0.064 0.004 0.004 0.004
28213 England 2012/13 Y Y 168 ST-167 complex Blood 0.094 0.003 0.004 0.006
28214 England 2012/13 Y Y 1655 ST-23 complex Blood 0.023 0.002 0.002 0.002
28215 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.002
28216 England 2012/13 Y Y 1655 ST-23 complex Blood 0.012 0.003 0.002 0.002
28217 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.002 0.003 0.004
28218 England 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.002 0.006
28219 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.002 0.006
28220 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.002 0.002 0.002
28221 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.002 0.004




28223 England 2012/13 Y Y 1655 ST-23 complex CSF 0.032 0.004 0.002 0.002
28224 England 2012/13 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.004
28225 England 2012/13 Y Y 3015 UA Blood 0.047 0.012 0.002 0.006
28226 England 2012/13 Y Y 23 ST-23 complex Blood 0.125 0.003 0.002 0.004
28227 England 2012/13 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.002 0.003
28228 England 2012/13 Y Y 1655 ST-23 complex Blood 0.032 0.006 0.004 0.004
28229 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.002 0.004
28230 England 2012/13 Y Y 10732 ST-23 complex Blood 0.047 0.004 0.002 0.004
28231 England 2012/13 Y Y 23 ST-23 complex Blood 0.094 0.004 0.004 0.008
28232 England 2012/13 Y Y 3342 ST-865 complex Blood 0.016 0.032 0.004 0.002
28233 England 2012/13 Y Y 4446 ST-23 complex Blood 0.094 0.003 0.006 0.006
28234 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
28235 England 2012/13 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
29727 Wales 2013/14 W W 11 ST-11 complex Blood 0.064 0.003 0.006 0.004
29895 Northern Ireland 2013/14 C C 11 ST-11 complex Blood 0.094 0.006 0.008 0.008
29897 England 2013/14 C C 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
29898 England 2013/14 C C 11 ST-11 complex Blood 0.094 0.006 0.008 0.004
30149 England 2013/14 W W 1617 ST-22 complex Blood 0.032 0.006 0.008 0.003
30169 Northern Ireland 2013/14 W W 11 ST-11 complex CSF 0.094 0.008 0.008 0.006
30210 England 2013/14 C C 11 ST-11 complex Blood 0.38 0.047 0.012 0.016
30211 England 2013/14 Y Y 23 ST-23 complex Blood 0.047 0.004 0.004 0.004
30212 England 2013/14 C C NK INCOMPLETE MLST CSF 0.25 0.125 0.008 0.012
30213 England 2013/14 C C NK INCOMPLETE MLST Blood 0.25 0.016 0.008 0.008
30214 England 2013/14 C C 11 ST-11 complex Blood 0.125 0.032 0.008 0.012
30215 England 2013/14 C C 11 ST-11 complex Blood 0.064 0.023 0.008 0.008
31162 England 2013/14 B B 11 ST-11 complex Blood 0.094 0.125 0.006 0.008
31163 England 2014/15 B B 485 ST-41/44 complex Blood 0.125 0.012 0.006 0.006
34502 England 2013/14 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.006 0.004
34503 England 2013/14 Y NK 1655 ST-23 complex Blood 0.032 0.003 0.006 0.004
34504 England 2013/14 B B 269 ST-269 complex Blood 0.047 0.002 0.006 0.002
34505 England 2013/14 B B 343 ST-32 complex Blood 0.38 0.008 0.008 0.023
34506 England 2013/14 B B 5972 ST-269 complex Blood 0.064 0.003 0.006 0.006
34507 England 2013/14 B B 41 ST-41/44 complex Joint 0.125 0.016 0.004 0.004
34508 England 2013/14 B B 1423 ST-41/44 complex Blood 0.094 0.006 0.008 0.006
34509 Wales 2013/14 B B 1855 ST-269 complex Blood 0.047 0.002 0.006 0.003
34510 England 2013/14 B B 1194 ST-41/44 complex Blood 0.064 0.023 0.004 0.002
34511 England 2013/14 B B 32 ST-32 complex Blood 0.125 0.008 0.008 0.008
34512 England 2013/14 W NK 184 ST-22 complex Blood 0.047 0.004 0.006 0.003
34513 England 2013/14 B B 9126 ST-174 complex Blood 0.094 0.003 0.006 0.006
34514 England 2013/14 B B 1214 ST-269 complex Blood 0.047 0.016 0.006 0.003
34515 England 2013/14 B B 749 ST-32 complex Blood 0.19 0.003 0.006 0.008
34516 England 2013/14 B B 213 ST-213 complex Blood 0.023 0.012 0.008 0.002
34517 England 2013/14 B B 41 ST-41/44 complex Blood 0.19 0.004 0.004 0.008
35422 England 2013/14 B B NK INCOMPLETE MLST Blood 0.19 0.016 0.004 0.016
35423 England 2013/14 W W 184 ST-22 complex Blood 0.125 0.023 0.006 0.004
35424 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.003 0.006
35426 England 2013/14 B B 11225 ST-41/44 complex Blood 0.064 0.016 0.006 0.006
35427 England 2013/14 B B 1946 ST-461 complex Blood 0.38 0.19 0.006 0.008
35428 England 2013/14 B B 34 ST-32 complex Blood 0.19 0.004 0.004 0.012
35429 England 2013/14 B B 1163 ST-269 complex CSF 0.047 0.003 0.006 0.006
35430 England 2013/14 B B 275 ST-269 complex Blood 0.064 0.004 0.006 0.006
35431 Northern Ireland 2013/14 B B 11226 ST-213 complex Blood 0.032 0.002 0.004 0.003
35432 England 2013/14 Y Y 1655 ST-23 complex Blood 0.19 0.006 0.008 0.023
35434 England 2013/14 B B 303 ST-41/44 complex Blood 0.25 0.008 0.004 0.012
35435 England 2013/14 Y Y 1655 ST-23 complex Joint 0.047 0.004 0.004 0.004
35436 England 2013/14 B B 461 ST-461 complex Blood 0.125 0.012 0.004 0.008
35437 England 2013/14 B B 7516 ST-41/44 complex Blood 0.023 0.006 0.004 0.008
35438 England 2013/14 B B 11227 ST-41/44 complex Blood 0.125 0.003 0.004 0.008
35439 England 2013/14 B B 1163 ST-269 complex Blood 0.19 0.002 0.006 0.008
35440 England 2013/14 B B 11229 ST-41/44 complex Blood 0.047 0.003 0.004 0.003
35441 England 2013/14 B B 283 ST-269 complex Blood 0.047 0.012 0.006 0.003
35442 Wales 2013/14 B B 213 ST-213 complex Blood 0.094 0.008 0.006 0.006
35443 England 2013/14 B B 269 ST-269 complex Blood 0.032 0.004 0.006 0.003
35444 England 2013/14 B B 11237 ST-269 complex Blood 0.023 0.008 0.003 0.003
35445 England 2013/14 Y Y 9842 ST-23 complex Blood 0.064 0.006 0.004 0.006
35446 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.006
35447 England 2013/14 B B 11238 ST-269 complex Blood 0.047 0.003 0.004 0.003
35448 England 2013/14 B B 1946 ST-461 complex CSF 0.5 0.004 0.004 0.008
35449 England 2013/14 W/Y W/Y 1624 ST-167 complex Blood 0.25 0.006 0.004 0.016
35450 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.064 0.006 0.004 0.004
35451 Wales 2013/14 B B 11239 ST-269 complex Blood 0.25 0.012 0.006 0.008
35452 England 2013/14 B B 162 ST-162 complex CSF 0.38 0.012 0.006 0.008
35453 England 2013/14 W W 184 ST-22 complex Blood 0.094 0.016 0.006 0.003
35454 England 2013/14 B B 269 ST-269 complex Blood 0.047 0.006 0.006 0.003
35456 Northern Ireland 2013/14 Y Y 23 ST-23 complex Blood 0.047 0.006 0.006 0.004
35457 England 2013/14 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.006
35458 Wales 2013/14 B B 11328 UA Blood 0.064 0.023 0.004 0.004
35459 England 2013/14 B B 2821 ST-41/44 complex CSF 0.064 0.008 0.004 0.004
35460 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.004 0.004
35461 England 2013/14 B B 1163 ST-269 complex Blood 0.19 0.003 0.004 0.006
35462 England 2013/14 B B 2314 ST-41/44 complex Blood 0.094 0.006 0.004 0.008
35463 England 2013/14 B B 10868 ST-41/44 complex Blood 0.023 0.002 0.004 0.002
35464 Wales 2013/14 B B NK INCOMPLETE MLST CSF 0.125 0.006 0.004 0.006
35465 England 2013/14 B B NK INCOMPLETE MLST Blood 0.047 0.023 0.006 0.004




35467 England 2013/14 B B 1194 ST-41/44 complex Blood 0.047 0.006 0.004 0.004
35468 England 2013/14 Y Y 1655 ST-23 complex Blood 0.25 0.004 0.004 0.008
35469 England 2013/14 B B 35 ST-35 complex Blood 0.064 0.008 0.006 0.003
35470 England 2013/14 B B 8380 ST-41/44 complex Blood 0.125 0.003 0.004 0.006
35471 England 2013/14 B B 41 ST-41/44 complex Blood 0.19 0.004 0.006 0.006
35472 England 2013/14 Y Y 1624 ST-167 complex Blood 0.125 0.004 0.006 0.012
35473 Wales 2013/14 B B 11243 UA Joint 0.064 0.016 0.004 0.004
35474 England 2013/14 B B 41 ST-41/44 complex Blood 0.094 0.016 0.006 0.008
35475 England 2013/14 B B 11329 UA CSF 0.19 0.003 0.008 0.008
35477 England 2013/14 B B 9180 ST-269 complex Blood 0.125 0.004 0.004 0.006
35478 England 2013/14 B B 41 ST-41/44 complex Blood 0.19 0.008 0.006 0.006
35480 England 2013/14 B B 461 ST-461 complex CSF 0.25 0.004 0.006 0.008
35481 England 2013/14 B B NK INCOMPLETE MLST Blood 0.19 0.002 0.006 0.006
35482 England 2013/14 B B 41 ST-41/44 complex Blood 0.047 0.008 0.006 0.003
35483 England 2013/14 B B 485 ST-41/44 complex Blood 0.19 0.006 0.008 0.006
35484 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.006 0.006
35485 England 2013/14 B B 1161 ST-269 complex Joint 0.25 0.008 0.006 0.004
35487 England 2013/14 Y Y 1655 ST-23 complex Pericardium 0.064 0.002 0.004 0.004
35488 England 2013/14 B B 213 ST-213 complex Blood 0.047 0.016 0.006 0.004
35489 England 2013/14 B B 485 ST-41/44 complex Blood 0.19 0.008 0.006 0.006
35491 England 2013/14 Y Y 23 ST-23 complex Blood 0.064 0.003 0.006 0.003
35492 England 2013/14 B B 1475 ST-41/44 complex Blood 0.047 0.016 0.008 0.004
35493 England 2013/14 B B 11245 UA Blood 0.047 0.004 0.006 0.004
35494 England 2013/14 B B 8004 ST-269 complex Blood 0.032 0.004 0.006 0.003
35495 England 2013/14 B B 11246 ST-269 complex Blood 0.094 0.023 0.012 0.006
35496 England 2013/14 B B NK INCOMPLETE MLST Blood 0.064 0.008 0.006 0.004
35497 England 2013/14 B B 41 ST-41/44 complex Blood 0.125 0.004 0.008 0.008
35498 England 2013/14 B B 32 ST-32 complex Blood 0.064 0.008 0.006 0.004
35499 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.006 0.006
35500 England 2013/14 B B 11 ST-11 complex Blood 0.064 0.016 0.008 0.006
35501 England 2013/14 Y Y 1627 ST-167 complex Joint 0.064 0.004 0.006 0.008
35502 England 2013/14 B B 11 ST-11 complex Blood 0.064 0.016 0.008 0.008
35503 England 2013/14 B B 41 ST-41/44 complex Blood 0.25 0.006 0.008 0.008
35504 England 2013/14 B B 41 ST-41/44 complex Blood 0.064 0.012 0.008 0.004
35505 England 2013/14 B B 35 ST-35 complex Blood 0.25 0.008 0.008 0.008
35506 England 2013/14 B B 269 ST-269 complex CSF 0.047 0.032 0.008 0.004
35508 England 2013/14 Y Y 23 ST-23 complex Blood 0.094 0.006 0.008 0.008
35509 England 2013/14 B B 41 ST-41/44 complex Blood 0.064 0.032 0.006 0.004
35510 England 2013/14 B B 136 ST-41/44 complex CSF 0.032 0.012 0.006 0.003
35511 England 2013/14 B B 60 ST-60 complex Blood 0.19 0.006 0.006 0.003
35512 England 2013/14 B B 575 ST-213 complex CSF 0.19 0.016 0.008 0.006
35513 England 2013/14 Y Y 23 ST-23 complex Blood 0.094 0.004 0.008 0.008
35514 England 2013/14 B B 213 ST-213 complex Blood 0.19 0.006 0.008 0.008
35515 England 2013/14 B B 269 ST-269 complex Blood 0.125 0.016 0.008 0.008
35516 England 2013/14 B B 213 ST-213 complex Blood 0.064 0.016 0.008 0.004
35517 England 2013/14 Y Y 114 ST-22 complex Blood 0.094 0.012 0.008 0.008
35518 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.008 0.006
35519 England 2013/14 B B 11250 ST-32 complex Blood 0.064 0.016 0.006 0.004
35520 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
35521 England 2013/14 B B 213 ST-213 complex CSF 0.047 0.006 0.004 0.004
35522 England 2013/14 B B 213 ST-213 complex Blood 0.032 0.012 0.004 0.008
35523 England 2013/14 Y Y 11254 ST-167 complex Blood 0.047 0.006 0.006 0.008
35524 England 2013/14 C C 9923 ST-60 complex Blood 0.125 0.006 0.004 0.006
35525 England 2013/14 B B 1161 ST-269 complex CSF 0.125 0.012 0.006 0.008
35526 England 2013/14 B B 485 ST-41/44 complex Blood 0.125 0.008 0.004 0.004
35527 England 2013/14 B B 2101 ST-213 complex Blood 0.032 0.004 0.004 0.004
35528 England 2013/14 B B 8023 ST-103 complex Blood 0.094 0.008 0.006 0.004
35529 England 2013/14 B B 11330 UA CSF 0.047 0.008 0.004 0.004
35530 England 2013/14 B B 11259 UA Blood 0.064 0.012 0.004 0.004
35531 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.064 0.006 0.008 0.008
35532 England 2013/14 B B 485 ST-41/44 complex Blood 0.19 0.008 0.006 0.004
35533 England 2013/14 B B 2799 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
35534 England 2013/14 B B 11261 ST-269 complex CSF 0.19 0.008 0.006 0.006
35535 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.006
35536 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
35537 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
35538 England 2013/14 Y Y 23 ST-23 complex Blood 0.047 0.004 0.004 0.004
35539 England 2013/14 B B 1194 ST-41/44 complex Blood 0.047 0.004 0.006 0.003
35540 England 2013/14 B B 11262 ST-213 complex Blood 0.064 0.016 0.006 0.006
35541 England 2013/14 B B 11263 ST-41/44 complex CSF 0.016 0.008 0.004 <0.002
35542 England 2013/14 B B 11265 ST-41/44 complex Blood 0.023 0.003 0.004 0.003
35543 England 2013/14 Y Y 23 ST-23 complex Blood 0.064 0.006 0.006 0.004
35544 England 2013/14 B B 1161 ST-269 complex Blood 0.19 0.008 0.006 0.006
35545 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.006 0.006
35546 England 2013/14 B B 32 ST-32 complex Blood 0.064 0.016 0.006 0.006
35547 England 2013/14 Y Y 1624 ST-167 complex CSF 0.125 0.006 0.004 0.016
35548 England 2013/14 B B 340 ST-41/44 complex Blood 0.047 0.008 0.006 0.003
35549 England 2013/14 B B 3446 ST-41/44 complex Blood 0.064 0.008 0.006 0.006
35550 England 2013/14 B B 6782 ST-41/44 complex Blood 0.094 0.012 0.006 0.004
35551 England 2013/14 C C 5133 ST-103 complex Blood 0.023 0.064 0.006 0.002
35552 Wales 2013/14 B B 5981 ST-41/44 complex Blood 0.064 0.008 0.006 0.004
35553 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.094 0.008 0.004 0.006
35554 England 2013/14 B B 34 ST-32 complex Blood 0.047 0.008 0.006 0.006
35555 England 2013/14 B B 1161 ST-269 complex Blood 0.094 0.016 0.016 0.008




35557 England 2013/14 B B 2506 ST-32 complex Blood 0.125 0.012 0.006 0.006
35558 England 2013/14 B B 575 ST-213 complex Blood 0.19 0.016 0.006 0.006
35559 England 2013/14 B B 9242 ST-269 complex CSF 0.064 0.004 0.006 0.006
35560 England 2013/14 W W 2638 ST-22 complex Blood 0.094 0.012 0.008 0.004
35561 England 2013/14 B B NK INCOMPLETE MLST Blood 0.064 0.012 0.008 0.003
35562 England 2013/14 B B 41 ST-41/44 complex Blood 0.094 0.047 0.008 0.004
35563 Wales 2013/14 B B 41 ST-41/44 complex Blood 0.25 0.012 0.006 0.008
35564 England 2013/14 B B 34 ST-32 complex Blood 0.25 0.032 0.006 0.016
35565 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
35566 England 2013/14 B B 154 ST-41/44 complex Blood 0.064 0.012 0.006 0.006
35567 England 2013/14 Y Y 1655 ST-23 complex Blood 0.094 0.012 0.006 0.008
35568 England 2013/14 B B 9180 ST-269 complex Blood 0.25 0.008 0.012 0.012
35569 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.008 0.008
35570 Wales 2013/14 B B 283 ST-269 complex Blood 0.064 0.004 0.006 0.004
35571 England 2013/14 B B 34 ST-32 complex Blood 0.032 0.002 0.006 0.003
35572 England 2013/14 B B 275 ST-269 complex Blood 0.094 0.004 0.006 0.008
35573 England 2013/14 B B 11266 ST-41/44 complex CSF 0.19 0.012 0.008 0.008
35574 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.006 0.008
35575 England 2013/14 B B 34 ST-32 complex CSF 0.094 0.008 0.008 0.006
35576 England 2013/14 B B 213 ST-213 complex Blood 0.125 0.016 0.006 0.006
35577 Northern Ireland 2013/14 B B 11865 ST-461 complex Blood 0.38 0.094 0.006 0.012
35578 Wales 2013/14 B B 5098 ST-41/44 complex Blood 0.064 0.004 0.008 0.004
35579 England 2013/14 B B 3116 ST-213 complex Blood 0.094 0.012 0.006 0.004
35580 England 2013/14 B B 461 ST-461 complex Blood 0.25 0.003 0.006 0.006
35582 England 2013/14 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.008 0.004
35583 England 2013/14 B B 11272 ST-18 complex Blood 0.125 0.032 0.008 0.016
35584 Northern Ireland 2013/14 B B 5986 ST-41/44 complex Blood 0.064 0.016 0.008 0.004
35585 England 2013/14 B B 3447 ST-41/44 complex Blood 0.064 0.008 0.008 0.008
35586 England 2013/14 B B 41 ST-41/44 complex Blood 0.064 0.008 0.008 0.008
35587 England 2013/14 B B 6789 ST-269 complex Blood 0.064 0.002 0.008 0.004
35588 England 2013/14 B B 749 ST-32 complex Blood 0.25 0.008 0.008 0.008
35589 England 2013/14 B B 32 ST-32 complex Blood 0.064 0.032 0.008 0.006
35590 England 2013/14 Y NK 23 ST-23 complex Blood 0.032 0.064 0.008 0.008
35591 England 2013/14 Y NK 23 ST-23 complex Blood 0.094 0.004 0.006 0.006
35592 Wales 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.008 0.006
35593 England 2013/14 C C 467 ST-269 complex CSF 0.064 0.016 0.008 0.006
35594 England 2013/14 B B 1475 ST-41/44 complex Blood 0.094 0.016 0.006 0.006
35595 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.006 0.004
35596 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.006 0.006
35597 England 2013/14 B B 11460 ST-41/44 complex CSF 0.064 0.006 0.006 0.004
35599 England 2013/14 Y Y 1655 ST-23 complex Blood 0.094 0.006 0.006 0.008
35600 England 2013/14 Y Y 23 ST-23 complex Blood 0.032 0.003 0.006 0.004
35601 England 2013/14 B B 282 ST-282 complex Blood 0.094 0.047 0.008 0.004
35602 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.064 0.064 0.006 0.006
35603 England 2013/14 B B 213 ST-213 complex Blood 0.094 0.016 0.008 0.006
35604 England 2013/14 B B 33 ST-32 complex Blood 0.047 0.012 0.008 0.006
35605 England 2013/14 B B 2455 ST-60 complex Blood 0.023 0.016 0.008 0.006
35606 England 2013/14 B B 5480 ST-41/44 complex Blood 0.064 0.008 0.006 0.004
35607 England 2013/14 W NK 114 ST-22 complex Blood 0.125 0.008 0.008 0.006
35609 Northern Ireland 2013/14 B B 9819 ST-41/44 complex Blood 0.047 0.032 0.008 0.006
35610 England 2013/14 W W 1617 ST-22 complex Blood 0.064 0.012 0.008 0.006
35611 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.064 0.008 0.006 0.008
35612 Wales 2013/14 B B 1946 ST-461 complex Blood 0.25 0.012 0.006 0.012
35613 England 2013/14 B B 41 ST-41/44 complex Blood 0.19 0.003 0.006 0.016
35615 England 2013/14 Y Y 1655 ST-23 complex Blood 0.032 0.006 0.006 0.003
35616 England 2013/14 Y Y 23 ST-23 complex Blood 0.094 0.004 0.006 0.006
35617 England 2013/14 B B NK INCOMPLETE MLST Blood 0.047 0.008 0.008 0.004
35619 England 2013/14 B B 11278 ST-32 complex Blood 0.094 0.032 0.012 0.006
35620 England 2013/14 Y Y 1655 ST-23 complex Blood 0.094 0.006 0.008 0.008
35623 Northern Ireland 2013/14 B B 1161 ST-269 complex Blood 0.125 0.125 0.008 0.012
35625 England 2013/14 B B 2314 ST-41/44 complex Blood 0.125 0.004 0.008 0.006
35626 England 2013/14 B B 8988 UA Blood 0.19 0.047 0.012 0.006
35627 England 2013/14 Y NK 1655 ST-23 complex Blood 0.047 0.006 0.006 0.006
35628 Northern Ireland 2013/14 C C 11 ST-11 complex Blood 0.064 0.016 0.008 0.008
35629 Wales 2013/14 B B 11279 ST-41/44 complex Blood 0.064 0.008 0.006 0.006
35630 England 2013/14 B B 269 ST-269 complex Blood 0.047 0.032 0.006 0.003
35631 England 2013/14 B B 1161 ST-269 complex Blood 0.047 0.023 0.006 0.008
35633 England 2013/14 B B 467 ST-269 complex Blood 0.064 0.008 0.006 0.006
35636 England 2013/14 B B 1774 ST-269 complex Blood 0.064 0.008 0.008 0.008
35637 England 2013/14 Y Y 11280 ST-23 complex Blood 0.064 0.004 0.006 0.006
35639 Northern Ireland 2013/14 B B 4145 ST-213 complex Blood 0.064 0.016 0.006 0.006
35640 England 2013/14 B B 1161 ST-269 complex Blood 0.094 0.012 0.006 0.012
35641 Wales 2013/14 NG E 11282 ST-1157 complex Blood 0.064 0.032 0.004 0.006
35642 England 2013/14 Y Y 23 ST-23 complex CSF 0.094 0.006 0.004 0.012
35644 England 2013/14 B B NK INCOMPLETE MLST Blood 0.032 0.006 0.003 0.006
35645 England 2013/14 B B 213 ST-213 complex Blood 0.047 0.023 0.006 0.006
35646 England 2013/14 B B 1423 ST-41/44 complex Blood 0.094 0.012 0.006 0.008
35647 England 2013/14 B B 7460 ST-32 complex CSF 0.064 0.032 0.004 0.008
35648 Wales 2013/14 Y Y NK INCOMPLETE MLST Blood 0.094 0.008 0.006 0.012
35649 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.004 0.006
35650 England 2013/14 C C 11 ST-11 complex Blood 0.25 0.023 0.006 0.012
35652 England 2013/14 C C NK INCOMPLETE MLST Blood 0.125 0.008 0.006 0.006
35653 England 2013/14 Y NK 1655 ST-23 complex Blood 0.047 0.004 0.004 0.008
35654 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.047 0.004 0.006 0.008




35656 England 2013/14 B B 409 ST-41/44 complex Blood 0.125 0.094 0.006 0.008
35657 England 2013/14 B B 409 ST-41/44 complex Blood 0.25 0.032 0.006 0.008
35658 England 2013/14 B B 11291 ST-269 complex Blood 0.047 0.006 0.006 0.004
35659 England 2013/14 C C 10482 ST-11 complex Joint 0.064 0.032 0.006 0.008
35660 Wales 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.016 0.006 0.006
35661 England 2013/14 W W 22 ST-22 complex Blood 0.064 0.006 0.004 0.003
35662 England 2013/14 B B 275 ST-269 complex Blood 0.125 0.004 0.006 0.006
35663 England 2013/14 B B 162 ST-162 complex Blood 0.047 0.016 0.006 0.004
35665 England 2013/14 Y Y 11293 ST-23 complex Blood 0.032 0.004 0.004 0.006
35666 England 2013/14 B B 32 ST-32 complex CSF 0.064 0.008 0.006 0.008
35667 Wales 2013/14 B B 11 ST-11 complex Blood 0.094 0.094 0.006 0.012
35668 England 2013/14 B B 162 ST-162 complex Blood 0.064 0.016 0.006 0.004
35669 England 2013/14 B B 1161 ST-269 complex Blood 0.032 0.023 0.006 0.004
35671 England 2013/14 B B NK INCOMPLETE MLST Blood 0.047 0.006 0.006 0.004
35672 England 2013/14 C C 11 ST-11 complex Blood 0.064 0.016 0.006 0.008
35673 England 2013/14 B B 1194 ST-41/44 complex Blood 0.032 0.032 0.004 0.003
35677 England 2013/14 B B 1161 ST-269 complex Blood 0.25 0.064 0.006 0.008
35678 England 2013/14 B B NK INCOMPLETE MLST Joint 0.064 0.032 0.004 0.006
35679 England 2013/14 B B 1089 ST-269 complex Blood 0.032 0.064 0.006 0.004
35680 England 2013/14 B B 275 ST-269 complex Blood 0.094 0.008 0.004 0.006
35681 England 2013/14 B B 41 ST-41/44 complex Blood 0.047 0.008 0.004 0.004
35682 England 2013/14 B B 34 ST-32 complex Blood 0.064 0.032 0.008 0.006
35683 Wales 2013/14 B B 1096 ST-32 complex CSF 0.064 0.064 0.006 0.006
35684 England 2013/14 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.004 0.006
35685 England 2013/14 Y Y 767 ST-167 complex Blood 0.047 0.006 0.004 0.006
35688 England 2013/14 C C 11 ST-11 complex Blood 0.094 0.008 0.006 0.012
35691 England 2013/14 Y Y NK INCOMPLETE MLST Blood 0.094 0.008 0.004 0.006
35692 England 2013/14 Y Y 1655 ST-23 complex Joint 0.064 0.004 0.004 0.004
35693 England 2013/14 C C 11 ST-11 complex Blood 0.047 0.016 0.006 0.006
35694 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.004
35695 England 2013/14 B B 5391 UA Blood 0.023 0.004 0.003 0.006
35696 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.008
35697 England 2013/14 Y Y 114 ST-22 complex Blood 0.064 0.012 0.006 0.008
35698 England 2013/14 B B 11296 ST-60 complex Blood 0.032 0.016 0.003 0.004
35699 England 2013/14 B B 4786 ST-32 complex CSF 0.19 0.012 0.006 0.008
35701 England 2013/14 B B 275 ST-269 complex CSF 0.064 0.012 0.006 0.008
35703 England 2013/14 B B 213 ST-213 complex Joint 0.19 0.006 0.004 0.008
35704 England 2013/14 B B 8511 ST-41/44 complex Blood 0.047 0.012 0.006 0.004
35705 England 2013/14 B B 11297 ST-41/44 complex Blood 0.023 0.047 0.004 0.003
35706 England 2013/14 C C 11 ST-11 complex Blood 0.125 0.032 0.004 0.016
35707 England 2013/14 C C 11298 ST-334 complex Blood 0.094 0.064 0.006 0.006
35708 England 2013/14 B B 2922 ST-41/44 complex Blood 0.25 0.016 0.006 0.012
35709 England 2013/14 W/Y W/Y 1655 ST-23 complex Blood 0.064 0.006 0.006 0.008
35710 England 2013/14 B B 60 ST-60 complex Blood 0.032 0.016 0.008 0.008
35711 England 2013/14 B B 11429 UA Blood 0.25 0.008 0.006 0.016
35712 England 2013/14 B B 213 ST-213 complex Blood 0.047 0.064 0.008 0.006
35713 England 2013/14 B B 1946 ST-461 complex Blood 0.75 0.094 0.006 0.016
35714 England 2013/14 B B 11299 UA Blood 0.064 0.012 0.006 0.006
35715 England 2013/14 B B 11300 ST-213 complex Blood 0.047 0.032 0.006 0.004
35716 England 2013/14 B B 1161 ST-269 complex Blood 0.047 0.023 0.008 0.012
35717 England 2013/14 Y Y 910 UA Blood 0.125 0.016 0.004 0.012
35718 England 2013/14 B B 213 ST-213 complex Blood 0.25 0.012 0.004 0.006
35719 England 2013/14 B B 5981 ST-41/44 complex Blood 0.064 0.008 0.006 0.004
35720 England 2013/14 B B 11301 UA Joint 0.064 0.023 0.003 0.004
35721 England 2013/14 Y Y 11331 ST-23 complex Blood 0.047 0.006 0.004 0.003
35723 England 2013/14 B B 1159 UA Blood 0.094 0.032 0.006 0.008
35724 England 2013/14 B B 11302 ST-32 complex Blood 0.19 0.016 0.006 0.016
35726 England 2013/14 B B 275 ST-269 complex Blood 0.094 0.012 0.006 0.004
35727 Wales 2013/14 B B 1946 ST-461 complex Blood 0.38 0.023 0.004 0.012
35729 Northern Ireland 2013/14 B B NK INCOMPLETE MLST Blood 0.064 0.006 0.006 0.006
35730 England 2013/14 B B 5151 UA Blood 0.25 0.006 0.006 0.008
35731 Wales 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
35732 England 2013/14 B B 1194 ST-41/44 complex Blood 0.047 0.023 0.006 0.004
35733 England 2013/14 B B 213 ST-213 complex Blood 0.19 0.023 0.004 0.006
35734 Wales 2013/14 B B 461 ST-461 complex CSF 0.094 0.064 0.004 0.012
35735 Wales 2013/14 B B 41 ST-41/44 complex Blood 0.047 0.023 0.008 0.004
35736 Wales 2013/14 B B 11303 UA Blood 0.19 0.012 0.004 0.004
35737 England 2013/14 B B 11304 ST-269 complex Blood 0.19 0.012 0.004 0.012
35738 England 2013/14 W W NK INCOMPLETE MLST Blood 0.125 0.003 0.004 0.002
35739 England 2013/14 B B 461 ST-461 complex Blood 0.19 0.016 0.004 0.008
35740 England 2013/14 B B 269 ST-269 complex Blood 0.047 0.008 0.008 0.004
35741 England 2013/14 B B NK INCOMPLETE MLST Blood 0.125 0.016 0.006 0.004
35742 England 2013/14 B B 4051 UA Blood 0.125 0.023 0.004 0.006
35743 England 2014/15 B B 213 ST-213 complex Blood 0.047 0.016 0.004 0.003
35744 England 2014/15 B B NK INCOMPLETE MLST Blood 0.094 0.016 0.004 0.004
35746 Wales 2014/15 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.006 0.006
35747 England 2014/15 B B 213 ST-213 complex Blood 0.047 0.023 0.004 0.004
35748 England 2014/15 B B 8061 UA Blood 0.25 0.006 0.003 0.016
35749 England 2014/15 B B 33 ST-32 complex Blood 0.094 0.012 0.006 0.006
35750 England 2014/15 B B 1946 ST-461 complex Blood 0.38 0.012 0.004 0.006
35751 England 2014/15 B B NK INCOMPLETE MLST Blood 0.25 0.012 0.006 0.012
35752 England 2014/15 B B 340 ST-41/44 complex Blood 0.047 0.016 0.003 0.003
35753 England 2014/15 B B NK INCOMPLETE MLST Blood 0.19 0.008 0.006 0.004
35755 England 2014/15 B B 1161 ST-269 complex Blood 0.064 0.008 0.006 0.006




35758 Wales 2014/15 B B 43 ST-41/44 complex Blood 0.047 0.002 0.004 0.047
35759 England 2014/15 B B 1194 ST-41/44 complex CSF 0.032 0.004 0.004 0.003
35760 England 2014/15 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.004 0.004
35761 England 2014/15 Y Y 23 ST-23 complex Blood 0.19 0.004 0.004 0.006
35762 Northern Ireland 2014/15 C C 11 ST-11 complex Joint 0.047 0.004 0.008 0.004
35764 England 2014/15 B B NK INCOMPLETE MLST Blood 0.047 0.004 0.006 0.003
35765 England 2014/15 B B 269 ST-269 complex Blood 0.047 0.008 0.006 0.003
35766 England 2014/15 B B 485 ST-41/44 complex Blood 0.125 0.008 0.006 0.006
35767 England 2014/15 Y NK 1655 ST-23 complex Blood 0.047 0.004 0.004 0.006
35768 Wales 2014/15 B B 5986 ST-41/44 complex Blood 0.094 0.016 0.004 0.006
35769 England 2014/15 B B 41 ST-41/44 complex Blood 0.047 0.004 0.004 0.004
35770 England 2014/15 B B 1161 ST-269 complex Blood 0.047 0.012 0.003 0.004
35771 England 2014/15 B B 485 ST-41/44 complex Blood 0.19 0.003 0.006 0.006
35772 England 2014/15 Y Y NK INCOMPLETE MLST Blood 0.032 0.004 0.004 0.003
35773 England 2014/15 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.004 0.004
35774 England 2014/15 B B 269 ST-269 complex Blood 0.023 0.008 0.006 0.002
35775 England 2014/15 C C 11 ST-11 complex Blood 0.064 0.023 0.094 0.006
35776 England 2014/15 B B 1157 ST-1157 complex Blood 0.032 0.008 0.004 0.004
35777 England 2014/15 C C 11332 ST-116 complex Blood 0.032 0.064 0.004 0.002
35778 England 2014/15 B B 11305 ST-269 complex Blood 0.023 0.008 0.006 0.002
35779 Northern Ireland 2014/15 B B 1214 ST-269 complex Blood 0.064 0.016 0.006 0.004
35780 England 2014/15 B B 485 ST-41/44 complex Blood 0.064 0.047 0.004 0.002
35781 England 2014/15 B B 1946 ST-461 complex Blood 0.19 0.012 0.004 0.004
35783 England 2014/15 B B 11306 UA Blood 0.094 0.016 0.008 0.006
35784 England 2014/15 B B 11307 UA Blood 0.094 0.004 0.004 0.006
35785 Wales 2014/15 B B 8049 ST-32 complex Blood 0.25 0.006 0.004 0.004
35787 England 2014/15 B B 11308 ST-269 complex Blood 0.008 0.006 0.004 0.002
35789 England 2014/15 B B 8054 ST-41/44 complex Blood 0.016 0.002 0.19 0.003
35790 England 2014/15 B B 8054 ST-41/44 complex Blood 0.064 0.006 0.004 0.004
35791 England 2014/15 W W 22 ST-22 complex Blood 0.064 0.047 0.004 0.004
35793 England 2014/15 B B 11309 ST-41/44 complex Blood 0.047 0.012 0.003 0.004
35794 England 2014/15 B B 340 ST-41/44 complex Blood 0.016 0.008 0.004 0.003
35795 England 2014/15 B B 485 ST-41/44 complex Blood 0.125 0.008 0.004 0.004
35797 England 2014/15 B B 11302 ST-32 complex Blood 0.125 0.006 0.004 0.008
35798 England 2014/15 B B 162 ST-162 complex Blood 0.047 0.012 0.008 0.004
35802 England 2014/15 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
35803 England 2014/15 B B 1423 ST-41/44 complex Blood 0.064 0.006 0.006 0.006
35804 England 2014/15 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.006 0.006
35805 England 2014/15 B B 340 ST-41/44 complex Blood 0.047 0.012 0.006 0.006
35830 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.006 0.004
37662 England 2013/14 B B 213 ST-213 complex Blood 0.047 0.012 0.006 0.004
37663 Wales 2013/14 B B 41 ST-41/44 complex Blood 0.094 0.064 0.004 0.012
37664 England 2013/14 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.004 0.006
37665 England 2013/14 B B 1161 ST-269 complex Blood 0.064 0.004 0.006 0.008
37666 England 2013/14 Y Y 23 ST-23 complex Blood 0.064 0.006 0.004 0.008
37667 England 2013/14 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.006 0.012
37668 England 2013/14 C C 11 ST-11 complex Blood 0.064 0.006 0.008 0.008
37669 England 2013/14 B B 41 ST-41/44 complex Blood 0.19 0.032 0.006 0.008
37672 England 2014/15 Y NG 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
37674 England 2014/15 B B 275 ST-269 complex Blood 0.19 0.006 0.004 0.006
37676 England 2014/15 Y NK 1624 ST-167 complex Blood 0.064 0.004 0.006 0.008
37677 England 2014/15 B B 275 ST-269 complex Blood 0.064 0.006 0.004 0.004
37678 England 2014/15 B B 1097 ST-41/44 complex Blood 0.047 0.008 0.006 0.004
37679 England 2014/15 C C 11 ST-11 complex Blood 0.19 0.023 0.006 0.008
37680 England 2014/15 B B 11465 ST-213 complex Blood 0.125 0.008 0.006 0.008
37682 England 2014/15 B B 2506 ST-32 complex Blood 0.125 0.006 0.006 0.008
37683 England 2014/15 B B 10817 ST-162 complex Blood 0.25 0.008 0.006 0.006
37684 England 2014/15 B B 1194 ST-41/44 complex Blood 0.032 0.006 0.006 0.003
37686 England 2014/15 B B 3754 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
37687 Wales 2014/15 C C 32 ST-32 complex Blood 0.047 0.064 0.006 0.004
37688 England 2014/15 B B 1163 ST-269 complex Blood 0.047 0.008 0.006 0.004
37689 England 2014/15 Y Y 11866 ST-23 complex Blood 0.047 0.004 0.004 0.004
37691 England 2014/15 Y NK 23 ST-23 complex Spleen 0.047 0.002 0.004 0.004
37694 England 2014/15 Y Y 1655 ST-23 complex Blood 0.047 0.012 0.006 0.004
37696 England 2014/15 B B 32 ST-32 complex Blood 0.047 0.012 0.006 0.004
37697 England 2014/15 Y Y 3582 ST-23 complex Blood 0.064 0.004 0.004 0.004
37698 England 2014/15 B B 269 ST-269 complex Blood 0.023 0.004 0.004 0.002
37700 England 2014/15 B B 3754 ST-41/44 complex Blood 0.032 0.006 0.004 0.002
37702 England 2014/15 B B 136 ST-41/44 complex Blood 0.047 0.006 0.004 0.002
37703 England 2014/15 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.003 0.002
37704 England 2014/15 B B 1161 ST-269 complex CSF 0.19 0.008 0.004 0.004
37705 England 2014/15 B B 1111 UA Joint 0.38 0.032 0.006 0.032
37706 England 2014/15 B B 11466 ST-269 complex Blood 0.032 0.006 0.006 0.004
37707 England 2014/15 B B 154 ST-41/44 complex Blood 0.032 0.006 0.004 0.004
37709 England 2014/15 C C 11 ST-11 complex Blood 0.064 0.006 0.006 0.004
37712 England 2014/15 B B 11467 ST-41/44 complex Blood 0.047 0.006 0.006 0.004
37713 England 2014/15 Y NK NK INCOMPLETE MLST Blood 0.19 0.004 0.003 0.008
37714 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.006 0.008
37715 England 2014/15 B B 1754 ST-60 complex Blood 0.032 0.006 0.003 0.004
37718 England 2014/15 B B 46 ST-41/44 complex Blood 0.064 0.008 0.008 0.004
37719 England 2014/15 B B 1097 ST-41/44 complex Blood 0.047 0.008 0.006 0.004
37720 England 2014/15 B B 5151 UA Blood 0.125 0.008 0.008 0.008
37721 Wales 2014/15 B B 11468 ST-461 complex Blood 0.25 0.016 0.006 0.008
37723 England 2014/15 B B 60 ST-60 complex Blood 0.032 0.003 0.008 0.004




37725 England 2014/15 B B 41 ST-41/44 complex Blood 0.023 0.003 0.008 0.002
37726 England 2014/15 B B 3635 ST-213 complex Blood 0.094 0.006 0.004 0.004
37727 England 2014/15 B B 6058 ST-41/44 complex Blood 0.25 0.012 0.006 0.008
37728 England 2014/15 C C 11 ST-11 complex Blood 0.064 0.004 0.006 0.002
37729 England 2014/15 Y Y 1466 ST-174 complex Blood 0.047 0.006 0.002 0.004
37730 Northern Ireland 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
37733 England 2014/15 B B 9881 ST-213 complex Blood 0.064 0.008 0.006 0.004
37734 England 2014/15 B B 32 ST-32 complex Blood 0.064 0.006 0.006 0.004
37735 England 2014/15 B B 3200 ST-4821 complex Blood 0.38 0.023 0.008 0.008
37737 England 2014/15 B B 409 ST-41/44 complex Blood 0.19 0.064 0.008 0.008
37740 England 2014/15 W NK 184 ST-22 complex CSF 0.125 0.016 0.008 0.004
37741 England 2014/15 B B 5342 ST-32 complex Blood 0.032 0.006 0.008 0.004
37743 England 2014/15 B B 41 ST-41/44 complex Blood 0.125 0.003 0.006 0.004
37744 England 2014/15 B B 11469 UA Blood 0.047 0.003 0.003 0.004
37745 England 2014/15 B B 749 ST-32 complex Blood 0.094 0.006 0.004 0.004
37750 England 2014/15 B NG 290 ST-32 complex Blood 0.094 0.012 0.008 0.006
37751 England 2014/15 Y NK 23 ST-23 complex Blood 0.064 0.008 0.006 0.006
37752 England 2014/15 C C 11 ST-11 complex Blood 0.19 0.023 0.008 0.006
37753 England 2014/15 B B 1214 ST-269 complex Blood 0.032 0.032 0.008 0.002
37755 England 2014/15 B B 1163 ST-269 complex Blood 0.047 0.004 0.006 0.004
37756 England 2014/15 B B 32 ST-32 complex Blood 0.19 0.006 0.006 0.004
37758 England 2014/15 C C 11 ST-11 complex Blood 0.19 0.032 0.008 0.008
37761 England 2014/15 B B 41 ST-41/44 complex Blood 0.125 0.004 0.006 <0.002
37762 England 2014/15 B NG 11470 ST-269 complex Blood 0.19 0.003 0.004 0.002
37763 England 2014/15 C C 11 ST-11 complex Blood 0.094 0.012 0.004 0.006
37764 Northern Ireland 2014/15 W NK 11 ST-11 complex Blood 0.032 0.003 0.006 0.002
37765 England 2014/15 Y NK 11868 ST-23 complex Blood 0.125 0.004 0.004 0.012
37766 England 2014/15 B B 11471 ST-269 complex CSF 0.064 0.003 0.004 0.003
37767 England 2014/15 B B 8380 ST-41/44 complex Blood 0.064 0.004 0.008 0.004
37768 England 2014/15 Y NK 11472 ST-23 complex Blood 0.064 0.008 0.008 0.006
37771 England 2014/15 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.004 0.004
37772 England 2014/15 B B 485 ST-41/44 complex Blood 0.094 0.006 0.006 0.003
37773 England 2014/15 B B 18 ST-18 complex CSF 0.032 0.002 0.006 0.002
37775 England 2014/15 B B 41 ST-41/44 complex Blood 0.19 0.004 0.004 0.006
37776 England 2014/15 B B 11473 ST-269 complex Blood 0.125 0.004 0.006 0.006
37777 England 2014/15 B B 1157 ST-1157 complex Blood 0.064 0.012 0.004 0.003
37779 England 2014/15 B B 11869 ST-41/44 complex CSF 0.125 0.004 0.004 0.004
37780 England 2014/15 B B 1946 ST-461 complex Blood 0.25 0.006 0.002 0.016
37781 England 2014/15 B B 1161 ST-269 complex CSF 0.19 0.003 0.006 0.006
37782 England 2014/15 B B 275 ST-269 complex CSF 0.032 0.008 0.006 0.002
37783 England 2014/15 B B 278 ST-35 complex Blood 0.094 0.004 0.004 0.003
37785 England 2014/15 B B 3989 UA Blood 0.19 0.012 0.004 0.006
37786 England 2014/15 Y NK 1624 ST-167 complex Blood 0.125 0.003 0.006 0.012
37787 England 2014/15 C C 11 ST-11 complex Blood 0.032 0.008 0.006 0.006
37788 England 2014/15 B B 213 ST-213 complex Blood 0.047 0.008 0.006 0.003
37789 England 2014/15 B B 34 ST-32 complex Blood 0.125 0.006 0.006 0.012
37790 England 2014/15 B B 1161 ST-269 complex Blood 0.064 0.032 0.008 0.004
37791 England 2014/15 B B 1354 ST-269 complex Blood 0.032 0.004 0.006 0.002
37792 England 2014/15 B B 1157 ST-1157 complex Blood 0.047 0.008 0.006 0.004
37794 England 2014/15 Y NG 1655 ST-23 complex Blood 0.064 0.004 0.006 0.004
37795 Wales 2014/15 Y Y 23 ST-23 complex CSF 0.25 0.004 0.006 0.016
37796 England 2014/15 Y NK 23 ST-23 complex Blood 0.094 0.006 0.006 0.004
37800 England 2014/15 B B 1161 ST-269 complex Blood 0.19 0.008 0.008 0.006
37802 England 2014/15 B B 485 ST-41/44 complex Blood 0.125 0.004 0.006 0.004
37803 England 2014/15 B B 485 ST-41/44 complex CSF 0.064 0.012 0.006 0.003
37804 England 2014/15 B B NK INCOMPLETE MLST Blood 0.047 0.008 0.006 0.003
37807 England 2014/15 B B 162 ST-162 complex Blood 0.064 0.006 0.008 0.003
37808 England 2014/15 Y NK 11474 ST-167 complex Blood 0.047 0.002 0.004 0.003
37810 England 2014/15 Y Y 168 ST-167 complex Blood 0.064 0.004 0.004 0.004
37812 England 2014/15 Y NK 1655 ST-23 complex Blood 0.047 0.004 0.006 0.003
37813 England 2014/15 Y Y 1624 ST-167 complex Blood 0.032 0.003 0.006 0.003
37814 England 2014/15 B B 485 ST-41/44 complex Blood 0.19 0.008 0.002 0.002
37815 England 2014/15 C C 11 ST-11 complex Blood 0.064 0.004 0.002 0.002
37816 England 2014/15 C C 11 ST-11 complex Blood 0.19 0.006 0.002 0.002
37817 England 2014/15 B B 11475 UA Blood 0.023 0.004 0.002 0.002
37818 England 2014/15 B B 213 ST-213 complex Blood 0.064 0.012 0.002 0.002
37819 England 2014/15 B B 1774 ST-269 complex Blood 0.047 0.004 0.002 0.002
37820 England 2014/15 Y Y 1655 ST-23 complex Blood 0.094 0.006 0.002 0.002
37823 England 2014/15 B B 11302 ST-32 complex Blood 0.125 0.002 0.002 0.016
37824 England 2014/15 B B 9176 ST-213 complex Blood 0.064 0.004 0.002 0.016
37825 England 2014/15 Y Y NK INCOMPLETE MLST Blood 0.047 0.002 0.002 0.016
37827 England 2014/15 Y NK 23 ST-23 complex Blood 0.25 0.002 0.002 0.002
37829 Northern Ireland 2014/15 B B 11870 ST-269 complex Blood 0.064 0.006 0.002 0.016
37830 England 2014/15 B B 1163 ST-269 complex Blood 0.125 0.006 0.002 0.016
37831 England 2014/15 B B 162 ST-162 complex Blood 0.064 0.012 0.002 0.016
37832 England 2014/15 B B 103 ST-103 complex Joint 0.023 0.004 0.002 0.002
37833 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.002 0.006
37835 England 2014/15 B B 1163 ST-269 complex Blood 0.064 0.004 0.002 0.006
37836 England 2014/15 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.002 0.006
37837 Wales 2014/15 B B 1161 ST-269 complex Blood 0.094 0.006 0.002 0.006
37838 England 2014/15 Y NK 1655 ST-23 complex Joint 0.064 0.004 0.002 0.008
37839 England 2014/15 B B 11476 UA Blood 0.032 0.002 0.002 0.004
37840 England 2014/15 W W 3849 ST-22 complex Blood 0.125 0.016 0.002 0.004
37841 England 2014/15 Y NK 23 ST-23 complex Blood 0.064 0.004 0.002 0.004




37843 England 2014/15 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.002 0.006
37844 England 2014/15 B B 1096 ST-32 complex Blood 0.064 0.006 0.002 0.006
37845 Wales 2014/15 W NK 11 ST-11 complex Blood 0.125 0.016 0.002 0.012
37846 England 2014/15 B B 213 ST-213 complex Blood 0.064 0.012 0.002 0.004
37847 England 2014/15 Y Y 23 ST-23 complex Joint 0.047 0.023 0.002 0.006
37848 England 2014/15 B NG 1096 ST-32 complex Blood 0.064 0.004 0.002 0.006
37849 England 2014/15 B B 11477 ST-41/44 complex Blood 0.094 0.004 0.002 0.006
37850 England 2014/15 Y NK 23 ST-23 complex CSF 0.125 0.003 0.002 0.006
37851 England 2014/15 Y NK 1624 ST-167 complex Blood 0.125 0.006 0.002 0.023
37852 Wales 2014/15 B B 1194 ST-41/44 complex CSF 0.047 0.008 0.002 0.004
37853 England 2014/15 Y  NK 23 ST-23 complex Blood 0.064 0.006 0.002 0.004
37858 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.002 0.006
37859 England 2014/15 Y NK 1655 ST-23 complex Blood 0.094 0.006 0.002 0.008
37863 England 2014/15 Y NK 1466 ST-174 complex Blood 0.064 0.016 0.002 0.008
37864 Wales 2014/15 W W 184 ST-22 complex Blood 0.094 0.023 0.002 0.006
37865 England 2014/15 B NG 41 ST-41/44 complex Blood 0.094 0.004 0.002 0.008
37866 Wales 2014/15 W NK 11 ST-11 complex Blood 0.064 0.008 0.008 0.006
37867 England 2014/15 Y NK 23 ST-23 complex Joint 0.064 0.004 0.002 0.004
37869 England 2014/15 Y NK 1655 ST-23 complex Blood 0.032 0.002 0.002 0.002
37871 Northern Ireland 2014/15 B B 269 ST-269 complex Blood 0.047 0.003 0.002 0.003
37872 England 2014/15 B B 1946 ST-461 complex Blood 0.094 0.002 0.002 0.004
37874 England 2014/15 B B 41 ST-41/44 complex Blood 0.094 0.003 0.002 0.002
37876 England 2014/15 B B 269 ST-269 complex Blood 0.047 0.012 0.012 0.004
37877 England 2014/15 B B 11478 ST-162 complex Blood 0.064 0.008 0.008 0.004
37878 England 2014/15 B B 11479 ST-213 complex Blood 0.023 0.004 0.003 0.003
37880 England 2014/15 B B 8956 ST-32 complex Blood 0.064 0.006 0.006 0.004
37883 Wales 2014/15 W NK 11 ST-11 complex Blood 0.047 0.006 0.006 0.006
37884 England 2014/15 B B 41 ST-41/44 complex Blood 0.094 0.003 0.003 0.003
37885 England 2014/15 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.008
37886 England 2014/15 B B 2100 ST-213 complex Blood 0.032 0.004 0.004 0.004
37887 England 2014/15 B B 1052 UA Blood 0.032 0.004 0.006 0.002
37888 England 2014/15 B B 269 ST-269 complex Blood 0.047 0.016 0.004 0.004
37889 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.004 0.008
37892 England 2014/15 NG NG 23 ST-23 complex Blood 0.094 0.004 0.004 0.004
37894 England 2014/15 C C 11 ST-11 complex Blood 0.125 0.006 0.004 0.006
37895 England 2014/15 Y NK 1655 ST-23 complex Blood 0.047 0.012 0.006 0.006
37896 England 2014/15 B B 60 ST-60 complex Blood 0.064 0.006 0.006 0.006
37897 England 2014/15 Y NK 1655 ST-23 complex Blood 0.032 0.003 0.004 0.004
37898 England 2014/15 B B 6135 ST-41/44 complex CSF 0.023 0.004 0.006 0.003
37899 England 2014/15 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.006 0.006
37900 England 2014/15 B B 863 UA Blood 0.25 0.012 0.008 0.012
37901 England 2014/15 B B 213 ST-213 complex Blood 0.125 0.016 0.008 0.008
37903 England 2014/15 B B 749 ST-32 complex Blood 0.094 0.004 0.006 0.008
37905 England 2014/15 B B 213 ST-213 complex Blood 0.094 0.012 0.006 0.006
37906 England 2014/15 B B 9352 ST-41/44 complex Blood 0.094 0.008 0.006 0.006
37908 England 2014/15 B B NK INCOMPLETE MLST CSF 0.125 0.006 0.006 0.008
37909 England 2014/15 B B 3282 ST-213 complex Blood 0.047 0.003 0.004 0.006
37911 England 2014/15 Y NK 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
37912 England 2014/15 B B 1764 ST-35 complex Blood 0.047 0.006 0.004 0.002
37913 England 2014/15 B B 41 ST-41/44 complex Blood 0.19 0.008 0.004 0.004
37914 England 2014/15 W NK 1655 ST-23 complex Blood 0.032 0.004 0.006 0.004
37916 England 2014/15 B B 4971 ST-41/44 complex Blood 0.047 0.006 0.006 0.002
37917 England 2014/15 Y NK 1655 ST-23 complex Blood 0.125 0.003 0.006 0.004
37918 Northern Ireland 2014/15 C C 11 ST-11 complex Blood 0.047 0.016 0.006 0.004
37919 England 2014/15 B B 11480 UA Blood 0.064 0.012 0.004 0.004
37920 England 2014/15 B B 1214 ST-269 complex Blood 0.023 0.004 0.004 0.002
37921 England 2014/15 B B 340 ST-41/44 complex Blood 0.032 0.008 0.006 0.004
37923 England 2014/15 Y NK 1655 ST-23 complex Blood 0.047 0.004 0.006 0.004
37924 England 2014/15 B B 275 ST-269 complex Blood 0.032 0.032 0.006 0.004
37925 England 2014/15 B B 41 ST-41/44 complex Blood 0.094 0.012 0.006 0.004
37926 England 2014/15 Y Y 10458 ST-23 complex Blood 0.064 0.006 0.006 0.004
37927 England 2014/15 B B 11481 ST-35 complex CSF 0.047 0.008 0.006 0.004
37928 Northern Ireland 2014/15 B B 2693 ST-269 complex Blood 0.047 0.008 0.006 0.002
37929 England 2014/15 B B 162 ST-162 complex Blood 0.047 0.016 0.008 0.004
37931 England 2014/15 B B 467 ST-269 complex Blood 0.047 0.008 0.006 0.002
37934 Wales 2014/15 W NK 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
37935 Wales 2014/15 B B 213 ST-213 complex Blood 0.032 0.006 0.004 0.002
37937 England 2014/15 Y NK 11 ST-11 complex Blood 0.047 0.008 0.008 0.002
37938 England 2014/15 Y NK 23 ST-23 complex Blood 0.047 0.004 0.006 0.004
37939 England 2014/15 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.006 0.008
37941 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.006 0.004
37943 England 2014/15 B B 269 ST-269 complex Blood 0.047 0.008 0.008 0.002
37944 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.006 0.004
37945 England 2014/15 B B 154 ST-41/44 complex Blood 0.032 0.006 0.006 0.002
37946 England 2014/15 NG Z 2123 UA Blood 0.094 0.016 0.006 0.008
37947 England 2014/15 B B 11482 ST-364 complex Blood 0.032 0.003 0.006 0.002
37948 England 2014/15 C C 11024 ST-269 complex Blood 0.032 0.023 0.004 0.002
37949 England 2014/15 C C 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
37950 England 2014/15 B NG 213 ST-213 complex Blood 0.047 0.032 0.004 0.002
37952 England 2014/15 B B 1991 ST-269 complex Blood 0.094 0.012 0.008 0.002
37953 England 2014/15 B B 485 ST-41/44 complex CSF 0.19 0.008 0.006 0.002
37954 Northern Ireland 2014/15 B B 1163 ST-269 complex Blood 0.047 0.023 0.006 0.002
37956 England 2014/15 B B 213 ST-213 complex Blood 0.047 0.012 0.004 0.004
37957 England 2014/15 B B 213 ST-213 complex Blood 0.047 0.012 0.006 0.004




37960 England 2014/15 B B 41 ST-41/44 complex Blood 0.047 0.008 0.006 0.004
37963 England 2014/15 Y NK 23 ST-23 complex Blood 0.094 0.008 0.006 0.004
37964 England 2014/15 W W 9316 UA Blood 0.047 0.006 0.004 0.004
37965 Northern Ireland 2014/15 B B 274 ST-41/44 complex Blood 0.032 0.016 0.006 0.004
37966 England 2014/15 B B 35 ST-35 complex Blood 0.19 0.003 0.004 0.012
37967 England 2014/15 C C 11 ST-11 complex Blood 0.047 0.012 0.006 0.004
37968 England 2014/15 B B 5815 ST-35 complex Blood 0.064 0.008 0.006 0.004
37969 England 2014/15 B B 11871 ST-213 complex Blood 0.064 0.023 0.006 0.004
37970 England 2014/15 B B 41 ST-41/44 complex Blood 0.094 0.008 0.006 0.004
37971 England 2014/15 B B 749 ST-32 complex Blood 0.19 0.004 0.004 0.004
37972 Northern Ireland 2014/15 B B 1161 ST-269 complex Blood 0.25 0.012 0.008 0.004
37973 England 2014/15 B B NK INCOMPLETE MLST Blood 0.064 0.012 0.006 0.002
37974 England 2014/15 C C 11024 ST-269 complex Joint 0.032 0.016 0.006 0.002
37975 England 2014/15 B B 1161 ST-269 complex CSF 0.047 0.008 0.006 0.002
37976 England 2014/15 B B 269 ST-269 complex Blood 0.064 0.006 0.006 0.004
37979 England 2014/15 Y Y 4183 ST-23 complex Blood 0.047 0.004 0.004 0.004
37982 England 2014/15 Y NK 1655 ST-23 complex Blood 0.047 0.004 0.004 0.002
37984 England 2014/15 B B 11872 ST-35 complex Blood 0.25 0.003 0.004 0.004
37985 England 2014/15 B B 1161 ST-269 complex CSF 0.125 0.006 0.004 0.004
37986 Northern Ireland 2014/15 W W 11 ST-11 complex Joint 0.064 0.004 0.006 0.004
37989 England 2014/15 B B 479 ST-269 complex Blood 0.047 0.006 0.006 0.002
37991 England 2014/15 B B 41 ST-41/44 complex Blood 0.047 0.008 0.004 0.002
37993 England 2014/15 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.006 0.002
37994 England 2014/15 B B 11483 UA Blood 0.064 0.006 0.008 0.002
37996 England 2014/15 B B 11889 UA CSF 0.094 0.012 0.006 0.003
37997 England 2014/15 B B 213 ST-213 complex Blood 0.25 0.016 0.008 0.004
38000 England 2014/15 B B 749 ST-32 complex Blood 0.19 0.012 0.006 0.004
38002 England 2014/15 B B 7622 UA Blood 0.047 0.016 0.006 0.002
38005 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.008 0.006 0.004
38006 England 2014/15 B B 1161 ST-269 complex Blood 0.125 0.008 0.008 0.006
38009 England 2014/15 B B 340 ST-41/44 complex Blood 0.047 0.012 0.008 0.004
38010 England 2014/15 Y NK 1655 ST-23 complex Blood 0.094 0.006 0.006 0.004
38012 England 2014/15 Y NK 23 ST-23 complex Blood 0.094 0.006 0.008 0.006
38013 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.006 0.004
38014 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.008 0.008 0.004
38015 England 2014/15 B B 1345 UA Joint 0.125 0.023 0.008 0.008
38016 England 2014/15 B B 11484 ST-269 complex CSF 0.19 0.047 0.006 0.006
38018 Northern Ireland 2014/15 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
38020 England 2014/15 B B 5151 UA Blood 0.25 0.016 0.006 0.012
38021 England 2014/15 Y NK 1655 ST-23 complex CSF 0.094 0.004 0.008 0.006
38022 England 2014/15 B B 11486 UA Blood 0.094 0.023 0.006 0.006
38025 England 2014/15 B B 11873 ST-41/44 complex Blood 0.047 0.008 0.006 0.003
38026 England 2014/15 B B 10696 ST-41/44 complex Blood 0.19 0.032 0.008 0.008
38028 England 2014/15 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.006 0.004
38030 England 2014/15 B B 8616 ST-269 complex Blood 0.125 0.004 0.004 0.004
38031 England 2014/15 B B 485 ST-41/44 complex Blood 0.19 0.008 0.004 0.006
38033 England 2014/15 B B 1161 ST-269 complex CSF 0.064 0.023 0.004 0.004
38036 England 2014/15 B B 8511 ST-41/44 complex Blood 0.064 0.016 0.004 0.003
38039 England 2014/15 B B 11874 ST-41/44 complex CSF 0.094 0.006 0.004 0.006
38041 England 2014/15 B B 41 ST-41/44 complex Blood 0.023 0.004 0.002 0.004
38042 Northern Ireland 2014/15 B B 1163 ST-269 complex Blood 0.25 0.006 0.002 0.012
38043 England 2014/15 B B 1161 ST-269 complex Blood 0.094 0.004 0.002 0.006
38044 England 2014/15 B B 485 ST-41/44 complex Blood 0.19 0.016 0.002 0.008
38045 England 2014/15 B B 269 ST-269 complex Blood 0.047 0.006 0.002 0.004
38046 England 2014/15 B B 1161 ST-269 complex Blood 0.19 0.012 0.002 0.006
38047 England 2014/15 B B 11488 ST-213 complex Blood 0.047 0.008 0.002 0.004
38050 England 2014/15 B B 11489 ST-213 complex Blood 0.094 0.012 0.008 0.008
38052 England 2014/15 B B 154 ST-41/44 complex CSF 0.047 0.006 0.004 0.004
38053 England 2014/15 Y NK 11875 ST-23 complex Blood 0.094 0.003 0.004 0.006
38054 England 2014/15 Y Y NK INCOMPLETE MLST Joint 0.023 0.002 0.004 0.003
38055 England 2014/15 C C 2000 ST-32 complex Blood 0.047 0.016 0.004 0.002
38056 England 2014/15 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
38057 England 2014/15 B B 11893 ST-41/44 complex Blood 0.047 0.064 0.004 0.003
38058 England 2014/15 B B 1161 ST-269 complex Blood 0.064 0.006 0.004 0.004
38061 England 2014/15 W NK 1617 ST-22 complex Blood 0.032 0.004 0.004 0.003
38062 England 2014/15 B B 1575 UA Blood 0.032 0.006 0.004 0.002
38068 England 2014/15 B B 3529 ST-269 complex Blood 0.032 0.008 0.004 0.003
38069 England 2014/15 B B 1946 ST-461 complex Blood 0.5 0.016 0.004 0.006
38070 England 2014/15 B B 11876 ST-461 complex Blood 0.125 0.004 0.003 0.006
38071 England 2014/15 W/Y W/Y 3015 UA Blood 0.094 0.016 0.004 0.004
38072 England 2014/15 B B 162 ST-162 complex Blood 0.047 0.023 0.004 0.002
38073 England 2014/15 B B 269 ST-269 complex Blood 0.047 0.012 0.004 0.002
38074 England 2014/15 B B 8758 ST-32 complex CSF 0.19 0.012 0.004 0.006
38075 England 2014/15 B B 1161 ST-269 complex Blood 0.19 0.004 0.004 0.004
38078 England 2014/15 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
38080 England 2014/15 B B 3192 UA CSF 0.064 0.008 0.002 0.006
38081 Wales 2014/15 B B 41 ST-41/44 complex Blood 0.047 0.012 0.004 0.002
38082 England 2014/15 B B 35 ST-35 complex Blood 0.125 0.023 0.004 0.002
38083 England 2014/15 B B 213 ST-213 complex Blood 0.094 0.016 0.004 0.003
38084 England 2014/15 B B 213 ST-213 complex CSF 0.25 0.016 0.004 0.004
38086 England 2014/15 B B 1946 ST-461 complex Blood 0.5 0.19 0.004 0.004
38087 England 2014/15 Y Y 11490 ST-23 complex Blood 0.064 0.008 0.003 0.004
38089 England 2014/15 B B 1791 ST-269 complex Blood 0.064 0.012 0.004 0.003
38090 England 2014/15 B B 4713 UA Blood 0.094 0.032 0.004 0.004




38092 England 2014/15 B B 7746 ST-41/44 complex Blood 0.064 0.012 0.002 0.003
38093 England 2014/15 Y NK NK INCOMPLETE MLST Blood 0.064 0.004 0.004 0.003
38094 England 2014/15 B B 2203 ST-41/44 complex Blood 0.064 0.004 0.004 0.003
38095 England 2014/15 B B 275 ST-269 complex Blood 0.064 0.006 0.004 0.003
38097 Wales 2014/15 B B 1096 ST-32 complex Blood 0.064 0.006 0.004 0.003
38098 England 2014/15 B B 485 ST-41/44 complex Blood 0.125 0.004 0.004 0.003
38099 England 2014/15 Y NK 1655 ST-23 complex Joint 0.064 0.004 0.004 0.003
38100 England 2014/15 B B 11227 ST-41/44 complex CSF 0.19 0.004 0.004 0.004
38103 England 2014/15 B B 1194 ST-41/44 complex Blood 0.047 0.008 0.004 0.002
38104 England 2014/15 Y Y 1655 ST-23 complex CSF 0.047 0.004 0.004 0.004
38105 England 2014/15 B B 1161 ST-269 complex CSF 0.25 0.012 0.004 0.004
38110 England 2014/15 B B 11492 ST-269 complex Blood 0.047 0.008 0.004 0.002
38111 England 2014/15 NG CNL 823 ST-198 complex Blood 0.19 0.032 0.004 0.004
38112 England 2014/15 B B 41 ST-41/44 complex CSF 0.19 0.008 0.004 0.003
38113 England 2014/15 B B 5151 UA CSF 0.125 0.004 0.004 0.004
38114 England 2014/15 W/Y W/Y 167 ST-167 complex Blood 0.047 0.008 0.004 0.004
38116 England 2014/15 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.004 0.003
38117 England 2014/15 B B 162 ST-162 complex Blood 0.25 0.023 0.008 0.004
38122 England 2013/14 B NG 213 ST-213 complex Blood 0.047 0.032 0.006 0.004
38123 England 2013/14 B B 213 ST-213 complex Blood 0.016 0.003 0.004 0.003
38124 England 2013/14 B B 3120 ST-213 complex CSF 0.064 0.008 0.006 0.006
38125 Wales 2013/14 B B 1946 ST-461 complex Blood 0.25 0.016 0.008 0.008
38129 England 2014/15 Y NK 1466 ST-174 complex Blood 0.094 0.004 0.002 0.003
38151 Wales 2014/15 W W 5121 ST-11 complex Blood 0.047 0.004 0.004 0.002
39002 England 2014/15 B B 41 ST-41/44 complex Blood 0.032 0.012 0.004 0.002
39318 England 2015/16 B B 11752 UA Blood 0.047 0.023 0.004 0.003
39319 England 2015/16 C C 11 ST-11 complex Blood 0.19 0.032 0.004 0.008
39321 England 2015/16 W/Y W/Y 1655 ST-23 complex CSF 0.064 0.004 0.004 0.004
39322 England 2015/16 B B 269 ST-269 complex Blood 0.032 0.016 0.002 0.002
39323 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.004 0.002
39324 England 2015/16 B B 11753 ST-41/44 complex Blood 0.094 0.032 0.004 0.004
39325 England 2015/16 B B NK INCOMPLETE MLST CSF 0.125 0.006 0.004 0.004
39326 Wales 2015/16 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.004
39327 England 2015/16 W W 184 ST-22 complex CSF 0.125 0.012 0.004 0.002
39329 England 2015/16 B B 4713 UA Blood 0.064 0.008 0.004 0.003
39330 England 2015/16 Y Y 23 ST-23 complex Blood 0.094 0.006 0.004 0.004
39332 Wales 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.008 0.003
39333 England 2015/16 W W NK INCOMPLETE MLST Blood 0.125 0.016 0.008 0.002
39334 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.008 0.003
39336 England 2015/16 B B 1049 ST-269 complex Blood 0.047 0.006 0.004 0.002
39338 England 2015/16 B B NK INCOMPLETE MLST Blood 0.047 0.006 0.004 0.002
39339 England 2015/16 Y NK 9253 ST-23 complex Blood 0.25 0.004 0.004 0.004
39343 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.094 0.008 0.008 0.004
39347 England 2015/16 Y Y 11754 ST-23 complex Blood 0.047 0.004 0.003 0.004
39348 England 2015/16 B B 1161 ST-269 complex Blood 0.094 0.023 0.006 0.008
39350 England 2015/16 B B 269 ST-269 complex Blood 0.047 0.006 0.002 0.004
39353 England 2015/16 C C 11 ST-11 complex Blood 0.25 0.023 0.004 0.006
39355 England 2015/16 B B 5151 UA Blood 0.19 0.006 0.004 0.003
39357 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.004 0.004 0.004
39360 England 2015/16 B B 337 ST-41/44 complex Blood 0.032 0.012 0.004 0.002
39361 England 2015/16 C C 11 ST-11 complex Blood 0.38 0.016 0.004 0.008
39362 England 2015/16 B B 303 ST-41/44 complex Blood 0.094 0.064 0.008 0.004
39363 England 2015/16 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.008 0.003
39364 England 2015/16 B B 1788 ST-41/44 complex Blood 0.064 0.008 0.004 0.002
39366 England 2015/16 B B 485 ST-41/44 complex CSF 0.25 0.012 0.008 0.006
39367 England 2015/16 B B 1946 ST-461 complex Blood 0.5 0.008 0.004 0.006
39370 England 2015/16 B B 41 ST-41/44 complex Blood 0.047 0.023 0.008 0.003
39371 England 2015/16 B B 479 ST-269 complex Blood 0.25 0.032 0.004 0.006
39372 England 2015/16 B B 9544 ST-41/44 complex Blood 0.064 0.008 0.002 0.004
39374 England 2015/16 B B NK INCOMPLETE MLST Blood 0.125 0.004 0.004 0.004
39375 England 2015/16 B B 41 ST-41/44 complex Blood 0.125 0.047 0.004 0.004
39376 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.008 0.006
39377 England 2015/16 Y Y 1466 ST-174 complex Blood 0.125 0.094 0.004 0.006
39378 Northern Ireland 2015/16 C C 11 ST-11 complex Blood 0.023 0.032 0.008 0.002
39379 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.016 0.008 0.004
39380 England 2015/16 NG B 11877 ST-162 complex Blood 0.5 0.032 0.008 0.023
39381 England 2015/16 B B 1617 ST-22 complex Blood 0.064 0.003 0.008 0.004
39382 England 2015/16 B B 1345 UA Blood 0.19 0.002 0.004 0.004
39384 England 2015/16 B B 11238 ST-269 complex Blood 0.064 0.047 0.008 0.003
39386 England 2015/16 B B 9088 UA Blood 0.064 0.003 0.004 0.003
39387 England 2015/16 W W 1286 ST-22 complex Blood 0.125 0.004 0.008 0.003
39388 England 2015/16 C C 11 ST-11 complex Blood 0.38 0.016 0.008 0.016
39389 England 2015/16 B B 11756 ST-32 complex Blood 0.047 0.023 0.008 0.002
39391 England 2015/16 B B 32 ST-32 complex Blood 0.25 0.032 0.008 0.006
39392 England 2015/16 B B 8955 ST-213 complex Blood 0.047 0.032 0.004 0.004
39393 England 2015/16 B B NK INCOMPLETE MLST Blood 0.047 0.006 0.008 0.003
39394 England 2015/16 B B 1194 ST-41/44 complex Blood 0.047 0.008 0.008 0.003
39397 England 2015/16 B B 11757 UA Blood 0.032 0.002 0.004 0.003
39399 England 2015/16 B B 1161 ST-269 complex CSF 0.064 0.094 0.004 0.003
39400 England 2015/16 B B 1194 ST-41/44 complex CSF 0.19 0.006 0.004 0.004
39402 England 2015/16 B B 10269 ST-41/44 complex Blood 0.125 0.012 0.004 0.004
39403 England 2015/16 C C 11 ST-11 complex Blood 0.125 0.016 0.004 0.064
39405 Northern Ireland 2015/16 B B 1157 ST-1157 complex Blood 0.032 0.012 0.004 0.003
39407 England 2015/16 B B 409 ST-41/44 complex Blood 0.38 0.125 0.004 0.008




39413 England 2015/16 B B 4051 UA BONE MARROW 0.19 0.023 0.004 0.004
39414 Wales 2015/16 B B 103 ST-103 complex Blood 0.094 0.016 0.004 0.004
39415 England 2015/16 B B 34 ST-32 complex Blood 0.125 0.008 0.004 0.008
39416 England 2015/16 W W 1281 ST-22 complex Blood 0.125 0.064 0.004 0.002
39417 England 2015/16 B B 213 ST-213 complex Blood 0.064 0.19 0.008 0.003
39418 England 2015/16 B B 11758 UA Blood 0.047 0.012 0.004 0.003
39419 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.003
39420 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
39422 Wales 2015/16 W W 11 ST-11 complex Joint 0.047 0.006 0.004 0.003
39424 England 2015/16 W W 9316 UA Blood 0.125 0.023 0.004 0.004
39425 England 2015/16 B B 1946 ST-461 complex Blood 0.19 0.008 0.004 0.004
39426 Wales 2015/16 Y Y 11754 ST-23 complex CSF 0.064 0.004 0.004 0.004
39432 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.008 0.008 0.006
39434 England 2015/16 B B 269 ST-269 complex Blood 0.094 0.023 0.008 0.003
39437 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.008 0.004
39439 England 2015/16 B B 5440 ST-41/44 complex Blood 0.094 0.012 0.008 0.004
39440 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.008 0.004 0.006
40321 Wales 2015/16 B B 3872 ST-213 complex Blood 0.38 0.016 0.004 0.008
40324 England 2015/16 B B 11880 ST-213 complex CSF 0.38 0.008 0.004 0.004
41452 England 2015/16 B B 1096 ST-32 complex Joint 0.064 0.016 0.008 0.004
41453 England 2015/16 B B 9194 ST-213 complex Blood 0.094 0.008 0.004 0.003
41454 England 2015/16 B B 749 ST-32 complex Blood 0.25 0.008 0.008 0.006
41456 England 2015/16 B B 1946 ST-461 complex Blood 0.5 0.012 0.004 0.008
41457 England 2015/16 B B 275 ST-269 complex CSF 0.094 0.004 0.004 0.002
41458 Wales 2015/16 W W 11 ST-11 complex Blood 0.094 0.002 0.008 0.003
41459 England 2015/16 B B 10651 ST-11 complex Blood 0.094 0.008 0.008 0.004
41460 England 2015/16 W W NK INCOMPLETE MLST Blood 0.5 0.023 0.008 0.008
41461 England 2015/16 B B 457 ST-35 complex Blood 0.064 0.004 0.004 0.002
41464 England 2015/16 B B 303 ST-41/44 complex Blood 0.38 0.032 0.008 0.008
41465 England 2015/16 B B 269 ST-269 complex Blood 0.094 0.012 0.008 0.003
41466 England 2015/16 Y Y 1655 ST-23 complex Blood 0.125 0.006 0.008 0.004
41468 England 2015/16 C C 11 ST-11 complex Blood 0.125 0.008 0.008 0.003
41471 England 2015/16 B B 485 ST-41/44 complex Blood 0.38 0.004 0.008 0.004
41472 England 2015/16 C C NK INCOMPLETE MLST Blood 0.38 0.032 0.008 0.094
41475 England 2015/16 B B 6058 ST-41/44 complex Blood 0.19 0.016 0.004 0.004
41476 England 2015/16 Y Y 23 ST-23 complex Blood 0.064 0.002 0.004 0.003
41477 England 2015/16 B B 485 ST-41/44 complex Blood 0.19 0.004 0.004 0.003
41479 England 2015/16 B B 4713 UA Blood 0.125 0.004 0.004 0.003
41480 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.004 0.002
41482 England 2015/16 B B 11917 ST-32 complex Blood 0.25 0.004 0.004 0.008
41484 England 2015/16 C C NK INCOMPLETE MLST Blood 0.19 0.032 0.004 0.004
41487 England 2015/16 B B 1161 ST-269 complex Blood 0.38 0.008 0.004 0.006
41488 England 2015/16 B B 4224 ST-213 complex Blood 0.064 0.008 0.004 0.003
41490 England 2015/16 B B 5849 UA Blood 0.125 0.008 0.004 0.004
41491 England 2015/16 B B 41 ST-41/44 complex Blood 0.094 0.004 0.004 0.003
41493 England 2015/16 C C 11 ST-11 complex Blood 0.38 0.023 0.004 0.008
41495 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.003 0.004 0.003
41496 England 2015/16 B B 1161 ST-269 complex Blood 0.19 0.016 0.006 0.006
41497 England 2015/16 Y Y 23 ST-23 complex Blood 0.094 0.003 0.004 0.003
41498 Wales 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.006 0.004
41499 England 2015/16 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
41500 England 2015/16 B B 213 ST-213 complex Blood 0.064 0.023 0.004 0.004
41503 England 2015/16 B B 2713 ST-41/44 complex Blood 0.047 0.004 0.004 0.003
41504 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.047 0.004 0.004 0.003
41505 England 2015/16 B B 1194 ST-41/44 complex Blood 0.047 0.008 0.006 0.004
41506 England 2015/16 B B 11755 ST-269 complex Blood 0.25 0.006 0.004 0.006
41507 England 2015/16 B B 482 ST-41/44 complex Blood 0.19 0.006 0.006 0.003
41508 England 2015/16 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.006
41509 England 2015/16 B B 7460 ST-32 complex Blood 0.38 0.012 0.004 0.008
41510 England 2015/16 B B 7460 ST-32 complex CSF 0.25 0.016 0.006 0.008
41511 England 2015/16 B B 6058 ST-41/44 complex Blood 0.25 0.016 0.006 0.008
41512 England 2015/16 B B 6359 ST-41/44 complex Blood 0.19 0.047 0.004 0.003
41513 England 2015/16 B B 1049 ST-269 complex Blood 0.047 0.004 0.004 0.003
41514 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.004 0.003
41517 Wales 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.002 0.003
41518 England 2015/16 B B 5534 ST-41/44 complex Blood 0.19 0.012 0.004 0.004
41520 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.032 0.003 0.004 0.003
41521 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
41523 England 2015/16 B B NK INCOMPLETE MLST Blood 0.023 0.006 0.002 <0.002
41524 England 2015/16 W W NK INCOMPLETE MLST Joint 0.047 0.008 0.004 0.004
41526 England 2015/16 NG NG 175 ST-175 complex Blood 0.19 0.004 0.004 0.004
41529 England 2015/16 Y Y 23 ST-23 complex Blood 0.064 0.006 0.004 0.003
41532 Wales 2015/16 B B NK INCOMPLETE MLST Blood 0.094 0.023 0.004 0.003
41534 England 2015/16 Y Y 1655 ST-23 complex Joint 0.064 0.004 0.004 0.003
41535 England 2015/16 Y Y 23 ST-23 complex Blood 0.064 0.012 0.004 0.004
41537 England 2015/16 B B 485 ST-41/44 complex Blood 0.25 0.008 0.004 0.008
41538 England 2015/16 B B 154 ST-41/44 complex Blood 0.094 0.004 0.004 0.004
41539 England 2015/16 W W 1281 ST-22 complex Blood 0.125 0.016 0.008 0.003
41540 Wales 2015/16 B B 1161 ST-269 complex Blood 0.19 0.012 0.008 0.016
41542 England 2015/16 B B NK INCOMPLETE MLST Blood 0.094 0.016 0.004 0.004
41544 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.064 0.006 0.006
41545 England 2015/16 B B NK INCOMPLETE MLST Blood 0.032 0.012 0.008 0.002
41546 Northern Ireland 2015/16 W W 11 ST-11 complex CSF 0.047 0.006 0.006 0.004
41548 England 2015/16 B B 11919 ST-60 complex Blood 0.19 0.012 0.004 0.003




41551 England 2015/16 Y Y 1466 ST-174 complex Blood 0.125 0.016 0.003 0.006
41553 England 2015/16 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
41554 England 2015/16 B B 485 ST-41/44 complex Blood 0.19 0.006 0.006 0.004
41555 England 2015/16 B B 60 ST-60 complex Blood 0.047 0.023 0.004 0.002
41556 England 2015/16 Y Y 23 ST-23 complex Blood 0.094 0.004 0.004 0.004
41557 England 2015/16 Y Y 1655 ST-23 complex CSF 0.064 0.008 0.004 0.004
41559 England 2015/16 B B 485 ST-41/44 complex Blood 0.25 0.016 0.006 0.006
42473 Northern Ireland 2015/16 B B 32 ST-32 complex Blood 0.25 0.006 0.004 0.004
42474 England 2015/16 Y Y 23 ST-23 complex Blood 0.094 0.004 0.004 0.004
42477 England 2015/16 B B 12173 ST-41/44 complex Blood 0.25 0.006 0.004 0.004
42479 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.003
42487 England 2015/16 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.003 0.004
42488 England 2015/16 B B 1161 ST-269 complex Blood 0.064 0.012 0.006 0.006
42490 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.004 0.004
42493 England 2015/16 W NK 1655 ST-23 complex Blood 0.047 0.004 0.004 0.002
42496 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.004
42498 England 2015/16 B B NK INCOMPLETE MLST Blood 0.032 0.004 0.003 <0.002
42499 England 2015/16 C C NK INCOMPLETE MLST Blood 0.19 0.5 0.004 0.094
42500 England 2015/16 W/Y W/Y NK INCOMPLETE MLST Blood 0.032 0.004 0.004 0.003
42501 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.016 0.004 0.006
42502 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.047 0.004 0.004 0.004
42507 England 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.006 0.004 0.006
42508 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.094 0.016 0.006 0.006
42509 England 2015/16 B B NK INCOMPLETE MLST Blood 0.125 0.047 0.004 <0.002
42510 England 2015/16 B B NK INCOMPLETE MLST Blood 0.047 0.006 0.004 0.006
42511 England 2015/16 B B NK INCOMPLETE MLST Blood 0.064 0.006 0.004 0.003
42513 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.19 0.006 0.004 0.012
42514 England 2015/16 B B NK INCOMPLETE MLST Blood 0.125 0.008 0.004 0.004
42515 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.003 0.004 0.003
42516 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.003 0.004 0.003
42518 England 2015/16 Y Y 12176 ST-23 complex Blood 0.047 0.003 0.004 0.004
42520 England 2015/16 B B 12017 UA Blood 0.023 <0.002 0.003 0.003
42521 England 2015/16 B B 213 ST-213 complex Blood 0.047 0.006 0.004 0.002
42522 England 2015/16 B B 2314 ST-41/44 complex Blood 0.094 0.004 0.004 0.004
42523 England 2015/16 B B 1791 ST-269 complex CSF 0.064 0.032 0.004 0.006
42524 England 2015/16 C C 11 ST-11 complex Blood 0.064 0.008 0.004 0.006
42527 Wales 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
42528 Wales 2015/16 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
42529 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
42531 England 2015/16 B B 11466 ST-269 complex Blood 0.032 0.012 0.004 0.002
42536 England 2015/16 B B 269 ST-269 complex Blood 0.064 0.008 0.004 0.003
42538 Northern Ireland 2015/16 Y NK 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
42539 England 2015/16 Y Y 3582 ST-23 complex Blood 0.125 0.008 0.004 0.008
42540 England 2015/16 C C 11 ST-11 complex Blood 0.38 0.047 0.004 0.012
42541 England 2015/16 C C 11 ST-11 complex Blood 0.38 0.008 0.004 0.006
42542 England 2015/16 B B 9194 ST-213 complex Blood 0.047 0.012 0.004 <0.002
42543 England 2015/16 Y NK 5436 UA Blood 0.064 0.023 0.004 0.004
42544 England 2015/16 B B 8988 UA Blood 0.25 0.125 0.008 0.004
42546 England 2015/16 B B 213 ST-213 complex Joint 0.25 0.008 0.004 0.006
42547 Wales 2015/16 B B 1946 ST-461 complex Blood 0.25 0.023 0.004 0.006
42548 England 2015/16 B B 1161 ST-269 complex Blood 0.125 0.006 0.004 0.004
42550 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.006 0.004 0.003
42554 England 2015/16 B B 2166 ST-269 complex CSF 0.064 0.012 0.004 0.002
42557 England 2015/16 Y NK 23 ST-23 complex Blood 0.094 <0.002 0.003 0.003
42558 England 2015/16 B B 8273 UA Blood 0.047 0.016 0.004 0.002
42559 England 2015/16 C C 11 ST-11 complex Blood 0.064 0.012 0.006 0.004
42560 England 2015/16 B B 1161 ST-269 complex Blood 0.094 0.008 0.004 0.003
42562 England 2015/16 B B 1096 ST-32 complex Blood 0.064 0.047 0.004 0.004
42563 England 2015/16 B B 461 ST-461 complex Blood 0.25 0.016 0.004 0.004
42565 England 2015/16 B B 6058 ST-41/44 complex Blood 0.19 0.047 0.004 0.004
42566 England 2015/16 C C 12020 ST-103 complex Blood 0.125 0.016 0.004 0.003
42567 England 2015/16 B B 12011 ST-213 complex Blood 0.25 0.016 0.004 0.004
42569 Northern Ireland 2015/16 C C NK INCOMPLETE MLST Blood 0.094 0.023 0.008 0.006
42571 England 2015/16 B B 571 ST-41/44 complex Blood 0.064 0.012 0.004 0.004
42574 England 2015/16 Y Y 1655 ST-23 complex Blood 0.047 0.016 0.004 0.003
42575 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.012 0.004 0.003
42577 England 2015/16 C C 11 ST-11 complex Blood 0.047 0.032 0.004 0.003
42578 England 2015/16 C C NK INCOMPLETE MLST Blood 0.25 0.016 0.004 0.006
42579 England 2015/16 B B 275 ST-269 complex Blood 0.064 0.064 0.004 0.004
42580 England 2015/16 B B 1111 UA Blood 0.38 0.032 0.004 0.032
42581 England 2015/16 C C 11 ST-11 complex Blood 0.094 0.016 0.004 0.006
42582 England 2015/16 Y Y 1655 ST-23 complex Blood 0.125 0.016 0.003 0.006
42583 England 2015/16 B B 213 ST-213 complex Blood 0.047 0.012 0.004 0.004
42584 England 2015/16 B B 12174 ST-461 complex CSF 0.25 0.008 0.004 0.006
42587 Wales 2015/16 B B 41 ST-41/44 complex Joint 0.047 0.006 0.004 <0.002
42588 England 2015/16 B B 41 ST-41/44 complex Blood 0.19 0.008 0.004 0.004
42589 England 2015/16 B B 162 ST-162 complex Blood 0.064 0.016 0.004 0.004
42590 Wales 2015/16 Y Y NK INCOMPLETE MLST Blood 0.047 0.004 0.004 0.003
42591 England 2015/16 B B 275 ST-269 complex Blood 0.064 0.004 0.004 0.003
42592 Wales 2015/16 B B 1090 ST-41/44 complex Blood 0.19 0.008 0.004 0.003
42593 England 2015/16 Y Y 23 ST-23 complex Blood 0.047 0.004 0.004 0.003
42594 England 2015/16 B B 1194 ST-41/44 complex Blood 0.125 0.008 0.006 0.006
42596 England 2015/16 Y Y 10730 ST-167 complex Blood 0.094 0.003 0.004 0.008
42597 England 2015/16 C C 11 ST-11 complex Blood 0.25 0.047 0.004 0.008




42599 Wales 2015/16 Y NK 23 ST-23 complex Blood 0.125 0.002 0.004 0.004
42600 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.004
42601 England 2015/16 B B 12177 ST-32 complex Blood 0.064 0.064 0.004 0.003
42602 England 2015/16 B B 213 ST-213 complex Blood 0.064 0.012 0.004 0.002
42603 England 2015/16 B B 1054 UA Blood 0.19 0.064 0.004 0.003
42604 England 2015/16 B B 12178 ST-213 complex Blood 0.032 0.006 0.004 0.003
42606 Wales 2015/16 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.004
42607 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.004
42608 England 2015/16 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.003
42609 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.008 0.004
42610 England 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.008 0.004 0.004
42611 England 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.012 0.004 0.004
42613 England 2015/16 Y Y 23 ST-23 complex Blood 0.125 0.004 0.004 0.008
42614 England 2015/16 Y Y 3015 UA Blood 0.047 0.012 0.004 0.004
42615 England 2015/16 C C 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
44635 England 2015/16 B B 749 ST-32 complex Blood 0.19 0.006 0.004 <0.002
44637 England 2015/16 B B 41 ST-41/44 complex Blood 0.25 0.006 0.004 0.006
44639 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.008 0.004 0.004
44641 England 2015/16 B B 41 ST-41/44 complex Blood 0.047 0.012 0.003 0.004
44696 England 2015/16 B B 213 ST-213 complex Blood 0.25 0.047 0.004 0.004
44698 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.004 0.003
44700 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.006 0.006 0.006
44701 England 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.008 0.004 0.004
44702 England 2015/16 B B NK INCOMPLETE MLST Blood 0.064 0.008 0.008 0.004
44703 England 2015/16 B B 1161 ST-269 complex Blood 0.19 0.006 0.004 0.003
44705 England 2015/16 B B 11395 ST-32 complex Blood 0.38 0.008 0.004 0.004
44706 England 2015/16 Y Y 11754 ST-23 complex Blood 0.19 0.008 0.006 0.006
44707 England 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.008 0.004 0.004
44709 England 2015/16 C C 5133 ST-103 complex Blood 0.064 0.012 0.004 0.003
44710 England 2015/16 B B 12345 ST-32 complex Blood 0.25 0.004 0.002 0.004
44711 England 2015/16 B B 269 ST-269 complex CSF 0.25 0.008 0.004 <0.002
44713 England 2015/16 B B NK INCOMPLETE MLST Blood 0.094 0.004 0.004 0.004
44715 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.064 0.004 0.006
44716 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.023 0.004 0.004
44717 Northern Ireland 2015/16 B B 213 ST-213 complex Blood 0.094 0.023 0.004 0.006
44720 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.006 0.006
44722 Wales 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.004 0.004 0.006
44723 England 2015/16 B B 1157 ST-1157 complex Blood 0.19 0.004 0.004 0.004
44725 Northern Ireland 2015/16 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
44726 England 2015/16 W W 22 ST-22 complex Blood 0.125 0.008 0.004 <0.002
44728 England 2015/16 C C 11 ST-11 complex Blood 0.094 0.008 0.008 0.006
44729 England 2015/16 B B 354 ST-269 complex Blood 0.064 0.006 0.006 0.003
44732 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.094 0.006 0.004 0.004
44734 England 2015/16 B B 9316 UA Blood 0.125 0.008 0.004 0.006
44735 England 2015/16 B B NK INCOMPLETE MLST Blood 0.094 0.006 0.006 0.004
44737 England 2015/16 B B 269 ST-269 complex Blood 0.047 0.008 0.006 0.002
44738 England 2015/16 Y Y 23 ST-23 complex Blood 0.125 0.008 0.008 0.006
44741 England 2015/16 C C 11 ST-11 complex Blood 0.047 0.016 0.004 <0.002
44743 England 2015/16 B B NK INCOMPLETE MLST CSF 0.125 0.012 0.008 0.004
44744 England 2015/16 B B 12215 ST-41/44 complex Blood 0.19 0.008 0.004 0.006
44745 England 2015/16 B B 485 ST-41/44 complex Blood 0.125 0.008 0.008 0.003
44747 England 2015/16 Y Y 23 ST-23 complex Blood 0.094 0.006 0.004 0.006
44748 England 2015/16 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.004 0.004
44749 England 2015/16 B B 12011 ST-213 complex Blood 0.25 0.008 0.002 <0.002
44750 Wales 2015/16 B B 1097 ST-41/44 complex Blood 0.064 0.012 <0.002 0.004
44751 England 2015/16 Y Y 23 ST-23 complex CSF 0.094 0.008 0.002 0.004
44752 England 2015/16 B B 41 ST-41/44 complex Blood 0.064 0.032 0.003 0.004
44756 England 2015/16 B B 2660 ST-213 complex CSF 0.094 0.064 0.004 <0.002
44757 England 2015/16 B B NK INCOMPLETE MLST CSF 0.25 0.012 0.004 0.003
44758 England 2015/16 B B 12224 ST-22 complex Blood 0.38 0.125 0.004 0.004
44760 England 2015/16 Y Y 23 ST-23 complex Blood 0.047 0.003 0.004 <0.002
44761 England 2015/16 Y Y 114 ST-22 complex Blood 0.125 0.008 0.006 0.004
44762 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.125 0.032 0.004 0.004
44764 England 2015/16 B B 8021 ST-213 complex CSF 0.125 0.023 0.004 0.003
44766 England 2015/16 B B 1163 ST-269 complex Blood 0.064 0.012 0.004 <0.002
44767 Wales 2015/16 W W 11 ST-11 complex Blood 0.094 0.004 0.004 0.004
44770 England 2015/16 C C 11 ST-11 complex Joint 0.19 0.006 0.004 0.004
44771 England 2015/16 B B 461 ST-461 complex Blood 0.125 0.047 0.004 0.003
44772 England 2015/16 B B 162 ST-162 complex Blood 0.125 0.023 0.008 0.004
44774 England 2015/16 B B 275 ST-269 complex Blood 0.125 0.023 0.004 0.003
44775 England 2015/16 Y NK 1655 ST-23 complex Blood 0.094 0.006 0.004 0.003
44776 England 2015/16 B B 1161 ST-269 complex Blood 0.38 0.023 0.004 0.004
44778 England 2015/16 B B 12226 ST-461 complex Blood 0.25 0.064 0.004 0.004
44779 England 2015/16 C C 11 ST-11 complex Blood 0.125 0.016 0.004 0.004
44780 England 2015/16 B B 1195 ST-269 complex Blood 0.032 0.008 0.004 0.002
44781 England 2015/16 B B 41 ST-41/44 complex Blood 0.19 0.003 0.004 0.003
44783 Wales 2015/16 B B NK INCOMPLETE MLST Blood 0.094 0.006 0.004 0.004
44787 England 2015/16 B B 7460 ST-32 complex Blood 0.25 0.012 0.002 0.008
44789 England 2015/16 Y Y NK INCOMPLETE MLST Joint 0.047 0.006 0.004 0.003
44791 England 2015/16 B B 60 ST-60 complex CSF 0.047 0.004 0.006 0.003
44792 England 2015/16 C C NK INCOMPLETE MLST Blood 0.19 0.012 0.004 0.006
44793 England 2015/16 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.004 <0.002
44794 England 2015/16 B B 41 ST-41/44 complex Blood 0.032 0.008 0.004 <0.002
44796 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.047 0.006 0.004 0.003




44799 England 2015/16 C C NK INCOMPLETE MLST Blood 0.125 0.004 0.003 0.006
44800 England 2015/16 B B NK INCOMPLETE MLST Blood 0.125 0.006 0.006 0.008
44801 England 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.008 0.008 0.006
44803 England 2015/16 B B 275 ST-269 complex Blood 0.047 0.023 0.006 0.003
44804 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.125 0.047 0.006 0.012
44805 England 2015/16 E E NK INCOMPLETE MLST Blood 0.094 0.125 0.006 0.006
44806 England 2015/16 C C 12227 ST-11 complex Blood 0.047 0.125 0.006 0.003
44807 England 2015/16 B B 41 ST-41/44 complex Blood 0.19 0.023 0.006 0.006
44808 England 2015/16 B B 41 ST-41/44 complex Blood 0.064 0.064 0.004 0.003
44809 Wales 2015/16 B B 41 ST-41/44 complex Blood 0.032 0.012 0.004 <0.002
44810 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.094 0.023 0.004 0.008
44811 England 2015/16 B B NK INCOMPLETE MLST Blood 0.5 0.016 0.004 0.047
44812 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.016 0.008 0.006
44813 England 2015/16 B B 11238 ST-269 complex Blood 0.064 0.032 0.006 0.004
44814 England 2015/16 Y Y 23 ST-23 complex Blood 0.064 0.004 0.004 0.004
44815 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.032 0.006 0.008
44816 England 2015/16 B B 12237 UA Blood 0.047 0.032 0.006 0.003
44817 England 2015/16 Y Y 1625 ST-23 complex Blood 0.19 0.006 0.004 0.023
44818 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.047 0.003 0.004 0.002
44819 England 2015/16 B B 461 ST-461 complex Blood 0.25 0.012 0.004 0.006
44820 Northern Ireland 2015/16 W W 11 ST-11 complex Blood 0.047 0.016 0.008 0.004
44821 England 2015/16 B B 1159 UA Blood 0.032 0.023 0.004 0.004
44822 England 2015/16 Y Y 1655 ST-23 complex Joint 0.064 0.004 0.006 0.003
44823 England 2015/16 B B 5849 UA Blood 0.094 0.008 0.006 0.004
44824 England 2015/16 B B 11 ST-11 complex Blood 0.38 0.25 0.004 0.012
44825 England 2015/16 B B 1163 ST-269 complex CSF 0.094 0.047 0.004 0.004
44826 England 2015/16 B B NK INCOMPLETE MLST Blood 0.047 0.016 0.006 0.002
44827 England 2015/16 B B NK INCOMPLETE MLST Blood 0.25 0.008 0.006 0.004
44830 England 2015/16 B B 12346 UA Blood 0.023 0.012 0.004 <0.002
44831 England 2015/16 B B NK INCOMPLETE MLST CSF 0.047 0.012 0.004 0.003
44834 England 2015/16 B B NK INCOMPLETE MLST Blood 0.19 0.064 0.008 0.008
44836 England 2015/16 Y Y NK INCOMPLETE MLST Blood 0.064 0.004 0.004 0.004
47017 England 2015/16 B B 3446 ST-41/44 complex Blood 0.064 0.004 0.008 0.003
47018 England 2015/16 B B 1161 ST-269 complex Blood 0.25 0.023 0.003 0.004
47259 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.003
47260 England 2015/16 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.004
47261 England 2015/16 B B 1403 ST-41/44 complex Blood 0.032 0.012 0.002 0.004
47264 England 2015/16 Y Y 10730 ST-167 complex Blood 0.094 0.006 0.004 0.006
47266 England 2015/16 C C 11 ST-11 complex Blood 0.064 0.016 0.006 0.008
47267 England 2015/16 B B 1161 ST-269 complex Blood 0.125 0.012 0.008 0.002
47268 England 2015/16 B B 1161 ST-269 complex Blood 0.38 0.023 0.006 0.008
47269 England 2016/17 B B 162 ST-162 complex Blood 0.38 0.016 0.004 0.008
47270 England 2016/17 Y Y 1655 ST-23 complex Blood 0.19 0.012 0.008 0.012
47272 England 2016/17 B B 162 ST-162 complex Blood 0.064 0.008 0.004 0.003
47276 England 2016/17 B B 1788 ST-41/44 complex CSF 0.064 0.006 0.004 0.002
47278 Wales 2016/17 B B 2314 ST-41/44 complex Blood 0.125 0.004 0.004 0.004
47279 England 2016/17 B B 41 ST-41/44 complex Blood 0.064 0.012 0.004 0.004
47281 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
47282 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
47283 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
47284 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.002
47285 England 2016/17 B B 1161 ST-269 complex Blood 0.125 0.008 0.008 0.006
47286 England 2016/17 B B 1195 ST-269 complex Blood 0.125 0.012 0.008 0.006
47288 Wales 2016/17 B B 1092 ST-269 complex CSF 0.064 0.008 0.004 0.003
47290 England 2016/17 NG CNL 12513 ST-198 complex Blood 0.125 0.19 0.004 0.006
47291 England 2016/17 B B 12509 ST-32 complex Blood 0.25 0.016 0.006 0.008
47292 England 2016/17 B B 1946 ST-461 complex Blood 0.25 0.012 0.004 0.006
47295 England 2016/17 Y Y 1655 ST-23 complex Blood 0.094 0.012 0.006 0.006
47297 England 2016/17 Y Y 1655 ST-23 complex Blood 0.25 0.016 0.004 0.004
47298 England 2016/17 C C 11 ST-11 complex CSF 0.094 0.012 0.008 0.006
47300 England 2016/17 B B 34 ST-32 complex Blood 0.19 0.006 0.006 0.012
47302 England 2016/17 Y NK 1655 ST-23 complex Blood 0.094 0.006 0.004 0.003
47306 England 2016/17 B B 2380 ST-35 complex Blood 0.094 0.012 0.008 0.003
47307 England 2016/17 B B 1098 ST-32 complex CSF 0.38 0.032 0.004 0.004
47308 England 2016/17 C C 11 ST-11 complex Blood 0.38 0.064 0.008 0.006
47309 England 2016/17 B B 275 ST-269 complex Blood 0.25 0.012 0.006 0.003
47310 England 2016/17 B B 336 UA Blood 0.25 0.006 0.006 0.006
47312 England 2016/17 B B 3641 ST-213 complex Blood 0.125 0.023 0.004 0.008
47313 England 2016/17 W W 1617 ST-22 complex Blood 0.38 0.004 0.004 0.008
47314 England 2016/17 B B 1194 ST-41/44 complex Blood 0.25 0.004 0.004 0.004
47315 England 2016/17 Y Y 1655 ST-23 complex Joint 0.047 0.004 0.004 0.003
47316 England 2016/17 Y Y 23 ST-23 complex Blood 0.094 0.004 0.004 0.004
47317 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.012 0.004 0.003
47319 England 2016/17 B B 1111 UA Blood 0.38 0.125 0.004 0.003
47320 England 2016/17 Y Y 23 ST-23 complex CSF 0.19 0.008 0.008 0.006
47321 Wales 2016/17 B B 5133 ST-103 complex Blood 0.032 0.023 0.004 0.002
47323 England 2016/17 B B 571 ST-41/44 complex CSF 0.064 0.006 0.004 0.003
47324 England 2016/17 Y Y 23 ST-23 complex Blood 0.094 0.004 0.004 0.006
47328 Wales 2016/17 B B 8049 ST-32 complex Blood 0.38 0.016 0.004 0.004
47330 England 2016/17 Y NK 1655 ST-23 complex Blood 0.125 0.004 0.004 0.004
47331 England 2016/17 B B 12510 UA Blood 0.125 0.047 0.008 0.006
47332 England 2016/17 B B 12510 UA Blood 0.125 0.047 0.006 0.006
47333 England 2016/17 B B 12512 ST-41/44 complex Blood 0.125 0.016 0.004 0.006
47335 England 2016/17 Y Y 1655 ST-23 complex Blood 0.094 0.008 0.004 0.003




47341 England 2016/17 B B 9316 UA Blood 0.125 0.064 0.004 0.003
47342 England 2016/17 B B 11466 ST-269 complex Blood 0.047 0.016 0.004 0.003
47343 England 2016/17 W W 184 ST-22 complex Blood 0.125 0.008 0.004 0.003
53052 Wales 2016/17 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
53055 England 2016/17 Y Y 10728 ST-167 complex Blood 0.19 0.006 0.008 0.012
53057 England 2016/17 B B 8988 UA Blood 0.19 0.032 0.008 0.006
53059 England 2016/17 B B 340 ST-41/44 complex Blood 0.125 0.006 0.004 0.004
53061 England 2016/17 Y Y 23 ST-23 complex Blood 0.064 0.006 0.004 0.002
53062 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.003
53063 England 2016/17 B B 41 ST-41/44 complex Blood 0.064 0.125 0.008 0.003
53065 England 2016/17 B B 485 ST-41/44 complex Blood 0.19 0.047 0.004 0.004
53066 England 2016/17 Y Y 23 ST-23 complex Blood 0.38 0.012 0.004 0.023
53068 England 2016/17 B B 12985 ST-213 complex Blood 0.25 0.008 0.004 0.003
53070 England 2016/17 B B 41 ST-41/44 complex Blood 0.19 0.008 0.004 0.006
53071 Wales 2016/17 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.002
53073 England 2016/17 B B 13091 ST-60 complex Blood 0.125 0.012 0.004 0.004
53075 England 2016/17 B B 1161 ST-269 complex Blood 0.19 0.006 0.004 0.006
53079 England 2016/17 W/Y W/Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
53083 England 2016/17 B B 269 ST-269 complex CSF 0.047 0.008 0.004 0.002
53085 England 2016/17 Y Y 13092 ST-23 complex Blood 0.047 0.003 0.004 0.003
53088 England 2016/17 C C 11 ST-11 complex Blood 0.064 0.004 0.004 0.004
53089 England 2016/17 C C 11 ST-11 complex Joint 0.047 0.016 0.004 0.004
53090 England 2016/17 C C 11 ST-11 complex Blood 0.25 0.012 0.004 0.004
53094 England 2016/17 B B 457 ST-35 complex Blood 0.032 0.032 0.004 <0.002
53095 England 2016/17 C C 11 ST-11 complex CSF 0.064 0.023 0.004 0.003
53097 England 2016/17 B B 1774 ST-269 complex Blood 0.125 0.023 0.004 0.003
53098 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.002
53099 England 2016/17 B B 13095 ST-32 complex Blood 0.19 0.003 0.004 0.004
53100 England 2016/17 C C 11 ST-11 complex Blood 0.125 0.016 0.004 0.003
53101 England 2016/17 B B 213 ST-213 complex Blood 0.19 0.012 0.004 0.006
53102 England 2016/17 B B 1475 ST-41/44 complex Blood 0.047 0.094 0.004 0.003
53103 Wales 2016/17 Y Y 23 ST-23 complex Blood 0.125 0.003 0.003 0.004
53104 England 2016/17 B B 1162 UA Blood 0.032 0.064 0.004 0.002
53105 England 2016/17 C C 11 ST-11 complex Blood 0.094 0.016 0.004 0.006
53106 England 2016/17 Y Y 13093 ST-23 complex Blood 0.094 0.004 0.004 0.008
53107 England 2016/17 B B 485 ST-41/44 complex Blood 0.125 0.006 0.004 0.003
53108 England 2016/17 Y Y 1655 ST-23 complex Joint 0.064 0.006 0.004 0.003
53109 England 2016/17 B B 10266 UA Blood 0.38 0.008 0.004 0.012
53111 England 2016/17 B B 1423 ST-41/44 complex Blood 0.047 0.008 0.004 0.003
53112 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.006
53114 England 2016/17 B B 32 ST-32 complex Blood 0.047 0.008 0.004 0.004
53115 England 2016/17 B B 1992 ST-41/44 complex CSF 0.125 0.004 0.004 0.003
53116 England 2016/17 B B 4146 ST-60 complex Blood 0.032 0.032 0.008 0.002
53117 England 2016/17 B B 1475 ST-41/44 complex Joint 0.064 0.006 0.004 0.003
53118 England 2016/17 B B 1161 ST-269 complex Blood 0.032 0.016 0.004 0.008
53120 Wales 2016/17 B B 12987 UA Blood 0.047 0.023 0.008 0.004
53122 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.003
53124 Wales 2016/17 B B 269 ST-269 complex Blood 0.064 0.047 0.004 0.004
53125 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.012 0.004 0.003
53126 England 2016/17 B B 3754 ST-41/44 complex Blood 0.032 0.004 0.008 0.003
53127 England 2016/17 B B 409 ST-41/44 complex Blood 0.125 0.064 0.004 0.006
53128 England 2016/17 B B 485 ST-41/44 complex Blood 0.19 0.016 0.004 0.004
53129 England 2016/17 B B 13094 ST-41/44 complex Blood 0.047 0.012 0.004 0.002
53130 England 2016/17 B B 283 ST-269 complex Blood 0.047 0.008 0.004 0.003
53131 England 2016/17 B B 11 ST-11 complex Blood 0.064 0.012 0.004 0.006
53132 England 2016/17 B B 34 ST-32 complex Blood 0.19 0.006 0.004 0.006
53134 England 2016/17 B B 13096 ST-32 complex Blood 0.047 0.006 0.004 0.004
53136 England 2016/17 B B 12988 UA CSF 0.064 0.004 0.004 0.004
53137 England 2016/17 B B 34 ST-32 complex Blood 0.125 0.006 0.004 0.012
53138 England 2016/17 B B 1049 ST-269 complex Blood 0.064 0.016 0.004 0.003
53140 England 2016/17 B B 8988 UA Blood 0.125 0.012 0.004 0.003
53144 Wales 2016/17 B B 12989 ST-269 complex Blood 0.032 0.008 0.004 0.002
53145 Wales 2016/17 B B 41 ST-41/44 complex Blood 0.032 0.006 0.004 0.002
53147 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
53148 England 2016/17 B B 41 ST-41/44 complex Blood 0.125 0.008 0.004 0.004
53152 England 2016/17 B B 32 ST-32 complex Blood 0.19 0.012 0.004 0.006
53153 England 2016/17 B B 8511 ST-41/44 complex Blood 0.047 0.004 0.004 0.003
53155 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
53156 Wales 2016/17 W W 11 ST-11 complex Blood 0.064 0.032 0.004 0.004
53157 England 2016/17 B B 41 ST-41/44 complex Blood 0.19 0.008 0.004 0.006
53158 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
53160 England 2016/17 C C 12227 ST-11 complex Blood 0.047 0.032 0.004 0.004
53161 England 2016/17 B B 3482 UA Blood 0.047 0.19 0.004 0.003
53162 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.004 0.004
53163 England 2016/17 B B 749 ST-32 complex Blood 0.125 0.008 0.004 0.006
53168 Wales 2016/17 W NK 11 ST-11 complex Blood 0.064 0.012 0.008 0.003
53169 England 2016/17 B B 1049 ST-269 complex Blood 0.032 0.006 0.008 0.002
53171 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
53172 Northern Ireland 2016/17 W W 11 ST-11 complex Blood 0.064 0.023 0.004 0.003
53173 England 2016/17 B B 18 ST-18 complex Blood 0.012 0.002 0.008 0.002
53174 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.003
53175 England 2016/17 B B 485 ST-41/44 complex Blood 0.094 0.006 0.008 0.004
53177 England 2016/17 B B 1049 ST-269 complex Blood 0.023 0.006 0.008 0.002
53180 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.008 0.006




53182 England 2016/17 B B 162 ST-162 complex Blood 0.032 0.023 0.008 0.002
53184 England 2016/17 B B 485 ST-41/44 complex Blood 0.125 0.016 0.008 0.003
53185 England 2016/17 B B 41 ST-41/44 complex Blood 0.094 0.012 0.004 0.003
53186 England 2016/17 B B 269 ST-269 complex Blood 0.047 0.006 0.008 0.003
53187 England 2016/17 B B 162 ST-162 complex Blood 0.047 0.012 0.008 0.004
53189 England 2016/17 B B 1161 ST-269 complex Blood 0.047 0.016 0.004 0.003
53191 England 2016/17 B B 12990 UA Blood 0.032 0.003 0.008 0.002
53193 England 2016/17 C C 11 ST-11 complex Blood 0.032 0.012 0.008 0.003
53197 England 2016/17 B B 2314 ST-41/44 complex Blood 0.094 0.006 0.004 0.003
53201 England 2016/17 Y Y 23 ST-23 complex Blood 0.032 0.002 0.004 0.003
53202 England 2016/17 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.004 0.003
53203 England 2016/17 Y Y 1655 ST-23 complex Joint 0.047 0.004 0.004 0.004
53204 England 2016/17 B B 162 ST-162 complex Blood 0.25 0.012 0.008 0.008
53205 England 2016/17 Y Y 6463 ST-23 complex Blood 0.094 0.006 0.004 0.008
53206 England 2016/17 B B 1721 ST-213 complex Blood 0.032 0.012 0.008 0.003
53209 England 2016/17 B B 41 ST-41/44 complex Blood 0.047 0.008 0.008 0.003
53210 England 2016/17 B B 41 ST-41/44 complex Blood 0.125 0.004 0.008 0.004
53211 England 2016/17 Y Y 23 ST-23 complex Blood 0.032 0.006 0.004 0.003
53214 England 2016/17 C C 11 ST-11 complex Blood 0.125 0.016 0.008 0.004
53216 England 2016/17 B B 13098 ST-213 complex Blood 0.016 0.004 0.004 <0.002
53218 Wales 2016/17 Y Y 23 ST-23 complex Blood 0.047 0.002 0.004 0.003
53219 England 2016/17 B B 461 ST-461 complex CSF 0.125 0.004 0.004 0.004
53220 England 2016/17 Y Y 23 ST-23 complex Blood 0.5 0.032 0.004 0.006
53221 Wales 2016/17 W W 11 ST-11 complex CSF 0.047 0.004 0.004 0.003
53223 Wales 2016/17 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.003
53224 Wales 2016/17 W W 11 ST-11 complex Blood 0.047 0.016 0.008 0.003
53225 England 2016/17 B B 213 ST-213 complex Blood 0.032 0.016 0.008 0.008
53227 England 2016/17 Y Y 23 ST-23 complex Blood 0.032 0.006 0.004 0.003
53228 England 2016/17 B B 1946 ST-461 complex Blood 0.25 0.023 0.004 0.006
53229 England 2016/17 B B 5266 ST-269 complex Blood 0.023 0.004 0.008 0.002
53234 England 2016/17 B B 467 ST-269 complex Blood 0.125 0.047 0.004 0.004
53235 England 2016/17 B B 41 ST-41/44 complex Blood 0.047 0.006 0.008 0.002
53238 England 2016/17 B B 1161 ST-269 complex Blood 0.064 0.004 0.008 0.004
53239 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
53240 England 2016/17 B B 213 ST-213 complex Blood 0.047 0.004 0.004 0.002
53241 England 2016/17 B B 2314 ST-41/44 complex CSF 0.094 0.012 0.008 0.004
53242 England 2016/17 B B 33 ST-32 complex Joint 0.047 0.003 0.008 0.002
53243 England 2016/17 B B 1163 ST-269 complex Blood 0.094 0.006 0.004 0.002
53245 England 2016/17 Y Y 1655 ST-23 complex Blood 0.023 0.002 0.004 0.003
53247 England 2016/17 B B 2561 ST-269 complex Blood 0.094 0.023 0.004 0.004
53248 England 2016/17 B B 11766 ST-41/44 complex Blood 0.023 0.003 0.004 0.002
53250 Northern Ireland 2016/17 B B 269 ST-269 complex Blood 0.023 0.023 0.008 0.003
53251 England 2016/17 Y Y 11520 UA Blood 0.094 0.004 0.008 0.004
53254 England 2016/17 B B 467 ST-269 complex Blood 0.38 0.19 0.008 0.012
53257 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.008 0.004
53258 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.008 0.004
53260 England 2016/17 B B 41 ST-41/44 complex Blood 0.25 0.006 0.008 0.003
53261 England 2016/17 Y Y 1624 ST-167 complex Blood 0.125 0.003 0.008 0.012
53262 England 2016/17 C C 11 ST-11 complex Blood 0.064 0.012 0.008 0.006
53263 England 2016/17 B B 1161 ST-269 complex Blood 0.047 0.008 0.004 0.003
53266 England 2016/17 B B 11480 UA Blood 0.094 0.004 0.004 0.006
53268 England 2016/17 W W 9316 UA Blood 0.094 0.023 0.004 0.003
53271 England 2016/17 B B 7746 ST-41/44 complex Blood 0.032 0.004 0.008 0.002
53272 England 2016/17 Y Y 3015 UA Blood 0.094 0.016 0.004 0.004
53273 England 2016/17 B B 485 ST-41/44 complex Blood 0.125 0.003 0.008 0.004
53276 England 2016/17 C C 11 ST-11 complex CSF 0.047 0.002 0.004 0.002
53277 England 2016/17 Y Y 1655 ST-23 complex Blood 0.032 0.002 0.004 0.003
53278 Northern Ireland 2016/17 C C 11 ST-11 complex Blood 0.016 <0.002 0.004 0.002
53280 England 2016/17 C C 11 ST-11 complex Blood 0.064 0.064 0.004 0.004
53281 England 2016/17 B B 32 ST-32 complex Blood 0.032 0.016 0.004 0.002
53282 England 2016/17 B B 1867 UA Blood 0.047 0.008 0.004 0.004
53283 England 2016/17 Y Y 23 ST-23 complex Blood 0.047 0.012 0.002 0.004
53285 England 2016/17 B B 12509 ST-32 complex Blood 0.125 0.008 0.004 0.006
53286 England 2016/17 B B 12991 ST-269 complex Blood 0.125 0.047 0.004 0.004
53288 England 2016/17 B B 2314 ST-41/44 complex Blood 0.094 0.064 0.004 0.003
53289 England 2016/17 B B 41 ST-41/44 complex Blood 0.016 0.002 0.004 <0.002
53290 England 2016/17 B B 12227 ST-11 complex Blood 0.032 0.023 0.004 0.002
53293 England 2016/17 B B 11466 ST-269 complex Blood 0.064 0.008 0.008 0.002
53294 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.003
53295 England 2016/17 B B 4562 ST-213 complex Blood 0.094 0.023 0.008 0.008
53298 England 2016/17 B B 275 ST-269 complex Blood 0.047 0.008 0.004 0.003
53299 England 2016/17 B B 32 ST-32 complex Blood 0.064 0.008 0.004 0.004
53302 Wales 2016/17 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
53303 England 2016/17 C C 11 ST-11 complex Blood 0.047 0.012 0.004 0.004
53304 England 2016/17 C C 11 ST-11 complex Blood 0.25 0.016 0.004 0.004
53305 Wales 2016/17 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.002
53306 England 2016/17 C C 11 ST-11 complex Blood 0.064 0.047 0.008 0.004
53310 England 2016/17 B B 1163 ST-269 complex Blood 0.094 0.004 0.004 0.004
53311 England 2016/17 B B 213 ST-213 complex Blood 0.19 0.012 0.004 0.006
53312 England 2016/17 E E 4146 ST-60 complex Blood 0.047 0.032 0.008 0.004
53313 England 2016/17 B B 9180 ST-269 complex Blood 0.125 0.064 0.004 0.003
53314 England 2016/17 B B 9180 ST-269 complex Blood 0.19 0.032 0.008 0.004
53316 Wales 2016/17 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
53317 England 2016/17 C C 11 ST-11 complex Blood 0.125 0.032 0.008 0.008




53319 England 2016/17 B B 213 ST-213 complex Blood 0.25 0.016 0.004 0.008
53320 England 2016/17 B B 41 ST-41/44 complex Blood 0.064 0.008 0.004 0.002
53321 England 2016/17 B B 7460 ST-32 complex Blood 0.25 0.004 0.004 0.004
53324 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
53326 England 2016/17 Y Y 168 ST-167 complex Blood 0.047 0.006 0.008 0.003
53327 Wales 2016/17 Y Y 1627 ST-167 complex Blood 0.064 0.006 0.004 0.004
53329 England 2016/17 B B 213 ST-213 complex Blood 0.047 0.008 0.004 0.003
53330 England 2016/17 Y Y 1655 ST-23 complex Blood 0.094 0.008 0.004 0.006
53331 England 2016/17 B B 10269 ST-41/44 complex Blood 0.125 0.008 0.004 0.003
53332 England 2016/17 B B 575 ST-213 complex Blood 0.125 0.008 0.004 0.003
53333 England 2016/17 B B 1791 ST-269 complex Blood 0.047 0.008 0.004 <0.002
53334 England 2016/17 Y Y 1378 ST-23 complex Blood 0.047 0.004 0.004 0.004
53335 England 2016/17 B B 41 ST-41/44 complex Blood 0.125 0.004 0.004 0.004
53336 England 2016/17 B B 749 ST-32 complex Blood 0.125 0.003 0.004 0.004
53337 Wales 2016/17 B B 12992 UA Blood 0.064 0.006 0.004 0.004
53342 England 2016/17 B B 1572 ST-1572 complex Blood 0.125 0.004 0.004 0.004
53345 England 2016/17 B B 213 ST-213 complex Blood 0.047 0.008 0.004 0.003
53348 England 2016/17 B B 41 ST-41/44 complex Blood 0.125 0.016 0.004 0.003
53349 England 2016/17 B B 162 ST-162 complex Blood 0.047 0.002 0.004 0.003
53351 England 2016/17 B B 213 ST-213 complex Blood 0.047 0.047 0.004 0.003
53353 England 2016/17 Y Y 23 ST-23 complex Blood 0.25 0.006 0.004 0.004
53356 Wales 2016/17 B B 1096 ST-32 complex Blood 0.047 0.032 0.004 0.004
53357 England 2016/17 B B 3818 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
53359 England 2016/17 B B 1161 ST-269 complex Blood 0.047 0.008 0.004 0.003
53361 England 2016/17 B B 11487 ST-41/44 complex CSF 0.047 0.012 0.004 0.002
53362 Wales 2016/17 C C 11 ST-11 complex Blood 0.047 0.023 0.008 0.004
53363 England 2016/17 B B 41 ST-41/44 complex Blood 0.047 0.008 0.004 0.002
53364 England 2016/17 B B 1157 ST-1157 complex Blood 0.032 0.004 0.004 0.002
53366 England 2016/17 B B 12993 ST-213 complex CSF 0.047 0.032 0.004 0.004
53370 England 2016/17 B B 839 ST-41/44 complex CSF 0.047 0.006 0.004 0.003
53373 England 2016/17 B B 340 ST-41/44 complex Blood 0.047 0.008 0.004 0.004
57961 England 2017/18 B B 41 ST-41/44 complex CSF 0.19 0.006 0.003 0.006
60546 England 2017/18 B B 1354 ST-269 complex Blood 0.047 0.008 0.004 0.002
60547 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.016 0.004 0.004
60548 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.004
60550 England 2017/18 NG B 13702 UA Blood 0.047 0.032 0.004 0.003
60551 England 2017/18 B B 13703 ST-41/44 complex Blood 0.19 0.006 0.004 0.004
60556 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
60560 Northern Ireland 2017/18 B B 1163 ST-269 complex Blood 0.25 0.006 0.004 0.006
60563 England 2016/17 B B 1161 ST-269 complex Blood 0.25 0.023 0.004 0.006
60564 Wales 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
60567 England 2017/18 C C 11 ST-11 complex Blood 0.094 0.012 0.006 0.004
60568 England 2017/18 C C 11 ST-11 complex Pericardium 0.25 0.023 0.004 0.008
60569 Northern Ireland 2017/18 Y Y 23 ST-23 complex Blood 0.047 0.004 0.003 0.002
60570 England 2016/17 B B 457 ST-35 complex Blood 0.047 0.047 0.008 0.004
60574 Wales 2017/18 B B 13704 ST-461 complex CSF 0.25 0.006 0.003 0.008
60577 England 2017/18 B B 1195 ST-269 complex Blood 0.032 0.012 0.004 <0.002
60580 England 2016/17 NG NG NK INCOMPLETE MLST Blood 0.023 0.032 0.004 0.002
60582 England 2017/18 B B 41 ST-41/44 complex Blood 0.125 0.004 0.004 <0.002
60583 England 2017/18 B B 13705 ST-41/44 complex Blood 0.094 0.012 0.004 0.003
60585 England 2017/18 C C 11 ST-11 complex Blood 0.38 0.094 0.004 0.004
60586 England 2017/18 B B 13706 ST-213 complex Blood 0.047 0.016 0.004 0.003
60588 England 2016/17 C C 11 ST-11 complex Blood 0.38 0.094 0.004 0.008
60593 England 2016/17 B B 13707 UA Blood 0.125 0.008 0.006 0.006
60594 England 2016/17 B B 269 ST-269 complex Blood 0.032 0.016 0.004 <0.002
60595 England 2017/18 B B 269 ST-269 complex Blood 0.032 0.004 0.004 0.004
60596 England 2017/18 C C 13708 UA Blood 0.047 0.012 0.004 0.003
60598 England 2016/17 B B 1161 ST-269 complex Blood 0.064 0.016 0.008 0.004
60600 England 2017/18 B B 41 ST-41/44 complex Blood 0.25 0.004 0.004 0.003
60602 Wales 2017/18 W W 11 ST-11 complex Blood 0.094 0.006 0.004 0.004
60604 England 2017/18 B B 1194 ST-41/44 complex Blood 0.064 0.006 0.004 0.003
60605 Wales 2016/17 W W 11 ST-11 complex Blood 0.064 0.023 0.008 0.004
60608 England 2017/18 B B 162 ST-162 complex Blood 0.125 0.008 0.004 0.003
60609 England 2017/18 B B 269 ST-269 complex Blood 0.032 0.023 0.004 0.002
60610 England 2016/17 B B 269 ST-269 complex Blood 0.047 0.008 0.008 0.004
60615 England 2016/17 C C 11 ST-11 complex Pericardium 0.094 0.023 0.008 0.004
60617 England 2017/18 C C 33 ST-32 complex Blood 0.064 0.008 0.004 0.002
60618 England 2017/18 B B 1161 ST-269 complex Blood 0.064 0.047 0.004 0.003
60620 England 2016/17 B B 275 ST-269 complex Blood 0.125 0.032 0.008 0.006
60622 England 2017/18 B B 485 ST-41/44 complex Blood 0.25 0.047 0.004 0.003
60623 England 2017/18 B B 41 ST-41/44 complex Blood 0.125 0.004 0.004 0.006
60625 England 2017/18 B B 41 ST-41/44 complex Blood 0.094 0.006 0.004 0.002
60626 England 2017/18 B B 749 ST-32 complex Blood 0.125 0.004 0.004 0.008
60627 England 2017/18 B B 41 ST-41/44 complex Blood 0.25 0.023 0.004 0.004
60628 England 2016/17 W W 114 ST-22 complex Blood 0.064 0.016 0.004 0.003
60630 Wales 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.003
60633 England 2016/17 B B 485 ST-41/44 complex CSF 0.19 0.016 0.008 0.003
60635 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.016 0.008 0.006
60636 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
60637 England 2017/18 B B 1341 ST-41/44 complex Blood 0.25 0.012 0.004 0.004
60638 England 2016/17 B B 13709 ST-41/44 complex Blood 0.064 0.008 0.004 <0.002
60640 England 2017/18 B B 7981 ST-269 complex Blood 0.094 0.016 0.006 0.002
60641 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.012 0.006 0.004
60643 England 2016/17 B B 1162 UA Blood 0.032 0.032 0.004 0.003




60647 England 2017/18 B B 1946 ST-461 complex Blood 0.25 0.016 0.004 0.004
60648 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.004
60650 England 2016/17 C C 11 ST-11 complex Blood 0.25 0.032 0.004 0.125
60652 England 2017/18 Y Y 11846 ST-103 complex Blood 0.125 0.008 0.004 0.008
60653 England 2017/18 W W 13710 UA Blood 0.094 0.032 0.004 0.003
60654 England 2017/18 B B 32 ST-32 complex Blood 0.064 0.012 0.004 0.004
60655 England 2016/17 B B NK INCOMPLETE MLST Blood 0.19 0.008 0.004 0.004
60658 England 2017/18 B B 213 ST-213 complex Blood 0.25 0.012 0.004 0.004
60659 England 2017/18 B B 32 ST-32 complex Blood 0.064 0.012 0.006 0.004
60660 England 2016/17 B B 5151 UA Blood 0.19 0.008 0.004 0.004
60662 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.004 0.004
60665 England 2017/18 B B 41 ST-41/44 complex Blood 0.125 0.006 0.004 0.004
60666 England 2017/18 B B 13711 UA Blood 0.19 0.006 0.006 0.012
60668 England 2016/17 B B 13712 UA Blood 0.064 0.006 0.004 0.004
60670 England 2017/18 B B 213 ST-213 complex Blood 0.032 0.032 0.004 0.003
60673 England 2016/17 B B 3754 ST-41/44 complex Blood 0.19 0.023 0.004 0.004
60677 England 2017/18 B B 2314 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
60678 England 2016/17 B B 8597 UA CSF 0.38 0.032 0.004 0.004
60679 England 2016/17 B B 1157 ST-1157 complex Blood 0.032 <0.002 0.002 0.003
60683 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
60684 England 2017/18 B B 7152 ST-1572 complex Blood 0.19 0.004 0.003 0.004
60687 England 2017/18 B B 33 ST-32 complex Blood 0.047 0.006 0.004 0.002
60688 Northern Ireland 2017/18 B B 13713 ST-269 complex Blood 0.047 0.032 0.003 0.003
60689 Wales 2017/18 W W 11 ST-11 complex Blood 0.19 0.047 0.006 0.012
60690 England 2016/17 B B 41 ST-41/44 complex Blood 0.064 0.008 0.004 0.003
60693 England 2017/18 W W 10033 UA Blood 0.064 0.032 0.004 0.008
60695 England 2016/17 Y Y 3582 ST-23 complex Blood 0.047 0.012 0.008 0.003
60697 England 2017/18 B B 275 ST-269 complex Blood 0.064 0.006 0.004 0.003
60698 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
60702 England 2017/18 B B 213 ST-213 complex Blood 0.032 0.032 0.004 0.003
60703 England 2017/18 B B 6607 ST-213 complex Blood 0.19 0.006 0.004 0.003
60705 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.003
60711 England 2017/18 Y Y 3582 ST-23 complex Blood 0.094 0.008 0.004 0.008
60712 Wales 2017/18 B B 1161 ST-269 complex Blood 0.19 0.012 0.004 0.004
60713 England 2016/17 W W 1286 ST-22 complex Blood 0.094 0.016 0.004 0.004
60715 Northern Ireland 2017/18 Y Y 1655 ST-23 complex Blood 0.016 0.003 0.003 <0.002
60716 England 2017/18 B B 9200 ST-41/44 complex Blood 0.094 0.006 0.002 0.004
60721 England 2017/18 Y Y 1466 ST-174 complex Blood 0.094 0.008 0.003 0.006
60725 England 2016/17 B B 839 ST-41/44 complex Blood 0.023 0.016 0.004 0.002
60732 England 2017/18 Y Y 1655 ST-23 complex Blood 0.19 0.004 0.004 0.006
60733 England 2017/18 B B 41 ST-41/44 complex Blood 0.032 0.032 0.004 0.002
60734 England 2017/18 B B 41 ST-41/44 complex Blood 0.032 0.003 0.004 0.002
60735 England 2016/17 C C 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
60737 England 2017/18 B B 162 ST-162 complex Blood 0.19 0.012 0.004 0.004
60738 England 2017/18 B B 213 ST-213 complex Blood 0.38 0.008 0.004 0.008
60739 England 2017/18 B B 41 ST-41/44 complex Blood 0.032 0.003 0.003 0.002
60740 England 2016/17 B B 7670 ST-41/44 complex Blood 0.19 0.023 0.004 0.004
60743 England 2017/18 B B 1214 ST-269 complex Blood 0.032 0.012 0.004 0.008
60744 England 2017/18 B B 11487 ST-41/44 complex CSF 0.047 0.006 0.004 0.003
60747 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.004 0.004
60748 England 2016/17 B B 213 ST-213 complex Blood 0.38 0.047 0.004 0.008
60749 England 2017/18 B B 136 ST-41/44 complex Blood 0.25 0.016 0.003 0.006
60751 England 2016/17 B B 4033 ST-41/44 complex Blood 0.125 0.004 0.004 0.003
60752 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.003 0.003
60755 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.016 0.004 0.004
60757 England 2016/17 B B 41 ST-41/44 complex Blood 0.032 0.008 0.008 0.004
60758 England 2017/18 B B 3754 ST-41/44 complex Blood 0.047 0.023 0.004 0.004
60761 Northern Ireland 2017/18 B B 10550 ST-35 complex Blood 0.38 0.008 0.004 0.012
60764 England 2017/18 C C 11 ST-11 complex Joint 0.064 0.023 0.006 0.004
60766 England 2016/17 B B 162 ST-162 complex Blood 0.19 0.012 0.004 0.006
60767 England 2017/18 B B 13714 ST-41/44 complex CSF 0.125 0.006 0.004 0.004
60768 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.004 0.003
60771 England 2017/18 B B 33 ST-32 complex Blood 0.047 0.032 0.004 0.004
60772 England 2016/17 B B 13715 UA Blood 0.064 0.003 0.004 0.004
60774 England 2017/18 B B 4531 ST-213 complex Blood 0.19 0.023 0.003 0.004
60775 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
60777 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.004 0.004
60779 England 2017/18 B B 41 ST-41/44 complex Blood 0.25 0.012 0.004 0.004
60780 England 2017/18 W W 12116 ST-22 complex Blood 0.016 0.004 0.004 0.002
60781 England 2017/18 B B 340 ST-41/44 complex Blood 0.047 0.094 0.008 0.003
60782 England 2017/18 B B 213 ST-213 complex Blood 0.047 0.032 0.004 0.004
60783 England 2016/17 B B 13716 ST-41/44 complex Blood 0.125 0.003 0.004 0.004
60785 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
60787 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.012 0.004 0.004
60788 England 2016/17 B B 41 ST-41/44 complex Blood 0.125 0.047 0.004 0.003
60789 England 2017/18 B B 13717 UA Blood 0.25 0.006 0.003 0.004
60793 England 2017/18 B B 2314 ST-41/44 complex Blood 0.064 0.004 0.004 0.003
60798 England 2016/17 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.004 0.003
60799 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.004
60804 Wales 2016/17 B B 3893 ST-41/44 complex CSF 0.125 0.023 0.004 0.004
60807 England 2017/18 B B 213 ST-213 complex Blood 0.25 0.008 0.004 0.004
60809 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.003
60810 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
60811 England 2016/17 B B 8750 ST-213 complex Blood 0.19 0.032 0.004 0.008




60814 England 2017/18 B B 13718 ST-162 complex Blood 0.25 0.016 0.004 0.006
60815 England 2016/17 B B 1161 ST-269 complex Blood 0.19 0.008 0.004 0.003
60816 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.032 0.004 0.004
60817 England 2017/18 C C 13719 UA Blood 0.25 0.064 0.004 0.004
60818 England 2017/18 B B 33 ST-32 complex Blood 0.064 0.032 0.004 0.004
60819 Wales 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
60820 England 2017/18 B B 18 ST-18 complex Blood 0.047 0.016 0.004 0.006
60821 England 2017/18 W W 2477 ST-60 complex Blood 0.047 0.002 0.003 <0.002
60822 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.016 0.004 0.003
60823 England 2017/18 B B 1159 UA Blood 0.125 0.004 0.004 0.004
60824 England 2017/18 B B 213 ST-213 complex Blood 0.023 0.003 0.003 0.003
60828 Wales 2017/18 C C 11 ST-11 complex Blood 0.032 0.023 0.008 0.003
60829 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.004
60831 England 2017/18 B B 485 ST-41/44 complex Blood 0.125 0.016 0.008 0.008
60834 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
60835 England 2016/17 B B 213 ST-213 complex Blood 0.032 0.032 0.004 0.006
60839 England 2017/18 B B 8988 UA Blood 0.25 0.012 0.006 0.006
60840 England 2017/18 NG C 278 ST-35 complex Blood 0.19 0.012 0.004 0.003
60843 England 2017/18 B B 154 ST-41/44 complex Blood 0.125 0.004 0.004 0.004
60845 England 2017/18 C C 11 ST-11 complex Blood 0.25 0.012 0.004 0.008
60846 England 2017/18 B B 571 ST-41/44 complex CSF 0.064 0.006 0.004 0.003
60852 England 2017/18 B B 9193 ST-213 complex Blood 0.047 0.032 0.004 0.003
60856 England 2017/18 B B 1194 ST-41/44 complex Blood 0.047 0.004 0.004 0.002
60858 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
60859 Wales 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.003
60861 England 2017/18 B B 2477 ST-60 complex Blood 0.125 0.023 0.004 0.006
60862 England 2016/17 B B 1163 ST-269 complex Blood 0.094 0.003 0.004 0.006
60865 England 2017/18 Y Y 168 ST-167 complex Blood 0.023 0.003 0.003 <0.002
60866 England 2017/18 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.004 0.003
60871 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.002
60872 England 2016/17 C C 11 ST-11 complex Blood 0.047 0.016 0.004 0.006
60874 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.006
60875 England 2017/18 B B 41 ST-41/44 complex Blood 0.047 0.008 0.004 0.003
60882 England 2017/18 B B 485 ST-41/44 complex Blood 0.25 0.004 0.004 0.008
60885 England 2016/17 B B 41 ST-41/44 complex Blood 0.094 0.016 0.004 0.002
60887 England 2017/18 B B 7193 ST-213 complex Blood 0.19 0.012 0.008 0.008
60888 England 2017/18 B B 1831 UA Blood 0.064 0.032 0.004 0.004
60890 England 2016/17 B B 5151 UA Blood 0.094 0.094 0.004 0.006
60892 England 2017/18 NG CNL 13722 ST-41/44 complex Blood 0.023 0.006 0.004 0.002
60894 England 2017/18 B B 213 ST-213 complex Blood 0.25 0.012 0.004 0.003
60897 England 2017/18 B B 13723 ST-461 complex Blood 0.125 0.004 0.002 0.004
60899 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.023 0.004 0.003
60900 England 2016/17 B B 1097 ST-41/44 complex Blood 0.032 0.008 0.004 0.003
60901 England 2017/18 B B 13724 ST-60 complex Blood 0.25 0.006 0.004 0.008
60902 Northern Ireland 2016/17 Y Y 11280 ST-23 complex Blood 0.064 0.006 0.004 0.004
60909 England 2017/18 B B 1161 ST-269 complex Blood 0.125 0.006 0.008 0.004
60910 England 2017/18 B B 13725 ST-865 complex Blood 0.047 0.006 0.003 0.002
60911 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.003 0.002
60912 England 2016/17 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.004
60914 England 2017/18 C C 11 ST-11 complex Blood 0.125 0.016 0.008 0.008
60915 England 2017/18 B B 1163 ST-269 complex Blood 0.125 0.004 0.004 0.003
60916 England 2017/18 Y Y 23 ST-23 complex Blood 0.094 <0.002 0.003 0.004
60917 England 2016/17 B B 213 ST-213 complex Blood 0.047 0.023 0.004 0.004
60920 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.012 0.004 0.004
60924 England 2017/18 B B NK INCOMPLETE MLST Blood 0.064 0.064 0.004 0.003
60930 England 2016/17 B B 1097 ST-41/44 complex Blood 0.064 0.016 0.004 0.003
60932 Wales 2017/18 W W 11 ST-11 complex Blood 0.047 0.016 0.004 0.003
60933 England 2017/18 B B 9199 UA Blood 0.125 0.004 0.003 0.004
60935 England 2016/17 B B NK INCOMPLETE MLST Blood 0.19 0.006 0.004 0.003
60937 England 2017/18 C C 11 ST-11 complex Blood 0.125 0.008 0.008 0.004
60938 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.006 0.004 0.004
60940 England 2016/17 B B 485 ST-41/44 complex Blood 0.094 0.008 0.004 0.008
60942 England 2016/17 B B 46 ST-41/44 complex Blood 0.047 0.008 0.004 0.003
60945 England 2017/18 B B 1194 ST-41/44 complex Blood 0.047 0.006 0.004 0.002
60946 England 2017/18 NG B 1163 ST-269 complex Blood 0.19 0.004 0.002 <0.002
60950 England 2017/18 B B 13726 ST-269 complex Blood 0.047 0.006 0.004 0.002
60951 England 2017/18 W W 3651 ST-22 complex Blood 0.064 0.008 0.004 0.004
60952 England 2016/17 C C 11 ST-11 complex Blood 0.064 0.012 0.004 0.006
60955 England 2017/18 B B 269 ST-269 complex CSF 0.016 0.003 0.004 0.002
60959 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.012 0.004 0.004
60960 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.003
60962 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.008 0.004 0.004
60964 England 2017/18 Y Y 23 ST-23 complex Blood 0.38 0.008 0.003 0.012
60968 England 2017/18 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.003 0.002
60969 England 2017/18 Y Y 12176 ST-23 complex Blood 0.064 0.008 0.004 0.003
60970 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.004
60972 England 2017/18 B B 275 ST-269 complex Blood 0.047 0.094 0.006 0.004
60973 England 2017/18 B B 41 ST-41/44 complex Blood 0.047 0.012 0.004 0.003
60974 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.008 0.006 0.004
60975 England 2016/17 B B 1159 UA Blood 0.047 0.004 0.004 0.004
60977 England 2017/18 Y Y 11280 ST-23 complex Blood 0.064 0.006 0.004 0.006
60978 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
60979 England 2017/18 B B 13727 ST-41/44 complex Blood 0.25 0.006 0.004 0.004
60980 England 2016/17 B B 2362 ST-41/44 complex Blood 0.19 0.008 0.008 0.006




60982 England 2016/17 B B 213 ST-213 complex Blood 0.064 0.016 0.004 0.006
60983 Northern Ireland 2016/17 C C 11 ST-11 complex Blood 0.047 0.023 0.004 0.002
60985 England 2017/18 Y Y 23 ST-23 complex Blood 0.064 0.004 0.004 0.004
60986 England 2017/18 Y Y 3582 ST-23 complex Blood 0.094 0.047 0.003 0.006
60988 England 2016/17 W W 2977 ST-174 complex Blood 0.125 0.016 0.004 0.008
60989 Wales 2017/18 B B 41 ST-41/44 complex Blood 0.125 0.003 0.004 0.012
60991 England 2017/18 B B 2314 ST-41/44 complex Blood 0.047 0.006 0.003 0.003
60992 Wales 2016/17 Y Y 23 ST-23 complex Blood 0.064 0.008 0.004 0.006
60993 England 2016/17 B B 269 ST-269 complex Blood 0.047 0.008 0.008 0.002
60995 England 2017/18 B B 13728 ST-269 complex Blood 0.25 0.008 0.004 0.006
60996 England 2017/18 B B 2314 ST-41/44 complex Blood 0.125 0.023 0.004 0.003
60999 England 2017/18 B B 749 ST-32 complex Blood 0.19 0.004 0.006 0.006
61001 England 2017/18 B B 1195 ST-269 complex Blood 0.094 0.008 0.004 0.004
61005 England 2016/17 B B 43 ST-41/44 complex Joint 0.064 0.012 0.004 0.004
61006 England 2017/18 C C 11 ST-11 complex Blood 0.047 0.016 0.004 0.003
61007 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
61009 England 2017/18 B B 2203 ST-41/44 complex Blood 0.064 0.012 0.004 0.003
61010 England 2016/17 B B 275 ST-269 complex Blood 0.023 0.008 0.004 <0.002
61012 Wales 2017/18 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.003
61013 England 2017/18 Y Y 1655 ST-23 complex Blood 0.094 0.016 0.004 0.008
61014 England 2017/18 B B 13730 ST-41/44 complex Blood 0.047 0.006 0.003 0.003
61015 England 2016/17 Y Y 1655 ST-23 complex Blood 0.064 0.016 0.004 0.004
61016 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.004
61017 England 2017/18 B B 43 ST-41/44 complex Blood 0.064 0.006 0.004 0.002
61018 England 2017/18 B B 9989 ST-32 complex Blood 0.19 0.016 0.004 0.006
61019 England 2017/18 B B 2380 ST-35 complex Blood 0.047 0.008 0.004 0.003
61021 England 2017/18 NG Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.003
61023 England 2017/18 C C 13731 ST-11 complex Blood 0.047 0.032 0.004 0.004
61024 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.008 0.006 0.003
61025 Wales 2017/18 B B 7460 ST-32 complex Blood 0.25 0.012 0.004 0.006
61026 England 2017/18 B B 749 ST-32 complex Blood 0.19 0.004 0.004 0.006
61027 England 2016/17 B B 154 ST-41/44 complex Blood 0.064 0.008 0.008 0.003
61028 England 2016/17 B B 213 ST-213 complex Blood 0.094 0.004 0.004 0.002
61029 England 2017/18 B B 41 ST-41/44 complex Blood 0.064 0.008 0.004 0.002
61030 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.004
61032 England 2016/17 C C 11 ST-11 complex Blood 0.094 0.016 0.008 0.008
61034 England 2017/18 B B 34 ST-32 complex Blood 0.19 0.012 0.004 0.004
61036 Wales 2017/18 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
61039 England 2017/18 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.004 0.004
61040 England 2017/18 B B 213 ST-213 complex Blood 0.064 0.023 0.004 0.003
61983 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
61984 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.016 0.006 0.003
61985 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
61986 England 2017/18 C C 13919 ST-11 complex Blood 0.047 0.008 0.004 0.004
61987 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.012 0.006 0.006
61988 England 2018/19 C C NK INCOMPLETE MLST Blood 0.047 0.023 0.003 0.004
61989 England 2018/19 C C 11 ST-11 complex Blood 0.047 0.023 0.008 0.003
61990 England 2018/19 C C 11 ST-11 complex Blood 0.094 0.023 0.006 0.004
63435 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.008 0.004 0.006
63436 England 2018/19 B B 2314 ST-41/44 complex Blood 0.19 0.004 0.004 0.003
63439 England 2017/18 B B 9775 ST-32 complex Blood 0.19 0.064 0.003 0.004
63440 England 2018/19 B B 485 ST-41/44 complex Blood 0.125 0.003 0.004 0.002
63442 England 2018/19 B B 213 ST-213 complex Blood 0.25 0.012 0.003 0.006
63445 England 2017/18 B B 35 ST-35 complex Blood 0.19 0.047 0.004 0.004
63446 England 2017/18 B B 4124 ST-269 complex Blood 0.125 0.003 0.003 0.004
63447 England 2018/19 B B 13441 ST-213 complex Blood 0.047 0.016 0.003 0.002
63451 England 2017/18 B B 15562 ST-213 complex Blood 0.047 0.012 0.004 0.003
63452 England 2017/18 B B 34 ST-32 complex Blood 0.19 0.047 0.004 0.004
63454 England 2017/18 B B 15560 ST-213 complex Blood 0.032 0.004 0.004 0.002
63455 England 2017/18 B B 1194 ST-41/44 complex Blood 0.047 0.016 0.004 0.003
63456 England 2017/18 B B 3635 ST-213 complex Blood Culture 0.064 0.016 0.003 0.003
63457 England 2018/19 B B 269 ST-269 complex Blood 0.047 0.004 0.004 <0.002
63458 England 2018/19 B B NK INCOMPLETE MLST Blood 0.047 0.006 0.004 0.002
63459 England 2018/19 B B 15563 ST-461 complex Blood 0.032 0.006 0.003 0.002
63460 England 2018/19 B B 41 ST-41/44 complex Blood 0.047 0.012 0.008 <0.002
63461 England 2018/19 B B 1194 ST-41/44 complex Blood 0.064 0.006 0.004 0.002
63468 England 2017/18 B B 213 ST-213 complex Blood 0.047 0.047 0.004 0.003
63469 England 2017/18 B B 1161 ST-269 complex Blood 0.19 0.006 0.002 0.003
63470 England 2018/19 B B 15531 ST-18 complex CSF 0.047 0.003 0.004 0.004
63473 England 2017/18 B B 8068 ST-282 complex Blood 0.047 0.016 0.003 0.002
63474 England 2018/19 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.002
63475 England 2018/19 B B 41 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
63476 England 2018/19 B B 9193 ST-213 complex Blood 0.047 0.016 0.004 0.002
63477 England 2018/19 B B 15542 ST-60 complex Blood 0.094 0.006 0.002 <0.002
63478 England 2018/19 B B 2314 ST-41/44 complex Blood 0.125 0.008 0.003 0.004
63479 England 2018/19 B B 1475 ST-41/44 complex Blood 0.064 0.012 0.004 0.003
63480 England 2018/19 B B 32 ST-32 complex Blood 0.047 0.094 0.008 0.002
63484 England 2017/18 B B 9180 ST-269 complex Blood 0.19 0.008 0.006 0.004
63485 England 2017/18 B B 1161 ST-269 complex Blood 0.094 0.047 0.004 0.004
63486 England 2017/18 B B 839 ST-41/44 complex Blood Culture 0.064 0.008 0.004 0.003
63487 England 2018/19 B B 1194 ST-41/44 complex Blood 0.047 0.003 0.004 <0.002
63488 England 2018/19 B B 213 ST-213 complex Blood 0.047 0.008 0.004 0.003
63491 England 2017/18 B B 2314 ST-41/44 complex Blood 0.094 0.012 0.003 0.002
63492 England 2018/19 B B 749 ST-32 complex Blood 0.125 0.006 0.002 0.006




63494 England 2018/19 B B 18 ST-18 complex Blood 0.25 0.012 0.003 0.008
63496 England 2018/19 B B 5682 ST-32 complex Blood 0.25 0.008 0.004 0.004
63497 England 2018/19 B B 213 ST-213 complex CSF 0.5 0.023 0.008 0.006
63498 England 2018/19 B B 46 ST-41/44 complex Blood 0.023 0.023 0.004 <0.002
63499 England 2018/19 B B 1157 ST-1157 complex Blood 0.125 0.004 0.004 0.003
63500 England 2018/19 B B 11306 UA Blood 0.064 0.047 0.006 0.002
63501 England 2018/19 B B 5682 ST-32 complex Blood 0.25 0.012 0.008 0.004
63503 England 2018/19 B B 41 ST-41/44 complex Blood 0.094 0.023 0.006 0.003
63504 England 2018/19 B B 1159 UA Blood Culture 0.25 0.006 0.004 0.004
63505 England 2018/19 B B 3478 ST-41/44 complex Blood 0.19 0.047 0.004 0.006
63506 England 2018/19 B B 485 ST-41/44 complex Blood 0.38 0.006 0.006 0.006
63507 England 2018/19 B B 15533 UA Blood 0.125 0.032 0.004 0.004
63508 England 2018/19 B B 213 ST-213 complex Blood 0.064 0.064 0.008 0.002
63509 England 2018/19 B B 1194 ST-41/44 complex Blood 0.064 0.006 0.006 <0.002
63510 England 2018/19 B B 485 ST-41/44 complex Blood 0.38 0.064 0.008 0.004
63511 England 2018/19 B B 485 ST-41/44 complex Blood 0.094 0.008 0.006 0.002
63512 England 2018/19 B B 162 ST-162 complex Blood 0.25 0.016 0.008 0.003
63513 England 2018/19 B B 485 ST-41/44 complex Blood 0.094 0.008 0.008 0.004
63515 England 2018/19 B B 11539 UA Blood 0.25 0.016 0.003 0.016
63516 England 2018/19 B B 14129 UA Blood 0.094 0.016 0.006 0.003
63517 England 2018/19 B B 7460 ST-32 complex Blood 0.25 0.125 0.004 0.006
63518 England 2018/19 B B 32 ST-32 complex Blood 0.047 0.006 0.004 0.003
63519 England 2018/19 B B 33 ST-32 complex Blood 0.047 0.006 0.004 0.002
63520 England 2018/19 B B 2288 ST-41/44 complex Blood 0.047 0.032 0.006 0.003
63521 England 2018/19 B B 7460 ST-32 complex Blood 0.38 0.008 0.004 0.006
63522 England 2018/19 B B 6765 ST-213 complex Blood 0.094 0.016 0.008 0.003
63523 England 2018/19 B B 15526 ST-41/44 complex Blood 0.38 0.094 0.006 0.004
63526 England 2018/19 B B 1774 ST-269 complex Blood 0.047 0.016 0.004 0.002
63527 England 2018/19 B B 40 ST-41/44 complex Blood 0.047 0.006 0.006 0.002
63528 England 2018/19 B B 15561 ST-269 complex Blood 0.064 0.006 0.004 0.002
63529 England 2018/19 B B 15534 UA Blood 0.064 0.012 0.004 0.002
63530 England 2018/19 B B 461 ST-461 complex Blood 0.25 0.016 0.008 0.006
63531 England 2018/19 B B 11755 ST-269 complex Blood 0.125 0.094 0.004 0.003
63532 England 2018/19 B B 1946 ST-461 complex Blood 0.5 0.064 0.008 0.008
63533 England 2018/19 B B 33 ST-32 complex Blood 0.064 0.094 0.006 0.003
63535 England 2018/19 C C 485 ST-41/44 complex Blood 0.125 0.006 0.004 0.003
63536 England 2018/19 C C 11 ST-11 complex Blood 0.19 0.012 0.003 0.006
63539 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.004 0.004 0.003
63540 England 2017/18 C C 11 ST-11 complex Blood 0.047 0.023 0.004 0.003
63542 England 2017/18 C C 11 ST-11 complex Blood 0.19 0.016 0.004 0.006
63543 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.008 0.006 0.004
63544 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.023 0.004 0.003
63545 England 2018/19 C C 5133 ST-103 complex Blood 0.016 0.006 0.004 <0.002
63546 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
63547 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.032 0.004 0.003
63548 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.012 0.004 0.004
63549 England 2018/19 C C 11 ST-11 complex Blood 0.094 0.012 0.006 0.004
63551 England 2018/19 C C 11 ST-11 complex Joint 0.38 0.094 0.006 0.023
63552 England 2018/19 C C 5133 ST-103 complex Blood 0.016 0.004 0.006 <0.002
63554 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.016 0.006 0.003
63555 England 2018/19 C C 11 ST-11 complex Blood Culture 0.047 0.016 0.008 0.003
63557 England 2018/19 C C 11 ST-11 complex Blood 0.094 0.032 0.008 0.004
63558 England 2018/19 C C 485 ST-41/44 complex Blood 0.25 0.012 0.004 0.004
63559 England 2018/19 NG B 14117 UA Blood 0.125 0.023 0.06 0.004
63576 England 2017/18 W W 9316 UA Blood 0.125 0.023 0.006 <0.002
63613 England 2018/19 W NK 3698 UA Blood 0.125 0.016 0.006 0.006
63635 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.004
63636 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.003 0.004
63638 England 2017/18 Y Y 23 ST-23 complex Blood 0.064 0.004 0.004 0.003
63639 England 2017/18 Y Y 15538 UA Blood 0.38 0.012 0.004 0.008
63640 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.003
63641 England 2018/19 Y Y 1655 ST-23 complex Blood Culture 0.047 0.006 0.003 0.002
63642 England 2017/18 Y Y 1655 ST-23 complex CSF 0.047 0.003 0.003 0.004
63643 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.003 0.002
63645 England 2018/19 Y Y 1466 ST-174 complex Blood 0.125 0.064 0.002 0.004
63646 England 2017/18 Y Y 23 ST-23 complex Blood 0.047 0.003 0.006 0.004
63647 England 2017/18 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.004 0.003
63648 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.003
63649 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.004
63650 England 2017/18 Y Y 1655 ST-23 complex Blood 0.032 0.006 0.004 0.002
63651 England 2017/18 Y NK 15559 ST-23 complex Blood 0.047 0.006 0.002 0.002
63653 England 2018/19 Y Y 23 ST-23 complex Blood 0.064 0.004 0.004 0.004
63654 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.002
63655 England 2017/18 Y Y 1655 ST-23 complex Joint 0.094 0.016 0.004 0.008
63656 England 2017/18 Y NK 23 ST-23 complex Blood 0.094 0.004 0.004 0.003
63657 England 2017/18 Y Y 23 ST-23 complex Blood 0.064 0.006 0.003 0.003
63659 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.002
63660 England 2018/19 Y NK 1655 ST-23 complex Blood 0.064 0.002 0.004 0.003
63661 England 2018/19 Y NK 114 ST-22 complex Blood 0.38 0.023 0.006 0.008
63662 England 2018/19 Y Y 3582 ST-23 complex Blood 0.125 0.008 0.004 0.006
63663 England 2018/19 Y Y 23 ST-23 complex Blood 0.064 0.008 0.004 0.004
63664 England 2018/19 Y Y 1655 ST-23 complex Blood 0.094 0.002 0.004 0.003
63666 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.003
63667 England 2018/19 Y NK 3582 ST-23 complex Blood 0.125 0.047 0.004 0.004




63670 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.012 0.004 0.003
70987 England 2017/18 B B 275 ST-269 complex Blood 0.38 0.004 0.004 0.004
70988 England 2017/18 B B 5151 UA Blood 0.19 0.008 0.004 0.006
70989 England 2017/18 B B 639 ST-32 complex Blood 0.094 0.016 0.004 0.004
70991 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.003
70992 Northern Ireland 2017/18 B B 269 ST-269 complex Blood Culture 0.064 0.016 0.004 0.003
70993 England 2017/18 B B 41 ST-41/44 complex Blood 0.064 0.006 0.004 0.002
70994 England 2017/18 B B 12345 ST-32 complex Blood 0.25 0.008 0.004 0.004
70999 England 2017/18 B B 3117 ST-213 complex Blood Culture 0.19 0.012 0.003 0.004
71001 Wales 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
71004 England 2017/18 B B 8988 UA Blood 0.19 0.016 0.004 0.004
71005 England 2017/18 B B 275 ST-269 complex Blood 0.094 0.012 0.004 0.003
71007 England 2017/18 B B 41 ST-41/44 complex Blood 0.064 0.016 0.003 0.002
71008 Northern Ireland 2017/18 C C 11 ST-11 complex Blood 0.064 0.016 0.006 0.006
71010 England 2017/18 B B 136 ST-41/44 complex Blood 0.064 0.002 0.002 0.002
71011 Wales 2017/18 C C 5238 UA Blood 0.125 0.008 0.004 0.004
71013 England 2017/18 Y Y 23 ST-23 complex Blood 0.064 0.004 0.004 0.006
71014 England 2017/18 B B 7460 ST-32 complex Blood 0.38 0.006 0.003 0.008
71015 England 2017/18 B B 1194 ST-41/44 complex Blood Culture 0.047 0.032 0.004 0.002
71016 England 2017/18 B B 213 ST-213 complex Blood 0.19 0.006 0.004 0.003
71017 England 2017/18 NG C 467 ST-269 complex CSF 0.125 0.004 0.004 0.004
71018 Northern Ireland 2017/18 B B 1161 ST-269 complex Blood 0.064 0.003 0.003 <0.002
71019 Wales 2017/18 W W 11 ST-11 complex Blood 0.032 0.047 0.004 0.002
71020 England 2017/18 B B 1721 ST-213 complex Blood 0.064 0.012 0.004 0.004
71021 England 2017/18 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.004 0.004
71022 England 2017/18 C C 278 ST-35 complex Blood 0.125 0.002 0.004 0.003
71023 England 2017/18 Y Y 12176 ST-23 complex Blood 0.064 0.012 0.004 0.006
71024 England 2017/18 B B 1161 ST-269 complex Blood Culture 0.094 0.008 0.004 0.003
71025 England 2017/18 B B 1161 ST-269 complex Blood Culture 0.094 0.012 0.004 0.004
71026 England 2017/18 Y Y 3582 ST-23 complex Blood Culture 0.125 0.016 0.004 0.006
71027 England 2017/18 B B 4224 ST-213 complex Blood 0.064 0.016 0.004 0.004
71028 England 2017/18 B B 269 ST-269 complex Blood 0.047 0.006 0.006 0.003
71029 England 2017/18 C C 11 ST-11 complex Blood 0.25 0.012 0.006 0.006
71034 England 2017/18 X X 5063 UA Blood 0.25 0.125 0.004 0.004
71035 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.004
71036 Wales 2017/18 C C 11 ST-11 complex Blood 0.047 0.023 0.004 0.003
71038 England 2017/18 C C 11 ST-11 complex Blood 0.19 0.094 0.003 0.008
71039 England 2017/18 B B 485 ST-41/44 complex Blood 0.25 0.006 0.004 0.004
71040 England 2017/18 B B 9989 ST-32 complex Blood 0.19 0.008 0.003 0.006
71041 England 2017/18 B B 1194 ST-41/44 complex Blood 0.047 0.004 0.004 0.002
71042 England 2017/18 B B 34 ST-32 complex Blood Culture 0.19 0.016 0.003 0.008
71044 England 2017/18 B B 485 ST-41/44 complex Blood 0.19 0.047 0.004 0.004
71047 Northern Ireland 2017/18 C C 11 ST-11 complex Blood 0.047 0.006 0.004 0.006
71048 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.094 0.004 0.006
71049 England 2017/18 C C 11 ST-11 complex Blood 0.023 0.002 0.003 0.002
71050 England 2017/18 B B 41 ST-41/44 complex Blood 0.125 0.008 0.002 0.004
71053 England 2018/19 B B 1161 ST-269 complex Blood 0.064 0.006 0.004 0.004
71055 England 2018/19 B B 485 ST-41/44 complex Blood 0.125 0.004 0.006 0.004
71056 England 2018/19 B B 213 ST-213 complex Blood 0.047 0.008 0.004 0.003
71057 Northern Ireland 2018/19 B B 1161 ST-269 complex Blood 0.19 0.008 0.006 0.004
71058 England 2018/19 B B 2899 ST-213 complex Blood 0.094 0.016 0.006 0.006
71059 England 2018/19 B B 15212 ST-269 complex Blood 0.032 0.032 0.004 0.002
71060 England 2018/19 C C 11 ST-11 complex Blood 0.047 0.047 0.008 0.003
71063 England 2018/19 B B 1214 ST-269 complex Blood 0.047 0.008 0.006 0.002
71065 England 2018/19 Y Y 23 ST-23 complex Blood 0.047 0.008 0.004 0.004
71066 England 2018/19 W W 9316 UA Blood Culture 0.125 0.008 0.004 0.003
71067 England 2018/19 B B 3496 ST-213 complex Blood 0.125 0.006 0.004 0.002
71068 England 2018/19 B B 3737 ST-1157 complex Blood 0.125 0.008 0.004 0.003
71070 England 2018/19 B B 41 ST-41/44 complex Blood 0.19 0.012 0.006 0.004
71072 England 2018/19 B B 485 ST-41/44 complex Blood 0.094 0.006 0.006 0.006
71073 England 2018/19 B B 7460 ST-32 complex Blood 0.38 0.012 0.006 0.003
71074 England 2018/19 B B 1097 ST-41/44 complex Blood 0.047 0.006 0.003 0.003
71076 England 2018/19 B B 41 ST-41/44 complex Blood 0.19 0.016 0.006 0.004
71077 England 2018/19 C C 11 ST-11 complex Blood 0.125 0.016 0.006 0.004
71078 England 2018/19 B B 41 ST-41/44 complex Blood 0.064 0.047 0.004 0.002
71079 England 2018/19 B B 15119 UA Blood 0.047 0.012 0.008 0.002
71081 Wales 2018/19 B B 485 ST-41/44 complex CSF 0.25 0.023 0.008 0.003
71082 England 2018/19 B B 12345 ST-32 complex Blood 0.25 0.006 0.006 0.004
71083 England 2017/18 B B 12173 ST-41/44 complex Blood 0.19 0.008 0.004 0.004
71084 England 2017/18 B B 6607 ST-213 complex Blood 0.19 0.008 0.004 0.004
71085 England 2017/18 C C 11 ST-11 complex Blood 0.25 0.016 0.004 0.006
71086 Wales 2017/18 B B 15205 ST-213 complex Blood 0.064 0.012 0.004 0.003
71087 Wales 2017/18 B B 1946 ST-461 complex Blood 0.25 0.023 0.003 0.006
71090 England 2018/19 Y Y 15206 ST-23 complex Blood 0.094 0.004 0.004 0.003
71091 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.003 0.004 0.002
71092 England 2018/19 B B 1976 UA Blood 0.047 0.016 0.006 0.004
71093 England 2018/19 Y Y 1655 ST-23 complex Blood 0.094 0.006 0.006 0.006
71094 Wales 2018/19 W W 11 ST-11 complex Blood 0.047 0.004 0.006 0.002
71095 England 2018/19 C C 11 ST-11 complex Blood 0.094 0.004 0.008 0.006
71096 England 2018/19 C C 11 ST-11 complex Blood 0.064 0.012 0.006 0.004
71097 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.006 0.003
71098 England 2018/19 B B 749 ST-32 complex Blood 0.19 0.023 0.008 0.006
71100 England 2018/19 B B 15213 ST-41/44 complex Blood 0.064 0.008 0.004 0.004
71101 England 2018/19 Y Y 23 ST-23 complex Blood 0.25 0.006 0.004 0.004




71104 England 2018/19 B B 213 ST-213 complex CSF 0.19 0.006 0.004 0.006
71105 England 2018/19 B B 275 ST-269 complex CSF 0.25 0.006 0.006 0.003
71108 England 2018/19 NG CNL 1103 ST-41/44 complex Blood 0.125 0.032 0.004 0.002
71109 England 2018/19 B B 213 ST-213 complex Blood 0.064 0.047 0.004 0.003
71110 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.006 0.004 0.003
71111 England 2018/19 B B 41 ST-41/44 complex Blood 0.125 0.004 0.006 0.004
71112 England 2018/19 NG B 213 ST-213 complex Blood 0.25 0.012 0.006 0.008
71114 England 2018/19 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.002 0.002
71116 England 2018/19 NG X 5063 UA Blood 0.25 0.023 0.006 0.012
71117 England 2018/19 W W 8172 ST-865 complex Blood 0.25 0.006 0.004 0.004
71118 England 2018/19 B B 9293 ST-162 complex Blood Culture 0.125 0.016 0.004 0.004
71119 England 2018/19 B B 33 ST-32 complex Blood 0.25 0.004 0.006 0.004
71120 England 2018/19 B B 154 ST-41/44 complex Blood 0.125 0.004 0.004 0.003
71122 England 2018/19 B B 41 ST-41/44 complex Blood 0.25 0.006 0.003 0.006
71123 England 2018/19 B B 9193 ST-213 complex Blood 0.094 0.004 0.004 0.008
71125 Wales 2018/19 C C 11 ST-11 complex Blood 0.064 0.004 0.006 0.003
71127 England 2018/19 B B 162 ST-162 complex Blood 0.064 0.006 0.004 0.003
71128 England 2018/19 C C 11 ST-11 complex Blood 0.38 0.032 0.004 0.008
71129 England 2018/19 B B 1161 ST-269 complex Blood 0.25 0.008 0.004 0.004
71130 England 2018/19 NG B 865 ST-865 complex Blood 0.064 0.016 0.002 0.006
71131 England 2018/19 C C 15207 ST-11 complex Blood 0.125 0.016 0.004 0.006
71132 Northern Ireland 2018/19 B B 2314 ST-41/44 complex Blood 0.125 0.032 0.003 0.004
71133 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.004 0.004 0.004
71134 England 2018/19 Y Y 1657 ST-23 complex Blood 0.094 0.003 0.004 0.004
71138 England 2018/19 B B 213 ST-213 complex Blood 0.125 0.004 0.003 0.004
71139 England 2018/19 B B 213 ST-213 complex Blood 0.064 0.012 0.004 0.004
71140 England 2018/19 B B 1161 ST-269 complex Blood 0.094 0.004 0.004 0.004
71141 England 2018/19 B B 6349 ST-41/44 complex Blood 0.25 0.064 0.004 0.008
71143 England 2018/19 B B 749 ST-32 complex Blood 0.38 0.008 0.006 0.012
71144 Wales 2018/19 Y Y 1655 ST-23 complex Blood 0.125 0.004 0.003 0.003
71146 England 2018/19 C C 12227 ST-11 complex Blood 0.064 0.008 0.004 0.004
71147 England 2018/19 B B 482 ST-41/44 complex Blood 0.125 0.032 0.006 0.004
71149 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.004
71150 England 2018/19 W W 3859 ST-22 complex Blood 0.125 0.008 0.004 0.003
71154 England 2018/19 B B 275 ST-269 complex Blood 0.047 0.006 0.006 0.004
71155 England 2018/19 B B 11 ST-11 complex Blood 0.19 0.012 0.004 0.008
71156 England 2018/19 Y Y 23 ST-23 complex Blood 0.047 0.002 0.003 0.003
71157 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.003 0.004 0.003
71158 England 2018/19 Y Y 1655 ST-23 complex Blood 0.25 0.003 0.004 0.006
71161 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.006 0.003
71163 England 2018/19 B B 7670 ST-41/44 complex Blood 0.19 0.002 0.004 0.004
71164 Wales 2018/19 B B 15208 ST-269 complex Blood 0.047 0.004 0.006 0.002
71165 England 2018/19 B B 414 ST-41/44 complex Blood 0.125 0.003 0.006 0.006
71166 England 2018/19 C C 11 ST-11 complex Blood 0.094 0.016 0.008 0.006
71167 England 2018/19 B B 162 ST-162 complex Blood 0.19 0.016 0.006 0.004
71168 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.003
71169 England 2018/19 B B 2314 ST-41/44 complex Blood 0.19 0.004 0.004 0.004
71171 England 2018/19 B B 11221 ST-213 complex Blood 0.19 0.016 0.004 0.004
71172 England 2018/19 B B 23 ST-23 complex Blood 0.094 0.004 0.004 0.006
71173 England 2018/19 B B 1946 ST-461 complex Blood 0.5 0.016 0.004 0.006
71174 England 2018/19 B B 35 ST-35 complex Blood 0.38 0.004 0.004 0.016
71175 England 2018/19 B B 14117 UA Blood 0.125 0.016 0.004 0.003
71176 England 2018/19 B B 14117 UA Blood 0.125 0.032 0.006 0.004
71177 England 2018/19 B B 41 ST-41/44 complex Blood 0.19 0.016 0.004 0.002
71178 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.032 0.004 0.003
85528 Northern Ireland 2017/18 B B 4051 UA Blood 0.064 0.032 0.003 0.003
85530 England 2017/18 C C 485 ST-41/44 complex Blood 0.19 0.008 0.004 0.004
85531 England 2017/18 B B 41 ST-41/44 complex Blood 0.064 0.008 0.004 0.002
85533 Northern Ireland 2017/18 C C 11 ST-11 complex CSF 0.094 0.016 0.006 0.006
85536 England 2017/18 W W 184 ST-22 complex Blood 0.023 0.002 0.004 0.002
85537 England 2017/18 B B 275 ST-269 complex CSF 0.094 0.006 0.004 0.003
85539 Wales 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.006 0.003
85541 England 2017/18 B B 485 ST-41/44 complex Blood 0.25 0.012 0.004 0.004
85542 England 2017/18 B B 340 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
85544 England 2017/18 Y Y 14356 ST-23 complex Blood 0.064 0.004 0.004 0.003
85545 Wales 2017/18 W W 11 ST-11 complex Blood 0.047 0.023 0.004 0.003
85547 England 2017/18 C C 11 ST-11 complex CSF 0.094 0.008 0.006 0.008
85548 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 <0.002 0.003
85549 England 2017/18 B B 485 ST-41/44 complex Blood 0.125 0.008 0.004 0.004
85550 England 2017/18 B B 162 ST-162 complex Blood 0.047 0.008 0.004 0.003
85551 England 2017/18 B B 2738 ST-269 complex Blood 0.064 0.012 0.004 0.008
85553 England 2017/18 NG B 485 ST-41/44 complex CSF 0.19 0.008 0.004 0.006
85554 England 2017/18 B B 14357 UA Blood 0.064 0.012 0.004 0.002
85555 England 2017/18 B B 14358 ST-269 complex Blood 0.047 0.023 0.03 0.002
85558 England 2017/18 B B 9193 ST-213 complex Blood 0.064 0.032 0.006 0.004
85559 England 2017/18 B B 14359 ST-865 complex Blood 0.25 0.006 0.006 0.012
85560 England 2017/18 B B 3526 ST-41/44 complex Blood 0.125 0.004 0.008 0.004
85561 England 2017/18 B B 1617 ST-22 complex Blood 0.047 0.003 0.004 0.004
85564 England 2017/18 B B 14360 ST-35 complex Blood 0.094 0.125 0.003 0.004
85565 England 2017/18 B B 461 ST-461 complex Blood 0.19 0.006 0.003 0.006
85566 England 2017/18 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.003 0.004
85567 England 2017/18 B B 354 ST-269 complex Blood 0.094 0.012 0.006 0.006
85568 England 2017/18 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.002 0.002
85570 England 2017/18 B B 14361 ST-461 complex CSF 0.047 0.006 0.004 0.003




85575 England 2017/18 C C 11 ST-11 complex Blood 0.064 0.032 0.004 0.004
85576 England 2017/18 W W 114 ST-22 complex Blood 0.064 0.012 0.004 0.004
85577 England 2017/18 B B 1354 ST-269 complex Blood 0.032 0.006 0.004 0.002
85578 England 2017/18 B B 1194 ST-41/44 complex Blood 0.047 0.006 0.004 0.003
85579 England 2017/18 B B 3496 ST-213 complex Blood 0.125 0.006 0.003 0.003
85580 England 2017/18 B B 485 ST-41/44 complex Blood 0.25 0.008 0.004 0.004
85582 England 2017/18 B B 485 ST-41/44 complex Blood 0.125 0.008 0.004 0.004
85583 England 2017/18 B B 14362 ST-461 complex Blood 0.19 0.012 0.002 0.006
85584 England 2017/18 B B 41 ST-41/44 complex Blood 0.19 0.008 0.002 0.003
85585 England 2017/18 Y Y 1466 ST-174 complex Blood 0.094 0.064 0.002 0.004
85587 England 2017/18 B B 275 ST-269 complex Blood 0.125 0.004 0.004 0.006
85588 England 2017/18 B B 162 ST-162 complex Blood 0.064 0.012 0.004 0.003
85589 England 2017/18 B B 41 ST-41/44 complex Blood 0.047 0.012 0.004 0.002
85591 England 2017/18 B B 14363 UA Blood 0.25 0.004 0.004 0.004
85592 Northern Ireland 2017/18 B B 162 ST-162 complex Blood 0.047 0.006 0.003 0.002
85593 England 2017/18 B B 6798 UA Blood 0.064 0.012 0.004 0.003
85594 England 2017/18 B B 1161 ST-269 complex Blood 0.19 0.012 0.003 0.003
85595 England 2017/18 B B 11621 UA Blood 0.032 0.006 0.003 <0.002
85596 England 2017/18 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.003 0.003
85597 England 2017/18 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.002 0.002
85598 England 2018/19 B B 4713 UA Blood 0.064 0.006 0.004 0.006
85600 England 2018/19 Y Y 23 ST-23 complex Blood 0.094 0.002 0.002 0.004
85601 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.006 0.004 0.003
85602 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.006 0.004 0.003
85603 England 2018/19 B B 1161 ST-269 complex Blood 0.5 0.006 0.003 0.004
85604 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.004 0.003 0.004
85605 England 2018/19 B B 14364 ST-41/44 complex Blood 0.125 0.006 0.004 0.003
85606 England 2018/19 B B 4237 ST-865 complex Blood 0.25 0.003 0.004 0.002
85623 England 2011/12 B B 41 ST-41/44 complex Blood 0.016 0.003 0.003 <0.002
89259 England 2018/19 B B 230 ST-32 complex Blood 0.064 0.023 0.18 0.003
94200 England 2017/18 B B 282 ST-282 complex Blood 0.125 0.032 0.006 0.008
94243 England 2017/18 B B 1161 ST-269 complex Blood 0.19 0.006 0.004 0.004
94245 England 2017/18 B B 12656 ST-41/44 complex Blood 0.19 0.006 0.003 0.004
94261 England 2017/18 B B 13095 ST-32 complex Blood 0.38 0.008 0.004 0.004
94263 England 2017/18 B B 22 ST-22 complex Blood 0.19 0.004 0.003 0.004
94265 England 2017/18 Y Y 1655 ST-23 complex Blood 0.032 0.004 0.003 0.002
94266 England 2018/19 B B 1157 ST-1157 complex Blood 0.047 0.006 0.003 0.003
94267 England 2018/19 B B 2506 ST-32 complex Blood 0.25 0.004 0.004 0.004
94268 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.004 0.004 0.002
94270 England 2018/19 B B 269 ST-269 complex Blood 0.125 0.006 0.004 <0.002
94275 England 2018/19 B B 15214 ST-41/44 complex Blood 0.047 0.003 0.004 <0.002
94277 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.002
94278 England 2018/19 B B 639 ST-32 complex Blood 0.047 0.047 0.004 0.002
94280 England 2018/19 Y Y 1655 ST-23 complex Blood 0.023 0.003 0.004 0.002
94281 Wales 2018/19 B B 5151 UA Blood 0.19 0.006 0.004 0.004
94283 England 2018/19 Y Y 23 ST-23 complex Blood 0.064 0.006 0.004 0.003
94284 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.008 0.004 0.003
94287 England 2018/19 Y Y 10730 ST-167 complex Blood 0.064 0.003 0.004 0.004
94288 Wales 2018/19 B B 162 ST-162 complex CSF 0.064 0.006 0.006 0.003
94290 England 2018/19 B B 1992 ST-41/44 complex Blood 0.19 0.023 0.004 0.003
94291 England 2018/19 B B 15209 UA Blood 0.25 0.012 0.004 0.006
94292 England 2018/19 C C 11 ST-11 complex Blood Culture 0.125 0.125 0.004 0.006
94293 England 2018/19 B B 485 ST-41/44 complex Blood Culture 0.19 0.006 0.004 0.004
94294 England 2018/19 B B 3122 ST-213 complex Blood 0.094 0.012 0.004 0.003
94296 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.006 0.004 0.003
94297 England 2018/19 B B 15215 UA Blood 0.38 0.047 0.004 0.008
94298 Wales 2018/19 W W 11 ST-11 complex Blood 0.064 0.003 0.003 0.003
94299 England 2018/19 B B 13441 ST-213 complex Blood 0.032 0.016 0.003 <0.002
94300 England 2018/19 B B 213 ST-213 complex Blood 0.016 0.004 0.003 <0.002
94301 England 2018/19 B B 1163 ST-269 complex Blood 0.064 0.004 0.003 0.003
94302 England 2018/19 Y Y 1655 ST-23 complex Blood 0.125 0.002 0.004 0.004
94303 England 2018/19 B B 5151 UA Blood 0.125 0.004 0.004 0.004
94305 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.003
94306 England 2018/19 C C 11 ST-11 complex Blood Culture 0.047 0.047 0.006 0.003
94307 England 2018/19 B B 1161 ST-269 complex Blood Culture 0.19 0.004 0.004 0.002
94393 England 2018/19 C C 15210 ST-41/44 complex Blood Culture 0.023 0.008 0.006 0.002
94395 England 2018/19 Y Y 11866 ST-23 complex Blood 0.047 0.004 0.004 0.004
94398 England 2018/19 Y Y 23 ST-23 complex Blood 0.125 0.004 0.004 0.008
94399 England 2018/19 B B 33 ST-32 complex Blood 0.064 0.004 0.004 0.002
94400 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.004 0.004 0.004
94401 England 2018/19 B B 9293 ST-162 complex Blood 0.125 0.012 0.008 0.004
94402 England 2018/19 B B 4713 UA Blood 0.064 0.006 0.008 0.006
94403 England 2018/19 Y Y 6463 ST-23 complex Blood 0.094 0.012 0.008 0.004
94404 England 2018/19 C C 485 ST-41/44 complex Blood 0.25 0.008 0.008 0.006
94406 England 2018/19 Y Y 1655 ST-23 complex Blood 0.094 0.006 0.004 0.003
94407 England 2018/19 B B 15216 UA Blood 0.064 0.003 0.004 0.003
94408 England 2018/19 Y Y 12176 ST-23 complex Blood 0.064 0.003 0.004 0.004
94409 England 2018/19 Y Y 23 ST-23 complex Joint 0.38 0.003 0.004 0.004
94410 England 2018/19 B B 15211 UA Blood 0.032 0.016 0.003 <0.002
94411 England 2018/19 B B 269 ST-269 complex Blood 0.047 0.004 0.006 0.003
94412 England 2018/19 Y Y 1655 ST-23 complex Blood 0.047 0.003 0.004 0.004
94413 England 2018/19 B B 1163 ST-269 complex Blood 0.38 0.006 0.006 0.016
94415 England 2018/19 Y Y 1655 ST-23 complex Blood 0.032 0.003 0.004 0.003
94418 England 2018/19 C C 11 ST-11 complex Blood 0.094 0.032 0.006 0.004




94420 England 2018/19 B B 41 ST-41/44 complex Blood 0.047 0.008 0.008 0.003
94423 England 2018/19 Y NK 1655 ST-23 complex Blood 0.064 0.006 0.006 0.006
94449 England 2018/19 B B 213 ST-213 complex Blood 0.047 0.008 0.004 0.003
94450 Wales 2018/19 B B 10297 UA Blood 0.094 0.032 0.004 0.004
94451 England 2018/19 B B 213 ST-213 complex Blood 0.023 0.032 0.004 <0.002
94452 England 2018/19 B B 485 ST-41/44 complex Blood 0.19 0.012 0.006 0.004
94453 England 2018/19 Y Y 1655 ST-23 complex Blood 0.064 0.008 0.006 0.004
94454 England 2018/19 B B 479 ST-269 complex Blood 0.047 0.012 0.004 0.002
94455 England 2018/19 B B 1163 ST-269 complex Bra in  0.19 0.004 0.003 0.004
94457 England 2018/19 B B 11238 ST-269 complex Blood 0.094 0.016 0.006 0.004
94464 England 2018/19 Y Y 1655 ST-23 complex Blood 0.094 0.004 0.004 0.003
94466 England 2018/19 B B 2314 ST-41/44 complex Blood 0.25 0.008 0.006 0.004
94467 England 2018/19 C C 11 ST-11 complex Blood 0.125 0.006 0.008 0.006
94468 England 2018/19 B B 41 ST-41/44 complex Blood 0.125 0.006 0.008 0.004
94469 England 2018/19 B B 33 ST-32 complex Blood 0.047 0.006 0.006 0.003
19968* England 2010/11 W W 11 ST-11 complex Blood 0.094 0.023 0.004 0.006
20057* England 2010/11 W W 11 ST-11 complex Blood 0.38 0.012 0.006 0.004
20154* England 2010/11 W W 11 ST-11 complex Blood 0.064 0.006 0.003 0.004
20158* England 2010/11 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
20216* England 2010/11 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
20226* England 2010/11 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
20247* England 2010/11 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
20288* England 2010/11 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
20368* England 2010/11 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.004
20424* England 2010/11 W W 11 ST-11 complex Joint 0.094 0.004 0.004 0.006
20436* England 2010/11 W W 11 ST-11 complex Blood 0.064 0.008 0.003 0.003
20449* England 2010/11 W W 11 ST-11 complex Blood 0.094 0.006 0.004 0.004
20460* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
20461* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.006
21123* England 2011/12 W W 1860 ST-11 complex Blood 0.064 0.008 0.004 0.004
21163* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
21206* England 2011/12 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
21216* England 2011/12 W W 11 ST-11 complex Blood 0.032 0.006 0.003 0.003
21298* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
21302* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.004 0.006 0.003
21305* England 2011/12 W W 11 ST-11 complex Blood 0.094 0.004 0.006 0.004
21334* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
21354* England 2011/12 W W 11 ST-11 complex Blood 0.064 0.006 0.006 0.004
21375* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.004
21377* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
21381* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.004 0.006 0.004
21386* England 2011/12 W W 10284 ST-11 complex Blood 0.064 0.008 0.004 0.006
21446* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.032 0.006 0.003
21492* England 2011/12 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.002
28114* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.003
28115* England 2012/13 W W 11 ST-11 complex Blood 0.032 <0.002 0.008 <0.002
28116* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.003
28117* England 2012/13 W W 11 ST-11 complex Blood 0.38 0.012 0.004 0.006
28119* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.003
28122* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.003 0.003 0.003
28125* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.004 0.002 0.003
28128* England 2012/13 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.004
28131* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.006 0.003 0.004
28132* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.006 0.003 0.004
28134* England 2012/13 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
28135* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.012 0.003 0.003
28136* England 2012/13 W W 11 ST-11 complex Blood 0.094 0.008 0.003 0.004
28137* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.008 0.003 0.004
28138* England 2012/13 W W 11 ST-11 complex Blood 0.38 0.016 0.004 0.012
28139* England 2012/13 W W 10651 ST-11 complex Blood 0.047 0.006 0.003 0.003
28141* England 2012/13 W W 11 ST-11 complex Blood 0.094 0.012 0.004 0.004
28142* England 2012/13 W W 11 ST-11 complex Blood 0.094 0.008 0.004 0.004
28143* England 2012/13 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.004
28144* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.006 0.003 0.003
28146* England 2012/13 W W 10651 ST-11 complex Blood 0.064 0.006 0.002 0.004
28147* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.012 0.003 0.004
28149* England 2012/13 W W 11 ST-11 complex Joint 0.047 0.008 0.003 0.004
28150* England 2012/13 W W 11 ST-11 complex Blood 0.032 0.008 0.003 0.003
28151* England 2012/13 W W 11 ST-11 complex Blood 0.047 0.012 0.003 0.003
28152* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.008 0.003 0.003
28153* England 2012/13 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.004
28154* England 2012/13 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
28156* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.004 0.006 0.004
28157* England 2012/13 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.003
28158* England 2012/13 W W 11 ST-11 complex Blood 0.094 0.012 0.012 0.006
28161* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.003
28162* England 2012/13 W W 11 ST-11 complex Blood 0.094 0.006 0.012 0.004
28163* England 2012/13 W W 11 ST-11 complex Blood 0.047 0.016 0.006 0.006
28164* England 2012/13 W W 11 ST-11 complex Blood 0.064 0.002 0.008 0.004
29721* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.004
29723* England 2013/14 W W 11 ST-11 complex Blood 0.125 0.008 0.008 0.012
29724* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
29725* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.006 0.006 0.006
29726* England 2013/14 W W 10651 ST-11 complex Blood 0.064 0.004 0.006 0.004




29729* England 2013/14 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.006
29730* England 2013/14 W W 11161 ST-11 complex Blood 0.064 0.016 0.008 0.006
29731* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.004
29732* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.004 0.006 0.006
29733* England 2013/14 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.004
29734* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.004 0.008 0.006
29735* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.004
29736* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.004
29737* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.006 0.006 0.006
30136* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.004
30137* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
30138* England 2013/14 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.008
30139* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.008
30140* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
30141* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
30143* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.016 0.006 0.004
30144* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.016 0.006 0.004
30145* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.003 0.008 0.003
30146* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.023 0.008 0.004
30147* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
30148* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.004
30150* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.004
30151* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.004 0.006 0.004
30152* England 2013/14 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.004
30153* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.003 0.006 0.003
30154* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
30155* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.012 0.006 0.004
30156* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.006
30157* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.006
30158* England 2013/14 W W 11 ST-11 complex Blood 0.125 0.023 0.006 0.008
30159* England 2013/14 W W 8621 ST-11 complex Blood 0.064 0.016 0.006 0.006
30160* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
30161* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.006
30162* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.006
30163* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.006
30164* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.006
30165* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.023 0.006 0.004
30166* England 2013/14 W W 10651 ST-11 complex Blood 0.094 0.008 0.008 0.006
30167* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.006
30168* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.004 0.006 0.006
31168* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
31169* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.003 0.006 0.004
35425* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.125 0.016 0.004
35507* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.047 0.008 0.004
35581* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.008
35598* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.004
35608* England 2013/14 W NG 11 ST-11 complex Blood 0.047 0.006 0.012 0.004
35614* England 2013/14 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.004
35618* England 2013/14 W W 11 ST-11 complex CSF 0.064 0.008 0.012 0.006
35621* England 2013/14 W W 11 ST-11 complex Blood 0.094 0.012 0.012 0.012
35622* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.008
35624* England 2013/14 W W 11 ST-11 complex Blood 0.094 0.012 0.012 0.008
35632* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.004 0.006 0.008
35634* England 2013/14 W W 11 ST-11 complex Blood 0.032 0.008 0.006 0.004
35635* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.023 0.008 0.008
35638* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.006
35643* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.016 0.006 0.006
35651* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.006
35664* England 2013/14 W W 11292 ST-11 complex Blood 0.064 0.012 0.006 0.008
35670* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.008
35674* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.006
35675* England 2013/14 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.003
35686* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.006
35687* England 2013/14 W W 10651 ST-11 complex Blood 0.125 0.016 0.006 0.012
35689* England 2013/14 W W 11 ST-11 complex Blood 0.064 0.023 0.006 0.006
35690* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
35700* England 2013/14 W W 10651 ST-11 complex Blood 0.064 0.012 0.006 0.006
35702* England 2013/14 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.004
35722* England 2013/14 W W 11 ST-11 complex Blood 0.125 0.032 0.008 0.008
35725* England 2013/14 W W 11 ST-11 complex Blood 0.094 0.023 0.006 0.008
35728* England 2013/14 W W 11 ST-11 complex Blood 0.094 0.016 0.006 0.006
35745* England 2014/15 W W NK INCOMPLETE MLST Blood 0.064 0.016 0.008 0.006
35754* England 2014/15 W W 11 ST-11 complex Blood 0.023 0.008 0.006 0.004
35756* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
35763* England 2014/15 W W 11 ST-11 complex Blood 0.125 0.016 0.008 0.008
35782* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.006 0.004
35786* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.004
35788* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
35792* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
35796* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.008 0.006 0.004
35799* England 2014/15 W W 11 ST-11 complex Joint 0.064 0.008 0.006 0.006
35800* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.016 0.006 0.003
35801* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.032 0.008 0.004
35807* England 2014/15 W W 10651 ST-11 complex Blood 0.064 0.012 0.006 0.004




35809* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
35810* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.003
35811* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.003
37670* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.004
37673* England 2014/15 W NK 10651 ST-11 complex Blood 0.047 0.023 0.006 0.003
37675* England 2014/15 W NK 10651 ST-11 complex Blood 0.064 0.006 0.008 0.004
37681* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.008 0.008 0.003
37685* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
37690* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.006 0.004
37692* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.004
37693* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.006 0.004
37699* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
37701* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.016 0.006 0.004
37708* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.006 0.006 0.004
37710* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.004
37711* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
37716* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.006 0.008 0.002
37717* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.006 0.006 0.004
37722* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.003 0.006 0.002
37731* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.002
37732* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
37736* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
37738* England 2014/15 W W 10651 ST-11 complex Blood 0.047 0.012 0.006 0.004
37739* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.006 0.006 0.004
37742* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
37746* England 2014/15 W NK 11867 ST-11 complex Blood 0.094 0.012 0.008 0.008
37747* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.002
37748* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.008 <0.002
37749* England 2014/15 W NK 10651 ST-11 complex Blood 0.064 0.008 0.008 0.003
37754* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.004
37757* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.008 0.008 0.002
37760* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
37769* England 2014/15 W NK 11 ST-11 complex Blood 0.19 0.008 0.008 0.006
37770* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
37774* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
37784* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.006 0.006 0.004
37793* England 2014/15 W W 11 ST-11 complex Blood 0.023 0.006 0.006 0.002
37797* England 2014/15 W NK 11 ST-11 complex Blood 0.38 0.023 0.008 0.016
37798* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.004 0.006 0.003
37799* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.006 0.006 0.002
37801* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.002
37805* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.008 0.008 0.003
37806* England 2014/15 W W 11 ST-11 complex Blood 0.125 0.023 0.008 0.006
37809* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.004 0.006 0.004
37811* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.012 0.008 0.004
37821* England 2014/15 W NK 11 ST-11 complex Blood 0.125 0.012 0.002 0.002
37822* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.002 0.002 0.016
37828* England 2014/15 W W 11 ST-11 complex Blood 0.094 0.004 0.002 0.016
37834* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.002 0.004
37854* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.012 0.002 0.006
37855* England 2014/15 W W NK INCOMPLETE MLST Blood 0.094 0.023 0.002 0.008
37856* England 2014/15 W NG 11 ST-11 complex Blood 0.047 0.008 0.002 0.004
37857* England 2014/15 W NK 11 ST-11 complex Blood 0.094 0.008 0.002 0.006
37860* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.006 0.002 0.004
37861* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.008 0.002 0.006
37862* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.006 0.002 0.004
37868* England 2014/15 W NK 11 ST-11 complex Blood 0.19 0.004 0.002 0.008
37870* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.004 0.002 0.004
37873* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.004 0.002 0.004
37875* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.004 0.002 0.004
37879* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.004 0.012 0.004
37881* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.004
37882* England 2014/15 W NK 11 ST-11 complex Blood 0.023 0.004 0.004 0.002
37890* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.016 0.008 0.006
37891* England 2014/15 W NK 11 ST-11 complex Blood 0.023 0.004 0.004 0.003
37893* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.008 0.006 0.006
37902* England 2014/15 W NK 10651 ST-11 complex Blood 0.064 0.016 0.006 0.006
37904* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.012 0.008 0.006
37907* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.012 0.006 0.006
37910* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.012 0.006 0.004
37915* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.047 0.008 0.004
37922* England 2014/15 W NK 10651 ST-11 complex Blood 0.047 0.008 0.006 0.004
37930* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.012 0.006 0.004
37933* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.012 0.006 0.002
37936* England 2014/15 W NK 11 ST-11 complex Joint 0.047 0.012 0.006 0.004
37940* England 2014/15 W W 11 ST-11 complex Joint 0.047 0.006 0.008 0.004
37942* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.012 0.006 0.004
37951* England 2014/15 W NK 11 ST-11 complex Blood 0.023 0.004 0.004 0.002
37958* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.002
37961* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.006 0.008 0.004
37962* England 2014/15 W NK NK INCOMPLETE MLST Blood 0.064 0.016 0.008 0.004
37977* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.002
37978* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.016 0.006 0.004
37981* England 2014/15 W NK 11 ST-11 complex Blood 0.094 0.016 0.008 0.008




37987* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.006 0.006 0.002
37988* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.004 0.006 0.002
37990* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
37992* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.004 0.006 0.002
37995* England 2014/15 W W 11 ST-11 complex CSF 0.064 0.008 0.008 0.003
37998* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.002
37999* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.064 0.008 0.002
38001* England 2014/15 W W 10651 ST-11 complex Blood 0.064 0.012 0.008 0.003
38003* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.003
38004* England 2014/15 W W 11 ST-11 complex Blood 0.094 0.047 0.008 0.004
38007* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.008 0.008 0.003
38008* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.094 0.008 0.003
38017* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.008 0.008 0.002
38024* England 2014/15 W NK 11 ST-11 complex Blood 0.094 0.012 0.008 0.004
38027* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
38029* England 2014/15 W W NK INCOMPLETE MLST Joint 0.064 0.023 0.008 0.004
38034* England 2014/15 W W 11 ST-11 complex Blood 0.094 0.012 0.004 0.006
38035* England 2014/15 W W NK INCOMPLETE MLST Blood 0.047 0.008 0.004 0.002
38037* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
38038* England 2014/15 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.006
38049* England 2014/15 W NK 11 ST-11 complex Joint 0.094 0.012 0.008 0.006
38059* England 2014/15 W W 10651 ST-11 complex Joint 0.094 0.016 0.004 0.004
38060* England 2014/15 W NK 11 ST-11 complex Blood 0.032 0.008 0.004 0.008
38063* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
38064* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
38065* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.003 0.004 0.002
38066* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
38067* England 2014/15 W NK 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
38076* England 2014/15 W W 11 ST-11 complex Blood 0.094 0.012 0.004 0.004
38079* England 2014/15 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.004
38085* England 2014/15 W NK 11 ST-11 complex Blood 0.094 0.012 0.004 0.003
38088* England 2014/15 W NK 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
38096* England 2014/15 W W 11491 ST-11 complex Blood 0.064 0.012 0.004 0.002
38101* England 2014/15 W NK 11 ST-11 complex Joint 0.064 0.008 0.004 0.002
38102* England 2014/15 W W NK INCOMPLETE MLST Blood 0.064 0.012 0.004 0.003
38106* England 2014/15 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
38108* England 2014/15 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
38109* England 2014/15 W W 11 ST-11 complex Joint 0.064 0.008 0.004 0.003
38115* England 2014/15 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.003
38520* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.002
39320* England 2015/16 W W 11 ST-11 complex Blood 0.25 0.006 0.004 0.004
39328* England 2015/16 W W 11 ST-11 complex Joint 0.064 0.016 0.004 0.004
39331* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
39335* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.003
39337* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
39340* England 2015/16 W W 11 ST-11 complex Blood 0.19 0.032 0.008 0.008
39341* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.002
39342* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.003
39344* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.003
39345* England 2015/16 W NK 11 ST-11 complex Blood 0.064 0.006 0.008 0.003
39346* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.012 0.008 0.003
39349* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.012 0.003 0.008
39352* England 2015/16 W W 11 ST-11 complex Joint 0.047 0.006 0.008 0.002
39356* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
39358* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.002
39365* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.016 0.008 0.003
39368* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.002
39369* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.25 0.008 0.002
39373* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.064 0.008 0.003
39385* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
39395* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.023 0.008 0.004
39396* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.094 0.008 0.004
39398* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.004 0.004 0.003
39401* England 2015/16 W W 11 ST-11 complex CSF 0.047 0.008 0.004 0.003
39404* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
39408* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.008
39410* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.002 0.008
39411* England 2015/16 W W 11 ST-11 complex Blood 0.004 0.012 0.004 0.008
39412* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.012 0.003 0.008
39421* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.002
39423* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
39427* England 2015/16 W W 11 ST-11 complex Joint 0.047 0.006 0.004 0.003
39429* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
39430* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.023 0.008 0.004
39431* England 2015/16 W W 11 ST-11 complex Blood 0.125 0.023 0.008 0.004
39433* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.008 0.004 0.003
39435* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.094 0.008 0.003
39436* England 2015/16 W W 11 ST-11 complex CSF 0.064 0.004 0.008 0.003
39438* England 2015/16 W W 11 ST-11 complex Blood 0.125 0.008 0.008 0.004
40322* England 2015/16 W W 11 ST-11 complex Blood 0.125 0.012 0.004 0.003
41451* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.19 0.008 0.002
41455* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
41462* England 2015/16 W W 11 ST-11 complex Blood 0.125 0.008 0.004 0.003
41463* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.004 0.004 0.003




41469* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
41470* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.016 0.008 0.003
41473* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.004 0.004 0.002
41478* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.008 0.004 0.003
41481* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.003 0.004 0.002
41483* England 2015/16 NG W 11 ST-11 complex Blood 0.094 0.016 0.008 0.004
41486* England 2015/16 W W 11 ST-11 complex Blood 0.125 0.016 0.004 0.004
41489* England 2015/16 W W NK INCOMPLETE MLST Blood 0.094 0.006 0.004 0.004
41494* England 2015/16 W W 11 ST-11 complex CSF 0.094 0.008 0.004 0.004
41501* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
41502* England 2015/16 W W 11 ST-11 complex Joint 0.094 0.008 0.006 0.004
41515* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.012 0.004 0.006
41516* England 2015/16 W W 11 ST-11 complex Blood 0.023 0.006 0.002 0.002
41519* England 2015/16 W NK 11 ST-11 complex Joint 0.094 0.047 0.008 0.004
41522* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.003 0.002
41525* England 2015/16 W W 11 ST-11 complex Blood 0.023 0.006 0.004 0.002
41530* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.004
41531* England 2015/16 W W 11 ST-11 complex CSF 0.064 0.006 0.004 0.003
41533* England 2015/16 W W 10651 ST-11 complex Blood 0.064 0.012 0.004 0.003
41536* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.004 0.004 0.002
41543* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.016 0.006 0.004
41547* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
41549* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
41552* England 2015/16 W W 10651 ST-11 complex Blood 0.094 0.008 0.006 0.006
41558* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.003
42475* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.016 0.006 0.003
42476* England 2015/16 W W 10651 ST-11 complex Blood 0.094 0.012 0.008 0.003
42478* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.008 0.004 <0.002
42480* England 2015/16 W NK 11 ST-11 complex Blood 0.047 0.006 0.004 <0.002
42481* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.012 0.004 0.003
42482* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.003
42483* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.003
42484* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
42485* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
42486* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
42489* England 2015/16 W NK 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
42491* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.008 0.006 <0.002
42492* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.012 0.004 <0.002
42494* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.002 0.004 0.002
42497* England 2015/16 W W 10651 ST-11 complex Blood 0.064 0.006 0.006 0.003
42504* England 2015/16 W W NK INCOMPLETE MLST Blood 0.032 0.016 0.004 <0.002
42505* England 2015/16 W W NK INCOMPLETE MLST Blood 0.064 0.006 0.004 0.003
42506* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.006 0.004 0.003
42512* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.006 0.008 <0.002
42517* England 2015/16 W NK 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
42519* England 2015/16 W NK 11 ST-11 complex Joint 0.047 0.004 0.004 0.003
42525* England 2015/16 W W 10651 ST-11 complex Blood 0.094 0.012 0.004 0.003
42530* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.006
42532* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.003
42533* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.008 0.004 0.006
42534* England 2015/16 W W NK UA Blood 0.094 0.012 0.004 0.006
42535* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.008 0.002 0.002
42545* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.004 0.004 0.006
42549* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.004 0.006 0.006
42551* England 2015/16 W NK 11 ST-11 complex Blood 0.047 0.008 <0.002 <0.002
42552* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.006 0.004 <0.002
42553* England 2015/16 W W 11 ST-11 complex Blood 0.19 0.006 0.004 0.002
42555* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.012 0.004 0.006
42556* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.006 <0.002
42561* England 2015/16 W W 10651 ST-11 complex Blood 0.064 0.016 0.004 0.003
42564* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.064 0.004 0.002
42568* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
42572* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
42573* England 2015/16 W W 10651 ST-11 complex Blood 0.047 0.012 0.004 0.003
42576* England 2015/16 W NK 11 ST-11 complex Blood 0.032 0.003 0.004 0.002
42585* England 2015/16 W W 11 ST-11 complex Joint 0.047 0.006 0.006 0.003
42586* England 2015/16 W W 10651 ST-11 complex Blood 0.064 0.012 0.004 0.004
42595* England 2015/16 W NK 11 ST-11 complex Blood 0.38 0.012 0.004 0.004
42605* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.016 0.004 0.003
42612* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.006
44636* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.003 0.002
44638* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.003 0.008 0.004
44640* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.002
44684* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.023 0.004 0.003
44685* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.008 0.003 0.003
44686* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.003 0.004 0.003
44687* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
44697* England 2015/16 W W NK INCOMPLETE MLST Blood 0.094 0.012 0.006 0.003
44699* England 2015/16 W W NK INCOMPLETE MLST Blood 0.064 0.003 0.004 0.003
44704* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
44708* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.004 0.004 0.004
44714* England 2015/16 W W 8621 ST-11 complex Blood 0.094 0.012 0.004 0.004
44718* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.016 0.004 0.003
44719* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.002




44724* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.008 0.006 0.003
44727* England 2015/16 W W 10651 ST-11 complex Joint 0.094 0.016 0.006 0.004
44730* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
44733* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
44736* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.004
44739* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.003 0.004 <0.002
44740* England 2015/16 W NK 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
44742* England 2015/16 W W 12208 ST-11 complex Blood 0.023 0.032 0.008 0.002
44753* England 2015/16 W W 11 ST-11 complex Joint 0.094 0.008 0.003 0.004
44759* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.008 0.004 0.003
44763* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.008 0.004 0.002
44765* England 2015/16 W W 11 ST-11 complex Joint 0.094 0.012 0.004 0.002
44768* England 2015/16 W W 11 ST-11 complex Blood 0.125 0.012 0.008 0.004
44769* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.047 0.006 0.003
44773* England 2015/16 W W 11 ST-11 complex Blood 0.094 0.125 0.008 0.003
44777* England 2015/16 W W 11 ST-11 complex Blood 0.25 0.125 0.008 0.008
44782* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.008 0.004 0.003
44784* England 2015/16 W W NK INCOMPLETE MLST Joint 0.064 0.012 0.004 0.003
44785* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.006 0.006 0.003
44786* England 2015/16 W W NK INCOMPLETE MLST Blood 0.064 0.012 0.008 0.004
44788* England 2015/16 W W NK INCOMPLETE MLST Blood 0.064 0.064 0.004 0.004
44790* England 2015/16 W W NK INCOMPLETE MLST Blood 0.094 0.012 0.006 0.006
44798* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.19 0.008 0.004
44802* England 2015/16 W W NK INCOMPLETE MLST Blood 0.094 0.012 0.006 0.004
44828* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.125 0.008 0.003
44829* England 2015/16 W W NK INCOMPLETE MLST Blood 0.064 0.012 0.006 0.003
44833* England 2015/16 W W NK INCOMPLETE MLST Blood 0.032 0.004 0.004 0.003
44835* England 2015/16 W W NK INCOMPLETE MLST Blood 0.047 0.008 0.004 0.002
47016* England 2015/16 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.004
47019* England 2015/16 W W 11 ST-11 complex Blood 0.125 0.016 0.004 0.004
47262* England 2015/16 W W 11 ST-11 complex Blood 0.032 0.006 0.006 0.002
47263* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.012 0.006 0.003
47265* England 2015/16 W W 11 ST-11 complex Blood 0.047 0.004 0.008 <0.002
47271* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.003
47273* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
47274* England 2016/17 W W 10651 ST-11 complex Blood 0.064 0.012 0.004 0.003
47275* England 2016/17 W W 10651 ST-11 complex Blood 0.064 0.008 0.004 0.004
47277* England 2016/17 W W 10651 ST-11 complex Blood 0.094 0.006 0.004 0.004
47280* England 2016/17 W W 10215 ST-11 complex Blood 0.047 0.023 0.002 0.004
47287* England 2016/17 W W 12511 ST-11 complex Blood 0.047 0.004 0.004 0.003
47289* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
47294* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.006 0.008 0.008
47296* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.023 0.006 0.003
47299* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.012 0.006 0.006
47301* England 2016/17 W W 11 ST-11 complex Blood 0.023 0.003 0.004 0.002
47303* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.003
47304* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
47305* England 2016/17 W NK 11 ST-11 complex Blood 0.032 0.006 0.008 0.002
47311* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.003
47322* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.012 0.008 0.004
47325* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
47326* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.004 <0.002
47329* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.008 0.006 0.004
47334* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.003
47336* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.003
47337* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.004
47338* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.003
47340* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
53050* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.12 0.004 0.003
53053* England 2016/17 W W 10651 ST-11 complex Blood 0.064 0.006 0.006 0.004
53054* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
53056* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.003 0.008 0.003
53058* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
53060* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.003
53064* England 2016/17 W W 10651 ST-11 complex Blood 0.064 0.016 0.006 0.003
53067* England 2016/17 W W 11 ST-11 complex CSF 0.064 0.012 0.004 0.004
53069* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
53072* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.125 0.008 0.003
53074* England 2016/17 W W 10651 ST-11 complex Blood 0.094 0.012 0.008 0.006
53076* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.003
53078* England 2016/17 W W 11 ST-11 complex Blood 0.023 0.004 0.004 0.003
53080* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
53081* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
53082* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
53084* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.016 0.004 0.004
53086* England 2016/17 W W 11 ST-11 complex Joint 0.064 0.008 0.004 0.008
53091* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.003 0.004 0.002
53092* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.002
53093* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.032 0.004 0.004
53096* England 2016/17 W W 11 ST-11 complex Blood 0.125 0.008 0.004 0.002
53110* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.064 0.004 0.004
53113* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
53119* England 2016/17 W W 11 ST-11 complex Blood 0.38 0.064 0.004 0.004
53121* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.006




53133* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.023 0.004 0.003
53135* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
53139* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
53141* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
53142* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
53143* England 2016/17 W W 11 ST-11 complex Joint 0.032 0.003 0.004 0.002
53146* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
53149* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
53150* England 2016/17 W W 1287 ST-11 complex Blood 0.047 0.016 0.004 0.003
53154* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
53159* England 2016/17 W W 13099 ST-11 complex Blood 0.064 0.032 0.004 0.004
53164* England 2016/17 W W 11 ST-11 complex Joint 0.25 0.008 0.004 0.004
53165* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.004 0.008 0.003
53166* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.003
53167* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.003
53170* England 2016/17 W W 11 ST-11 complex Blood 0.125 0.023 0.008 0.006
53176* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.003
53179* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.003
53183* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.003 0.008 0.004
53188* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.003
53190* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.003
53192* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
53194* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.004
53195* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
53196* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
53198* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
53199* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.003
53200* England 2016/17 W W 11 ST-11 complex Blood 0.125 0.004 0.008 0.004
53208* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.016 0.008 0.006
53212* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.002
53213* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.003
53215* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.004 0.008 0.006
53217* England 2016/17 W NK 11 ST-11 complex Blood 0.047 0.006 0.008 0.004
53222* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.012 0.008 0.006
53226* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.002
53230* England 2016/17 W W 11 ST-11 complex Blood 0.25 0.006 0.008 0.006
53231* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.004
53232* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.003
53233* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
53236* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.002
53237* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.003
53244* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.004
53249* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.003
53252* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.004
53255* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.008 0.004
53256* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.003
53259* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.002
53264* England 2016/17 W W 11 ST-11 complex Joint 0.047 0.003 0.008 0.002
53267* England 2016/17 W W 11 ST-11 complex Blood 0.19 0.008 0.008 0.004
53269* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.003
53270* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.003 0.004 0.002
53274* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.19 0.004 0.003
53275* England 2016/17 W W 11 ST-11 complex Blood 0.023 0.002 0.004 0.002
53279* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
53284* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.016 0.004 0.003
53287* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
53291* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
53292* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.002
53296* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.004
53297* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.023 0.004 0.002
53300* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.003
53301* England 2016/17 NG W 11 ST-11 complex Blood 0.047 0.023 0.008 0.003
53307* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.125 0.008 0.004
53308* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
53309* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
53315* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
53322* England 2016/17 W W 11 ST-11 complex Blood 0.023 0.004 0.004 0.002
53323* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.004
53325* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
53328* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.003
53338* England 2016/17 W W 11 ST-11 complex Blood 0.023 0.006 0.004 <0.002
53339* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
53340* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
53341* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
53343* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
53344* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
53346* England 2016/17 W W 13097 ST-11 complex Blood 0.064 0.023 0.008 0.006
53347* England 2016/17 W W 11 ST-11 complex Blood 0.19 0.006 0.008 0.006
53350* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
53352* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.002
53354* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.003
53355* England 2016/17 W W 11 ST-11 complex Blood 0.023 0.003 0.004 <0.002
53358* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.004
53360* England 2016/17 W W 11 ST-11 complex Blood 0.023 0.008 0.004 0.002




53367* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.003
53368* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.016 0.008 0.004
53369* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
53371* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
53372* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
60544* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60545* England 2017/18 W W 11 ST-11 complex Blood 0.19 0.008 0.006 0.004
60549* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
60552* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.004
60553* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.004
60555* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.002
60557* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
60558* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60562* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.002
60565* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.032 0.006 0.006
60572* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.002
60579* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.002
60587* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60589* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.004 0.004 0.006
60590* England 2017/18 W W 11 ST-11 complex Blood 0.023 0.012 0.004 <0.002
60591* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60592* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60597* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.19 0.003 0.003
60601* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
60603* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.004
60612* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
60613* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.016 0.006 0.003
60614* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
60619* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60631* England 2017/18 W W 11 ST-11 complex Blood 0.38 0.016 0.004 0.006
60632* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
60642* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.016 0.006 0.004
60645* England 2016/17 W W 11 ST-11 complex Blood 0.125 0.004 0.008 0.004
60649* England 2017/18 W W 11 ST-11 complex Joint 0.064 0.004 0.006 0.003
60657* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60663* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
60671* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.004 0.006 0.003
60672* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
60674* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.003
60675* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60676* England 2017/18 W W NK INCOMPLETE MLST Blood 0.016 0.008 0.004 <0.002
60681* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.006
60682* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.003
60685* England 2016/17 W W NK INCOMPLETE MLST Blood 0.125 0.032 0.008 0.004
60692* England 2017/18 W W 11 ST-11 complex Blood 0.023 0.012 0.004 0.002
60694* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
60699* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.032 0.006 0.003
60700* England 2016/17 W W 11 ST-11 complex Blood 0.094 0.016 0.004 0.008
60706* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60707* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
60708* England 2016/17 W W 11 ST-11 complex Joint 0.38 0.032 0.008 0.006
60710* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.004
60718* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.016 0.008 0.002
60720* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60723* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.032 0.008 0.003
60724* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
60726* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
60728* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
60729* England 2017/18 W W 11 ST-11 complex Blood 0.25 0.004 0.004 0.004
60730* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60731* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
60736* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
60746* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
60750* England 2017/18 W W 11 ST-11 complex Blood 0.38 0.012 0.004 0.006
60753* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.003
60754* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
60756* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.003
60762* England 2017/18 W W 10651 ST-11 complex Blood 0.094 0.023 0.006 0.006
60763* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
60765* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
60769* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
60770* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
60773* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60776* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60778* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.004
60784* England 2017/18 W W 11 ST-11 complex Blood 0.25 0.016 0.003 0.003
60786* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.023 0.004 0.004
60791* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.023 0.003 0.002
60792* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.002
60795* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.023 0.004 0.003
60796* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.008 0.003
60797* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
60801* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.023 0.004 0.003
60802* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.004




60805* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
60808* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.003 0.004 0.003
60825* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
60830* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.004
60833* England 2017/18 W W 13720 ST-11 complex Blood 0.064 0.023 0.008 0.004
60837* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.004
60844* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.016 0.006 0.004
60850* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
60853* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.008 0.003
60867* England 2016/17 W W 12511 ST-11 complex Blood 0.047 0.012 0.008 0.003
60876* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.002
60877* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60880* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.008 0.006 0.003
60883* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.016 0.006 0.004
60884* England 2017/18 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.003
60889* England 2017/18 W W 10651 ST-11 complex Blood 0.125 0.016 0.004 0.006
60893* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60895* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
60898* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.012 0.004 0.002
60905* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.003 0.004 0.003
60906* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60907* England 2016/17 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.003
60919* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.004
60922* England 2017/18 W W 10651 ST-11 complex Blood 0.094 0.012 0.008 0.004
60923* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
60925* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.002 0.004 0.003
60927* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.008 0.003
60928* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60929* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.003 0.003 0.002
60934* England 2017/18 W W 11 ST-11 complex CSF 0.064 0.006 0.004 0.003
60939* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.032 0.004 0.004
60941* England 2017/18 W W 10651 ST-11 complex Joint 0.064 0.008 0.006 0.003
60947* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.004
60949* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.004
60954* England 2017/18 W W 11 ST-11 complex CSF 0.064 0.012 0.008 0.004
60956* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
60957* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.016 0.004 0.003
60963* England 2017/18 W W 11 ST-11 complex Blood 0.094 0.006 0.004 0.004
60965* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
60987* England 2016/17 W W 11 ST-11 complex Blood 0.047 0.016 0.008 0.003
60990* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.003
60994* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
60997* England 2016/17 W W 13729 ST-11 complex Blood 0.047 0.008 0.004 0.004
61000* England 2017/18 W W 11 ST-11 complex Blood 0.094 0.023 0.006 0.006
61002* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
61003* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.002
61004* England 2017/18 W W 10651 ST-11 complex CSF 0.094 0.008 0.004 0.004
61008* England 2017/18 W W 10651 ST-11 complex Blood 0.064 0.016 0.004 0.003
61020* England 2016/17 W W 11 ST-11 complex Blood 0.19 0.006 0.004 0.004
61031* England 2017/18 W W 3419 ST-11 complex CSF 0.064 0.012 0.004 0.004
61035* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.004 0.006 0.002
61037* England 2016/17 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.004
61038* England 2016/17 W W 11 ST-11 complex Blood 0.38 0.012 0.004 0.004
61569* England 2017/18 W W 11 ST-11 complex Blood 0.19 0.008 0.004 0.004
61570* England 2017/18 W W 13920 ST-11 complex Blood 0.38 0.016 0.004 0.016
61571* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
61572* England 2017/18 W W 11 ST-11 complex Blood 0.19 0.004 0.006 0.003
63561* England 2018/19 NG W 11 ST-11 complex Blood 0.047 0.023 0.002 0.002
63564* England 2017/18 W W 11 ST-11 complex Blood 0.094 0.012 0.006 0.004
63565* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
63566* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
63568* England 2018/19 W W 11 ST-11 complex Blood 0.094 0.008 0.004 0.003
63569* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.002
63570* England 2018/19 W W 11 ST-11 complex Joint 0.047 0.006 0.004 0.003
63571* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.012 0.003 0.004
63572* England 2018/19 W W 11 ST-11 complex Blood 0.032 0.008 0.004 0.006
63574* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
63575* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.094 0.004 0.002
63577* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
63578* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
63580* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.004 0.004 0.002
63581* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
63582* England 2018/19 W NK 11 ST-11 complex Blood 0.047 0.004 0.004 0.003
63583* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.006
63586* England 2016/17 W W 11 ST-11 complex Joint 0.064 0.008 0.008 0.004
63587* England 2017/18 W W 11 ST-11 complex Blood 0.38 0.016 0.004 0.006
63588* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.004 0.003 0.002
63589* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
63592* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.016 0.004 0.002
63593* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.004 0.004 0.003
63594* England 2018/19 W W 10651 ST-11 complex Blood 0.064 0.012 0.004 0.004
63597* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.016 0.004 <0.002
63598* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.004
63599* England 2017/18 W W 11 ST-11 complex Blood 0.38 0.012 0.004 0.004




63601* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.003
63603* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.003
63604* England 2018/19 W W 11 ST-11 complex Blood 0.032 0.003 0.006 0.002
63606* England 2018/19 W NK 11 ST-11 complex Blood 0.047 0.016 0.004 0.002
63607* England 2018/19 W W 11 ST-11 complex Joint 0.064 0.047 0.008 0.003
63608* England 2018/19 W W 11 ST-11 complex Blood 0.023 0.003 0.004 <0.002
63609* England 2018/19 W W 11 ST-11 complex Blood 0.25 0.032 0.006 0.006
63610* England 2018/19 W W 11 ST-11 complex Blood 0.023 0.004 0.004 <0.002
63611* England 2018/19 W NK 15541 ST-11 complex Joint 0.047 0.016 0.008 0.003
63612* England 2018/19 W W 11 ST-11 complex Blood Culture 0.064 0.008 0.006 0.002
63614* England 2018/19 W W 11 ST-11 complex Joint 0.064 0.004 0.008 0.003
63615* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.023 0.004 0.004
63616* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.047 0.006 0.003
63617* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.006 0.008 0.003
63618* England 2018/19 W W 4977 ST-11 complex Blood 0.25 0.012 0.004 0.004
63619* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.016 0.004 0.003
63620* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.032 0.008 0.004
63621* England 2018/19 W W 4977 ST-11 complex Blood 0.25 0.016 0.008 0.008
63622* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.19 0.008 0.003
63623* England 2018/19 W W 11 ST-11 complex Blood 0.25 0.012 0.006 0.006
63624* England 2018/19 W NK 11 ST-11 complex Blood 0.064 0.006 0.008 0.003
63625* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.012 0.008 0.004
63628* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.012 0.008 0.003
63629* England 2018/19 W NK 11 ST-11 complex Joint 0.094 0.016 0.004 0.003
63630* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
63631* England 2018/19 W NK 11 ST-11 complex Blood 0.047 0.006 0.006 0.002
63632* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.004
70990* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.006 0.004 0.003
70995* England 2017/18 W W 11 ST-11 complex Blood 0.023 0.008 0.004 <0.002
70996* England 2017/18 W W 11 ST-11 complex Blood Culture 0.047 0.008 0.006 0.004
70997* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.003
70998* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.004
71000* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
71002* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.003
71003* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.125 0.004 0.006
71006* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
71009* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.012 0.004 0.003
71012* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
71030* England 2017/18 W W 10651 ST-11 complex Blood 0.064 0.012 0.008 0.004
71031* England 2017/18 W W 11 ST-11 complex Blood 0.023 0.008 0.004 0.002
71032* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
71033* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.012 0.004 0.003
71037* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.016 0.004 0.002
71043* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.008 0.003 0.004
71045* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.003
71046* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.004
71051* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.003 0.002
71052* England 2017/18 W W 11 ST-11 complex Blood 0.75 0.19 0.004 0.008
71061* England 2018/19 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
71062* England 2018/19 W W 11 ST-11 complex Joint 0.19 0.003 0.006 0.003
71064* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.032 0.006 0.003
71069* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.004
71071* England 2018/19 W W 11 ST-11 complex Blood 0.19 0.006 0.004 0.003
71075* England 2018/19 W NK 11 ST-11 complex Blood 0.032 0.006 0.006 0.003
71080* England 2018/19 W W 3419 ST-11 complex Blood 0.094 0.008 0.006 0.004
71088* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.002
71089* England 2018/19 W W 11 ST-11 complex Blood 0.25 0.008 0.004 0.004
71099* England 2018/19 W W 11 ST-11 complex Blood 0.094 0.008 0.008 0.004
71102* England 2018/19 W W 11 ST-11 complex Joint 0.047 0.006 0.006 0.002
71106* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.032 0.006 0.002
71107* England 2018/19 W W 11 ST-11 complex CSF 0.047 0.004 0.004 0.002
71113* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.003
71115* England 2018/19 W W 11 ST-11 complex Blood 0.094 0.016 0.006 0.004
71121* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.006 0.008 0.003
71124* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.003
71126* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
71135* England 2018/19 W W 10651 ST-11 complex Blood 0.047 0.016 0.004 0.004
71136* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
71137* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
71142* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.003
71148* England 2018/19 W W 11 ST-11 complex Blood 0.25 0.004 0.004 0.004
71151* England 2018/19 W W 11 ST-11 complex Blood 0.032 0.004 0.006 0.003
71152* England 2018/19 W W 11 ST-11 complex Blood 0.19 0.004 0.004 0.006
71153* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.003 0.006 0.004
71159* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.003
71160* England 2018/19 W W 11 ST-11 complex Blood 0.094 0.032 0.006 0.006
71162* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.003 0.004 0.003
71170* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.006 0.006 0.002
85527* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.012 0.006 0.003
85532* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.012 0.004 0.003
85535* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.003
85538* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.032 0.004 0.003
85540* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.008 0.006 0.004
85543* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.047 0.004 0.003
85546* England 2017/18 W W 11 ST-11 complex Joint 0.5 0.016 0.006 0.008
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*=Isolate panel 3. NG = non-groupable. CNL = capsular null. UA = unassigned. NK = not 













85552* England 2017/18 W W 11 ST-11 complex CSF 0.047 0.006 0.004 0.003
85556* England 2017/18 W W 11 ST-11 complex Blood 0.19 0.004 0.004 0.006
85562* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
85563* England 2017/18 W W 1287 ST-11 complex Blood 0.064 0.012 0.004 0.004
85569* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 0.002
85571* England 2017/18 W W 11 ST-11 complex Blood 0.064 0.016 0.004 0.002
85572* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.004 0.004 0.002
85574* England 2017/18 W W 11 ST-11 complex CSF 0.047 0.004 0.003 0.003
85581* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.003 0.003
85586* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
85590* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.003 <0.002
85599* England 2018/19 W W 11 ST-11 complex Blood 0.38 0.032 0.004 0.006
91759* England 2015/16 W NK 11 ST-11 complex Blood 0.064 0.25 0.004 0.003
91760* England 2018/19 W W 11 ST-11 complex Blood 0.5 0.023 0.004 0.004
91761* England 2018/19 W NK 11 ST-11 complex Blood 0.38 0.012 0.004 0.004
91762* England 2018/19 W W 11 ST-11 complex Blood 0.5 0.008 0.004 0.006
91763* England 2018/19 W W 11 ST-11 complex Blood 0.38 0.008 0.006 0.006
91764* England 2018/19 W W 13920 ST-11 complex Blood 0.38 0.023 0.006 0.016
91765* England 2018/19 W W 11 ST-11 complex Blood 0.38 0.016 0.008 0.006
91766* England 2018/19 W W 11 ST-11 complex Blood 0.38 0.012 0.006 0.004
94185* England 2017/18 W W 11 ST-11 complex Blood 0.032 0.006 0.004 <0.002
94186* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.008 0.006 0.003
94262* England 2017/18 W W 11 ST-11 complex Blood 0.19 0.004 0.004 0.008
94264* England 2017/18 W W 11 ST-11 complex Blood 0.047 0.006 0.004 <0.002
94269* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.008 0.004 0.003
94272* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.004 0.004 0.004
94276* England 2018/19 W W 10651 ST-11 complex Blood 0.094 0.006 0.004 0.003
94282* England 2018/19 W W 6881 ST-11 complex Blood 0.064 0.006 0.004 0.003
94285* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.008 0.004 0.003
94286* England 2018/19 W W 11 ST-11 complex Blood 0.032 0.006 0.004 0.002
94304* England 2018/19 W W 11 ST-11 complex Blood 0.032 0.002 0.004 0.003
94394* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.003
94396* England 2018/19 W W 11 ST-11 complex Blood 0.25 0.023 0.004 0.004
94397* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.006 0.006 0.003
94405* England 2018/19 W NK 11 ST-11 complex Blood 0.094 0.032 0.008 0.004
94414* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.006 0.006 0.003
94416* England 2018/19 W W 11 ST-11 complex Blood 0.25 0.008 0.006 0.004
94417* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.012 0.006 0.004
94421* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.008 0.008 0.004
94448* England 2018/19 W W 11 ST-11 complex Blood 0.064 0.016 0.008 0.004
94458* England 2018/19 W W 11 ST-11 complex Blood 0.094 0.012 0.006 0.004
94459* England 2018/19 W W 11 ST-11 complex Blood 0.094 0.016 0.006 0.003
94465* England 2018/19 W W 11 ST-11 complex Blood Culture 0.125 0.016 0.008 0.004
94470* England 2018/19 W W 11 ST-11 complex Blood 0.047 0.012 0.006 0.003
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Appendix 2: Isolate panel 2; Results chapter 3.2. 
 


















































1 41526 M15 240953 England 2015 Invasive 175 ST-175 complex NG 12 662 583
1 41727 LNP28435 France 2016 Carrier 175 ST-175 complex NG 152 662 583
1 41896 AR03921_T0 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 41897 AR03921_T7 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 42666 AR04432_T0 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 42668 AR04432_T9 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 42784 16-180 Sweden 2016 Invasive 175 ST-175 complex NG 187 662 583
1 47101 PT42 Italy 2016 Carrier 175 ST-175 complex NG 152 662 583
1 47115 PT56 Italy 2016 Carrier 175 ST-175 complex NG 152 662 583
1 49960 PL41818 England 2015 Carrier 175 ST-175 complex NG 12 662 583
1 50082 PR40977 England 2015 Carrier 175 ST-175 complex NG 12 662 583
1 52572 CA41519 Wales 2015 Carrier 175 ST-175 complex NG 152 662 583
1 52614 CM41908 England 2015 Carrier 175 ST-175 complex NG 12 662 583
1 52715 WG40897 England 2015 Carrier 175 ST-175 complex NG 12 662 583
1 60134 AR03481 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 60143 AR03921 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 60308 AR05331 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 61207 AR04332 Ethiopia 2014 Carrier 175 ST-175 complex NG 12 662 583
1 84075 2939 Italy 2017 Invasive 175 ST-175 complex NG 12 662 583
1 84968 05-016 Norway 2018 Carrier 175 ST-175 complex NG 12 662 583
1 85033 16-018 Norway 2018 Carrier 175 ST-175 complex NG 12 662 583
1 88632 BT36315V1C England 2018 Carrier 175 ST-175 complex NG 12 662 583
1 89565 M19 240346 England 2019 Conjunctivitis 175 ST-175 complex NG 313 662 583
1 89712 M19 240348 England 2019 Conjunctivitis 175 ST-175 complex NG 313 662 583
1 89713 M19 240363 England 2019 Invasive 175 ST-175 complex NG 313 662 583
1 91539 Nmiss3084 Italy 2018 Invasive 175 ST-175 complex NG 12 662 583
1 92641 42-017 Norway 2019 Carrier 175 ST-175 complex NG 12 662 583
1 93629 DE13567 Germany 2016 Invasive 175 ST-175 complex NG 187 909 583
1 93630 DE13592 Germany 2016 Invasive 175 ST-175 complex NG 187 909 583
1 93631 DE13875 Germany 2016 Invasive 175 ST-175 complex NG 12 662 583
1 93679 DE14494 Germany 2019 Invasive 175 ST-175 complex NG 313 662 583
2 52813 2586 Italy 2014 Invasive 5770 ST-175 complex C 12 1 69
2 54027 M37089 Brazil 2014 NK 6525 UA NG 12 14 14
2 54044 M37122 Brazil 2014 NK 6525 UA NG 12 14 14
2 54058 M37152 Brazil 2014 NK 5770 ST-175 complex NK 12 1 14
2 85387 1593673 Spain 2018 NK 5770 ST-175 complex Y 12 220 14
3 29440 10378 South Africa 2003 NK 6218 ST-175 complex W 12 1 14
3 34630 NM255 USA 2000 NK 2980 ST-175 complex X 12 22 1364
3 59828 52707 South Africa 2017 Invasive 6218 ST-175 complex Y 12 3 14
4 25822 16570 South Africa 2004 Invasive 175 ST-175 complex Y 12 4 14
4 25823 677 South Africa 2005 Invasive 175 ST-175 complex Y 12 4 14
4 25826 8465 South Africa 2006 Invasive 175 ST-175 complex Y 12 4 14
4 25829 8246 South Africa 2006 Invasive 175 ST-175 complex Y 12 4 14
4 25834 13160 South Africa 2004 Invasive 175 ST-175 complex Y 12 4 14
4 25840 11244 South Africa 2007 Invasive 175 ST-175 complex Y 12 4 14
4 25847 12870 South Africa 2007 Invasive 175 ST-175 complex Y 12 4 14
4 25852 1026 South Africa 2005 Invasive 175 ST-175 complex Y 12 4 14
4 25872 9371 South Africa 2003 Invasive 175 ST-175 complex Y 12 4 14
4 25874 9558 South Africa 2003 Invasive 175 ST-175 complex Y 12 4 14
4 40423 44133 South Africa 2014 Invasive 175 ST-175 complex W/Y 12 4 14
4 40588 9634 South Africa 2003 Invasive 175 ST-175 complex C 12 4 14
4 40593 10369 South Africa 2003 Invasive 175 ST-175 complex C 12 4 14
4 40644 15734 South Africa 2004 Invasive 175 ST-175 complex C 12 4 14
5 40583 9281 South Africa 2003 Invasive 8447 ST-175 complex C 12 5 583
5 57336 AR00302 Ethiopia 2014 NK 8447 ST-175 complex C 12 4 583
5 60403 AR07092 Ethiopia 2014 NK 8447 ST-175 complex C 12 4 583
6 46995 M22783 Niger 2003 NK 2881 ST-175 complex W 12 4 583
6 46997 M22804 Niger 2005 NK 2881 ST-175 complex W 12 4 583
6 46998 M22809 Benin 2006 NK 2881 ST-175 complex W 12 4 583
6 46999 M22811 Niger 2006 NK 2881 ST-175 complex W 12 4 583
6 47000 M22819 Benin 2007 NK 2881 ST-175 complex W 12 4 583
6 47001 M22822 Togo 2007 NK 2881 ST-175 complex W 12 4 583
6 47002 M22828 Burkina Faso 2008 NK 2881 ST-175 complex W 12 4 583
6 47004 M24705 Burkina Faso 2010 NK 8638 ST-175 complex W 12 4 583
6 49369 2007461 Togo 2007 Invasive 2881 ST-175 complex W 12 4 583
6 50827 LNP26952 France 2012 Invasive 2881 ST-175 complex W 12 4 583
6 57891 15446 Spain 2002 Invasive 2881 ST-175 complex W 12 4 583
6 57893 17106 Spain 2005 Invasive 2881 ST-175 complex W 12 4 583
6 58241 M27619 Burkina Faso 2012 Invasive 9357 ST-175 complex W 12 4 583
6 58291 M25431 Burkina Faso 2012 Invasive 2881 ST-175 complex W 12 NK 1636
n/a 20118 M10 240763 England 2010 Invasive 4051 UA B 3 1 8
n/a 21116 M11 240475 England 2011 Invasive 4051 UA B 3 1 19
n/a 27784 M12 240644 England 2012 Invasive 4051 UA B 3 428 265
n/a 30177 M97 252137 England 1997 Invasive Incomplete UA W 12 2 5
n/a 35742 M14 240369 England 2014 Invasive 4051 UA B 3 14 8
n/a 39413 953 England 2015 Invasive 4051 UA B 3 14 8
n/a 85528 M18 240129 Northern Ireland 2018 Invasive 4051 UA B 3 3 8
n/a 85969 Nm360601 China 2006 Invasive 5540 UA C 379 4 5
n/a 93680 DE14495 Germany 2019 Invasive Incomplete UA Y 12 912 5
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Appendix 3: Isolate panel 3; Results chapter 3.3. 
 
NG = non-groupable. ST = sequence type. CC = clonal complex.   
PubMLST 
ID






20444 2011 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.064 59
38011 2015 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.064 59
42526 2016 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.064 59
47344 2016 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.047 59
72494 2017 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.047 59
72496 2017 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.064 59
60904 2017 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.094 59
60578 2018 NG W 2 3 4 3 8 4 6 11 ST-11 complex 0.064 59
94456 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.047 59
63605 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.047 59
63626 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.25 1086
91767 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.75 253
91769 2019 W NK 2 3 4 3 8 4 6 11 ST-11 complex 0.5 253
63590 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.125 59
63584 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.064 59
63585 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.064 59
63591 2019 W W 2 3 4 3 8 4 6 11 ST-11 complex 0.094 59
63567 2019 W W 2 3 4 17 8 4 6 1287 ST-11 complex 0.094 59
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Appendix 4: PenA alleles harboured by PenR and PenI IMD isolates in England, Wales and 
Northern Ireland 2010/11 – 2018/19. 
  
NEIS1753_1 and penA1 = wild type alleles. The scale bar represents the amino acid position. 
PenR = Penicillin-resistant, PenI = Penicillin-susceptible, increased exposure according to 
EUCAST guidelines. PenA alleles among PenI isolates represented by four or more isolates.  
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Appendix 5: IMD isolates of ST-275 and ST-269 clusters of the ST-269 clonal complex in 
England, Wales and Northern Ireland 2010/11-2018/19. 
 
  
Neighbor-Net phylogenetic network based on a comparison 1605 core genome loci among 
ST-269 clonal complex isolates (n=507). The scale bar indicates the number of different loci 









Appendix 6: PenA alleles on PubMLST with the P551S amino acid substitution.   
 
 




Appendix 7: Isolates on PubMLST with penA alleles containing the P551S amino acid 
substitution.  
 

















ID Country Year Disease Penicillin MIC (mg/L) penA allele
9217 Czech Republic 1995 invasive (unspecified/other) 0.016 171
40556 South Africa 2005 meningitis 0.047 171
17690 Norway 2006 invasive (unspecified/other) 0.064 171
40756 South Africa 2005 meningitis 0.064 171
15674 Ireland 2008 NK 0.094 324
17121 Greece 2003 NK 0.094 111
17122 Greece 2003 NK 0.094 111
17123 Greece 2003 NK 0.094 111
17124 Greece 2003 NK 0.094 111
17125 Greece 2003 NK 0.094 111
17126 Greece 2003 NK 0.094 111
17127 Greece 2003 NK 0.094 111
28138 UK [England] 2013 invasive (unspecified/other) 0.38 171
910 UK [England] 1999 carrier NK 171
26557 Ireland 2013 carrier NK 324
26910 Ireland 2013 invasive (unspecified/other) NK 324
49523 UK [Wales] 2015 carrier NK 324
61917 Czech Republic 2018 invasive (unspecified/other) NK 171
94513 Sweden NK NK NK 324
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Appendix 8: Variable loci between PenR isolate 28138 and two closely related PenS isolates 
28132 and 28135. 
 
Isolates were compared on 1605 core genome loci. PenS = Penicillin-susceptible, standard 
exposure; PenR = Penicillin-resistant according to EUCAST guidelines. X = isolate missing 
complete gene.  
Locus Product 28132 28135 28138
NEIS0011 hypothetical protein 2 232 2
NEIS0012 hypothetical protein 70 71 70
NEIS0013 hypothetical protein 46 85 46
NEIS0071 putative lipoprotein 152 9 9
NEIS0129 30S ribosomal protein S10 1 1 15
NEIS0167 amino acid transporter 1 X 1
NEIS0213 pilin glycosyltransferase 448 X X
NEIS0257 ribosome-associated GTPase 1 220 1
NEIS0263 hypothetical protein 1 1 X
NEIS0276 putative rotamase 357 377 357
NEIS0290 adenylosuccinate lyase X 38 38
NEIS0338 ferric siderophore receptor protein 1 246 1
NEIS0380 O-acetyltransferase X 509 X
NEIS0402 putative lipopolysaccharide biosynthesis translocase 48 25 25
NEIS0408 type IV secretin protein 5 1441 5
NEIS0430 hypothetical protein 1 244 1
NEIS0470 putative integral membrane protein 227 1 1
NEIS0524 putative peptidase 28 1 1
NEIS0568 glycosyltransferase X 199 X
NEIS0586 MafB toxin 2 190 2
NEIS0599 alternative toxic C-terminal extremity 2 42 42
NEIS0638 GTP-binding protein Era 1 1 X
NEIS0651 IgA1 protease X 37 37
NEIS0690 HPr kinase/phosphorylase 1 1 235
NEIS0717 hypothetical protein 103 2 2
NEIS0760 hypothetical protein 2 2 X
NEIS0827 type IV biogenesis protein 303 303 255
NEIS0828 type IV biogenesis protein 267 267 446
NEIS0829 type IV biogenesis protein 1155 1245 1246
NEIS0932 dihydrolipoamide succinyltransferase E2 component (EC 2.3.1.61) 250 1 1
NEIS0933 dihydrolipoamide dehydrogenase 1 251 1
NEIS0944 putative outer-membrane receptor protein 163 285 163
NEIS1002 hypothetical protein 1 1 82
NEIS1018 gamma-glutamyltranspeptidase 1 1 123
NEIS1066 putative periplasmic protein 93 5 93
NEIS1072 hypothetical protein 1 94 1
NEIS1093 sulfate adenylate transferase subunit 1 1 175 1
NEIS1099 putative GTP-binding protein 1 263 1
NEIS1103 inosine 5'-monophosphate dehydrogenase 1 269 1
NEIS1129 hypothetical protein 110 1 1
NEIS1131 putative ATP-dependent protease 1 337 1
NEIS1156 hypothetical protein X 3 26
NEIS1170 putative P-type cation-transporting ATPase X 1 1
NEIS1185 aspartate ammonia-lyase 1 272 1
NEIS1188 putative dnaJ-family protein 224 252 224
NEIS1296 pseudouridine synthase 1 145 1
NEIS1326 glucose-6-phosphate isomerase (EC 5.3.1.9) 1 255 1
NEIS1342 cytolysin secretion ABC transporter 1 151 1
NEIS1378 DNA mismatch repair protein 1 1 X
NEIS1442 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 175 1 1
NEIS1447 acetate kinase 1 124 1
NEIS1504 hypothetical protein 129 1 1
NEIS1518 alanyl-tRNA synthetase 1 321 1
NEIS1526 two component sensor kinase 103 2 2
NEIS1532 hypothetical protein 1 115 1
NEIS1533 histidine-binding periplasmic protein 1 X 1
NEIS1535 potassium transporter peripheral membrane component 189 1 1
NEIS1607 DedA family integral membrane protein 1 168 1
NEIS1633 drug efflux protein X 1 X
NEIS1635 transcriptional regulator 1 1 217
NEIS1684 aspartyl-tRNA synthetase 1 397 1
NEIS1743 cell division protein 1 134 1
NEIS1750 hypothetical protein 2 X X
NEIS1753 penicillin-binding protein 2 59 59 332
NEIS1772 quinolinate synthetase 1 249 1
NEIS1776 beta-phosphoglucomutase 1 1 X
NEIS1777 maltose phosphorylase 351 1 1
NEIS1783 outer membrane protein class 4 2 132 2
NEIS1838 type IV biogenesis protein 2 148 2
NEIS1870 hypothetical protein X 1 1
NEIS1879 hypothetical protein 119 1 1
NEIS1891 LysR family transcriptional regulator 1 X 1
NEIS1927 cadmium resistance protein 26 26 73
NEIS1943 outer membrane peptidase X 186 2
NEIS1951 putative sodium-dependent inner membrane transport protein 64 165 64
NEIS1954 frataxin-like protein 133 10 10
NEIS1982 bifunctional ornithine acetyltransferase/N-acetylglutamate synthase protein 192 1 1
NEIS2021 thiamine biosynthesis protein ThiC 1 361 1
NEIS2030 putative periplasmic protein 245 1 1
NEIS2042 phosphoenolpyruvate carboxylase 1 1 377
NEIS2098 putative mafS10 cassette 1 9 1
NEIS2123 RNA polymerase sigma factor 1 1 100
NEIS2133 electron transfer flavoprotein beta-subunit 1 196 1
NEIS2138 DNA mismatch repair protein MutS X X 1




Appendix 9: MtrR alleles on PubMLST containing the S32W amino acid substitution.  
 
               






Appendix 10: PenA alleles on PubMLST harbouring four out of the five amino acid 
substitutions associated with conferring reduced susceptibility or resistance to penicillin 
(F504L, A510V, I515V, H541N). 
 
 
PenA1 = wild type penA allele. The scale bar indicates the amino acid position.   
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Appendix 11: Meningococcal isolates on PubMLST harbouring penA alleles (other than 
penA327) containing four out of the five amino acid substitutions associated with conferring 
reduced susceptibility or resistance to penicillin (F504L, A510V, I515V, H541N). 
 










15176 Czech Republic 1993 invasive (unspecified/other) 0.016 622
17810 Ireland 2009 NK 0.064 292
42622 UK [Scotland] 2014 invasive (unspecified/other) 0.09 178
17689 Norway 2006 invasive (unspecified/other) 0.094 178
15778 Canada 2009 meningitis 0.094 330
15780 Canada 2009 meningitis 0.094 330
71753 New Zealand 2013 invasive (unspecified/other) 0.12 330
19389 Ireland 2012 NK 0.19 372
20716 Ireland 2012 invasive (unspecified/other) 0.25 387
35145 Australia 2014 septicaemia 0.25 565
16974 France 2005 invasive (unspecified/other) 0.38 65
18703 Ireland 2006 invasive (unspecified/other) 0.5 361
35607 UK [England] 2014 invasive (unspecified/other) NK 648
29618 Ireland 2006 invasive (unspecified/other) NK 361
19059 France 2012 invasive (unspecified/other) NK 178
20727 Ireland 2012 carrier NK 372
21025 Ireland 2012 septicaemia NK 387
26888 Ireland 2012 invasive (unspecified/other) NK 330
26890 Ireland 2012 invasive (unspecified/other) NK 387
38411 Greece 2014 carrier NK 664
40194 France 2013 NK NK 684
41867 France 2016 invasive (unspecified/other) NK 614
46694 UK [Scotland] 2015 carrier NK 178
49288 Finland 2016 NK NK 330
52814 Italy 2014 NK NK 774
52974 Canada 2009 invasive (unspecified/other) NK 330
53002 Canada 2009 invasive (unspecified/other) NK 330
56674 Canada 2009 NK NK 330
56675 Canada 2009 NK NK 330
57541 Ireland 2006 invasive (unspecified/other) NK 361
58168 Sweden 2017 invasive (unspecified/other) NK 292
71580 New Zealand 2017 NK NK 292
72823 Portugal 2019 septicaemia NK 330
93523 Brazil 2016 carrier NK 292
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Appendix 12: PenA alleles on PubMLST containing the G545S amino acid substitution.  
 
 
PenA1 = wild type penA allele. The scale indicates the amino acid position.  
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Appendix 13: The cefotaxime-resistant ST-162 clonal complex isolate and closely related 







Neighbor-Net phylogenetic network based on a comparison 1605 core genome loci among 
PubMLST ST-162 CC isolates (n=72). The closest related cefotaxime-susceptible isolates to 
the cefotaxime-resistant isolate are highlighted (n=19). Isolates are labelled with PubMLST 







Appendix 14: Probable recombination events among variable loci of cefotaxime-resistant ST-
162 clonal complex isolate 20267 and the closely related cefotaxime-susceptible ST-162 
clonal complex isolates.  
 
Isolates were compared in terms of all NEIS loci. PubMLST IDs of compared ST-162 clonal 
complex isolates can be found in Appendix 13. Species distribution refers to the number of 
isolates identified on PubMLST.  NB = N. Bergeri, NG = N. gonorrhoea, NM = N. meningitidis, 




NEIS0098 aspartate carbamoyltransferase catalytic subunit 162 4 x NM
NEIS0099 pyrI 93 7 x NM
NEIS0100 hypothetical protein 3 3,180 x NM
NEIS0101 hypothetical protein 2 3, 283 x NM
NEIS0102 peptide deformylase 8 1,347 x NM
NEIS0103 methionyl-tRNA formyltransferase 9 799 x NM
NEIS0104 SUN-family protein 1 5,608 x NM
NEIS0105 hypothetical protein 1 7,983 x NM
NEIS0106 putative two-component sensor kinase 286 1 x NM
NEIS0244 NADH dehydrogenase subunit G 257 1 x NM
NEIS0245 NADH dehydrogenase I chain H 36 100 x NM
NEIS0246 NADH dehydrogenase subunit I 142 1 x NM
NEIS0247 NADH dehydrogenase I chain J 163 32 x NM
NEIS0248 NADH dehydrogenase subunit K 122 1 x NM
NEIS0709 phosphoribosylaminoimidazole-succinocarboxamide synthase 4 3,874 x NM
NEIS0710 polynucleotide phosphorylase/polyadenylase 223 1 x NM
NEIS1017 serine hydroxymethyltransferase 42 235 x NM
NEIS1018 gamma-glutamyltranspeptidase 62 1 x NM
NEIS1020 hypothetical protein 2 6, 801 x NM
NEIS1021 hypothetical protein 52 638 x NM
NEIS1022 fructose-1,6-bisphosphatase (EC 3.1.3.11) 24 545 x NM
NEIS1024 hypothetical protein 42 616 x NM
NEIS1026 putative integral membrane protein 33 1,503 x NM
NEIS1027 dihydroneopterin aldolase 85 7 x NM
NEIS1028 hypothetical protein 20 560 x NM
NEIS1029 camphor resistance protein CrcB 27 645 x NM
NEIS1030 putative integral membrane protein 33 251 x NM
NEIS1031 putative cell-division protein 102 4 x NM
NEIS1032 gamma-glutamyl phosphate reductase 136 1 x NM
NEIS1033 gamma-glutamyl kinase 19 246 x NM
NEIS1364 PorA, porin, class 1 outer membrane protein 246 5 x NM
NEIS1365 transcription elongation factor GreA 41 1,244 x NM; 2 x NG
NEIS1366 3-phosphoshikimate 1-carboxyvinyltransferase 200 1 x NM
NEIS1435 nicotinate phosphoribosyltransferase 6 491 x NM
NEIS1436 arginyl-tRNA synthetase 28 489 x NM
NEIS1552 hypothetical protein 1 520 x NM; 5 x NG
NEIS1553 Lipid A phosphoethanolamine transferase 81 8 x NM
NEIS1554 phosphoserine aminotransferase 30 123 x NM
NEIS1555 hypothetical protein 26 118 x NM
NEIS1556 transcription elongation factor NusA 52 108 x NM
NEIS1557 translation initiation factor IF-2 124 2 x NM
NEIS1558 putative integral membrane protein 101 4 x NM
NEIS1559 putative integral membrane protein 56 455 x NM
NEIS1560 hemolysin 12 503 x NM
NEIS1562 putative sodium:alanine symporter 34 465 x NM
NEIS1563 hypothetical protein 113 62 x NM
NEIS1686 putative integral membrane protein 60 11 x NM
NEIS1687 outer membrane phospholipase A precursor (ec 3.1.1.32) 44 18 x NM
NEIS1688 30S ribosomal protein S20 3 1,157 x NM; 3 x NG
NEIS1690 NK 548 1 x NM
NEIS1691 NK 592 1 x NM
NEIS1745 UDP-N-acetylmuramoyl-L-alanyl-D-glutamate synthetase 233 1 x NM
NEIS1746 hypothetical protein 220 1 x NM
NEIS1747 phospho-N-acetylmuramoyl-pentapeptide- transferase 159 1 x NM
NEIS1748 putative periplasmic protein 31 14 x NB; 2 x NM
NEIS1749 UDP-MurNAc-pentapeptide synthetase 265 1 x NM
NEIS1751 UDP-N-acetylmuramoylalanyl-D-glutamate--2, 6-diaminopimelate ligase 1616 1 x NM
NEIS1753 penicillin-binding protein 2 379 1 x NM
NEIS1754 putative small periplasmic protein 23 22 x NP; 3 x NM
NEIS1755 S-adenosyl-methyltransferase MraW 266 1 x NM
NEIS1756 cell division protein MraZ 60 4 x NB; 3 x NM
NEIS1757 hypothetical protein 98 2 x NB, 2 x NM
NEIS1759 undecaprenyl pyrophosphate phosphatase 46 59 x NB, 2 x NM
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Appendix 15: Alignment of NEIS1753 allele 379 with NEIS1753 alleles among cefotaxime-
susceptible PenR IMD isolates in England, Wales and Northern Ireland, 2010/11-2018/19.    
 
NEIS1753_1 = wild type allele. PenR = Penicillin-resistant. The scale bar indicates the 
amino acid position. Amino acid positions 501 and 511 are highlighted.   
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Appendix 17: PubMLST isolates harbouring an mtrR allele with a frameshift within the first 
60 amino acids.  
 


















Appendix 18: RpoB alleles among IMD isolates in England, Wales and Northern Ireland 
2010/11-2018/19 and the respective rifampicin MIC values.  
 
  
<0.002 0.002 0.003 0.004 0.006 0.008 0.012 0.016 0.023 0.032 0.047 0.064 0.094 0.12 0.125 0.19 0.25 0.5 >32
1 1 3 1 3 1 2 1 1 13
2 3 14 30 40 37 27 16 3 14 7 7 5 1 204
4 1 25 56 119 128 116 83 86 44 43 23 7 10 11 1 1 754
5 7 17 28 45 21 17 19 11 6 3 4 3 2 183
6 2 2 2 4 4 2 2 1 2 21
7 2 6 10 7 6 7 5 2 1 3 1 50
8 1 3 1 1 1 1 1 9
9 2 8 42 140 198 229 177 113 54 31 12 7 5 1 7 7 2 1035
18 1 14 54 105 130 134 72 39 22 24 14 14 4 3 1 631
21 1 1 2 4 3 3 3 1 1 1 20
27 2 1 1 2 1 1 8
28 1 6 13 23 39 31 27 25 16 12 2 4 2 3 1 205
31 2 6 2 5 2 1 1 1 2 1 23
33 1 1
34 7 34 127 246 138 95 55 63 24 22 13 7 2 1 1 835
38 1 1 2 1 1 3 1 2 1 13
40 1 1
42 2 4 6 5 5 1 2 1 2 1 29
44 1 1
58 1 1 2
63 1 1
69 1 2 3
70 1 1
72 1 2 4 5 3 4 1 1 2 23






80 1 1 2











210 2 1 3
216 1 1















Total 14 102 342 734 757 701 499 392 188 167 81 59 34 1 31 15 3 1 1 4122
Rifampicin MIC (mg/L)
rpoB  allele Total
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Appendix 19: Alignment of wild type rpoB gene and rpoB alleles found among rifampicin-
resistant IMD isolates in England, Wales and Northern Ireland 2010/11-2018/19.  
 
 
NIES0123 = full length rpoB gene. NEIS0123 = allele 1 = wild type rpoB allele. The scale bar 



























* = ciprofloxacin-resistant. NK = not known.  
gyrA  allele Number of isolates
MIC or MIC range 
(mg/L) 





1 475 <0.002-0.008 None
2 497 <0.002-0.012 None
3 354 <0.002-0.008 None
4 2,072 <0.002-0.016 None
5 19 0.002-0.006 None
6 1 0.5* T91I
8 1 0.18* T91I
10 1 0.094* D95N
11 15 0.002-0.008 None
12 626 <0.002-0.03 None
17 7 0.002-0.006 None
18 1 0.006 None
20 2 0.003-0.004 None
21 3 0.004-0.008 None
22 8 0.002-0.008 None
23 3 0.002-0.004 None
24 4 0.003-0.008 None
25 3 0.002-0.004 None
26 1 0.004 None
27 1 0.003 None
28 9 0.003-0.006 None
29 2 0.003-0.006 None
39 1 0.003 None
46 1 0.008 None
131 1 0.004 None
132 1 0.002 None
133 1 0.004 None
136 1 0.006 None
144 1 0.008 None
146 1 0.19* T91I
191 1 0.004 None
200 2 0.006-0.008 None
296 1 0.06* D95N
383 1 0.004 None
384 1 0.004 None
386 1 0.008 None




Appendix 21: Alignment of gyrA alleles harboured by IMD isolates in England, Wales and 
Northern Ireland 2010/11-2018/19.  
  
 
NEIS1320 = full length wild type gyrA allele. The scale bar indicates the amino acid position. 
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Appendix 22:  GyrA alleles among ST-175 clonal complex isolates. 
  
 
NEIS1320 = full length wild type gyrA allele. The scale bar indicates the amino acid position. 
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Appendix 23:  Serogroup W ST-11 clonal complex isolates belonging to penicillin resistance-































Lineage Cluster Strain ID Isolate Country Year Penicillin MIC (mg/L) penA
1 A Original UK strain 53284 M17 240100 England 2017 0.032 1
1 A Original UK strain 41501 M15 240918 England 2015 0.047 1
1 A Original UK strain 42530 M16 240070 England 2016 0.047 1
1 A Original UK strain 35581 M14 240090 England 2014 0.064 1
1 A Original UK strain 47289 M16 240544 England 2016 0.064 1
1 A Original UK strain 53067 M16 240727 England 2016 0.064 1
1 A Original UK strain 53159 M16 240855 England 2016 0.064 1
1 A Original UK strain 53269 M17 240073 England 2017 0.064 1
1 A Original UK strain 60736 M17 240288 England 2017 0.064 1
1 A Original UK strain 63577 M18 240504 England 2018 0.064 1
1 A Original UK strain 53072 M16 240734 England 2016 0.094 1
1 A Original UK strain 41486 M15 240896 England 2015 0.125 1
1 A Original UK strain 26898 12002_2013 Ireland 2013 NK 1
1 A Original UK strain 26899 12003_2013 Ireland 2013 NK 1
1 A Original UK strain 26914 12018_2013 Ireland 2013 NK 1
1 A Original UK strain 36131 12004_2015 Ireland 2015 NK 1
1 A Original UK strain 93237 SMG-19-1551 Scotland 2017 NK 1
1 A Original UK strain 83924 18-520 Sweden 2018 NK 1
1 B Original UK strain 71591 NZ17MI0022 New Zealand 2017 0.03 9
1 B Original UK strain 63630 M19 240302 England 2019 0.047 1
1 B Original UK strain 61569 M18 240285 England 2018 0.19 9
1 B Original UK strain 71558 NZ16MI0056 New Zealand 2016 0.25 9
1 B Original UK strain 71587 NZ17MI0018 New Zealand 2017 0.25 9
1 B Original UK strain 71621 NZ17MI0056 New Zealand 2017 0.25 9
1 B Original UK strain 71642 NZ17MI0078 New Zealand 2017 0.25 9
1 B Original UK strain 53230 M17 240029 England 2017 0.25 9
1 B Original UK strain 71664 NZ18MI0018 New Zealand 2018 0.25 9
1 B Original UK strain 71669 NZ18MI0023 New Zealand 2018 0.25 9
1 B Original UK strain 71677 NZ18MI0031 New Zealand 2018 0.25 9
1 B Original UK strain 71682 NZ18MI0037 New Zealand 2018 0.25 9
1 B Original UK strain 71685 NZ18MI0040 New Zealand 2018 0.25 9
1 B Original UK strain 71693 NZ18MI0050 New Zealand 2018 0.25 9
1 B Original UK strain 71695 NZ18MI0053 New Zealand 2018 0.25 9
1 B Original UK strain 71697 NZ18MI0055 New Zealand 2018 0.25 9
1 B Original UK strain 71730 NZ18MI0091 New Zealand 2018 0.25 9
1 B Original UK strain 71738 NZ19MI0001 New Zealand 2018 0.25 9
1 B Original UK strain 71740 NZ19MI0003 New Zealand 2018 0.25 9
1 B Original UK strain 63618 M19 240268 England 2019 0.25 9
1 B Original UK strain 63621 M19 240281 England 2019 0.25 9
1 B Original UK strain 42595 M16 240163 England 2016 0.38 9
1 B Original UK strain 53119 M16 240794 England 2016 0.38 9
1 B Original UK strain 58822 W-6665_Str Greece 2017 0.38 9
1 B Original UK strain 61038 M17 240289 England 2017 0.38 9
1 B Original UK strain 60708 M17 240467 England 2017 0.38 9
1 B Original UK strain 63587 M18 240200 England 2018 0.38 9
1 B Original UK strain 63599 M18 240344 England 2018 0.38 9
1 B Original UK strain 60750 M18 240004 England 2018 0.38 9
1 B Original UK strain 60631 M18 240078 England 2018 0.38 9
1 B Original UK strain 85599 M18 240404 England 2018 0.38  9
1 B Original UK strain 91761 M18 240534 England 2018 0.38  9
1 B Original UK strain 91763 M18 240612 England 2018 0.38  9
1 B Original UK strain 71596 NZ17MI0027 New Zealand 2017 0.5 9
1 B Original UK strain 71609 NZ17MI0041 New Zealand 2017 0.5 9
1 B Original UK strain 71626 NZ17MI0062 New Zealand 2017 0.5 9
1 B Original UK strain 71666 NZ18MI0020 New Zealand 2018 0.5 9
1 B Original UK strain 71670 NZ18MI0024 New Zealand 2018 0.5 9
1 B Original UK strain 71699 NZ18MI0057 New Zealand 2018 0.5 9
1 B Original UK strain 71703 NZ18MI0061 New Zealand 2018 0.5 9
1 B Original UK strain 71705 NZ18MI0064 New Zealand 2018 0.5 9
1 B Original UK strain 71708 NZ18MI0067 New Zealand 2018 0.5 9
1 B Original UK strain 71713 NZ18MI0073 New Zealand 2018 0.5 9
1 B Original UK strain 71715 NZ18MI0075 New Zealand 2018 0.5 9
1 B Original UK strain 71716 NZ18MI0076 New Zealand 2018 0.5 9
1 B Original UK strain 71717 NZ18MI0077 New Zealand 2018 0.5 9
1 B Original UK strain 71719 NZ18MI0079 New Zealand 2018 0.5 9
1 B Original UK strain 71720 NZ18MI0080 New Zealand 2018 0.5 9
1 B Original UK strain 71724 NZ18MI0084 New Zealand 2018 0.5 9
1 B Original UK strain 71734 NZ18MI0096 New Zealand 2018 0.5 9
1 B Original UK strain 91760 M18 240449 England 2018 0.5   9
1 B Original UK strain 91762 M18 240582 England 2018 0.5   9
1 B Original UK strain 91769 M19 240386 England 2019 0.5 9
1 B Original UK strain 71052 M18 240297 England 2018 0.75 9
1 B Original UK strain 91767 M19 240384 England 2019 0.75 9
1 B Original UK strain 71711 NZ18MI0071 New Zealand 2018 1 9
1 B Original UK strain 51888 NMLW080 Canada 2015 NK 9
1 B Original UK strain 50313 2161610 The Netherlands 2016 NK 9
1 B Original UK strain 41966 16-92 Sweden 2016 NK 9
1 B Original UK strain 42206 LNP28508 France 2016 NK 9
1 B Original UK strain 42409 LNP28524 France 2016 NK 9
1 B Original UK strain 51880 NMLW110 Canada 2016 NK 9
1 B Original UK strain 55150 2171500 The Netherlands 2017 NK 9
1 B Original UK strain 58172 17-610 Sweden 2017 NK 9
1 B Original UK strain 57906 22480 Spain 2017 NK 9
1 B Original UK strain 57912 22565 Spain 2017 NK 9
1 B Original UK strain 88953 NIID669 Japan 2017 NK 9
1 B Original UK strain 55579 12018-17 Ireland 2017 NK 9
1 B Original UK strain 93909 171049 Ireland 2017 NK 9
1 B Original UK strain 56731 NLMW135 Canada 2017 NK 9
1 B Original UK strain 57819 NMLW159 Canada 2017 NK 9
1 B Original UK strain 59006 NML2017-159 Canada 2017 NK 9
1 B Original UK strain 63003 NML2017-135 Canada 2017 NK 9
1 B Original UK strain 85089 NML2018-164 Canada 2018 NK 1
1 B Original UK strain 83998 2182164 The Netherlands 2018 NK 9
1 B Original UK strain 71726 NZ18MI0087 New Zealand 2018 NK 9
1 B Original UK strain 93936 181026 Ireland 2018 NK 9
1 B Original UK strain 63006 NML2018-019 Canada 2018 NK 9
1 B Original UK strain 63008 NML2018-030 Canada 2018 NK 9
1 B Original UK strain 63009 NML2018-039 Canada 2018 NK 9
1 B Original UK strain 63010 NML2018-044 Canada 2018 NK 9
1 B Original UK strain 63020 NML2018-102 Canada 2018 NK 9
1 B Original UK strain 63021 NML2018-103 Canada 2018 NK 9
1 B Original UK strain 85078 NML2018-130 Canada 2018 NK 9
1 B Original UK strain 85087 NML2018-153 Canada 2018 NK 9
1 B Original UK strain 85088 NML2018-163 Canada 2018 NK 9
1 B Original UK strain 85090 NML2018-168 Canada 2018 NK 9
1 B Original UK strain 85094 NML2018-183 Canada 2018 NK 9
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Appendix 23 continued 
 
Apparent frameshift due to an extra 'A' at poly-A tract (nucleotide 1667 of NEIS1753) 
leading to a lengthened peptide with n=22 amino acid mismatches. Given that penicillin 
binding protein 2 (encoded by penA) is essential, this frameshift would need confirming 
with Sanger sequence analysis. NK= not known.  
1 B Original UK strain 85099 NML2018-192 Canada 2018 NK 9
1 B Original UK strain 86970 2190148 The Netherlands 2019 NK 9
1 B Original UK strain 85271 19-50 Sweden 2019 NK 9
1 B Original UK strain 88981 19-228 Sweden 2019 NK 9
1 B Original UK strain 63357 Nmen108 Spain 2019 NK 9
1 B Original UK strain 63360 Nmen120 Spain 2019 NK 9
1 B Original UK strain 63362 Nmen123 Spain 2019 NK 9
1 B Original UK strain 91800 Nmen89 Spain 2019 NK 9
1 B Original UK strain 93847 Nmen101 Spain 2019 NK 9
1 B Original UK strain 93962 191001 Ireland 2019 NK 9
1 B Original UK strain 93985 191030 Ireland 2019 NK 9
1 B Original UK strain 71883 NML2019-158 Canada 2019 NK 9
1 B Original UK strain 89245 NML2019-044 Canada 2019 NK 9
1 B Original UK strain 72761 Nmen152 Spain 2020 NK 9
1 B Original UK strain 57573 12-590-208 Sweden NK NK 9
1 B Original UK strain 51212 Nmiss2913 Italy NK NK 9
2 A UK 2013 strain 44820 M16_240451 Northern Ireland 2016 0.047 1
2 A UK 2013 strain 63561 M18 240396 England 2018 0.047 1
2 A UK 2013 strain 71159 M19 240035 England 2019 0.047 1
2 A UK 2013 strain 47337 M16 240684 England 2016 0.064 1
2 A UK 2013 strain 53052 M16_240706 Wales 2016 0.064 1
2 A UK 2013 strain 53346 M17 240192 England 2017 0.064 1
2 A UK 2013 strain 60769 M17 240488 England 2017 0.064 1
2 A UK 2013 strain 60949 M17 240551 England 2017 0.064 1
2 A UK 2013 strain 61031 M17 240811 England 2017 0.064 1
2 A UK 2013 strain 72496 M17 240488b England 2017 0.064 1
2 A UK 2013 strain 60601 M18 240072 England 2018 0.064 1
2 A UK 2013 strain 60663 M18 240085 England 2018 0.064 1
2 A UK 2013 strain 63566 M18 240408 England 2018 0.064 1
2 A UK 2013 strain 71003 M18 240189 England 2018 0.064 1
2 A UK 2013 strain 71009 M18 240207 England 2018 0.064 1
2 A UK 2013 strain 71043 M18 240273 England 2018 0.064 1
2 A UK 2013 strain 85571 M18 240304 England 2018 0.064 1
2 A UK 2013 strain 94269 M18 240420 England 2018 0.064 1
2 A UK 2013 strain 94282 M18 240506 England 2018 0.064 1
2 A UK 2013 strain 63595 M18 240458 Wales 2018 0.064 1
2 A UK 2013 strain 63615 M19 240248 England 2019 0.064 1
2 A UK 2013 strain 63632 M19 240315 England 2019 0.064 1
2 A UK 2013 strain 63627 M19 240211 Wales 2019 0.064 1
2 A UK 2013 strain 53084 M16 240748 England 2016 0.094 1
2 A UK 2013 strain 63564 M18 240148 England 2018 0.094 1
2 A UK 2013 strain 63568 M18 240444 England 2018 0.094 1
2 A UK 2013 strain 71115 M18 240613 England 2018 0.094 1
2 A UK 2013 strain 71080 M19 240191 England 2019 0.094 1
2 A UK 2013 strain 94459 M19 240187 England 2019 0.094 1
2 A UK 2013 strain 44668 2160005 The Netherlands 2016 NK 1
2 A UK 2013 strain 57471 24170 Ireland 2017 NK 1
2 A UK 2013 strain 57477 24176 Ireland 2017 NK 1
2 A UK 2013 strain 63137 SMG-19-1949 Scotland 2017 NK 1
2 A UK 2013 strain 60002 LNP29989abd France 2018 NK 1
2 A UK 2013 strain 84915 DE14146 Germany 2018 NK 1
2 A UK 2013 strain 84914 DE14141 Germany 2018 NK 1
2 A UK 2013 strain 84917 DE14193 Germany 2018 NK 1
2 A UK 2013 strain 84916 DE14183 Germany 2018 NK 1
2 A UK 2013 strain 84921 DE14223 Germany 2018 NK 1
2 A UK 2013 strain 93948 181039 Ireland 2018 NK 1
2 A UK 2013 strain 58191 SMG_18_163 Scotland 2018 NK 1
2 A UK 2013 strain 61289 18-87 Sweden 2018 NK 1
2 A UK 2013 strain 59769 2180800_I The Netherlands 2018 NK 1
2 A UK 2013 strain 59770 2180800_II The Netherlands 2018 NK 1
2 A UK 2013 strain 88183 DE14424 Germany 2019 NK 1
2 A UK 2013 strain 72830 Nm_67-19 Portugal 2019 NK 1
2 A UK 2013 strain 85392 SMG-19-325 Scotland 2019 NK 1
2 A UK 2013 strain 88879 Nmen56 Spain 2019 NK 1
2 A UK 2013 strain 71947 SMG-20-114 Scotland 2020 NK 1
2 B UK 2013 strain 60784 M17 240755 England 2017 0.25 14
2 B UK 2013 strain 71089 M18 240494 England 2018 0.25  14
2 B UK 2013 strain 63609 M19 240309 England 2019 0.25 14
2 B UK 2013 strain 94416 M19 240109 England 2019 0.25  14
2 B UK 2013 strain 94396 M19 240063 England 2019 0.25  14
2 B UK 2013 strain 63626 M19 240358 England 2019 0.25 14
2 B UK 2013 strain 71148 M19 240018 England 2019 0.25  14
2 B UK 2013 strain 63623 M19 240347 England 2019 0.25 14
2 B UK 2013 strain 91765 M19 240292 England 2019 0.38  14
2 B UK 2013 strain 91766 M19 240316 England 2019 0.38  14
2 B UK 2013 strain 85546 M18 240166 England 2018 0.5 14
2 B UK 2013 strain 84118 18-469 Sweden 2018 NK 14
2 B UK 2013 strain 93335 SMG-19-1582 Scotland 2019 NK 14
3 n/a UK 2013 strain 61570 M18 240314 England 2018 0.38 540
3 n/a UK 2013 strain 91764 M19 240214 England 2019 0.38  540
3 n/a UK 2013 strain 57913 22569 Spain 2017 NK 1
3 n/a UK 2013 strain 72893 SMG-20-623 Scotland 2020 NK 1
4 n/a Original UK strain 52889 16.8710760 Scotland 2016 0.006 1
4 n/a Original UK strain 28128 M12 240826 England 2012 0.047 1
4 n/a Original UK strain 39365 M15 240730 England 2015 0.047 1
4 n/a Original UK strain 71064 M19 240144 England 2019 0.047 1
4 n/a Original UK strain 28161 M13 240467 England 2013 0.064 1
4 n/a Original UK strain 29734 M13 240538 England 2013 0.064 1
4 n/a Original UK strain 39408 M15 240794 England 2015 0.064 1
4 n/a Original UK strain 28143 M13 240158 England 2013 0.094 1
4 n/a Original UK strain 37797 M15 240010 England 2015 0.38 9
4 n/a Original UK strain 51883 NMLW083 Canada 2014 NK 1
4 n/a Original UK strain 38995 15.8700107 Scotland 2015 NK 1
4 n/a Original UK strain 39000 15.8703957 Scotland 2015 NK 1
5 n/a Original UK strain 28117 M12 240663 England 2012 0.38 435
5 n/a Original UK strain 26993 90149v1 UK NK NK 1
Singleton n/a Original UK strain 28138 M13 240066 England 2013 0.38 171
6 n/a South American strain 38120 M14 240447b England 2014 0.047 1
6 n/a South American strain 37845 M15 240066 Wales 2015 0.125 1
6 n/a South American strain 20057 M10 240671 England 2010 0.38 9
6 n/a South American strain 36848 2593 Italy 2014 NK 1
6 n/a South American strain 36779 107507 Finland 2015 NK 1
6 n/a South American strain 36781 107497 Finland 2015 NK 1
6 n/a South American strain 46098 LNP28711 France 2016 NK 1
6 n/a South American strain 31319 M10208 Chile NK NK 1
6 n/a South American strain 40501 M18774 USA 2009 NK #
6 n/a South American strain 31323 M1412 Chile NK NK 1
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Appendix 24:  Identification of non-MGL serogroup W ST-11 clonal complex isolates of the 













UK 2013 strain isolate
Shortlisted isolates*
Argentinian reference strain isolates
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Appendix 24 Continued 
 
Core genome comparison based on 1605 core genome loci among non-MGL serogroup W 
ST-11 clonal complex isolates (n=2,214). Genomes split into eight groups (a-h). Each 
network includes the South American reference strain isolates (n=5; PubMLST IDs 31148, 
31149, 31150, 31151, 31152) and an original UK strain reference strain (PubMLST ID 
30154). The number of different loci among the 1605 compared is represented by the scale 











Appendix 25:  Serogroup W ST-11 clonal complex isolates of penicillin resistance-associated 
lineage 1 (Willerton et al., 2021). 
 
 
Core genome comparison based on 1605 core genome loci among serogroup W ST-11 
clonal complex isolates of penicillin resistance-associated lineage 1. the number of 
different loci among the 1605 compared is represented by the scale bar. 
Non-Australian penicillin resistance-


















Appendix 26:  Serogroup W ST-11 clonal complex isolates of penicillin resistance-associated 
lineage 2 (Willerton et al., 2021). 
 
 
Core genome comparison based on 1605 core genome among serogroup W ST-11 clonal 
complex isolates of penicillin resistance-associated lineage 2 (n=62). The number of 




Non-UK 2013 penicil l in 
resistance-associated 
l ineage reference genome 
(37722) 
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